[go: up one dir, main page]

WO2025096660A1 - Compositions and inhibitors of polrmt - Google Patents

Compositions and inhibitors of polrmt Download PDF

Info

Publication number
WO2025096660A1
WO2025096660A1 PCT/US2024/053724 US2024053724W WO2025096660A1 WO 2025096660 A1 WO2025096660 A1 WO 2025096660A1 US 2024053724 W US2024053724 W US 2024053724W WO 2025096660 A1 WO2025096660 A1 WO 2025096660A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
cyclopropyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/053724
Other languages
French (fr)
Inventor
Andrew Griffin
Simon Giroux
Paul Charifson
Jeremy Green
Andrew Mckenzie
Gabriel Martinez Botella
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pretzel Therapeutics Inc
Original Assignee
Pretzel Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pretzel Therapeutics Inc filed Critical Pretzel Therapeutics Inc
Publication of WO2025096660A1 publication Critical patent/WO2025096660A1/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • the present disclosure relates to POLRMT modulators, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof.
  • the present disclosure also relates to novel oxadiazole compositions, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof.
  • the present disclosure also relates to methods of making the modulator compounds and/or oxadiazole compositions.
  • the present disclosure further relates to methods of using such compounds and compositions, including to inhibit or promote POLRMT.
  • POLRMT Human mitochondrial RNA polymerase
  • CTD C- terminal polymerase domain
  • NTD N-terminal domain
  • NTE N- terminal extension
  • POLRMT biochemistry While aspects of POLRMT biochemistry are known, its full physiological role in mitochondrial gene expression and homeostasis, as well as its underlying impact in the etiology of various disease states, remains unclear. Its dysfunction and/or deregulation impacts mitochondrial metabolism, sometimes through the OXPHOS system, which ultimately contributes to many metabolic, degenerative and age-related diseases such as cancer, diabetes, obesity, and Alzheimer's disease. Pharmacological inhibition of POLRMT is one means by which to gain a further understanding of the role of this polymerase in cell physiology and the development of disease. Regulation of metabolic mechanisms, including oxidative phosphorylation, with POLRMT modulators affords an opportunity for intervention in complex disorders.
  • the present disclosure is directed to compounds, pharmaceutically acceptable salts of the compounds, and methods of using the compounds, salts of the compounds to treat various neurodegenerative and metabolic disorders, cancer, and also disorders related to aging and mitochondrial diseases.
  • the present disclosure provides a compound, which, according to an embodiment of the present disclosure is a compound represented by Formula (I), [0007]
  • X 1 -X 5 are each independently a hydrogen, a halogen, a hydroxy, a cyano, a C 1 -C 6 alkyl, a substituted C 1 -C 6 alkyl, a C 3 -C 6 cycloalkyl, a substituted C 3 -C 6 cycloalkyl, a C 1 -C 6 alkoxy, optionally substituted with an aryl, a C 3 -C 10 cycloalkyl, -C(O)NH 2 , - C(O)NHY 1 , -C(O)NY 1 Y 2 , -COOH, -C(O)OY 1 , -Y 1 COOH, or -Y 1 OY 2 .
  • Y 1 and Y 2 are each independently a C 1 -C 6 alkyl optionally substituted with one or more halogen or hydroxy.
  • X6-X8 are each independently a C, N, S, or O.
  • R 3 is a halogen, a hydrogen, a C 1 -C 6 alkyl, a C 1 -C 6 alkyl substituted with one or more halogen, or a C 3 -C 6 cycloalkyl.
  • R 4 is a hydrogen, a C 1 -C 6 alkyl, or a C 1 -C 6 alkyl substituted with one or more halogen.
  • R 3 and R 4 are optionally interconnected they form a C 3 -C 6 cycloalkyl, a substituted C 3 -C 6 cycloalkyl, 5-membered heterocyclic ring, a substituted 5- membered heterocyclic ring, 6-membered heterocyclic ring, a substituted 6-membered heterocyclic ring, a phenyl ring, or a substituted phenyl ring.
  • A1 and A2 are each independently a hydrogen, a C 1 -C 6 alkyl, a substituted C 1 -C 6 alkyl, an aryl, substituted aryl, a C 3 -C 6 cycloalkyl, a substituted C 3 -C 6 cycloalkyl, a C3-C6 heterocyclyl, substituted C 3 -C 6 heterocyclyl, or absent.
  • A1 and A2 may optionally be substituted with one or more members selected from the group consisting of halogen, ester, ether, carboxylic acid, -C(O)NH 2 , -CS(O) 2 Y 3 , a -CY 1 S(O) 2 Y 3 .
  • Y 3 is independently hydrogen or C 1 -C 4 alkyl optionally substituted with one or more groups selected from the group consisting of halogen, hydroxyl, C 1 -C 4 haloalkoxyl, and C 1 -C 4 alkoxyl.
  • Some aspects of the present disclosure include compounds described above, wherein the compound has a POLRMT IC 50 of 200 nM or less. [0017] Some aspects of the present disclosure include a pharmaceutical composition comprising a compound according to any of the previous claims. [0018] Some aspects of the present disclosure are directed towards a method of inhibiting the activity of POLRMT comprising administering a compound of any of the previous claims to a subject in need thereof. [0019] Other aspects and iterations of the present disclosure are detailed below. DETAILED DESCRIPTION OF THE INVENTION [0020] Modulators of POLRMT are useful in compositions and methods suitable for treating many disorders, such as cancer, neurodegenerative disorders, metabolic disorders, as well as diseases related to aging and mitochondrial diseases.
  • novel compositions their pharmaceutically acceptable salts, and pharmaceutical compositions thereof.
  • compounds of Formulae (I), (IIa), (IIa-2), (IIb-1), (IIb-2)a, (IIc), (IIc-1), (IIc-2a), (IIc-2b), (IId), (IIe), (IIf), (III), (IIIa), (IIIb), (IV), (IVa), (IVb), (Va), (Va-1), (Vb), and (Vb-1) pharmaceutically acceptable salts thereof, prodrugs thereof, and pharmaceutical compositions comprising such compounds, their salts, or their prodrugs that are useful as inhibitors of POLRMT.
  • alkyl refers to both branched- and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms in a specified range.
  • C 1 -C 6 alkyl means linear or branched chain alkyl groups, including all possible isomers, having 1, 2, 3, 4, 5, or 6 carbon atoms.
  • alkyl groups allow for substituents to be located on any of the carbon atoms.
  • a substituted C 3 alkyl group allows for the substituent to be located on any of the three carbon atoms.
  • alkoxy or “alkoxyl” as used herein refers to an -O-alkyl group.
  • C 1 -C 4 alkoxyl means -O- C 1 -C 4 alkyl.
  • alkoxyl include methoxyl, ethoxyl, propoxyl (e.g., n-propoxyl and isopropoxyl), and the like.
  • haloalkoxy or “haloalkoxyl” as used herein refers to an -O-alkyl group in which at least one of the hydrogen atoms of the alkyl group is replaced with a halogen atom.
  • haloalkoxyl examples include trifluoromethoxyl, 2,2,2-trifluoroethoxyl, and the like.0027
  • alkanoyl or “acyl” as used herein refers to an -C(O)-alkyl group.
  • C 1 -C 6 alkanoyl means -C(O)-C 1 -C 6 alkyl.
  • alkanoyl include acetyl, propionyl, butyryl, and the like.
  • bicyclic refers to a saturated or unsaturated 6- to 12- membered ring consisting of two joined cyclic substructures, and includes fused, bridged, and spiro bicyclic rings.
  • heterocyclic refers to a bicyclic ring that contains 1 or more heteroatom(s) in one or more rings that are optionally substituted or oxidized, and may be selected from nitrogen (including N-oxides), oxygen, sulfur (including oxidized forms such as sulfones and sulfonates), phosphorus (including oxidized forms such as phosphates), boron, etc.
  • heterobicyclic rings include, but are not limited to, 8-azabicyclo[3.2.1]octan-8- yl, 3-oxa-8-azabicyclo[3.2.1]octan-8-yl, 8-oxa-3- azabicyclo[3.2.1]octan-3-yl, and 5-methyl-2,5- diazabicyclo[2.2.1]heptan-2-yl.
  • cycloalkyl refers to a cyclized alkyl ring having the indicated number of carbon atoms in a specified range.
  • C 3 -C 6 cycloalkyl encompasses each of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • aryl refers to a monocyclic or fused bicyclic ring system having the characteristics of aromaticity, wherein at least one ring contains a completely conjugated pi-electron system.
  • aryl groups contain 6 to 14 carbon atoms (“C 6 - C 14 aryl”) or preferably, 6 to 12 carbon atoms (“C 6 -C 12 aryl”).
  • Fused aryl groups may include an aryl ring (e.g., a phenyl ring) fused to another aryl ring, or fused to a saturated or partially unsaturated carbocyclic or heterocyclic ring.
  • the point of attachment to the base molecule on such fused aryl ring systems may be a C atom of the aromatic portion or a C or N atom of the non-aromatic portion of the ring system.
  • Examples, without limitation, of aryl groups include phenyl, biphenyl, naphthyl, anthracenyl, indanyl, indenyl, and tetrahydronaphthyl.
  • cycloaryl herein refers to a polycyclic group wherein an aryl group is fused to a 5- or 6-membered aliphatic or heterocyclic ring.
  • C 6 -C 12 cycloaryl means a C 6 - C 12 aryl fused to a 5- or 6-membered aliphatic or heterocyclic ring.
  • C 6 cycloaryl is 2,3-dihydrobenzo[b][1,4]dioxine.
  • heteroaryl refers to (i) a 5- or 6-membered ring having the characteristics of aromaticity containing at least one heteroatom selected from N, O and S, wherein each N is optionally in the form of an oxide, and (ii) a 9- or 10- membered bicyclic fused ring system, wherein the fused ring system of (ii) contains at least one heteroatom independently selected from N, O and S, wherein each ring in the fused ring system contains zero, one or more than one heteroatoms, at least one ring is aromatic, each N is optionally in the form of an oxide, and each S in a ring which is not aromatic is optionally S(O) or S(O) 2 .
  • heteroaryl groups typically contain 5 to 14 ring atoms (“5-14 membered heteroaryl”), and preferably 5 to 12 ring atoms (“5-12 membered heteroaryl”).
  • Heteroaryl rings are attached to the base molecule via a ring atom of the heteroaromatic ring, such that aromaticity is maintained.
  • Suitable 5- and 6-membered heteroaromatic rings include, for example, pyridyl, 3-fluroropyridyl, 4-fluoropyridyl, 3- methoxypyridyl, 4-methoxypyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, thienyl, furanyl, imidazolyl, pyrazolyl, triazolyl (i.e., 1,2,3-triazolyl or 1,2,4- triazolyl), tetrazolyl, oxazolyl, isooxazolyl, oxadiazolyl (i.e., the 1,2,3-, 1,2,4-, 1,2,5- (furazanyl), or 1,3,4- isomer), oxatriazolyl, thiazolyl, isothiazolyl, and thiadiazolyl.
  • pyridyl
  • Suitable 9- and 10-membered heterobicyclic, fused ring systems include, for example, benzofuranyl, indolyl, indazolyl, naphthyridinyl, isobenzofuranyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, chromenyl, quinolinyl, isoquinolinyl, benzopiperidinyl, benzofuranyl, imidazo[1,2-a]pyridinyl, benzotriazolyl, indazolyl, indolinyl, and isoindolinyl.
  • heteroaryloxy refers to an -O- heteroaryl group.0035
  • heterocycle refers to a stable 3- to 10-membered monocyclic, non-aromatic ring that is either saturated or unsaturated, and that consists of carbon atoms and from one to two heteroatoms selected from the group consisting of N, O, and S.
  • Examples include oxiranyl, aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, 1,4-dioxanyl, morpholinyl, piperazinyl, azepanyl, oxepanyl, and oxazepanyl.
  • oxo refers to a group which consists of oxygen which is double bonded to carbon or any other element.
  • the term “imine” as used herein refers to a group containing a carbon-nitrogen double bond.
  • deuterium refers to an isotope of hydrogen that has one proton and one neutron in its nucleus and that has twice the mass of ordinary hydrogen. Deuterium herein is represented by the symbol “D”.
  • deuterated by itself or used to modify a compound or group as used herein refers to the presence of at least one deuterium atom attached to carbon.
  • deuterated compound refers to a compound which contains one or more carbon-bound deuterium(s).
  • a deuterated compound of the present invention when a particular position is designated as having deuterium, it is understood that the abundance of deuterium at that position is substantially greater than the natural abundance of deuterium, which is about 0.015 %.
  • the term “undeuterated” or “non-deuterated” as used herein refers to the ratio of deuterium atoms of which is not more than the natural isotopic deuterium content, which is about 0.015 %; in other words, all hydrogen are present at their natural isotopic percentages. Unless otherwise stated, when a position is designated specifically as “H” or “hydrogen”, the position is understood to have hydrogen at its natural abundance isotopic composition.
  • isotopic enrichment factor refers to the ratio between the isotope abundance and the natural abundance of a specified isotope.
  • isotopologue refers to a species in which the chemical structure differs from a specific compound of the invention only in the isotopic composition thereof.
  • substantially free of other stereoisomers means less than 10 % of other stereoisomers, preferably less than 5 % of other stereoisomers, more preferably less than 2 % of other stereoisomers and most preferably less than 1 % of other stereoisomers are present.
  • salt refers to a salt that is not biologically or otherwise undesirable (e.g., not toxic or otherwise harmful).
  • a salt of a compound of the invention is formed between an acid and a basic group of the compound, or a base and an acidic group of the compound.
  • the invention when the compounds of the invention contain at least one basic group (i.e., groups that may be protonated), the invention includes the compounds in the form of their acid addition salts with organic or inorganic acids such as, for example, but not limited to salts with hydrogen chloride, hydrogen bromide, phosphoric acid, sulfuric acid, nitric acid, benzenesulfonic acid, acetic acid, citric acid, glutamic acid, lactic acid, and methanesulfonic acid.
  • organic or inorganic acids such as, for example, but not limited to salts with hydrogen chloride, hydrogen bromide, phosphoric acid, sulfuric acid, nitric acid, benzenesulfonic acid, acetic acid, citric acid, glutamic acid, lactic acid, and methanesulfonic acid.
  • the invention when compounds of the invention contain one or more acidic groups (e.g., a carboxylic acid), the invention includes the pharmaceutically acceptable salts of the compounds formed with but not limited to
  • salts include, but are not limited to, sodium salts, potassium salts, calcium salts, magnesium salts or salts with ammonia or organic amines such as, for example, ethylamine, ethanolamine, triethanolamine or amino acids. Additional examples of such salts may be found in Stahl, P. H. et al. Pharmaceutical Salts: Properties, Selection, and Use, 2nd Revised Edition, Wiley, 2011. [0042]
  • the term “prodrug” as used herein refers to derivatives of compounds of the invention which may have reduced pharmacological activity, but can, when administered to a patient, be converted into the inventive compounds.
  • prodrugs Design and use of prodrugs may be found in “Pro- drugs as Novel Delivery Systems,” Vol.14, ACS Symposium Series (T Higuchi and W Stella) and “Bioreversible Carriers in Drug Design,” Pergamon Press, 1987 (ed. E B Roche, American Pharmaceutical Association), the disclosures of which are incorporated herein by reference in their entireties.
  • treatment include their generally accepted meanings, i.e., the management and care of a patient for the purpose of preventing, reducing the risk in incurring or developing a given condition or disease, prohibiting, restraining, alleviating, ameliorating, slowing, stopping, delaying, or reversing the progression or severity, and holding in check existing characteristics of a disease, disorder, or pathological condition, including the alleviation or relief of symptoms or complications, or the cure or elimination of the disease, disorder, or condition.
  • terapéuticaally effective amount refers to that amount of compound of the invention that will elicit the biological or medical response of a tissue, system, animal, or human that is being sought by a researcher, veterinarian, medical doctor or other.
  • a therapeutically effective amount of the compounds of the invention will vary and will depend on the diseases treated, the severity of the disease, the route of administration, and the gender, age, and general health condition of the subject to whom the compound is being administered.
  • the therapeutically effective amount may be administered as a single dose once a day, or as split doses administered multiple (e.g., two, three or four) times a day.
  • the therapeutically effective amount may also be administered through continuous dosing, such as through infusion or with an implant.
  • X 1 -X 5 are each independently a hydrogen, a halogen, a hydroxy, a cyano, a C 1 -C 6 alkyl, a substituted C 1 -C 6 alkyl, a C 3 -C 6 cycloalkyl, a substituted C 3 -C 6 cycloalkyl, a C 1 -C 6 alkoxy, optionally substituted with an aryl, a C 3 -C 10 cycloalkyl, -C(O)NH 2 , -C(O)NHY 1 , - C(O)NY 1 Y 2 , -COOH, -C(O)OY 1 , -Y 1 COOH, or -
  • X1-X5 may each independently be a hydrogen, a halogen, a hydroxy, a cyano, a C 1 -C 6 alkyl, a substituted C 1 -C 6 alkyl, a C 3 -C 6 cycloalkyl, a substituted C 3 -C 6 cycloalkyl, a C 1 -C 6 alkoxy, optionally substituted with an aryl, a C 3 -C 10 cycloalkyl, -C(O)NH 2 , -C(O)NHY 1 , - C(O)NY 1 Y 2 , -COOH, -C(O)OY 1 , -Y 1 COOH, or -Y 1 OY 2 , wherein Y 1 and Y 2 are each independently a C 1 -C 6 alkyl optionally substituted with one or more halogen or hydroxy.
  • R3 and R4 may optionally be interconnected to form a C 3 -C 6 cycloalkyl, a substituted C3-C6 cycloalkyl, 5-membered heterocyclic ring, a substituted 5-membered heterocyclic ring, a phenyl ring, or a substituted phenyl ring.
  • A1 and A2 are each independently be one or more members selected from the group consisting of halogen, ester, ether, carboxylic acid, -C(O)NH 2 , -CS(O) 2 Y 3 , a - CY 1 S(O) 2 Y 3 , wherein Y 3 may be independently a hydrogen or a C 1 -C 4 alkyl optionally substituted with one or more groups selected from the group consisting of a halogen, a hydroxyl, a C 1 -C 4 haloalkoxyl, and a C 1 -C 4 alkoxyl.
  • a 1 and A 2 may each independently be -C(O)NY 3 Y 4 , -CY1(O)NY 3 Y 4 , or - NY 3 Y 4 .
  • Y 3 is independently a hydrogen or a C 1 -C 4 alkyl optionally substituted with one or more groups selected from the group consisting of a halogen, a hydroxyl, a C 1 -C 4 haloalkoxyl, and a C 1 -C 4 alkoxyl.
  • Y 4 is independently Y 3 , cyano, C 3 -C 6 cycloheteroalkyl, C 1 -C 6 amide, C 1 -C 6 amine, C 1 -C 6 carboxyl, aryl, C 1 -C 6 alkyl optionally substituted with one or more halogen groups, 5- or 6-membered heterocyclyl, or C 3 -C 6 cycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 hydroxy, or -C(O)C 1 -C 4 alkyl optionally substituted with one or more halogen groups.
  • Y 3 and Y 4 are attached to the same nitrogen atom, Y 3 and Y 4 together with their connecting nitrogen form a 4- to 6-membered heterocyclic ring optionally containing one or more heteroatoms that is N, O, S, S(O), SO 2 , or S(O)NY 3 , and such heterocyclic ring is optionally substituted with one or more groups, each group independently selected from the group consisting of halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxyl, C 1 -C 4 haloalkoxyl, carboxyl, oxo, and C1-C4 ⁇ alkylcarboxylate.
  • X1-X5 may each independently be a hydrogen, a halogen, a hydroxy, a cyano, a C 1 -C 6 alkyl, a substituted C 1 -C 6 alkyl, a C 3 -C 6 cycloalkyl, a substituted C 3 -C 6 cycloalkyl, a C 1 -C 6 alkoxy, optionally substituted with an aryl, a C 3 -C 10 cycloalkyl, -C(O)NH 2 , -C(O)NHY 1 , - C(O)NY 1 Y 2 , -COOH, -C(O)OY 1 , -Y 1 COOH, or -Y 1 OY 2 , wherein
  • R 3 may be a halogen, a hydrogen, a C 1 -C 6 alkyl, a C 1 -C 6 alkyl substituted with one or more halogen, or a C 3 -C 6 cycloalkyl.
  • R4 may be a hydrogen, a C 1 -C 6 alkyl, or a C 1 -C 6 alkyl substituted with one or more halogen.
  • R 3 and R 4 may optionally be interconnected to form a C 3 -C 6 cycloalkyl, a substituted C 3 -C 6 cycloalkyl, 5-membered heterocyclic ring, a substituted 5-membered heterocyclic ring, 6-membered heterocyclic ring, a substituted 6-membered heterocyclic ring, a phenyl ring, or a substituted phenyl ring.
  • R 10 -R 15 may each independently be a hydrogen, an alkoxy, a halogen, a C 1 -C 6 alkyl, or a carboxylic acid.
  • X 1 may be a C 1 -C 6 alkyl or a halogen.
  • X 2 may be a hydrogen or a halogen.
  • X 3 may be a hydrogen, a halogen, or a C 1 -C 6 alkyl.
  • X 4 may be hydrogen.
  • X 5 may be a hydrogen or a C 1 -C 6 alkyl.
  • at least two of X 2 - X 5 are hydrogen.
  • at least three of X 2 - X 5 are hydrogen.
  • X 2 - X 5 may be hydrogen.
  • X 1 may be methyl or Cl.
  • X 2 may be Cl or hydrogen and X 3 may be methyl, F, Cl, or hydrogen.
  • R 3 may be a hydrogen, a methyl or -CHF 2 .
  • R 4 may be hydrogen.
  • R 10 -R 15 may each independently be a hydrogen, a methyl, a methoxy, a halogen, a carboxylic acid, or an amide.
  • R 3 may be -CHF 2 , methyl, or hydrogen, and R 4 is hydrogen.
  • the X 1 may be halogen or methyl and R 3 may be methyl, -CHF 2 , or - CF 3 .
  • the X 2 may be hydrogen or halogen and R 3 may be methyl, -CHF 2 , or -CF 3 .
  • the X 3 may be hydrogen or halogen and R 3 may be methyl, -CHF 2 , or -CF 3 .
  • X 1 -X 3 may each be independently hydrogen, halogen, or methyl, and R 3 may be methyl, -CHF 2 , or -CF 3 .
  • X 1 -X 3 may each be independently hydrogen, halogen, or methyl, and R 3 -R 4 are independently hydrogen, methyl, -CHF 2 , or -CF 3 .
  • at least one of R 10 -R 15 is carboxylic acid.
  • R 10 -R 11 is carboxylic acid
  • at least one of R 12 -R 13 is carboxylic acid
  • at least one of R 14 -R 15 is carboxylic acid.
  • R 12 -R 13 may each independently be hydrogen, fluorine, methyl, methoxy, or carboxylic acid.
  • R 10 -R 11 and R 14 -R 15 may be hydrogen and the compound may be represented by Formula (IIa-2): [0084] In some embodiments of Formula (IIa-2), X 1 -X 5 may each independently be hydrogen, halogen, or C 1 -C 6 alkyl.
  • R 3 may be halogen, hydrogen, C 1 -C 6 alkyl, substituted C 1 -C 6 alkyl, or C 3 -C 6 cycloalkyl.
  • R4 may be hydrogen, C 1 -C 6 alkyl, or substituted C 1 -C 6 alkyl.
  • R 12 and R 13 are each independently a C 1 -C 6 alkyl, a hydrogen, a halogen, a carboxylic acid, an alkoxy, or an amide.
  • X 1 may be methyl.
  • X 3 may be a halogen or a hydrogen.
  • X 2 , X 4 , and X 5 may be hydrogen.
  • R 3 may be hydrogen, C 1 -C 6 alkyl, or substituted C 1 -C 6 alkyl.
  • R 4 may be hydrogen.
  • R 12 and R 13 may each independently be hydrogen, carboxylic acid, alkoxy, or amide.
  • X 1 may be methyl
  • X 2 , X 4 , and X 5 are hydrogen
  • X 3 may be a halogen or a hydrogen
  • R 3 may be hydrogen, C 1 -C 6 alkyl, or substituted C 1 -C 6 alkyl
  • R 4 may be hydrogen
  • R 12 and R 13 may each independently be hydrogen, carboxylic acid, alkoxy, or amide.
  • R3 may be difluoromethyl.
  • R 10 may be carboxylic acid and R 11 may be hydrogen.
  • R 10 may be amide and R 11 may be hydrogen.
  • X 1 may be a halogen.
  • X 2 may be hydrogen or halogen.
  • X 3 may be methyl, halogen, or hydrogen.
  • X 4 and X 5 may be hydrogen
  • X 1 may be a halogen
  • X 2 is hydrogen or halogen
  • X 3 is methyl, halogen, or hydrogen
  • X 4 and X 5 are hydrogen
  • R 3 may be difluoromethyl
  • R 4 may be hydrogen
  • R 12 and R 13 are each independently hydrogen or carboxylic acid.
  • R 10 may be carboxylic acid and R 11 may be methoxy.
  • R 10 may be carboxylic acid and R 11 may be methyl.
  • C. Compounds with Formulae (IIb-1) & (IIb-2) [0107] The present disclosure is directed to a compound, or a pharmaceutically acceptable salt thereof, according to Formulae (IIb-1) & (IIb-2): Formula (IIb-1); or
  • X 1 -X 5 may each independently be a hydrogen, a halogen, a hydroxy, a cyano, a C 1 -C 6 alkyl, a substituted C 1 -C 6 alkyl, a C 3 -C 6 cycloalkyl, a substituted C 3 -C 6 cycloalkyl, a C 1 -C 6 alkoxy, optionally substituted with an aryl, a C 3 -C 10 cycloalkyl, -C(O)NH 2 , -C(O)NHY 1 , - C(O)NY 1 Y 2 , -COOH, -C(O)OY 1 , -Y 1 COOH, or -Y 1 OY 2 , wherein Y 1 and Y 2 are each independently a C 1 -C 6 alkyl optionally substituted with one or more halogen or hydroxy.
  • R 3 may be a halogen, a hydrogen, a C 1 -C 6 alkyl, a C 1 -C 6 alkyl substituted with one or more halogen, or a C 3 -C 6 cycloalkyl.
  • R4 may be a hydrogen, a C 1 -C 6 alkyl, or a C 1 -C 6 alkyl substituted with one or more halogen.
  • R3 and R4 may optionally be interconnected to form a C 3 -C 6 cycloalkyl, a substituted C 3 -C 6 cycloalkyl, 5-membered heterocyclic ring, a substituted 5-membered heterocyclic ring, 6-membered heterocyclic ring, a substituted 6-membered heterocyclic ring, a phenyl ring, or a substituted phenyl ring.
  • R 20 -R 29 may each independently be a hydrogen, a C 1 -C 6 alkyl, a carboxylic acid, an amide, a substituted amide, an alkoxy, or a halogen.
  • X 1 may be a C 1 -C 6 alkyl.
  • X 1 may be a methyl.
  • X 2 and X 4 may be hydrogen.
  • X 3 may be a hydrogen or halogen.
  • X 5 may be a hydrogen or a C 1 -C 6 alkyl.
  • at least two of X 2 - X 5 may be hydrogen.
  • at least three of X 2 - X 5 may be hydrogen.
  • X 2 -X 5 may be hydrogen.
  • R 3 may be a hydrogen, a methyl, or -CHF 2 .
  • R 4 may be hydrogen.
  • R 20 -R 29 are each independently a hydrogen, a C 1 -C 6 alkyl, an alkoxy, a halogen, a carboxylic acid, amide, or a substituted amide.
  • the substituted amide may be substituted with one or more C 1 -C 6 alkyl.
  • at least one of R20-R29 may be carboxylic acid, amide, or substituted amide.
  • At least one of R20-R21 may be carboxylic acid, amide, or substituted amide.
  • at least one of R22-R23 may be carboxylic acid, amide, or substituted amide.
  • at least one of R24-R25 may be carboxylic acid, amide, or substituted amide.
  • at least one of R26-R27 may be carboxylic acid, amide, or substituted amide.
  • at least one of R28-R29 may be carboxylic acid, amide, or substituted amide.
  • X1 may be halogen or methyl and R3 may be hydrogen, methyl, CHF 2 , or CF 3 .
  • X2 may be hydrogen or halogen and R3 may be hydrogen, methyl, CHF 2 , or CF 3 .
  • X3 may be hydrogen or halogen and R3 may be hydrogen, methyl, CHF 2 , or CF 3 .
  • X1-X3 may each independently be hydrogen, halogen, or methyl, and R 3 is H, methyl, CHF 2 , or CF 3 .
  • X 1 -X 3 may each independently be hydrogen, halogen, or methyl
  • X 4 - X 5 may each independently be hydrogen or halogen
  • R 3 -R 4 may independently be hydrogen, methyl, CHF 2 , or CF 3
  • X 1 -X 3 may each independently be hydrogen, fluorine, chlorine, bromine, or methyl
  • X 4 -X 5 are each independently hydrogen or halogen
  • R 3 -R 4 are independently hydrogen, methyl, CHF 2 , or CF 3 .
  • at least one of R 20 -R 29 may be carboxylic acid.
  • R 20 -R 23 may be carboxylic acid.
  • at least one of R 24 -R 25 may be carboxylic acid.
  • at least one of R 26 -R 29 may be carboxylic acid.
  • R 24 -R 25 may each independently be hydrogen, fluorine, methyl, methoxy, or carboxylic acid.
  • R 24 -R 25 may each independently be hydrogen or carboxylic acid.
  • wherein R 3 and R 4 may be interconnected to form a 5-membered cyclic ring.
  • R 3 and R 4 may be interconnected to form a phenyl ring.
  • D. Compounds with Formulas (IIc), (IIc-1), (IIc-2a), and (IIc-2b) [0145] The present disclosure is directed to a compound, or a pharmaceutically acceptable salt thereof, according to Formula (IIc): [0146]
  • X1-X5 may each independently be a hydrogen, a halogen, a hydroxy, a cyano, a C 1 -C 6 alkyl, a substituted C 1 -C 6 alkyl, a C 3 -C 6 cycloalkyl, a substituted C 3 -C 6 cycloalkyl, a C 1 -C 6 alkoxy, optionally substituted with an aryl, a C 3 -C 10 cycloalkyl, -C(O)NH 2 , -C(O)NHY 1 , - C(O)
  • Y 1 and Y 2 may each be independently a C 1 -C 6 alkyl optionally substituted with one or more halogen or hydroxy.
  • R 3 may be a halogen, a hydrogen, a C 1 -C 6 alkyl, a C 1 -C 6 alkyl substituted with one or more halogen, or a C 3 -C 6 cycloalkyl.
  • R4 may be a hydrogen, a C 1 -C 6 alkyl, or a C 1 -C 6 alkyl substituted with one or more halogen.
  • R 3 and R 4 may optionally be interconnected to form a C 3 -C 6 cycloalkyl, a substituted C 3 -C 6 cycloalkyl, 5-membered heterocyclic ring, a substituted 5-membered heterocyclic ring, 6-membered heterocyclic ring, a substituted 6-membered heterocyclic ring, a phenyl ring, or a substituted phenyl ring.
  • a 3 is a hydrogen, a C 1 -C 6 alkyl, a C 2 -C 6 branched alkyl, a C 1 -C 6 alkyl substituted with heterocyclyl, a C 1 -C 6 alkyl substituted with a substituted heterocyclyl, or a C 1 -C 6 alkyl substituted C 1 -C 6 alkoxy.
  • B is -C(O)OH, -C(O)NH 2 , C(O)NHY 3 , C(O)NY 3 Y 4 , -CS(O) 2 Y 3 , - Y 3 CS(O)2Y 3 , or absent.
  • Y 3 and Y 4 may each independently be a C1-C4 alkyl optionally substituted with one or more groups selected from the group consisting of a halogen, a hydroxyl, a C 1 -C 4 haloalkoxyl, and a C 1 -C 4 alkoxyl.
  • X1 is a hydrogen, a halogen, a cyano, a C 1 -C 6 alkyl, a substituted C 1 - C 6 alkyl, a C 3 -C 6 cycloalkyl, a substituted C 3 -C 6 cycloalkyl, a C 1 -C 6 alkoxy, a C 1 -C 6 cycloalkoxy, - COOH, -C(O)NH 2 , -C(O)NHY 1 , or -C(O)NY 1 Y 2 and Y 1 and Y 2 are methyl.
  • X1 is a C 1 -C 6 alkyl.
  • the C 1 -C 6 alkyl may be methyl or ethyl.
  • X1 is halogen.
  • the halogen may be fluorine, chlorine, or bromine.
  • the C 3 -C 6 cycloalkyl may be cyclopropyl
  • X1 may be -CH 2 OCH 3 , -CH 2 OH, or -CF 3 .
  • X1 may be -C(O)NH 2 , -C(O)NHCH 3 , or -C(O)NCH 3 CH 3 .
  • X2 and X3 may be a hydrogen, a halogen, or a C 1 -C 6 alkyl.
  • X4 may be a hydrogen, a halogen, a hydroxy, a methoxy, a C 1 -C 6 alkyl, or a substituted C 1 -C 6 alkyl.
  • the substituted C 1 -C 6 alkyl may be -CH 2 OH.
  • X5 may be a hydrogen, halogen, hydroxy, methoxy, a C 1 -C 6 alkyl, or a substituted C 1 -C 6 alkyl.
  • a 3 may be a C 1 -C 6 alkyl or substituted C 1 -C 6 alkyl and B is carboxylic acid.
  • a 3 may be methyl, ethyl, 1-methyl-methyl, dimethyl-methyl, methyl ethyl, dimethyl ethyl, or methyl-cyclopropyl.
  • the methyl may be connected to a thiazole via a carbon-carbon bond.
  • the methyl may also be connected to a phenyl or a cyclopropyl.
  • the substituted C 1 -C 6 alkyl may be substituted methyl, substituted ethyl, or substituted propyl.
  • the substituted methyl may be -C(H)(CH 3 ).
  • the substituted ethyl may be -CH 2 CH(OCH 3 ), -CH 2 CH(OH), - CH 2 C(CH 3 )H, or CH 2 C(CH 3 ) 2 .
  • X 1 may be C 1 -C 6 alkyl or halogen.
  • X 2 may be hydrogen or halogen.
  • X 3 may be hydrogen, C 1 -C 6 alkyl, or halogen.
  • X 4 may be hydrogen.
  • X 1 may be C 1 -C 6 alkyl or hydrogen.
  • R 3 may be C 1 -C 6 alkyl substituted with one or more halogen.
  • R3 may be -CHF 2 or -CF 3 .
  • R4 may be hydrogen.
  • X1-X5 may each independently be hydrogen, a halogen, or a C 1 -C 6 alkyl.
  • X3-X4 may each independently be hydrogen, methyl, cyclopropyl, - CHF 2 , or -CF 3 .
  • A3 may be substituted with at least one halogen, ester, ether, or carboxylic acid. [0173] In some examples, A3 may be substituted with at least one -C(O)NH 2 , -CS(O) 2 Y 3 , or - CY 1 S(O) 2 Y 3 . [0174] In some examples, B may be carboxylic acid, amide, methanesulfonamide, methoxy, substituted amide, amine, substituted amine, or substituted sulfoxide.
  • B may be amine or substituted amine with Formula (IIc-1): [0176] In some embodiments of Formula (IIc-1), X1 may be a C 1 -C 6 alkyl. [0177] In some embodiments of Formula (IIc-1), X2-X5 may be hydrogen. [0178] In some embodiments of Formula (IIc-1), R 3 may be -CHF 2 . [0179] In some embodiments of Formula (IIc-1), R 4 may be hydrogen. [0180] In some embodiments of Formula (IIc-1), A 3 may be a C 1 -C 6 alkyl.
  • B 3 and B 4 may each independently be hydrogen or a C 1 -C 6 alkyl.
  • X 1 is a C 1 -C 6 alkyl
  • X 2 -X 5 are hydrogen
  • R 3 is - CHF 2
  • R 4 is hydrogen
  • A3 is a C 1 -C 6 alkyl
  • B 3 and B 4 are each independently hydrogen or a C 1 -C 6 alkyl.
  • B may be amide or substituted amide with Formula (IIc-2a) or Formula (IIc-2b): Formula (IIc-2a); or
  • X 1 may be C 1 -C 6 alkyl or halogen.
  • X 2 -X 4 may be hydrogen or halogen.
  • X 5 may be hydrogen, halogen, or C 1 -C 6 alkyl.
  • R 3 may be -CHF 2 , -CF 3 or a C 3 - C 6 cycloalkyl.
  • R4 may be hydrogen.
  • A3 may be a C 1 -C 6 alkyl or branched C 1 -C 6 alkyl.
  • B3 and B4 may be each independently hydrogen, a C 1 -C 6 alkyl, a substituted a C 1 -C 6 alkyl, a C 3 -C 6 cycloalkyl, a substituted a C 3 -C 6 cycloalkyl, a C 3 -C 6 heterocyclyl, a substituted a C 3 -C 6 heterocyclyl, phenyl, substituted phenyl.
  • A3 may be ethyl and B may be methanesulfonamide [0197] In some embodiments of Formulae (IIc-2a) and (IIc-2b), A3 may be ethyl and B may be methoxy. [0198] In some embodiments of Formulae (IIc-2a) and (IIc-2b), A3 may be ethyl and B may be substituted sulfoxide. [0199] In some embodiments of Formulae (IIc-2a) and (IIc-2b), R3 may be -CHF 2 , halogen, cyclopropyl, or methyl.
  • X 1 -X 5 may each independently be a hydrogen, a halogen, a hydroxy, a cyano, a C 1 -C 6 alkyl, a substituted C 1 -C 6 alkyl, a C 3 -C 6 cycloalkyl, a substituted C 3 -C 6 cycloalkyl, a C 1 -C 6 alkoxy, optionally substituted with an aryl, a C 3 -C 10 cycloalkyl, -C(O)NH 2 , -C(O)NHY 1 , - C(O)NY 1 Y 2 , -COOH, -C(O)OY 1 , -Y 1 COOH, or -Y 1 OY 2 .
  • Y 1 and Y 2 may each be independently a C 1 -C 6 alkyl optionally substituted with one or more halogen or hydroxy.
  • R3 may be a halogen, a hydrogen, a C 1 -C 6 alkyl, a C 1 -C 6 alkyl substituted with one or more halogen, or a C 3 -C 6 cycloalkyl.
  • R4 may be a hydrogen, a C 1 -C 6 alkyl, or a C 1 -C 6 alkyl substituted with one or more halogen.
  • the C 1 -C 6 alkyl may be methyl.
  • R4 may be hydrogen.
  • R30-R34 may be hydrogen.
  • R30 may be methyl, methoxy, carboxylic acid, -C(O)OCH 3 , cyano, amide, or substituted amide.
  • R31 may be methyl, methoxy, carboxylic acid, -C(O)OCH 3 , cyano, amide, or substituted amide.
  • R32 may be methyl, methoxy, carboxylic acid, -C(O)OCH 3 , cyano, amide, or substituted amide.
  • R33 may be methyl, methoxy, carboxylic acid, -C(O)OCH 3 , cyano, amide, or substituted amide.
  • R34 may be methyl, methoxy, carboxylic acid, -C(O)OCH 3 , cyano, amide, or substituted amide.
  • at least two of R30-R34 may be hydrogen, -OCH 3 , -COOH, -C(O)NH 2 , -C(O)NHCH 3 , cyano, methyl, - C(O)OCH 3 , or fluorine.
  • At least one of R 30 -R 34 may be methyl.
  • at least two of R 30 -R 34 may be carboxylic acid, amide, ester, ether, cyano, or methyl. F.
  • X 1 -X 5 are each independently a hydrogen, a halogen, a hydroxy, a cyano, a C 1 -C 6 alkyl, a substituted C 1 -C 6 alkyl, a C 3 -C 6 cycloalkyl, a substituted C 3 -C 6 cycloalkyl, a C 1 -C 6 alkoxy, optionally substituted with an aryl, a C 3 -C 10 cycloalkyl, -C(O)NH 2 , -C(O)NHY 1 , - C(O)NY 1 Y 2 , -COOH, -C(O)OY 1 , -Y 1 COOH, or -Y 1 OY 2 ; Y 1 and Y 2 are each independently a C 1 -C 6
  • X 1 may be a C 1 -C 6 alkyl or a halogen. In some examples, X 1 may be methyl. In some examples, X 1 may be chlorine. [0234] In some embodiments, X 2 , X 4 , and X 5 may be hydrogen. [0235] In some embodiments, X 3 may be a hydrogen or halogen. [0236] In some embodiments, at least two of X 2 -X 5 may be hydrogen. [0237] In some embodiments, at least three of X 2 -X 5 may be hydrogen. [0238] In some embodiments, X2-X5 may be hydrogen.
  • R3 may be straight or branched C 1 -C 6 alkyl optionally substituted with one or more halogen.
  • the straight or branched C 1 -C 6 alkyl may be substituted with one or more fluorine.
  • R3 may be -CHF 2 or -CF 3 .
  • R4 may be hydrogen.
  • X1-X3 may each independently be hydrogen, fluorine, chlorine, bromine, or methyl
  • X4-X5 may each independently be hydrogen or halogen
  • R3-R4 may each independently be hydrogen, methyl, -CHF 2 , or -CF 3 .
  • X 1 -X 5 are each independently a hydrogen, a halogen, a hydroxy, a cyano, a C 1 -C 6 alkyl, a substituted C 1 -C 6 alkyl, a C 3 -C 6 cycloalkyl, a substituted C 3 -C 6 cycloalkyl, a C 1 -C 6 alkoxy, optionally substituted with an aryl, a C 3 -C 10 cycloalkyl, -C(O)NH 2 , -C(O)NHY 1 , - C(O)NY 1 Y 2 , -COOH, -C(O)OY 1 , -Y 1 COOH, or -Y 1 OY 2 ; Y 1 and Y 2 are each independently a C 1 -C 6 alkyl
  • X1 and X2 may be halogen.
  • the halogen may be fluorine or chlorine.
  • X2, X3, and X5 may be hydrogen.
  • at least two of X2-X5 may be hydrogen.
  • at least three of X2-X5 may be hydrogen.
  • at least one Y may be nitrogen.
  • R30-R34 may each independently be a hydrogen or absent.
  • R3 may be -CH(CH 3 ) 2 . H.
  • X1-X5 may each independently be a hydrogen, a halogen, a hydroxy, a cyano, a C 1 -C 6 alkyl, a substituted C 1 -C 6 alkyl, a C 3 -C 6 cycloalkyl, a substituted C 3 -C 6 cycloalkyl, a C 1 -C 6 alkoxy, optionally substituted with an aryl, a C 3 -C 10 cycloalkyl, -C(O)NH 2 , -C(O)NHY 1 , - C(O)NY 1 Y 2 , -COOH, -C(O)OY 1 , -Y 1 COOH, or -Y 1 OY 2 .
  • Y 1 and Y 2 may each be independently a C 1 -C 6 alkyl optionally substituted with one or more halogen or hydroxy.
  • R 3 may be a halogen, a hydrogen, a C 1 -C 6 alkyl, a C 1 -C 6 alkyl substituted with one or more halogen, or a C 3 -C 6 cycloalkyl.
  • R 4 may be a hydrogen, a C 1 -C 6 alkyl, or a C 1 -C 6 alkyl substituted with one or more halogen.
  • R 3 and R 4 may optionally be interconnected to form a C 3 -C 6 cycloalkyl, a substituted C 3 -C 6 cycloalkyl, 5-membered heterocyclic ring, a substituted 5-membered heterocyclic ring, 6-membered heterocyclic ring, a substituted 6-membered heterocyclic ring, a phenyl ring, or a substituted phenyl ring.
  • a 1 and A 2 may each independently be a hydrogen, a C 1- C 6 alkyl, a substituted C 1 -C 6 alkyl, an aryl, substituted aryl, a C 3 -C 6 cycloalkyl, a substituted C 3 -C 6 cycloalkyl, a C 3 -C 6 heterocyclyl, substituted C 3 -C 6 heterocyclyl, or absent.
  • a 1 and A 2 may optionally be substituted with one or more members selected from the group consisting of halogen, ester, ether, carboxylic acid, -C(O)NH 2 , -CS(O) 2 Y 3 , a -CY 1 S(O) 2 Y 3 .
  • Y 3 may independently be a hydrogen or a C 1 -C 4 alkyl optionally substituted with one or more groups selected from the group consisting of a halogen, a hydroxyl, a C 1 -C 4 haloalkoxyl, and a C 1 -C 4 alkoxyl.
  • the present disclosure is directed to a compound with any one or Formulae (IIIa), (IIIb), (IVa), and (IVb):
  • X 1 may be C 1 -C 6 alkyl.
  • X 2 , X 3 , and X 5 may be hydrogen.
  • X 4 may be hydrogen or fluorine.
  • a 1 and A 2 may each be independently a hydrogen, a C 1- C 6 alkyl, a substituted C 1 -C 6 alkyl, an aryl, substituted aryl, a C 3 -C 6 cycloalkyl, a substituted C 3 -C 6 cycloalkyl, a C 3 -C 6 heterocyclyl, or substituted C 3 -C 6 heterocyclyl.
  • a 1 and A 2 may optionally be substituted with one or more members selected from the group consisting of halogen, ester, ether, carboxylic acid, -C(O)NH 2 , -CS(O) 2 Y 3 , a -CY 1 S(O) 2 Y 3 .
  • R3 may be C 1 -C 6 alkyl substituted with one or more halogen.
  • R4 may be a hydrogen.
  • X1 may be methyl.
  • X4 may behydrogen or fluorine.
  • at least two of X2-X5 may be hydrogen.
  • At least three of X 2 -X 5 are hydrogen.
  • a 1 and A 2 may be substituted C 1 -C 6 alkyl.
  • a 1 and A 2 may be substituted ethyl. The ethyl may be substituted with carboxylic acid or amide.
  • a 1 and A 2 may be -CH(CH 3 )COOH.
  • a 1 and A 2 may be -CH 2 CH 3 COOH.
  • a 1 and A 2 may be -CH 2 CH 3 CONH 2 .
  • A1 and A2 may be substituted C 3 -C 6 cycloalkyl.
  • the substituted C 3 -C 6 cycloalkyl may be a cyclobutyl or cyclohexyl substituted with one or more carboxylic acid.
  • A1 and A2 may be substituted phenyl. The phenyl may be substituted with one or more carboxylic acid.
  • R3 may be -CHF 2 or -CF 3 .
  • X1-X5 may each independently be hydrogen, halogen, or methyl. I.
  • X 1 -X 5 are each independently a hydrogen, a halogen, a hydroxy, a cyano, a C 1 -C 6 alkyl, a substituted C 1 -C 6 alkyl, a C 3 -C 6 cycloalkyl, a substituted C 3 -C 6 cycloalkyl, a C 1 -C 6 alkoxy, optionally substituted with an aryl, a C 3 -C 10 cycloalkyl, -C(O)NH 2 , -C(O)NHY 1 , - C(O)NY 1 Y 2 , -COOH, -C(O)OY 1 , -Y 1 COOH, or -Y 1
  • a 1 -A 2 are independently hydrogen or methyl.
  • X 1 -X 5 may be independently hydrogen, halogen, or methyl.
  • R3-R4 may be independently hydrogen, -CHF 2 or -CF 3 .
  • A1 may be absent and the compound is with Formula (Va-1) or Formula (Vb-1):
  • X 1 is C 1 -C 6 alkyl
  • X 2 , X 3 , and X 5 are hydrogen
  • X 4 is hydrogen or halogen
  • A2 is C 1 -C 6 alkyl
  • R3 is hydrogen or C 1 -C 6 alkyl substituted with one or more halogen
  • R4 is hydrogen.
  • at least two of X2-X5 may be hydrogen.
  • at least three of X2-X5 may be hydrogen.
  • X2-X5 may be hydrogen.
  • the C 1 -C 6 alkyl may be methyl.
  • the C 1 -C 6 alkyl substituted with one or more halogen may be - CHF 2 or -CF 3 .
  • J. Compounds [0287] The disclosure is intended to encompass the compounds listed below and the non- stereochemistry and the alternative stereochemistry of the compounds listed below.
  • the compound is Compound 1, or a pharmaceutically acceptable salt thereof: [0289] In certain embodiments, the compound is Compound 2, or a pharmaceutically acceptable salt thereof: [0290] In certain embodiments, the compound is Compound 3, or a pharmaceutically acceptable salt thereof: [0291] In certain embodiments, the compound is Compound 4, or a pharmaceutically acceptable salt thereof: [0292] In certain embodiments, the compound is Compound 5, or a pharmaceutically acceptable salt thereof: [0293] In certain embodiments, the compound is Compound 6, or a pharmaceutically acceptable salt thereof: [0294] In certain embodiments, the compound is Compound 7, or a pharmaceutically acceptable salt thereof: [0295] In certain embodiments, the compound is Compound 8, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 9, or a pharmaceutically acceptable salt thereof: [0297] In certain embodiments, the compound is Compound 10, or a pharmaceutically acceptable salt thereof: [0298] In certain embodiments, the compound is Compound 11, or a pharmaceutically acceptable salt thereof: [0299] In certain embodiments, the compound is Compound 12, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 13, or a pharmaceutically acceptable salt thereof: [0301] In certain embodiments, the compound is Compound 14, or a pharmaceutically acceptable salt thereof: [0302] In certain embodiments, the compound is Compound 15, or a pharmaceutically acceptable salt thereof: [0303] In certain embodiments, the compound is Compound 16, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 17, or a pharmaceutically acceptable salt thereof: [0305] In certain embodiments, the compound is Compound 18, or a pharmaceutically acceptable salt thereof: [0306] In certain embodiments, the compound is Compound 19, or a pharmaceutically acceptable salt thereof: [0307] In certain embodiments, the compound is Compound 20, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 21, or a pharmaceutically acceptable salt thereof: [0309] In certain embodiments, the compound is Compound 22, or a pharmaceutically acceptable salt thereof: [0310] In certain embodiments, the compound is Compound 23 or a pharmaceutically acceptable salt thereof: [0311] In certain embodiments, the compound is Compound 24, or a pharmaceutically acceptable salt thereof: [0312] In certain embodiments, the compound is Compound 25, or a pharmaceutically acceptable salt thereof: [0313] In certain embodiments, the compound is Compound 26, or a pharmaceutically acceptable salt thereof: [0314] In certain embodiments, the compound is Compound 27, or a pharmaceutically acceptable salt thereof: [0315] In certain embodiments, the compound is Compound 28, or a pharmaceutically acceptable salt thereof: [0316] In certain embodiments, the compound is Compound 29, or a pharmaceutically acceptable salt thereof: [0317] In certain embodiments, the compound is Compound 30, or a pharmaceutically acceptable salt thereof: [0318] In certain embodiments, the compound is Compound 31,
  • the compound is Compound 32, or a pharmaceutically acceptable salt thereof: [0320] In certain embodiments, the compound is Compound 33, or a pharmaceutically acceptable salt thereof: [0321] In certain embodiments, the compound is Compound 34, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 332, or a pharmaceutically acceptable salt thereof: [0323] In one embodiment, the compound is Compound 333, or a pharmaceutically acceptable salt thereof: [0324] In one embodiment, the compound is Compound 348, or a pharmaceutically acceptable salt thereof: [0325] In one embodiment, the compound is Compound 349, or a pharmaceutically acceptable salt thereof: [0326] In one embodiment, the compound is Compound 358, or a pharmaceutically acceptable salt thereof: [0327] In one embodiment, the compound is Compound 359, or a pharmaceutically acceptable salt thereof: [0328] In one embodiment, the compound is Compound 368, or a pharmaceutically acceptable salt thereof: [0329] In one embodiment, the compound is Compound 369, or a pharmaceutically acceptable salt thereof: [0330] In certain embodiments, the compound is Compound 35, or a pharmaceutically acceptable salt thereof: [0331] In certain embodiments, the compound is Compound 36, or a pharmaceutically acceptable salt thereof: .
  • the compound is Compound 46, or a pharmaceutically acceptable salt thereof: [0342] In certain embodiments, the compound is Compound 47, or a pharmaceutically acceptable salt thereof: . [0343] In certain embodiments, the compound is Compound 48, or a pharmaceutically acceptable salt thereof: [0344] In certain embodiments, the compound is Compound 49, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 50, or a pharmaceutically acceptable salt thereof: [0346] In certain embodiments, the compound is Compound 51, or a pharmaceutically acceptable salt thereof: [0347] In certain embodiments, the compound is Compound 52, or a pharmaceutically acceptable salt thereof: [0348] In one embodiment, the compound is Compound 316, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 317, or a pharmaceutically acceptable salt thereof: [0350] In one embodiment, the compound is Compound 335, or a pharmaceutically acceptable salt thereof: [0351] In one embodiment, the compound is Compound 336, or a pharmaceutically acceptable salt thereof: [0352] In one embodiment, the compound is Compound 346, or a pharmaceutically acceptable salt thereof: [0353] In one embodiment, the compound is Compound 347, or a pharmaceutically acceptable salt thereof: [0354] In one embodiment, the compound is Compound 355, or a pharmaceutically acceptable salt thereof: [0355] In one embodiment, the compound is Compound 356, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 366, or a pharmaceutically acceptable salt thereof: [0357] In one embodiment, the compound is Compound 367, or a pharmaceutically acceptable salt thereof: [0358] In certain embodiments, the compound is Compound 53, or a pharmaceutically acceptable salt thereof: [0359] In certain embodiments, the compound is Compound 54, or a pharmaceutically acceptable salt thereof: [0360] In certain embodiments, the compound is Compound 55, or a pharmaceutically acceptable salt thereof: [0361] In certain embodiments, the compound is Compound 56, or a pharmaceutically acceptable salt thereof: [0362] In certain embodiments, the compound is Compound 57, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 58, or a pharmaceutically acceptable salt thereof: [0364] In certain embodiments, the compound is Compound 59, or a pharmaceutically acceptable salt thereof: [0365] In certain embodiments, the compound is Compound 60, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 61, or a pharmaceutically acceptable salt thereof: [0367] In certain embodiments, the compound is Compound 62, or a pharmaceutically acceptable salt thereof: [0368] In certain embodiments, the compound is Compound 63, or a pharmaceutically acceptable salt thereof: [0369] In certain embodiments, the compound is Compound 64, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 65, or a pharmaceutically acceptable salt thereof: [0371] In certain embodiments, the compound is, Compound 66, or a pharmaceutically acceptable salt thereof: [0372] In certain embodiments, the compound is, Compound 67, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 68, or a pharmaceutically acceptable salt thereof: [0374] In certain embodiments, the compound is Compound 69, or a pharmaceutically acceptable salt thereof: [0375] In certain embodiments, the compound is Compound 70, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 71, or a pharmaceutically acceptable salt thereof: .
  • the compound is Compound 72, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 73, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 74, or a pharmaceutically acceptable salt thereof: [0380] In certain embodiments, the compound is Compound 75, or a pharmaceutically acceptable salt thereof: [0381] In one embodiment, the compound is Compound 319, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 320, or a pharmaceutically acceptable salt thereof: [0383] In one embodiment, the compound is Compound 324, or a pharmaceutically acceptable salt thereof: [0384] In one embodiment, the compound is Compound 325, or a pharmaceutically acceptable salt thereof: [0385] In one embodiment, the compound is Compound 326, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 327, or a pharmaceutically acceptable salt thereof: [0387] In one embodiment, the compound is Compound 328, or a pharmaceutically acceptable salt thereof: [0388] In one embodiment, the compound is Compound 329, or a pharmaceutically acceptable salt thereof: [0389] In one embodiment, the compound is Compound 330, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 331, or a pharmaceutically acceptable salt thereof: [0391] In one embodiment, the compound is Compound 334, or a pharmaceutically acceptable salt thereof: [0392] In one embodiment, the compound is Compound 337, or a pharmaceutically acceptable salt thereof: [0393] In one embodiment, the compound is Compound 338, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 350, or a pharmaceutically acceptable salt thereof: [0395] In one embodiment, the compound is Compound 351, or a pharmaceutically acceptable salt thereof: [0396] In one embodiment, the compound is Compound 352, or a pharmaceutically acceptable salt thereof: [0397] In one embodiment, the compound is Compound 353, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 354, or a pharmaceutically acceptable salt thereof: [0399] In one embodiment, the compound is Compound 357, or a pharmaceutically acceptable salt thereof: [0400] In one embodiment, the compound is Compound 360, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 361, or a pharmaceutically acceptable salt thereof: [0402] In one embodiment, the compound is Compound 362, or a pharmaceutically acceptable salt thereof: [0403] In one embodiment, the compound is Compound 363, or a pharmaceutically acceptable salt thereof: [0404] In one embodiment, the compound is Compound 364, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 365, or a pharmaceutically acceptable salt thereof: [0406] In one embodiment, the compound is Compound 370, or a pharmaceutically acceptable salt thereof: [0407] In one embodiment, the compound is Compound 371, or a pharmaceutically acceptable salt thereof: [0408] In certain embodiments, the compound is Compound 76, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 77, or a pharmaceutically acceptable salt thereof: [0410] In certain embodiments, the compound is Compound 78, or a pharmaceutically acceptable salt thereof: [0411] In certain embodiments, the compound is Compound 79, or a pharmaceutically acceptable salt thereof: [0412] In certain embodiments, the compound is Compound 80, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 81, or a pharmaceutically acceptable salt thereof: [0414] In certain embodiments, the compound is Compound 82, or a pharmaceutically acceptable salt thereof: [0415] In certain embodiments, the compound is Compound 83, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 84, or a pharmaceutically acceptable salt thereof: [0417] In certain embodiments, the compound is Compound 85, or a pharmaceutically acceptable salt thereof: [0418] In certain embodiments, the compound is Compound 86, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 87, or a pharmaceutically acceptable salt thereof: [0420] In certain embodiments, the compound is Compound 88, or a pharmaceutically acceptable salt thereof: [0421] In certain embodiments, the compound is Compound 89, or a pharmaceutically acceptable salt thereof: [0422] In certain embodiments, the compound is Compound 90, or a pharmaceutically acceptable salt thereof: [0423] In certain embodiments, the compound is Compound 91, or a pharmaceutically acceptable salt thereof: [0424] In certain embodiments, the compound is Compound 92, or a pharmaceutically acceptable salt thereof: [0425] In certain embodiments, the compound is Compound 93, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 94, or a pharmaceutically acceptable salt thereof: [0427] In certain embodiments, the compound is Compound 95, or a pharmaceutically acceptable salt thereof: [0428] In certain embodiments, the compound is Compound 96, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 97, or a pharmaceutically acceptable salt thereof: [0430] In certain embodiments, the compound is Compound 98, or a pharmaceutically acceptable salt thereof: [0431] In certain embodiments, the compound is Compound 99, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 100, or a pharmaceutically acceptable salt thereof: [0433] In certain embodiments, the compound is Compound 101, or a pharmaceutically acceptable salt thereof: [0434] In certain embodiments, the compound is Compound 102, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 103, or a pharmaceutically acceptable salt thereof: [0436] In certain embodiments, the compound is Compound 104, or a pharmaceutically acceptable salt thereof: [0437] In certain embodiments, the compound is Compound 105, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 106, or a pharmaceutically acceptable salt thereof: [0439] In certain embodiments, the compound is Compound 107, or a pharmaceutically acceptable salt thereof: [0440] In certain embodiments, the compound is Compound 108, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 109, or a pharmaceutically acceptable salt thereof: [0442] In certain embodiments, the compound is Compound 110, or a pharmaceutically acceptable salt thereof: [0443] In certain embodiments, the compound is Compound 111, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 112, or a pharmaceutically acceptable salt thereof: [0445] In certain embodiments, the compound is Compound 113, or a pharmaceutically acceptable salt thereof: [0446] In certain embodiments, the compound is Compound 114, or a pharmaceutically acceptable salt thereof: [0447] In certain embodiments, the compound is Compound 115, or a pharmaceutically acceptable salt thereof: . [0448] In certain embodiments, the compound is Compound 116, or a pharmaceutically acceptable salt thereof: [0449] In certain embodiments, the compound is Compound 117, or a pharmaceutically acceptable salt thereof: [0450] In certain embodiments, the compound is Compound 118, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 119, or a pharmaceutically acceptable salt thereof: [0452] In certain embodiments, the compound is Compound 120, or a pharmaceutically acceptable salt thereof: [0453] In certain embodiments, the compound is Compound 121, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 122, or a pharmaceutically acceptable salt thereof: [0455] In certain embodiments, the compound is Compound 123, or a pharmaceutically acceptable salt thereof: [0456] In certain embodiments, the compound is Compound 124, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 125, or a pharmaceutically acceptable salt thereof: [0458] In certain embodiments, the compound is Compound 126, or a pharmaceutically acceptable salt thereof: [0459] In certain embodiments, the compound is Compound 127, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 128, or a pharmaceutically acceptable salt thereof: [0461] In certain embodiments, the compound is Compound 129, or a pharmaceutically acceptable salt thereof: [0462] In certain embodiments, the compound is Compound 130, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 131, or a pharmaceutically acceptable salt thereof: [0464] In certain embodiments, the compound is Compound 132, or a pharmaceutically acceptable salt thereof: [0465] In certain embodiments, the compound is Compound 133, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 134, or a pharmaceutically acceptable salt thereof: [0467] In certain embodiments, the compound is Compound 135, or a pharmaceutically acceptable salt thereof: [0468] In certain embodiments, the compound is Compound 136, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 137, or a pharmaceutically acceptable salt thereof: [0470] In certain embodiments, the compound is Compound 138, or a pharmaceutically acceptable salt thereof: [0471] In certain embodiments, the compound is Compound 139, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 140, or a pharmaceutically acceptable salt thereof: [0473] In certain embodiments, the compound is Compound 141, or a pharmaceutically acceptable salt thereof: [0474] In certain embodiments, the compound is Compound 142, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 146, or a pharmaceutically acceptable salt thereof: [0479] In certain embodiments, the compound is Compound 147, or a pharmaceutically acceptable salt thereof: [0480] In certain embodiments, the compound is Compound 148, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 149, or a pharmaceutically acceptable salt thereof: [0482] In certain embodiments, the compound is Compound 150, or a pharmaceutically acceptable salt thereof: [0483] In certain embodiments, the compound is Compound 151, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 152, or a pharmaceutically acceptable salt thereof: .
  • the compound is Compound 153, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 154, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 155, or a pharmaceutically acceptable salt thereof: [0488] In certain embodiments, the compound is Compound 156, or a pharmaceutically acceptable salt thereof: [0489] In certain embodiments, the compound is Compound 157, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 158, or a pharmaceutically acceptable salt thereof: [0491] In certain embodiments, the compound is Compound 159, or a pharmaceutically acceptable salt thereof: [0492] In certain embodiments, the compound is Compound 160, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 161, or a pharmaceutically acceptable salt thereof: [0494] In one embodiment, the compound is Compound 162, or a pharmaceutically acceptable salt thereof: [0495] In one embodiment, the compound is Compound 163, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 164, or a pharmaceutically acceptable salt thereof: [0497] In one embodiment, the compound is Compound 165, or a pharmaceutically acceptable salt thereof: [0498] In one embodiment, the compound is Compound 166, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 167, or a pharmaceutically acceptable salt thereof: [0500] In one embodiment, the compound is Compound 168, or a pharmaceutically acceptable salt thereof: [0501] In one embodiment, the compound is Compound 169, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 170, or a pharmaceutically acceptable salt thereof. [0503] In one embodiment, the compound is Compound 171, or a pharmaceutically acceptable salt thereof: [0504] In one embodiment, the compound is Compound 172, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 173, or a pharmaceutically acceptable salt thereof: [0506] In one embodiment, the compound is Compound 174, or a pharmaceutically acceptable salt thereof: [0507] In one embodiment, the compound is Compound 175, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 176, or a pharmaceutically acceptable salt thereof: [0509] In one embodiment, the compound is Compound 177, or a pharmaceutically acceptable salt thereof: [0510] In one embodiment, the compound is Compound 178, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 179, or a pharmaceutically acceptable salt thereof: [0512] In one embodiment, the compound is Compound 180, or a pharmaceutically acceptable salt thereof: [0513] In one embodiment, the compound is Compound 181, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 182, or a pharmaceutically acceptable salt thereof: [0515] In one embodiment, the compound is Compound 183, or a pharmaceutically acceptable salt thereof: [0516] In one embodiment, the compound is Compound 184, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 185, or a pharmaceutically acceptable salt thereof: [0518] In one embodiment, the compound is Compound 186, or a pharmaceutically acceptable salt thereof: [0519] In one embodiment, the compound is Compound 187, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 188, or a pharmaceutically acceptable salt thereof: [0521] In one embodiment, the compound is Compound 189, or a pharmaceutically acceptable salt thereof: [0522] In one embodiment, the compound is Compound 190, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 191, or a pharmaceutically acceptable salt thereof: [0524] In one embodiment, the compound is Compound 192, or a pharmaceutically acceptable salt thereof: [0525] In one embodiment, the compound is Compound 193, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 194, or a pharmaceutically acceptable salt thereof: [0527] In one embodiment, the compound is Compound 195, or a pharmaceutically acceptable salt thereof: [0528] In one embodiment, the compound is Compound 196, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 197, or a pharmaceutically acceptable salt thereof: [0530] In one embodiment, the compound is Compound 198, or a pharmaceutically acceptable salt thereof: [0531] In one embodiment, the compound is Compound 199, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 200, or a pharmaceutically acceptable salt thereof: [0533] In one embodiment, the compound is Compound 201, or a pharmaceutically acceptable salt thereof: [0534] In one embodiment, the compound is Compound 202, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 203, or a pharmaceutically acceptable salt thereof: [0536] In one embodiment, the compound is Compound 204, or a pharmaceutically acceptable salt thereof: [0537] In one embodiment, the compound is Compound 205, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 206, or a pharmaceutically acceptable salt thereof: [0539] In one embodiment, the compound is Compound 207, or a pharmaceutically acceptable salt thereof: [0540] In one embodiment, the compound is Compound 208, or a pharmaceutically acceptable salt thereof: [0541] In one embodiment, the compound is Compound 209, or a pharmaceutically acceptable salt thereof: [0542] In one embodiment, the compound is Compound 210, or a pharmaceutically acceptable salt thereof: [0543] In one embodiment, the compound is Compound 211, or a pharmaceutically acceptable salt thereof: [0544] In one embodiment, the compound is Compound 212, or a pharmaceutically acceptable salt thereof: [0545] In one embodiment, the compound is Compound 213, or a pharmaceutically acceptable salt thereof: [0546] In one embodiment, the compound is Compound 214, or a pharmaceutically acceptable salt thereof: [0547] In one embodiment, the compound is Compound 215, or a pharmaceutically acceptable salt thereof: [0548] In one embodiment,
  • the compound is Compound 218, or a pharmaceutically acceptable salt thereof: [0551] In one embodiment, the compound is Compound 219, or a pharmaceutically acceptable salt thereof: [0552] In one embodiment, the compound is Compound 220, or a pharmaceutically acceptable salt thereof: [0553] In one embodiment, the compound is Compound 221, or a pharmaceutically acceptable salt thereof: [0554] In one embodiment, the compound is Compound 222, or a pharmaceutically acceptable salt thereof: [0555] In one embodiment, the compound is Compound 223, or a pharmaceutically acceptable salt thereof: [0556] In one embodiment, the compound is Compound 224, or a pharmaceutically acceptable salt thereof: [0557] In one embodiment, the compound is Compound 225, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 226, or a pharmaceutically acceptable salt thereof: [0559] In one embodiment, the compound is Compound 227, or a pharmaceutically acceptable salt thereof: [0560] In one embodiment, the compound is Compound 228, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 229, or a pharmaceutically acceptable salt thereof: [0562] In one embodiment, the compound is Compound 230, or a pharmaceutically acceptable salt thereof: [0563] In one embodiment, the compound is Compound 231, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 232, or a pharmaceutically acceptable salt thereof: [0565] In one embodiment, the compound is Compound 233, or a pharmaceutically acceptable salt thereof: [0566] In one embodiment, the compound is Compound 234, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 235, or a pharmaceutically acceptable salt thereof: [0568] In one embodiment, the compound is Compound 236, or a pharmaceutically acceptable salt thereof: [0569] In one embodiment, the compound is Compound 237, or a pharmaceutically acceptable salt thereof: [0570] In one embodiment, the compound is Compound 238, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 239, or a pharmaceutically acceptable salt thereof: [0572] In one embodiment, the compound is Compound 240, or a pharmaceutically acceptable salt thereof: [0573] In one embodiment, the compound is Compound 241, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 242, or a pharmaceutically acceptable salt thereof: [0575] In one embodiment, the compound is Compound 243, or a pharmaceutically acceptable salt thereof: [0576] In one embodiment, the compound is Compound 244, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 248, or a pharmaceutically acceptable salt thereof: [0581] In one embodiment, the compound is Compound 249, or a pharmaceutically acceptable salt thereof: [0582] In one embodiment, the compound is Compound 250, or a pharmaceutically acceptable salt thereof: [0583] In one embodiment, the compound is Compound 251, or a pharmaceutically acceptable salt thereof: [0584] In one embodiment, the compound is Compound 252, or a pharmaceutically acceptable salt thereof: [0585] In one embodiment, the compound is Compound 253, or a pharmaceutically acceptable salt thereof: [0586] In one embodiment, the compound is Compound 254, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 255, or a pharmaceutically acceptable salt thereof: [0588] In one embodiment, the compound is Compound 256, or a pharmaceutically acceptable salt thereof: [0589] In one embodiment, the compound is Compound 257, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 258, or a pharmaceutically acceptable salt thereof: [0591] In one embodiment, the compound is Compound 259, or a pharmaceutically acceptable salt thereof: [0592] In one embodiment, the compound is Compound 260, or a pharmaceutically acceptable salt thereof: [0593] In one embodiment, the compound is Compound 261, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 262, or a pharmaceutically acceptable salt thereof: [0595] In one embodiment, the compound is Compound 263, or a pharmaceutically acceptable salt thereof: [0596] In one embodiment, the compound is Compound 264, or a pharmaceutically acceptable salt thereof: [0597] In one embodiment, the compound is Compound 265, or a pharmaceutically acceptable salt thereof: [0598] In one embodiment, the compound is Compound 266, or a pharmaceutically acceptable salt thereof: [0599] In one embodiment, the compound is Compound 267, or a pharmaceutically acceptable salt thereof: [0600] In one embodiment, the compound is Compound 268, or a pharmaceutically acceptable salt thereof: [0601] In one embodiment, the compound is Compound 269, or a pharmaceutically acceptable salt thereof: [0602] In one embodiment, the compound is Compound 270, or a pharmaceutically acceptable salt thereof: [0603] In one embodiment, the compound is Compound 271, or a pharmaceutically acceptable salt thereof: [0604] In one embodiment, the compound is
  • the compound is Compound 286, or a pharmaceutically acceptable salt thereof: [0619] In one embodiment, the compound is Compound 287, or a pharmaceutically acceptable salt thereof: [0620] In one embodiment, the compound is Compound 288, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 289, or a pharmaceutically acceptable salt thereof: [0622] In one embodiment, the compound is Compound 290, or a pharmaceutically acceptable salt thereof: [0623] In one embodiment, the compound is Compound 291, or a pharmaceutically acceptable salt thereof: [0624] In one embodiment, the compound is Compound 292, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 293, or a pharmaceutically acceptable salt thereof: [0626] In one embodiment, the compound is Compound 294, or a pharmaceutically acceptable salt thereof: [0627] In one embodiment, the compound is Compound 295, or a pharmaceutically acceptable salt thereof: [0628] In one embodiment, the compound is Compound 296, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 297, or a pharmaceutically acceptable salt thereof: [0630] In one embodiment, the compound is Compound 298, or a pharmaceutically acceptable salt thereof: [0631] In one embodiment, the compound is Compound 299, or a pharmaceutically acceptable salt thereof: [0632] In one embodiment, the compound is Compound 300, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 301, or a pharmaceutically acceptable salt thereof: [0634] In one embodiment, the compound is Compound 302, or a pharmaceutically acceptable salt thereof: [0635] In one embodiment, the compound is Compound 303, or a pharmaceutically acceptable salt thereof: [0636] In one embodiment, the compound is Compound 304, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 305, or a pharmaceutically acceptable salt thereof: [0638] In one embodiment, the compound is Compound 306, or a pharmaceutically acceptable salt thereof: [0639] In one embodiment, the compound is Compound 307, or a pharmaceutically acceptable salt thereof: [0640] In one embodiment, the compound is Compound 308, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 309, or a pharmaceutically acceptable salt thereof: [0642] In one embodiment, the compound is Compound 310, or a pharmaceutically acceptable salt thereof: [0643] In one embodiment, the compound is Compound 311, or a pharmaceutically acceptable salt thereof: [0644] In one embodiment, the compound is Compound 312, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 313, or a pharmaceutically acceptable salt thereof: [0646] In one embodiment, the compound is Compound 314, or a pharmaceutically acceptable salt thereof: [0647] In one embodiment, the compound is Compound 315, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 318, or a pharmaceutically acceptable salt thereof: [0649] In one embodiment, the compound is Compound 321, or a pharmaceutically acceptable salt thereof: [0650] In one embodiment, the compound is Compound 322, or a pharmaceutically acceptable salt thereof: [0651] In one embodiment, the compound is Compound 323, or a pharmaceutically acceptable salt thereof: [0652] In one embodiment, the compound is Compound 339, or a pharmaceutically acceptable salt thereof: [0653] In one embodiment, the compound is Compound 340, or a pharmaceutically acceptable salt thereof: [0654] In one embodiment, the compound is Compound 341, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 342, or a pharmaceutically acceptable salt thereof: [0656] In one embodiment, the compound is Compound 343, or a pharmaceutically acceptable salt thereof: [0657] In one embodiment, the compound is Compound 344, or a pharmaceutically acceptable salt thereof: [0658] In one embodiment, the compound is Compound 345, or a pharmaceutically acceptable salt thereof:
  • the compound is Compound 372, or a pharmaceutically acceptable salt thereof: [0660] In one embodiment, the compound is Compound 373, or a pharmaceutically acceptable salt thereof: [0661] In one embodiment, the compound is Compound 374, or a pharmaceutically acceptable salt thereof: [0662] In one embodiment, the compound is Compound 375, or a pharmaceutically acceptable salt thereof:
  • the compounds inhibits POLRMT.
  • the compounds promote POLRMT.
  • the compounds of the present invention may contain asymmetric carbon atoms (sometimes as the result of a deuterium atom) and thereby may exist as either individual stereoisomers or mixtures of the enantiomers or mixtures of diastereomers. Accordingly, a compound of the present invention may exist as either a racemic mixture, a mixture of diastereomers, or as individual stereoisomers that are substantially free of other stereoisomers. Synthetic, separation, or purification methods to be used to obtain an enantiomer of a given compound are known in the art and are applicable for obtaining the compounds identified herein.
  • the compounds of the present invention may contain double bonds that may exist in more than one geometric isomer. Examples of such double bonds are carbon- carbon double bonds which form alkenes. In the case of carbon-carbon double bonds, the geometric isomers may be E or Z isomers.
  • Compounds of the present invention may exist in amorphous form and/or one or more crystalline forms. As such all amorphous and crystalline forms and mixtures thereof of the compounds of the invention are intended to be included within the scope of the present invention.
  • some of the compounds of the present invention may form solvates with water (i.e., a hydrate) or common organic solvents.
  • Such solvates and hydrates, particularly the pharmaceutically acceptable solvates and hydrates, of the compounds of this invention are likewise encompassed within the scope of the compounds of the invention and the pharmaceutically acceptable salts thereof, along with un-solvated and anhydrous forms of such compounds.
  • deuterium isotope content at the deuterium substituted position is greater than the natural isotopic deuterium content (0.015%), more preferably greater than 50%, more preferably greater than 60%, more preferably greater than 75%, more preferably greater than 90%, more preferably greater than 95%, more preferably greater than 97%, more preferably greater than 99%. It will be understood that some variation of natural isotopic abundance may occur in any compound depending upon the source of the reagents used in the synthesis. Thus, a preparation of undeuterated compounds may inherently contain small amounts of deuterated isotopologues, such amounts being insignificant as compared to the degree of stable isotopic substitution of the deuterated compounds of the invention.
  • deuterium may affect how a molecule interacts with enzymes, thereby impacting enzyme kinetics. While in certain cases the increased mass of deuterium as compared to hydrogen may stabilize a compound and thereby improve activity, toxicity, or half-life, such impact is not predictable. In other instances deuteration may have little to no impact on these properties, or may affect them in an undesirable manner. Whether and/or how such replacement will impact drug properties may only be determined if the drug is synthesized, evaluated, and compared to its non-deuterated counterpart. Because some drugs have multiple sites of metabolism or more than one active sites for binding to a target, it is unpredictable as to which sites may benefit by deuterium replacement or to what extent isotope enrichment is necessary to produce a beneficial effect.
  • reaction temperature varies depending on the reagents and solvents to be used, unless otherwise specified, it is generally -78 °C to 300 °C, preferably -78 °C to 150 °C.
  • a reagent is used in 0.5 equivalent to 20 equivalents, preferably 0.8 equivalent to 5 equivalents, relative to the substrate.
  • the reagent is used in 0.001 equivalent to 1 equivalent, preferably 0.01 equivalent to 0.2 equivalent, relative to the substrate.
  • the reagent is also a reaction solvent, the reagent is used in a solvent amount.
  • the reaction of each step is performed without solvent or by dissolving or suspending in a suitable solvent.
  • the solvent include the following. Alcohols: methanol, ethanol, tert-butyl alcohol, 2- methoxyethanol and the like; ethers: diethyl ether, diphenyl ether, tetrahydrofuran, 1,2- dimethoxyethane and the like; aromatic hydrocarbons: chlorobenzene, toluene, xylene and the like; saturated hydrocarbons: cyclohexane, hexane and the like; amides: N,N- dimethylformamide, N-methylpyrrolidone and the like; halogenated hydrocarbons: dichloromethane, carbon tetrachloride and the like; nitriles: acetonitrile and the like; sulfoxides: dimethyl sulfoxide and the like; aromatic organic bases: pyridine and the like; acid
  • reaction of each step is performed according to a known method, for example, the methods described in “Reactions and Syntheses: In the Organic Chemistry Laboratory 2nd Edition” (Lutz F. Tietze, Theophil Eicher, Ulf Diederichsen, Andreas Speicher, Nina Schützenmeister) Wiley, 2015; “Organic Syntheses Collective Volumes 1 – 12” (John Wiley & Sons Inc); “Comprehensive Organic Transformations, Third Edition” (Richard C. Larock) Wiley, 2018 and the like.
  • Deuterated POLRMT modulators of the present invention may be prepared using chemical reactions known to a person of ordinary skill in the art using deuterated starting materials or reagents. Deuterium-containing reagents are well known in the art and may be prepared using known procedures or purchased from commercial sources.
  • the deuterated compounds obtained may be characterized by analytical techniques known to persons of ordinary skill in the art. For example, nuclear magnetic resonance (“NMR”) may be used to determine a compound’s structure while mass spectroscopy (“MS”) may be used to determine the amount of deuterium atom in the compound by comparison to its non-deuterated form.
  • NMR nuclear magnetic resonance
  • MS mass spectroscopy
  • Compositions [0680] The present invention further includes pharmaceutical compositions of the compounds or a pharmaceutically acceptable salt of said compounds.
  • the pharmaceutical compositions comprise one or more pharmaceutically acceptable excipients, such excipients being compatible with other ingredients in the composition and also being not toxic or otherwise harmful.
  • excipients include carriers, lubricants, binders, disintegrants, solvents, solubilizing agents, suspending agents, isotonic agents, buffers, soothing agents, preservatives, antioxidants, colorants, taste-modifying agents, absorbents, and/or wetting agents.
  • excipients include carriers, lubricants, binders, disintegrants, solvents, solubilizing agents, suspending agents, isotonic agents, buffers, soothing agents, preservatives, antioxidants, colorants, taste-modifying agents, absorbents, and/or wetting agents.
  • the pharmaceutical compositions of the invention include those suitable for oral, rectal, nasal, topical, buccal, sublingual, vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration. Such compositions may be prepared by any methods well known in the art of pharmaceutical formulations and pharmacy. See, e.g., Remington: The Science and Practice of Pharmacy, Elsevier Science, 23rd ed. (
  • Formulations for parenteral administration include sterile aqueous or non- aqueous solutions, suspensions, or emulsions.
  • aqueous carriers may be used, e.g., water, buffered water, saline, and the like.
  • suitable vehicles include polypropylene glycol, polyethylene glycol, vegetable oils, hydrogels, gelatin, hydrogenated naphthalenes, and injectable organic esters, such as ethyl oleate.
  • Such formulations may also contain auxiliary substances, such as preserving, wetting, buffering, emulsifying, and/or dispersing agents.
  • compositions intended for oral use may be prepared in solid or liquid forms, according to any method known to a person of ordinary skill in the art for the manufacture of pharmaceutical compositions.
  • Solid dosage forms for oral administration include capsules (both soft and hard gelatin capsules), tablets, powders, and granules. Generally, these pharmaceutical preparations contain active ingredients admixed with pharmaceutically acceptable excipients.
  • excipients include, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, sucrose, glucose, mannitol, cellulose, starch, calcium phosphate, sodium phosphate, kaolin and the like; binding agents, buffering agents, and/or lubricating agents (e.g., magnesium stearate) may also be used. Tablets and capsules may additionally be prepared with release-controlling coatings such as enteric coatings. The compositions may optionally contain sweetening, flavoring, coloring, perfuming, and preserving agents in order to provide a more palatable preparation. [0683] In another embodiment, a pharmaceutical composition of this invention further comprises a second therapeutic agent.
  • inert diluents such as calcium carbonate, sodium carbonate, lactose, sucrose, glucose, mannitol, cellulose, starch, calcium phosphate, sodium phosphate, kaolin and the like
  • binding agents e.g., magnesium
  • the second therapeutic agent may be selected from any pharmaceutically active compound; preferably the second therapeutic agent is known to correct mitochondrial dysfunction.
  • the compounds of the invention and second therapeutic agent may be administered together (within less than 24 hours of one another, consecutively or simultaneously) but in separate pharmaceutical compositions.
  • the compounds on the invention and second therapeutic agent may be administered separately (e.g., more than 24 hours of one another.) If the second therapeutic agent acts synergistically with the compounds of this invention, the therapeutically effective amount of such compounds and/or the second therapeutic agent may be less that such amount required when either is administered alone.
  • the compounds described herein may be administered in combination with a chemotherapeutic agent.
  • chemotherapeutic agents include, but are not limited to, Abitrexate (Methotrexate Injection), Abraxane (Paclitaxel Injection), Actemra (Tocilizumab), Adcetris (Brentuximab Vedotin Injection), Adriamycin (Doxorubicin), Adrucil Injection (5-FU (fluorouracil)), Afinitor (Everolimus), Afinitor Disperz (Everolimus), Aldara (Imiquimod), Alimta (PEMET EXED), Alkeran Injection (Melphalan Injection), Alkeran Tablets (Melphalan), Aredia (Pamidronate), Arimidex (Anastrozole), Aromasin (Exemestane), Arran
  • Acceptable 1 H NMR shifts and masses are within 5% of the reported values (i.e., all reported measurement values herein also include ⁇ 5%, ⁇ 4%, ⁇ 3%, ⁇ 2%, and/or ⁇ 1%). All reported LCMS values herein also include ⁇ 5%, ⁇ 4%, ⁇ 3%, ⁇ 2%, and/or ⁇ 1%. [0687] The abbreviations used herein are known to a person of ordinary skill in the art.
  • a partial list of abbreviations that may be used herein include: acetonitrile (MeCN), ammonium carbonate (NH4)2CO3, ammonium chloride (NH4Cl), aqueous (aq.), 1,1’- bis(diphenylphosphino)ferrocene (dppf), 1,3-bis(diphenylphosphino)propane (dppp), bis(pinacolato)diboron (B2pin2), N- bromosuccinimide (NBS), bromo-tris-pyrrolidino- phosphonium hexafluorophosphate (PyBroP),boron tribromide (BBr 3 ), butyl lithium (BuLi), calculated (Calcd.), cesium carbonate (Cs 2 CO 3 ), dichloromethane (DCM, CH 2 Cl 2 ), N,N-dicyclohexylcarbodiimide (DCC), dichloroethane (DCE), diethyl
  • Table 1 provides a listing of example compounds of the present invention and IC 50 values for inhibition of POLRMT.
  • Example 1 Synthesis of 3-(1-(5-fluoro-2-methylphenyl)cyclopropyl)-5-(1-methyl-5- (trifluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Compound 301)
  • Compound 301 Synthesis of 1-(5-fluoro-2-methylphenyl)cyclopropane-1-carbonitrile, 2
  • Step 1 To a stirred solution of KOH (2.3 g, 40.2 mmol) in water (10 mL), 2-(5-fluoro-2- methylphenyl)acetonitrile (1, 500 mg, 3.4 mmol) and TBAB (216 mg, 0.67 mmol) were added at 0 °C.
  • Example 2 Synthesis of 5-(1,5-dimethyl-1H-pyrazol-3-yl)-3-(1-(5-fluoro-2- methylphenyl)cyclopropyl)-1,2,4-oxadiazole
  • Example 2 [0694] 5-(1,5-dimethyl-1H-pyrazol-3-yl)-3-(1-(5-fluoro-2-methylphenyl)cyclopropyl)-1,2,4- oxadiazole was synthesized Scheme 1 using 1,5-dimethyl-1H-pyrazole-3-carboxylic acid.
  • LCMS (ESI) Calcd for C 17 H 17 FN 4 O: 312.1, found [M+H] + 313.2.
  • Example 3 Synthesis of 3-(1-(5-fluoro-2-methylphenyl)cyclopropyl)-5-(1-methyl-1H- pyrazol-3-yl)-1,2,4-oxadiazole (Example 3): [0695] 3-(1-(5-fluoro-2-methylphenyl)cyclopropyl)-5-(1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole was synthesized following Scheme 1 using 1-methyl-1H-pyrazole-3-carboxylic acid.
  • LCMS (ESI) Calcd for C 16 H 15 FN 4 O: 298.1, found [M+H] + 299.2.
  • Example 4 Synthesis of 5-(5-cyclopropyl-1-methyl-1H-pyrazol-3-yl)-3-(1-(5-fluoro-2- methylphenyl)cyclopropyl)-1,2,4-oxadiazole (Example 4): [0696] 5-(5-cyclopropyl-1-methyl-1H-pyrazol-3-yl)-3-(1-(5-fluoro-2-methylphenyl)cyclopropyl)- 1,2,4-oxadiazole was synthesized following Scheme 1 using 5-cyclopropyl-1-methyl-1H- pyrazole-3-carboxylic acid.
  • Example 5 Synthesis of 3-(1-(5-fluoro-2-methylphenyl)cyclopropyl)-5-(5-isopropyl-1- methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 5) [0697] 3-(1-(5-fluoro-2-methylphenyl)cyclopropyl)-5-(5-isopropyl-1-methyl-1H-pyrazol-3-yl)- 1,2,4-oxadiazole was synthesized following Scheme 1 using 5-isopropyl-1-methyl-1H-pyrazole- 3-carboxylic acid.
  • Example 6 Synthesis of 3-(1-(5-fluoro-2-methylphenyl)cyclopropyl)-5-(1-phenyl-1H- pyrazol-3-yl)-1,2,4-oxadiazole (Example 6) [0698] 3-(1-(5-fluoro-2-methylphenyl)cyclopropyl)-5-(1-phenyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole was synthesized following Scheme 1 using 1-phenyl-1H-pyrazole-3-carboxylic acid.
  • LCMS (ESI) Calcd for C 21 H 17 FN 4 O: 360.3, found [M+H] + 361.2.
  • Example 7 Synthesis of 3-(1-(5-fluoro-2-methylphenyl)cyclopropyl)-5-(5-isopropyl-1- (pyridin-2-yl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 7) [0699] 3-(1-(5-fluoro-2-methylphenyl)cyclopropyl)-5-(5-isopropyl-1-(pyridin-2-yl)-1H-pyrazol-3- yl)-1,2,4-oxadiazole was synthesized following Scheme 1 using 5-isopropyl-1-(pyridin-2-yl)-1H- pyrazole-3-carboxylic acid.
  • Example 8 Synthesis of 3-(1-(5-fluoro-2-methylphenyl)cyclopropyl)-5-(1-(2- fluorophenyl)-5-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 8) [0700] 3-(1-(5-fluoro-2-methylphenyl)cyclopropyl)-5-(1-(2-fluorophenyl)-5-methyl-1H-pyrazol-3- yl)-1,2,4-oxadiazole was synthesized following Scheme 1 using 1-(2-fluorophenyl)-5-methyl-1H- pyrazole-3-carboxylic acid.
  • Example 9 Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(3- fluorophenyl)cyclopropyl)-1,2,4-oxadiazole (Example 9) [0701] Synthesis of 1-(3-fluorophenyl)cyclopropane-1-carbonitrile, 6 [Step 1]: To a stirred solution of KOH (3.7 g, 66.6 mmol) in water(10 mL), 2-(3-fluorophenyl)acetonitrile (5, 750 mg, 5.6 mmol) and TBAB (360 mg, 1.1 mmol) were added at 0 °C.
  • Example 10 Synthesis of 3-(1-(3-fluorophenyl)cyclopropyl)-5-(1-methyl-5- (trifluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 10) [0705] 3-(1-(3-fluorophenyl)cyclopropyl)-5-(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-1,2,4- oxadiazole was synthesized following Scheme 2 using 1-methyl-5-(trifluoromethyl)-1H- pyrazole-3-carboxylic acid.
  • Example 12 Synthesis of 5-(1,5-dimethyl-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazole [0707] Synthesis of 1-(o-tolyl)cyclopropane-1-carbonitrile, 10 [Step 1]: To a stirred solution of NaOH (31.79 g, 457 mmol) in water (50 mL), 2-(o-tolyl)acetonitrile (9, 5 g, 38.1 mmol) and TBAB (2.46 g, 7.62 mmol) were added at 0 °C.
  • Example 13 Synthesis of 5-(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 13) [0711] 5-(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazole was synthesized following Scheme 3 using 1-methyl-5-(trifluoromethyl)-1H-pyrazole- 3-carboxylic acid.
  • Example 14 Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 14) [0713] 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazole was synthesized following Scheme 3 using 5-(difluoromethyl)-1-methyl-1H-pyrazole- 3-carboxylic acid.
  • Example 17 Synthesis of 5-(5-(difluoromethyl)-1-(2-methoxyethyl)-1H-pyrazol-3-yl)-3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 17) [0719] Synthesis of ethyl 5-(difluoromethyl)-1-(2-methoxyethyl)-1H-pyrazole-3-carboxylate, 15 [Step 1]: To a stirred solution of ethyl 5-(difluoromethyl)-1H-pyrazole-3-carboxylate (13, 2.0 g, 10.5 mmol) in DMF (50 mL) at 0°C, sodium hydride (505 mg, 12.6 mmol) was added at 0 o C.
  • aqueous phase was acidified with 1 N aqueous solution of hydrochloric acid to ⁇ pH-5 and extracted with a mixture of dichloromethane and isopropyl alcohol (9:1). Combined organic extract was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford 5-(difluoromethyl)-1-(2-methoxyethyl)-1H-pyrazole-3-carboxylic acid (16, 320 mg).
  • Example 18 Synthesis of 3-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5- yl)-1H-pyrazol-1-yl)propenamide (Example 18) [0724] Synthesis of ethyl 1-(3-amino-3-oxo-propyl)-5-(difluoromethyl)pyrazole-3-carboxylate, 18 and ethyl 2-(3-amino-3-oxo-propyl)-5-(difluoromethyl)pyrazole-3-carboxylate, 18a [Step 1]: To a stirred solution of ethyl 5-(difluoromethyl)-1H-pyrazole-3-carboxylate (13, 500 mg, 2.6 mmol) in dimethylformamide (25 mL), potassium carbonate (1.8 g, 13.1 mmol) was added.
  • the reaction mixture was stirred at ambient temperature for 3 h. After completion, the volatiles were evaporated under reduced pressure.
  • the aqueous phase was acidified with 1 N aqueous solution of hydrochloric acid to ⁇ pH-5 and extracted with a mixture of ethyl acetate and isopropyl alcohol (1:9). Combined organic extracts was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure.
  • reaction mixture was stirred at ambient temperature for 16 h. After completion, the reaction mixture was diluted with ethyl acetate and washed with water and brine. Combined organic extracts was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure.
  • the products were purified by combi-flash chromatography to afford the first product as (Z)-3-(5-((((amino(1-(o-tolyl)cyclopropyl)methylene)amino)oxy)carbonyl)-3-(difluoromethyl)- 1H-pyrazol-1-yl)propanamide (20a, 120 mg) and the second product as (Z)-3-(3-((((amino(1-(o- tolyl)cyclopropyl)methylene)amino)oxy)carbonyl)-5-(difluoromethyl)-1H-pyrazol-1- yl)propanamide (20, 90 mg).
  • Example 19 Synthesis of 5-(1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 19) [0729] Synthesis of 5-(1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole, 25 [Step 1]: To a suspension of methyl 1H-pyrazole-3-carboxylate (265 mg, 2.1 mmol) and (Z)-N'-hydroxy-1- (o-tolyl)cyclopropane-1-carboximidamide (11, 400 mg, 2.1 mmol) in toluene (4 mL) was added potassium carbonate (581 mg, 4.2 mmol), and the reaction mixture was heated to reflux.
  • Example 21 Synthesis of 5-(5-methyl-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 21) [0733] Synthesis of 5-(5-methyl-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole, 27 [Step 1]: To a suspension of methyl 5-methyl-1H-pyrazole-3-carboxylate ( 295 mg, 2.1 mmol) and (Z)-N'-hydroxy-1-(o-tolyl)cyclopropane-1-carboximidamide (11, 400 mg, 2.1 mmol) in toluene (4 mL) was added potassium carbonate (581 mg, 4.2 mmol), and the reaction mixture was heated to reflux.
  • potassium carbonate 581 mg, 4.2 m
  • Example 23 Synthesis of 3-(3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (trifluoromethyl)-1H-pyrazol-1-yl)propanoic acid (Example 23) [0739] Synthesis of methyl 5-(trifluoromethyl)-1H-pyrazole-3-carboxylate, 31 [Step 1]: To a stirred solution of 5-(trifluoromethyl)-1H-pyrazole-3-carboxylic acid (30, 900 mg, 5.0 mmol) in methanol (20 mL) at 0 °C was added thionyl chloride (0.73 mL, 10.0 mmol) dropwise.
  • Example 24 Synthesis of 3-(3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (trifluoromethyl)-1H-pyrazol-1-yl)propanamide (Example 24) [0746] Synthesis of 1-(o-tolyl)-N'-((5-(trifluoromethyl)-1H-pyrazole-3-carbonyl)oxy)cyclopropane- 1-carboximidamide, 35 [Step 1]: To a stirred solution of N'-hydroxy-1-(o-tolyl)cyclopropane-1- carboximidamide (11, 500 mg, 2.6 mmol) and 5-(trifluoromethyl)-1H-pyrazole-3-carboxylic acid (520 mg, 2.9 mmol) in dichloromethane (8 mL) were added DIPEA (1.4 mL, 7.9 mmol), EDC.HCl (1.0 g, 5.3 mmol)
  • Example 25 Synthesis of 3-(5-cyclopropyl-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5- yl)-1H-pyrazol-1-yl)propanoic acid (Example 25) [0750] Synthesis of methyl 5-cyclopropyl-1H-pyrazole-3-carboxylate, 38 [Step 1]: To a stirred solution of 5-cyclopropyl-1H-pyrazole-3-carboxylic acid (37, 1.5 g, 9.8 mmol) in methanol (30 mL) at 0 °C was added thionyl chloride (1.4 mL, 19.7 mmol) dropwise.
  • Example 26 Synthesis of 5-(1-(2-(methylsulfonyl)ethyl)-5-(trifluoromethyl)-1H-pyrazol-3- yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 26) [0755] Synthesis of 3-(1-(o-tolyl)cyclopropyl)-5-(5-(trifluoromethyl)-1H-pyrazol-3-yl)-1,2,4- oxadiazole, 32 [Step 1]: To a stirred solution of (Z)-N'-hydroxy-1-(o-tolyl)cyclopropane-1- carboximidamide (11, 410 mg, 2.2 mmol) and ethyl 5-(trifluoromethyl)-1H-pyrazole-3- carboxylate (450 mg, 2.2 mmol) in toluene (6 mL) was added potassium carbonate (600 mg, 4.3 mmol
  • Example 27 Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)-N-methylacetamide (Example 27)
  • Example 28 Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)-N,N-dimethylacetamide (Example 28) [0764] Synthesis of ethyl 5-(difluoromethyl)-1-(2-(dimethylamino)-2-oxoethyl)-1H-pyrazole-3- carboxylate, 48 [Step 1]: To a stirred solution of 2-(5-(difluoromethyl)-3-(ethoxycarbonyl)-1H- pyrazol-1-yl)acetic acid (44, 350 mg, 1.4 mmol) in dry dimethylformamide (5 mL), N,N- diisopropylethylamine (0.9 mL, 4.9 mmol) and N-methylmethanamine hydrochloride (1.2 g, 14.1
  • Example 29 Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)-N,N-dimethylacetamide (Example 29) [0768] Synthesis of ethyl 5-(difluoromethyl)-1-(2-(oxetan-3-ylamino)-2-oxoethyl)-1H-pyrazole-3- carboxylate, 3 [Step 1]: To a stirred solution of 2-(5-(difluoromethyl)-3-(ethoxycarbonyl)-1H- pyrazol-1-yl)acetic acid (44, 300 mg, 1.2 mmol) in dry tetrahydrofuran (10 mL), n-methyl morpholine (245 mg, 2.4 mmol) and isobutyl chloroformate (165 mg, 1.2
  • Example 30 Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)-1-(piperazin-1-yl)ethan-1-one (Example 30) [0772] Synthesis of tert-butyl 4-(2-(5-(difluoromethyl)-3-(ethoxycarbonyl)-1H-pyrazol-1- yl)acetyl)piperazine-1-carboxylate, 55 [Step 1]: To a stirred solution of 2-(5-(difluoromethyl)-3- (ethoxycarbonyl)-1H-pyrazol-1-yl)acetic acid (44, 300 mg, 1.2 mmol) in dichloromethane (5 mL), N,N-diisopropylethylamine (0.04 mL, 0.2 mmol) and propane
  • tert-butyl piperazine-1- carboxylate 54, 225 mg, 1.2 mmol was added and the reaction mixture was stirred at ambient temperature for 16 h. After completion, the reaction mixture was diluted with dichloromethane, washed with saturated solution of aqueous sodium bicarbonate followed by brine. Combined organic extracts was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by flash column chromatography to afford tert-butyl 4-(2-(5-(difluoromethyl)-3-(ethoxycarbonyl)-1H-pyrazol-1-yl)acetyl)piperazine-1-carboxylate (55, 450 mg).
  • Example 31 Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)-N-(2-(dimethylamino)ethyl)acetamide (Example 31) [0776] Synthesis of ethyl 5-(difluoromethyl)-1-(2-((2-(dimethylamino)ethyl)amino)-2-oxoethyl)- 1H-pyrazole-3-carboxylate, 58 [Step 1]: To a stirred solution of 2-(5-(difluoromethyl)-3- (ethoxycarbonyl)-1H-pyrazol-1-yl)acetic acid (44, 300 mg, 1.2 mmol) in dichloromethane (5 mL) were added DIPEA (0.6 mL, 3.6 mmol) and propy
  • Example 32 Synthesis of N-(2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)ethyl)acetamide
  • Example 32 [0780] Synthesis of ethyl 1-(2-((tert-butoxycarbonyl)amino)ethyl)-5-(difluoromethyl)-1H- pyrazole-3-carboxylate, 61
  • Step 1] To a stirred solution of ethyl 5-(difluoromethyl)-1H-pyrazole- 3-carboxylate (13, 200 mg, 1.0 mmol) in tetrahydrofuran (5 mL), potassium tert-butoxide (355 mg, 3.1 mmol) was added.
  • reaction mixture was heated at 80 °C for 30 min and tert-butyl N-(2-bromoethyl)carbamate (235 mg, 1.0 mmol) was added.
  • the resulting reaction mixture was heated at 80 °C for 6 h.
  • the reaction mixture was quenched with crushed ice, extracted with ethyl acetate and washed with ice cold water and brine. Combined organic extracts was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure.
  • aqueous phase was acidified with 1 N aqueous solution of hydrochloric acid to ⁇ pH-5 and extracted with a mixture of dichloromethane and isopropyl alcohol (9:1). Combined organic extracts was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford 1-(2-acetamidoethyl)-5- (difluoromethyl)-1H-pyrazole-3-carboxylic acid (64, 140 mg).
  • Example 34 Synthesis of 5-(5-(difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-3- yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 34) [0788] Synthesis of ethyl 5-(difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazole-3- carboxylate, 67 [Step 1]: To a stirred suspension of ethyl 5-(difluoromethyl)-1H-pyrazole-3- carboxylate (13, 1.0 g, 5.3 mmol) and potassium carbonate (2.9 g, 21.0 mmol) in DMF (60 mL) at 0 °C, 1-bromo-2-(methylsulfonyl)ethane (1.5 g, 7.9 mmol) was added.
  • reaction mixture was stirred at ambient temperature for 16 h. After completion, the reaction mixture was diluted with ethyl acetate and washed with ice-cold water and brine. Combined organic extract was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure.
  • Example 35 Synthesis of 3-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)propanoic acid (Example 35) [0794] Synthesis of tert-butyl 3-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol- 5-yl)-1H-pyrazol-1-yl)propanoate, 71 [Step 1]: To a stirred suspension of 5-(5-(difluoromethyl)- 1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (70, 400 mg, 1.3 mmol) and potassium carbonate (1.2 g, 8.9 mmol) in dimethylformamide (10 m
  • Examples 36a & 36b 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5- yl)-1H-pyrazol-1-yl)-N,N-dimethylethan-1-amine (Example 36a) & 2-(3-(difluoromethyl)-5- (3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)-N,N-dimethylethan-1- amine (Example 36b)
  • peak-1 2-(5- (difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)-N,N- dimethylethan-1-amine (36a, 14 mg) and peak-2 as 2-(3-(difluoromethyl)-5-(3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)-N,N-dimethylethan-1-amine (36b, 25 mg).
  • Example 37 Synthesis of N-(2-amino-2-oxoethyl)-2-(5-(difluoromethyl)-3-(3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)acetamide (Example 37)
  • tert-butyl-2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)acetate 70, 120 mg
  • tert-butyl 2-(3-(difluoromethyl)-5-(3-(1- (o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)acetate 72a, 200 mg.
  • Example 38 Synthesis of 1-((5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)cyclopropane-1-carboxylic acid (Example 38) [0803] Synthesis of ethyl 1-((5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5- y l)-1H-pyrazol-1-yl)methyl)cyclopropane-1-carboxylate, 74 [Step 1]: To a stirred solution of 5-[5- (difluoromethyl)-1H-pyrazol-3-yl]-3-[1-(o-tolyl)cyclopropyl]-1,2,4-oxadiazole (70, 200 mg, 0.632 mmol) in ace
  • Example 39 Synthesis of 3-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)-2,2-dimethylpropanoic acid (Example 39)
  • Scheme 26 [0805] Synthesis of 3-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)-2,2-dimethylpropanoic acid, Example 39 and 3-(3-(difluoromethyl)-5-(3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)-2,2-dimethylpropanoic acid,
  • Example 178 [Step 1]: To a stirred solution of
  • Example 41 Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)-N-methylethan-1-amine (Example 41) [0810] Synthesis of tert-butyl (2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol- 5-yl)-1H-pyrazol-1-yl)ethyl)(methyl)carbamate, 75 [Step 1]: To a stirred solution of triphenylphosphine (1.2g , 1.9 mmol) in THF (15 mL) and DIAD (383.6 mg, 1.9 mmol) at 0 °C, 5-(5-(difluoromethyl)-1H-pyrazol-3-yl)-3-(1-
  • Example 43 Synthesis of N-(2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)ethyl)methanesulfonamide (Example 43) [0817] Synthesis of ethyl tert-butyl (2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)ethyl)carbamate, 77 [Step 1]: To a stirred solution of 5-(5- (difluoromethyl)-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (70, 340 mg, 1.0 mmol) in
  • Example 44 Synthesis of 2-[5-(difluoromethyl)-3-[3-[1-(o-tolyl)cyclopropyl]-1,2,4-oxadiazol-5-yl]- 1H-pyrazol-1-yl]acetic acid (Example 44) Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol- 1-yl)acetic acid, Example 44 [Step 1]: To a stirred solution of tert-butyl 2-(5-(difluoromethyl)-3- (3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)acetate (72, 200 mg, 0.5 mmol) in dichloromethane (10 mL), trifluoroacetic acid (0.36 m
  • Example 45 Synthesis of N-(2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)ethyl)-N-methylacetamide (Example 45) Sc e e 3 [0820] Synthesis of tert-butyl (2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol- 5-yl)-1H-pyrazol-1-yl)ethyl)(methyl)carbamate, 79 [Step 1]: To a stirred solution of triphenylphosphine (1.2g , 1.9 mmol) in THF (15 mL) and DIAD (383.6 mg, 1.9 mmol) at 0 °C, 5-(5-(difluoromethyl)-1H-
  • Example 47 Synthesis of (2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)acetyl)glycine (Example 47) [0824] Synthesis of tert-butyl (2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol- 5-yl)-1H-pyrazol-1-yl)acetyl)glycinate, 81 [Step 1]: To a stirred solution of 2-[5-(difluoromethyl)- 3-[3-[1-(o-tolyl)cyclopropyl]-1,2,4-oxadiazol-5-yl]-1H-pyrazol-1-yl]acetic acid (Example 44, 220 mg, 0.6 mmol)
  • tert-butyl g lycinate 157 mg, 1.2 mmol was added and the resulting reaction mixture was allowed to stir at ambient temperature for 16 h.
  • the reaction mixture was diluted with dichloromethane, washed with saturated solution of sodium bicarbonate followed by brine wash. Combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure.
  • Example 48 Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)-N-(2-methoxyethyl)acetamide (Example 48) [0826] Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)-N-(2-methoxyethyl)acetamide, Example 48 [Step 1]: To a stirred solution of 2-(5- (difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)acetic acid (Example 44, 70 mg,
  • Example 49 Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)-N-(2-hydroxyethyl)acetamide
  • Scheme 36 [0827] Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)-N-(2-hydroxyethyl)acetamide
  • Example 49 [Step 1]: To a stirred solution of 2-(5- (difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)acetic acid (Example 44, 120 mg, 0.3
  • Example 50 Synthesis of (S)-2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)-1-(3-(dimethylamino)pyrrolidin-1-yl)ethan-1-one (Example 50) [0828] Synthesis of (S)-2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 1H-pyrazol-1-yl)-N-(2-hydroxyethyl)acetamide, Example 50 [Step 1]: To a stirred solution of 2- (5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1
  • Example 54 Synthesis of 3-(5-cyclopropyl-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5- yl)-1H-pyrazol-1-yl)propenamide (Example 54) [0836] Synthesis of 3-(5-cyclopropyl-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)propenamide, Example 54 [Step 5]: To a stirred solution of 3-(5-cyclopropyl-3-(3-(1- (o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)propanoic acid (Example 22, 60 mg, 0.16 mmol) in DMF (3 mL), were added HATU (90 mg, 0.24 mmol), DIPEA (0.
  • Examples 55a & 55b Synthesis of 5-(4-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 55a) and 5-(4-(difluoromethyl)-1-methyl-1H- pyrazol-5-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 55b)
  • Example 56 Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-2-(1-(o- t olyl)cyclopropyl)oxazole (Example 56) [0840] Synthesis of 5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl chloride, 88 [Step 1]: To a stirred solution of 5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carboxylic acid (87, 140 mg, 0.8 mmol) in SOCl 2 (5.0 mL, 70 mmol) was heated at 60 °C added and stirred for 2 h.
  • Example 56 Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-2-(1-(o- tolyl)cyclopropyl)oxazole (Example 56) [0843] Synthesis of 1-(o-tolyl)cyclopropane-1-carboxylic acid, 92 [Step 1]: To a stirred solution of 1-(o-tolyl)cyclopropane-1-carbonitrile (10, 1.00 g, 6 mmol) in 4M LiOH.H 2 O aq. solution (8.0 mL, 25 mmol) was refluxed at 100 °C for 24h with continue stirring.
  • reaction mixture was stirred at ambient temperature for 1 h.
  • the reaction mixture was concentrated under reduced pressure, diluted with water and extracted with 1,2 dichloromethane. The organic extracts were then separated and under reduced pressure.
  • the product was purified by reverse phase prep HPLC purification to afford N-(2-(5-(difluoromethyl)- 1-methyl-1H-pyrazol-3-yl)-2-oxoethyl)-1-(o-tolyl)cyclopropane-1-carboxamide (94, 120 mg).
  • Examples 57a & 57b Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(5- (difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 57a) [0849] Synthesis of ethyl 5-(difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazole-3- carboxylate, 67 [Step 1]: To a stirred suspension of ethyl 5-(difluoromethyl)-1H-pyrazole-3- carboxylate (13, 1 g, 5.3 mmol) and potassium carbonate (2.9 g, 21.03 mmol) in dimethylformamide (60 mL) at 0 °C, 1-bromo-2-(methylsulfonyl)ethane (1.
  • Example 57b was isolated as other regio-isomer.
  • Examples 58-64 were synthesized in a manner similar to Example 57 from the corresponding pyrazole carboxylic acid.
  • Example 58 Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-(2- (methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Examples 58) [0855] 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-(2- (methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole was synthesized following Scheme 45 using 1-bromo-2-(methylsulfonyl)ethane.
  • Examples 59 & 60 Synthesis of (S)-2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)propanamide, (Example 59) and (R)-2-(3-(3- (1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1- yl)propenamide (Example 60) [0856] (S)-2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)propenamide and (R)-2-(3-
  • Example 61 Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-(3- (methylsulfonyl)propyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 61) [0860] 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-(3- (methylsulfonyl)propyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 61)was synthesized following Scheme 45 using 1-bromo-3-(methylsulfonyl)propane.
  • Example 62 Synthesis of 3-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)thietane 1,1-dioxide (Example 62) [0861] 3-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)thietane 1,1-dioxide (Example 62) was synthesized following Scheme 45 using 3-bromothietane 1,1-dioxide.
  • Example 63 Synthesis of 3-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)propenamide (Example 63) [0862] 3-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)propenamide (Example 63) was synthesized following Scheme 45 using 3- bromopropanamide.
  • Example 64 Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)acetamide (Example 64) [0863] 2-(5-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-3-(difluoromethyl)- 1H-pyrazol-1-yl)acetamide (Example 64) was synthesized following Scheme 45 using 3-2- bromoacetamide. LCMS (ESI) Calcd.
  • Example 66 Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-N-(2,2,2 trifluoroethyl)acetamide (Example 66) [0868] 2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-N-(2,2,2-trifluoroethyl)acetamid (Example 66) was synthesized following Scheme 46 using 2,2,2-trifluoroethan-1-amine.
  • Example 67 Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-N-(2-hydroxyethyl)acetamide (Example 67) [0869] 2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-N-(2-hydroxyethyl)acetamide (Example 67) was synthesized following Scheme 46 using 2-aminoethan-1-ol.
  • Example 68 Synthesis of N-(2-amino-2-oxoethyl)-2-(3-(3-(1-(2-chloro-4- fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)acetamide
  • Example 68 N-(2-Amino-2-oxoethyl)-2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol- 5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)acetamide
  • Example 68 was synthesized following Scheme 46 using 2-aminoacetamide.
  • Example 69 Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-N-(2-hydroxyethyl)-N-methylacetamide (Example 69) [0871] 2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-N-(2-hydroxyethyl)-N-methylacetamide (Example 69) was synthesized following Scheme 46 using 2-(methylamino)ethan-1-ol.
  • Example 72 Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (Example 72) [0874] 2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (Example 72) was synthesized following Scheme 46 using 2,2,2-trifluoro-N-methylethan-1-amine.
  • Example 73 Synthesis of (R)-2-(2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)acetamido)propenamide (Example 73) [0875] (R)-2-(2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)acetamido)propanamide (Example 73) was synthesized following Scheme 46 using (R)-2-aminopropanamide.
  • Example 74 Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-N-(2-(dimethylamino)ethyl)-N-methylacetamide (Example 74) [0876] 2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-N-(2-(dimethylamino)ethyl)-N-methylacetamide (Example 74) was synthesized following Scheme 46 using N 1 ,N 1 ,N 2 -trimethylethane-1,2-diamine.
  • Example 75 Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-N-(2-methoxyethyl)-N-methylacetamide (Example 75) [0877] 2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-N-(2-methoxyethyl)-N-methylacetamide (Example 75) was synthesized following Scheme 46 using 2-methoxy-N-methylethan-1-amine.
  • Example 76 Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-N-(2-hydroxy-2-methylpropyl)acetamide (Example 76) [0878] 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-N-(2-hydroxy-2-methylpropyl)acetamide (Example 76) was synthesized following Scheme 46 using 1-amino-2-methylpropan-2-ol.
  • Example 77 Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-N-((1-methylpiperidin-4-yl)methyl)acetamide (Example 77) [0879] 2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-N-((1-methylpiperidin-4-yl)methyl)acetamide (Example 77) was synthesized following Scheme 46 using (1-methylpiperidin-4-yl)methanamine.
  • Example 78 Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-N-(1-cyanocyclopropyl)acetamide (Example 78) [0880] 2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-N-(1-cyanocyclopropyl)acetamide (Example 78) was synthesized following Scheme 46 using 1-aminocyclopropane-1-carbonitrile.
  • Example 79 Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-N-(2-(methylamino)-2-oxoethyl)acetamide (Example 79) [0881] 2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-N-(2-(methylamino)-2-oxoethyl)acetamide (Example 79) was synthesized following Scheme 46 using 2-amino-N-methylacetamide.
  • Example 80 Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-N-(cyclopropylmethyl)acetamide (Example 80) [0882] 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-N-(cyclopropylmethyl)acetamide (Example 80) was synthesized following Scheme 46 using cyclopropylmethanamine.
  • Example 81 Synthesis of N-(2-amino-2-oxoethyl)-2-(3-(3-(1-(2-chloro-4- fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)-N- methylacetamide (Example 81) [0883] N-(2-Amino-2-oxoethyl)-2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol- 5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)-N-methylacetamide (Example 81) was synthesized following Scheme 46 using 2-(methylamino)acetamide.
  • Example 82 Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-N-(cyclobutylmethyl)acetamide (Example 82) [0884] 2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-N-(cyclobutylmethyl)acetamide was synthesized following Scheme 46 using cyclobutylmethanamine.
  • Example 83 Synthesis of (S)-2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5- yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)-1-(3-methoxypyrrolidin-1-yl)ethan-1-one (Example 83) [0885] (S)-2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)-1-(3-methoxypyrrolidin-1-yl)ethan-1-one (Example 83) was synthesized following Scheme 46 using (S)-3-methoxypyrrolidine.
  • Example 84 Synthesis of (R)-2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5- yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)-1-(3-methoxypyrrolidin-1-yl)ethan-1-one (Example 84) [0886] (R)-2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)-1-(3-methoxypyrrolidin-1-yl)ethan-1-one (Example 84) was synthesized following Scheme 46 using (R)-3-methoxypyrrolidine.
  • Example 85 Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-1-(3-methoxyazetidin-1-yl)ethan-1-one (Example 85) [0887] 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-1-(3-methoxyazetidin-1-yl)ethan-1-one (Example 85) was synthesized following Scheme 46 using 3-methoxyazetidine.
  • Example 86 Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-1-(3,3-difluoropyrrolidin-1-yl)ethan-1-one (Example 86) [0888] 2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-1-(3,3-difluoropyrrolidin-1-yl)ethan-1-one (Example 86) was synthesized following Scheme 46 using 3,3-difluoropyrrolidine.
  • Example 87 Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-1-(pyrrolidin-1-yl)ethan-1-one (Example 87) [0889] 2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-1-(pyrrolidin-1-yl)ethan-1-one (Example 87) was synthesized following Scheme 46 using pyrrolidine.
  • Example 88 Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-1-(3,3-difluoroazetidin-1-yl)ethan-1-one (Example 88) [0890] 2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-1-(3,3-difluoroazetidin-1-yl)ethan-1-one (Example 88) was synthesized following Scheme 46 using 3,3-difluoroazetidine.
  • Example 89 Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-N-(2-hydroxy-2-methylpropyl)-N-methylacetamide (Example 89) [0891] 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-N-(2-hydroxy-2-methylpropyl)-N-methylacetamide (Example 89) was synthesized following Scheme 46 using 2-methyl-1-(methylamino)propan-2-ol.
  • Examples 90 & 91 Synthesis of (S)-2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)-N-(tetrahydrofuran-3-yl)acetamide (Example 90) & (R)-2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)-N-(tetrahydrofuran-3-yl)acetamide (Example 91) [0892] (S)-2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5
  • Preparative chiral HPLC method SFC preparative purification was performed on Pic Solution 175 instrument equipped with Knauer UV Detector 40D by using C Amylose A (30.0 mm x 250mm ), 5 ⁇ Column operating at 35 oC temperature, maintaining flow rate of 110 ml/min, using 75 % CO2 in super critical state & 25% of methanol as mobile phase, Run this isocratic mixture up to 14.0 minutes and also maintained the isobaric condition of 100 bar at 254 nm wavelength.
  • Example 92 Synthesis of (S)-2-(2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)acetamido)propenamide (Example 92) [0896] (S)-2-(2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)acetamido) propanamide (Example 92) was synthesized following Scheme 46 using 2-aminopropanamide.
  • Preparative chiral HPLC method SFC preaparative purification was performed on Pic Solution 175 instrument equipped with Knauer UV Detector 40D by using I Cullulose J (30.0 mm x 250 mm), 5 min column operating at 35 °C temperature, maintaining flow rate of 90 mL/min, using 85% CO2 in super critical state and 15% of MeOH mobile phase. Run this isocratic mixture up to 14 min and also maintained the isobaric condition of 100 bar at 220 nm.
  • Example 93 Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-N-(piperidin-4-ylmethyl)acetamide (Example 93)
  • Scheme 47 [0898] Synthesis of tert-butyl 4-((2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)acetamido)methyl)piperidine-1-carboxylate, 101 [Step 1]: tert-Butyl 4-((2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadia
  • Example 94 Synthesis of (2-(3-(3-(1-(2-chloro-4-fluorophenyl) cyclopropyl)-1,2,4-oxadiazol-5- yl)-5-(difluoromethyl)-1H-pyrazol-1-yl) acetyl) glycine (Example 94)
  • Example 96 Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-(piperazin-1-yl)ethan-1-one (Example 96) Scheme 50 [0905] Synthesis of tert-butyl 4-(2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)acetyl)piperazine-1-carboxylate, 106 [Step 1]: tert-Butyl 4-(2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-
  • Examples 97 & 98 Synthesis of (R)-2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)propanoic acid (Example 97) and (S)-2-(3-(3- (1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1- yl)propanoic acid (Example 98) Scheme 51 [0907] Synthesis of tert-butyl 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5- yl)-5-(difluoromethyl)-1H-pyrazol-1-y
  • Example 99 Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(5-methyl-1-(2- (methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 99) [0912] Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(5-methyl-1H-pyrazol-3-yl)- 1,2,4-oxadiazole, 113 [Step 1]: 3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-5-(5-methyl-1H- p yrazol-3-yl)-1,2,4-oxadiazole 113 was synthesized following Scheme 49 using methyl 5- methyl-1H-pyrazole-3-carboxylate.
  • Example 100 Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(1-(2- (methylsulfonyl)ethyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 100) [0914] Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(5-(trifluoromethyl)-1H-pyrazol- 3-yl)-1,2,4-oxadiazole, 115 [Step 1]: 3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-5-(5- (trifluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole 115 was synthesized following Scheme 49 using methyl 5-(trifluoromethyl)-1H-pyrazole-3-carboxylate.
  • Example 101 Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)-N-(oxetan-3-yl)acetamide (Example 101)
  • Scheme 54 [0916] Synthesis of ethyl 5-(difluoromethyl)-1-(2-(oxetan-3-ylamino)-2-oxoethyl)-1H-pyrazole-3- carboxylate, 116 (Step-1): Ethyl 5-(difluoromethyl)-1-(2-(oxetan-3-ylamino)-2-oxoethyl)-1H- pyrazole-3-carboxylate (116) was synthesized following Scheme 49 using oxetan-3-amine.
  • Example 102 Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(1-(2- (methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 102)
  • Examples 103a & 103b Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(4- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 103a) [0920] Synthesis of methyl 4-formyl-1-methyl-1H-pyrazole-3-carboxylate, 120 & 120a [Step 1]: To a solution of methyl 4-formyl-1H-pyrazole-3-carboxylate (119, 700 mg, 4.5 mmol) in DMF (5 mL), K 2 CO 3 (1.2 g, 9.0 mmol) was added and the reaction mixture was stirred for 15 minutes under nitrogen atmosphere.
  • Example 104 Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(4,5-dimethyl-1- (2-(methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 104) Scheme 57 [0923] Synthesis of (Z)-1-(2-chloro-4-fluorophenyl)-N'-((4,5-dimethyl-1H-pyrazole-3- carbonyl)oxy)cyclopropane-1-carboximidamide, 123 [Step-1]: To a stirred solution of 4,5- dimethyl-1H-pyrazole-3-carboxylic acid (122, 120 mg, 0.9 mmol) and (Z)-1-(2-chloro-4- fluorophenyl)-N'-hydroxycyclopropane-1-carboximidamide (215 mg, 0.9 mmol) in dichloromethane (2 mL), DI
  • Example 105 Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(1-(2- (methylsulfonyl)ethyl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-1,2,4-oxadiazole (Example 105) [0926] Synthesis of (Z)-1-(2-chloro-4-fluorophenyl)-N'-((1,4,5,6-tetrahydrocyclopenta[c]pyrazole- 3-carbonyl)oxy)cyclopropane-1-carboximidamide, 126 [Step-1]: To a stirred solution of 1,4,5,6- tetrahydrocyclopenta[c]pyrazole-3-carboxylic acid (125, 110 mg, 0.7 mmol) and (Z)-1-(2-chloro- 4-fluorophenyl)-N'-hydroxycyclopropane-1-car
  • Examples 106a & 106b Synthesis of 5-(5-Bromo-4-methyl-1-(2-(methylsulfonyl)ethyl)-1H- pyrazol-3-yl)-3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazole (Example 106a) and 5-(3-bromo-4-methyl-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-5-yl)-3-(1-(2-chloro-4- fluorophenyl)cyclopropyl)-1,2,4-oxadiazole (Example 106b) [0929] Synthesis of methyl 5-bromo-4-methyl-1H-pyrazole-3-carboxylate, 129 [Step 1]: To a solution of methyl 4-methyl-1H-pyrazole-3-carboxylate (128, 100 mg, 0.7 mmol) in water (1 mL),
  • Methyl 5- bromo-4-methyl-1H-pyrazole-3-carboxylate (129, 80 mg, 0.37 mmol) was added to the reaction mixture and the resulting reaction mixture was heated at 100 °C for 16 h. After completion, volatiles were evaporated, diluted with ethyl acetate and washed with water (twice). The combined organic layer was dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure.
  • Example 107 Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(1,4-dimethyl-1H- pyrazol-3-yl)-1,2,4-oxadiazole (Example 107) [0934] Synthesis of (Z)-1-(2-chloro-4-fluorophenyl)-N'-((1,4-dimethyl-1H-pyrazole-3- carbonyl)oxy)cyclopropane-1-carboximidamide, 132 [Step 1]: To a solution of (Z)-1-(2-chloro-4- fluorophenyl)-N'-hydroxycyclopropane-1-carboximidamide (185 mg, 0.811 mmol) and 1,4- dimethyl-1H-pyrazole-3-carboxylic acid ( 131, 125 mg, 0.89 mmol) in dichloromethane (1 mL), DIPEA ( 0.39 mL, 2.21 mmol ),
  • Example 108 Synthesis of 3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol- 5-yl)-4-methyl-1-(2-(methylsulfonyl)ethyl)-1H-pyrazole-5-carbaldehyde (Example 108) [0936] Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(4-methyl-1-(2- (methylsulfonyl)ethyl)-5-vinyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole, 133 [Step 1]: To a stirred solution of 5-(5-bromo-4-methyl-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-3-(1-(2-chloro-4- fluorophenyl)cyclopropyl)-1,2,4-
  • Example 110 Synthesis of 2-(2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)acetamido)-2-methylpropanoic acid (Example 110)
  • Examples 111a & 111b Synthesis of 1-((3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)- 1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)methyl)cyclopropane-1-carboxylic acid (Example 111a) and 1-((5-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol- 5-yl)-3-(difluoromethyl)-1H-pyrazol-1-yl)methyl)cyclopropane-1-carboxylic acid (Example 111b) [0941] Synthesis of 1-((3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-
  • reaction mixture was stirred for 15 min and ethyl 1- (bromomethyl) cyclopropanecarboxylate (210 mg, 1 mmol) was added. Resulting reaction mixture was stirred at ambient temperature for 16 h, quenched with saturated aqueous ammonium chloride solution and extracted with ethyl acetate and washed with water followed by brine wash. Combined organic extracts were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure.
  • 1 H NMR 400 MHz, DMSO-d 6 ): ⁇ H 7.85-7.6 (m, 2H), 7.50-7.47 (dd, 1H), 7.27-7.22 (m, 1H), 7.20 (s, 1H), 4.47 (s, 2H), 1.71 (m, 2H), 1.47-1.44 (m, 2H), 1.11 (s, 2H), 1.02 (s, 2H).
  • Example 111b LCMS (ESI) Calcd.
  • Example 112 Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1- phenylcyclopropyl)-1,2,4-oxadiazole (Example 112) [0942] Synthesis of ethyl 5-(difluoromethyl)-1H-pyrazole-3-carboxylate, 13 [Step-1]: 2,2- difluoroethan-1-amine (138, 5.0 g, 61.7 mmol), tert-Butyl nitrite (8.8 mL, 74.0 mmol) and acetic acid (0.4 mL, 6.2 mmol) was taken in chloroform (5 ml) and heated to 55 °C for 20 min.
  • Example 113 Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2-fluoro-5- methylphenyl)cyclopropyl)-1,2,4-oxadiazole (Example 113) [0951] 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2-fluoro-5- methylphenyl)cyclopropyl)-1,2,4-oxadiazole was synthesized following Scheme 64 using (Z)-N'- ((5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)-1-(2-fluoro-5- methylphenyl)cyclopropane-1-carboximidamide.
  • Example 114 Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(pyridin-2- yl)cyclopropyl)-1,2,4-oxadiazole (Example 114) [0952] 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(pyridin-2-yl)cyclopropyl)-1,2,4- oxadiazole was synthesized following Scheme 64 using (Z)-N'-((5-(difluoromethyl)-1-methyl-1H- pyrazole-3-carbonyl)oxy)-1-(pyridin-2-yl)cyclopropane-1-carboximidamide.
  • Example 115 Synthesis of 3-(1-(2-bromophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1- methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 115) [0953] 3-(1-(2-bromophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4- oxadiazole was synthesized following Scheme 64 using (Z)-1-(2-bromophenyl)-N'-((5- (difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide.
  • Example 116 Synthesis of 3-(1-(2-chlorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1- methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 116) [0954] 3-(1-(2-chlorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4- oxadiazole was synthesized following Scheme 64 using (Z)-1-(2-chlorophenyl)-N'-((5- (difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide.
  • Example 117 Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(pyridin-3- yl)cyclopropyl)-1,2,4-oxadiazole (Example 117) [0955] 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(pyridin-3-yl)cyclopropyl)-1,2,4- oxadiazole was synthesized following Scheme 64 using (Z)-N'-((5-(difluoromethyl)-1-methyl-1H- pyrazole-3-carbonyl)oxy)-1-(pyridin-3-yl)cyclopropane-1-carboximidamide.
  • Example 118 Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(pyridin-4- yl)cyclopropyl)-1,2,4-oxadiazole (Example 118) [0956] 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(pyridin-4-yl)cyclopropyl)-1,2,4- oxadiazole was synthesized following Scheme 64 using (Z)-N'-((5-(difluoromethyl)-1-methyl-1H- pyrazole-3-carbonyl)oxy)-1-(pyridin-4-yl)cyclopropane-1-carboximidamide.
  • Example 119 Synthesis of 3-(1-(3-chloro-5-fluorophenyl)cyclopropyl)-5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 119) [0957] 3-(1-(3-chloro-5-fluorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3- yl)-1,2,4-oxadiazole was synthesized following Scheme 64 using (Z)-1-(3-chloro-5- fluorophenyl)-N'-((5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1- carboximidamide.
  • Example 120 Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(2-(5-fluoro-2- methylphenyl)propan-2-yl)-1,2,4-oxadiazole (Example 120) [0958] 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(2-(5-fluoro-2-methylphenyl)propan-2- yl)-1,2,4-oxadiazole was synthesized following Scheme 64 using (Z)-N'-((5-(difluoromethyl)-1- methyl-1H-pyrazole-3-carbonyl)oxy)-1-(3-fluoro-5-methylphenyl)cyclopropane-1- carboximidamide.
  • Example 121 Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(p- tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 121) [0959] 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(p-tolyl)cyclopropyl)-1,2,4- oxadiazole was synthesized following Scheme 64 using (Z)-N'-((5-(difluoromethyl)-1-methyl-1H- pyrazole-3-carbonyl)oxy)-1-(p-tolyl)cyclopropane-1-carboximidamide.
  • Example 122 Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(m- tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 122) [0960] 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(m-tolyl)cyclopropyl)-1,2,4- oxadiazole was synthesized following Scheme 64 using (Z)-N'-((5-(difluoromethyl)-1-methyl-1H- pyrazole-3-carbonyl)oxy)-1-(m-tolyl)cyclopropane-1-carboximidamide.
  • Example 123 Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(3- methylpyridin-2-yl)cyclopropyl)-1,2,4-oxadiazole (Example 123) [0961] 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(3-methylpyridin-2-yl)cyclopropyl)- 1,2,4-oxadiazole was synthesized following Scheme 64 using (Z)-N'-((5-(difluoromethyl)-1- methyl-1H-pyrazole-3-carbonyl)oxy)-1-(3-methylpyridin-2-yl)cyclopropane-1-carboximidamide.
  • Example 124 Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 124) [0962] 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3- yl)-1,2,4-oxadiazole was synthesized following Scheme 64 using (Z)-N'-((5-(difluoromethyl)-1- methyl-1H-pyrazole-3-carbonyl)oxy)-1-(2-(trifluoromethyl)phenyl)cyclopropane-1- carboximidamide.
  • Example 125 Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2- methylpyridin-3-yl)cyclopropyl)-1,2,4-oxadiazole (Example 125) [0963] 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2-methylpyridin-3-yl)cyclopropyl)- 1,2,4-oxadiazole was synthesized following Scheme 64 using (Z)-N'-((5-(difluoromethyl)-1- methyl-1H-pyrazole-3-carbonyl)oxy)-1-(2-methylpyridin-3-yl)cyclopropane-1-carboximidamide.
  • Example 126 Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2,5- difluorophenyl)cyclopropyl)-1,2,4-oxadiazole (Example 126) [0964] 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2,5-difluorophenyl)cyclopropyl)- 1,2,4-oxadiazole was synthesized following Scheme 64 using (Z)-N'-((5-(difluoromethyl)-1- methyl-1H-pyrazole-3-carbonyl)oxy)-1-(2,5-difluorophenyl)cyclopropane-1-carboximidamide.
  • Example 127 Synthesis of 3-(1-(2-chloro-5-fluorophenyl)cyclopropyl)-5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 127) [0965] 3-(1-(2-chloro-5-fluorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3- yl)-1,2,4-oxadiazole was synthesized following Scheme 64 using (Z)-1-(2-chloro-5- fluorophenyl)-N'-((5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1- carboximidamide.
  • Example 128 Synthesis of 3-(1-(2-chloro-3-fluorophenyl)cyclopropyl)-5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 128) [0966] 3-(1-(2-chloro-3-fluorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3- yl)-1,2,4-oxadiazole was synthesized following Scheme 64 using (Z)-1-(2-chloro-3- fluorophenyl)-N'-((5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1- carboximidamide.
  • Example 129 Synthesis of (5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2,5- dimethylphenyl) cyclopropyl)-1,2,4-oxadiazole (Example 129) [0967] (5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2,5-dimethylphenyl) cyclopropyl)- 1,2,4-oxadiazole was synthesized following Scheme 64 using (Z)-N'-((5-(difluoromethyl)-1- methyl-1H-pyrazole-3-carbonyl)oxy)-1-(2,5-dimethylphenyl)cyclopropane-1-carboximidamide.
  • Example 130 Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2-methyl- 5-(trifluoromethyl)phenyl)cyclopropyl)-1,2,4-oxadiazole (Example 130) [0968] 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2-methyl-5-(trifluoromethyl)phenyl) cyclopropyl) -1,2,4-oxadiazole was synthesized following Scheme 64 using (Z)-N'-((5- (difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)-1-(2-methyl-5- (trifluoromethyl)phenyl)cyclopropane-1-carboximidamide.
  • Example 131 Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2- phenoxyphenyl)cyclopropyl)-1,2,4-oxadiazole (Example 131) [0969] 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2-phenoxyphenyl)cyclopropyl)- 1,2,4-oxadiazole was synthesized following Scheme 64 using (Z)-N'-((5-(difluoromethyl)-1- methyl-1H-pyrazole-3-carbonyl)oxy)-1-(2-phenoxyphenyl)cyclopropane-1-carboximidamide.
  • Example 132 Synthesis of 2-(1-(5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4- oxadiazol-3-yl)cyclopropyl)benzoic acid (Example 132)
  • Example 133 Synthesis of 2-(1-(5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4- oxadiazol-3-yl)cyclopropyl)benzamide (Example 133)
  • Example 134 Synthesis of 2-(1-(5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4- oxadiazol-3-yl)cyclopropyl)-N-methylbenzamide (Example 134) Scheme 67 [0978] Synthesis of 2-(1-(5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3- yl)cyclopropyl)-N-methylbenzamide, Example 134 [Step 1]: To a stirred solution of 2-(1-(5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3-yl)cyclopropyl)benzoic acid (Example 132, 100 mg, 0.3 mmol) in DMF (2 mL), N,N-diisopropylethylamine (0.2
  • Example 135 Synthesis of 2-(1-(5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4- oxadiazol-3-yl)cyclopropyl)-N,N-dimethylbenzamide (Example 135) [0979] Synthesis of 2-(1-(5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3- yl)cyclopropyl)-N,N-dimethylbenzamide, 135 [Step 1]: To a stirred solution of 2-(1-(5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3-yl)cyclopropyl)benzoic acid (132, 100 mg, 0.3 mmol) in DMF (2 mL), N,N-diisopropylethylamine (0.2
  • Example 136 Synthesis of 2-(1-(5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4- oxadiazol-3-yl)cyclopropyl)benzonitrile (Example 136) [0980] Synthesis of 2-(1-(5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3- yl)cyclopropyl)benzonitrile, 136 [Step 1]: To a solution of 2-(1-(5-(5-(difluoromethyl)-1-methyl- 1H-pyrazol-3-yl)-1,2,4-oxadiazol-3-yl)cyclopropyl)benzamide (133, 90 mg, 0.3 mmol) and triethylamine (0.25 mL, 1.5 mmol) in dry dichloromethane (5 mL) at 0 °C, triflu
  • Example 137 Synthesis of (2-(1-(5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4- oxadiazol-3-yl)cyclopropyl)phenyl)methanol (Example 137) [0981] Synthesis of (2-(1-(5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3- yl)cyclopropyl)phenyl)methanol, Example 138 [Step 1]: To a stirred solution of 2-(1-(5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3-yl)cyclopropyl)benzaldehyde (149, 200 mg, 0.6 mmol) in THF (3 mL), sodium borohydride (45 mg, 1.2 mmol) was added at
  • Example 138 Synthesis of (2-(1-(5-(5-(difluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3- yl)cyclopropyl)phenyl)methanol (Example 138) [0983] Synthesis of (2-(1-(5-(5-(difluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3- yl)cyclopropyl)phenyl)methanol, Example 138 [Step 1]: To a stirred solution of 2-(1-(5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3-yl)cyclopropyl)benzaldehyde (149, 30 mg, 0.1 mmol) in tetrahydrofuran (1 mL), sodium borohydride (6.6 mg, 0.2mmol) was added at 0
  • Example 139 Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2- ethylphenyl)cyclopropyl)-1,2,4-oxadiazole (Example 139) [0984] Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2- ethylphenyl)cyclopropyl)-1,2,4-oxadiazole, Example 139 [Step 6]: A stirred solution of 5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2-vinylphenyl)cyclopropyl)-1,2,4-oxadiazole (148, 150 mg, 0.4 mmol) in ethanol (4 mL) was purged with Argon gas for 5 min.
  • Example 140 Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2-(methyl- d 3 )phenyl)cyclopropyl)-1,2,4-oxadiazole (Example 140) Scheme 73 [0985] Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2-(methyl- d3)phenyl)cyclopropyl)-1,2,4-oxadiazole, Example 140, (Step-1): To a stirred solution of 3-(1-(2- bromophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 115, 80 mg, 0.2 mmol) in 1,4-dioxane (2 mL) and water (0.5mL) mixture,
  • Example 141 Synthesis of 3-(1-(2-cyclopropylphenyl)cyclopropyl)-5-(5-(difluoromethyl)-1- methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 141)
  • Example 142 Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2-fluoro-6- methylphenyl)cyclopropyl)-1,2,4-oxadiazole (Example 142)
  • Scheme 75 [0987] Synthesis of 2-(2-fluoro-6-methylphenyl)acetonitrile, 151
  • Step 1 To a stirred solution of 2-(bromomethyl)-1-fluoro-3-methylbenzene (150, 1.0 g, 4.9 mmol) in acetonitrile (10 mL), K 2 CO 3 (1.4 g, 9.9 mmol) was added followed by trimethylsilylformonitrile (0.9 mL, 7.4 mmol) and the resulting reaction mixture was heated at 100 °C for 16h.
  • Example 144 Synthesis of 3-(1-(5-bromo-2-methylphenyl)cyclopropyl)-5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 144) [0998] Synthesis of 4-bromo-2-(bromomethyl)-1-methylbenzene, 163 [Step 1]: To a suspension of (5-bromo-2-methylphenyl) methanol (162, 1.5 g, 7.5 mmol) in dichloromethane (10 mL), PBr 3 (0.8 mL, 8.2 mmol) was added drop wise at 0 °C and the reaction mixture was stirred at same temperature for 1h.
  • PBr 3 0.8 mL, 8.2 mmol
  • Example 145 Synthesis of (3-(1-(5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4- oxadiazol-3-yl)cyclopropyl)-4-methylphenyl)methanol (Example 145) [1004] Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2-methyl-5- vinylphenyl)cyclopropyl)-1,2,4-oxadiazole, 169 [Step 1]: To a stirred solution of potassium vinyl trifluoroborate (2, 80 mg, 0.6 mmol) in 1,4-dioxane (8 mL):Water (2mL) mixture, K 2 CO 3 (255 mg, 1.8 mmol) and 3-(1-(5-bromo-2-methylphenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-methyl-1H-
  • Example 146 Synthesis of 3-(1-(2-(cyclopentyloxy)phenyl)cyclopropyl)-5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 146)
  • Scheme 79 [1007] Synthesis of 2-(2-(cyclopentyloxy)phenyl)acetonitrile, 172 [Step 1]: To a stirred solution of 2-(2-hydroxyphenyl)acetonitrile (171, 500 mg, 4 mmol) and bromocyclopentane (840 mg, 5.5 mmol) in DMSO (5 mL), K 2 CO 3 was added (1.0 g, 7.5 mmol).
  • Example 147 Synthesis of 3-(1-(5-chloro-2-methylphenyl)cyclopropyl)-5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 147)
  • Example 150 Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(5-fluoro-2- methylphenyl)cyclopropyl)isoxazole (Example 150)
  • Example 151 Synthesis of 3-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-5-(1-(5-fluoro-2- methylphenyl)cyclopropyl)-1,2,4-oxadiazole (Example 151) [1033] Synthesis of 5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carboxamide, 197 [Step 1: To a stirred solution of 5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carboxylic acid (87, 200 mg, 1.2 mmol) in THF (2mL) and DMF (1mL) were added HOBt (230 mg, 1.70 mmol),EDC.HCl (330 mg, 1.70 mmol) and DIPEA (0.62 mL, 4.6 mmol) followed by (NH 4 ) 2 CO 3 (440 mg, 4.6 mmol) and stirred the reaction mixture at ambient temperature for 17 h.
  • Example 152 Synthesis of 2-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-5-(1-(5-fluoro-2- methylphenyl)cyclopropyl)-1,3,4-oxadiazole (Example 152)
  • Scheme 84 [1038] Synthesis of 1-(5-fluoro-2-methylphenyl)cyclopropane-1-carbohydrazide, 202 [Step 1]: To a stirred solution of 1-(5-fluoro-2-methylphenyl)cyclopropane-1-carboxylic acid (201, 500 mg, 2.6 mmol) in DMA (2mL) was added DIPEA (0.9 mL, 5.2 mmol) followed by EDC.HCl (494 mg, 2.6 mmol) and HOBT (348 mg, 2.6 mmol) and stirred at 0 °C for 15 mins.
  • Example 153 Synthesis of 3-(1-(2-chloro-3-fluorophenyl)cyclopropyl)-5-(1-methyl-5- (trifluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 153)
  • Scheme 85 [1041] Synthesis of 1-methyl-5-(trifluoromethyl)-1H-pyrazole-3-carboxylic acid, 205 [Step 1] : To a stirred solution of ethyl 1-methyl-5-(trifluoromethyl)-1H-pyrazole-3-carboxylate (204, 450 mg, 2.20 mmol) in THF(2 mL), methanol(1 mL) and water (0.5 mL), LiOH.H 2 O ( 278 mg, 6.61 mmol) was added at 0 °C and the reaction mixture was stirred for 12h at ambient temperature.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides novel oxadiazole compounds and compounds that are inhibitors of mitochondrial RNA polymerase.

Description

COMPOSITIONS AND INHIBITORS OF POLRMT CROSS-REFERENCE TO APPLICATIONS [0001] The present application claims priority to US provisional application number 63/546,388 filed on October 30, 2023, the entirety of which is incorporated herein. FIELD OF THE INVENTION [0002] The present disclosure relates to POLRMT modulators, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The present disclosure also relates to novel oxadiazole compositions, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The present disclosure also relates to methods of making the modulator compounds and/or oxadiazole compositions. The present disclosure further relates to methods of using such compounds and compositions, including to inhibit or promote POLRMT. BACKGROUND OF THE INVENTION [0003] Human mitochondrial RNA polymerase, POLRMT (also referred to as h- mtRNAP), is a nuclear-encoded single-subunit DNA-dependent RNA polymerase. POLRMT is 1230 amino acids in length and consists of three distinct regions: (1) a C- terminal polymerase domain (CTD) (residues 648–1230); (2) an N-terminal domain (NTD) (residues 369–647); and (3) an N- terminal extension (NTE) (residues 1–368). See, e.g., Arnold, J.J., et al., “Human mitochondrial RNA polymerase: Structure-function, mechanism and inhibition,” Biochim. Biophys. Acta, 1819, 948-960 (2012). It is structurally related to the single-subunit RNA polymerase encoded by bacteriophage T7. The CTD is also known as the catalytic domain due to its function of catalyzing nucleotide incorporation into a growing RNA molecule during transcription. This domain is highly conserved across species, whereas by contrast the NTE demonstrates significant sequence variability, suggesting organism-specific roles for this domain of POLRMT. [0004] POLRMT is of fundamental importance for both expression and replication of the human mitochondrial genome. While aspects of POLRMT biochemistry are known, its full physiological role in mitochondrial gene expression and homeostasis, as well as its underlying impact in the etiology of various disease states, remains unclear. Its dysfunction and/or deregulation impacts mitochondrial metabolism, sometimes through the OXPHOS system, which ultimately contributes to many metabolic, degenerative and age-related diseases such as cancer, diabetes, obesity, and Alzheimer's disease. Pharmacological inhibition of POLRMT is one means by which to gain a further understanding of the role of this polymerase in cell physiology and the development of disease. Regulation of metabolic mechanisms, including oxidative phosphorylation, with POLRMT modulators affords an opportunity for intervention in complex disorders. In view of the numerous and varied roles of POLRMT, the need exists for potent and specific modulators of POLRMT. SUMMARY OF THE INVENTION [0005] Briefly, therefore, the present disclosure is directed to compounds, pharmaceutically acceptable salts of the compounds, and methods of using the compounds, salts of the compounds to treat various neurodegenerative and metabolic disorders, cancer, and also disorders related to aging and mitochondrial diseases. [0006] In a first aspect of the present disclosure, the present disclosure provides a compound, which, according to an embodiment of the present disclosure is a compound represented by Formula (I),
Figure imgf000003_0001
[0007] In some embodiments, X1-X5 are each independently a hydrogen, a halogen, a hydroxy, a cyano, a C1-C6 alkyl, a substituted C1-C6 alkyl, a C3-C6 cycloalkyl, a substituted C3-C6 cycloalkyl, a C1-C6 alkoxy, optionally substituted with an aryl, a C3-C10 cycloalkyl, -C(O)NH2, - C(O)NHY1, -C(O)NY1Y2, -COOH, -C(O)OY1, -Y1COOH, or -Y1OY2. [0008] In some embodiments, Y1 and Y2 are each independently a C1-C6 alkyl optionally substituted with one or more halogen or hydroxy. [0009] In some embodiments, X6-X8 are each independently a C, N, S, or O. [0010] In some embodiments, R3 is a halogen, a hydrogen, a C1-C6 alkyl, a C1-C6 alkyl substituted with one or more halogen, or a C3-C6 cycloalkyl. [0011] In some embodiments, R4 is a hydrogen, a C1-C6 alkyl, or a C1-C6 alkyl substituted with one or more halogen. [0012] In some embodiments, if R3 and R4 are optionally interconnected they form a C3-C6 cycloalkyl, a substituted C3-C6 cycloalkyl, 5-membered heterocyclic ring, a substituted 5- membered heterocyclic ring, 6-membered heterocyclic ring, a substituted 6-membered heterocyclic ring, a phenyl ring, or a substituted phenyl ring. [0013] In some embodiments, A1 and A2 are each independently a hydrogen, a C1-C6 alkyl, a substituted C1-C6 alkyl, an aryl, substituted aryl, a C3-C6 cycloalkyl, a substituted C3-C6 cycloalkyl, a C3-C6 heterocyclyl, substituted C3-C6 heterocyclyl, or absent. [0014] In some embodiments, A1 and A2 may optionally be substituted with one or more members selected from the group consisting of halogen, ester, ether, carboxylic acid, -C(O)NH2, -CS(O)2Y3, a -CY1S(O)2Y3. [0015] In some embodiments, Y3 is independently hydrogen or C1-C4 alkyl optionally substituted with one or more groups selected from the group consisting of halogen, hydroxyl, C1-C4 haloalkoxyl, and C1-C4 alkoxyl. [0016] Some aspects of the present disclosure include compounds described above, wherein the compound has a POLRMT IC50 of 200 nM or less. [0017] Some aspects of the present disclosure include a pharmaceutical composition comprising a compound according to any of the previous claims. [0018] Some aspects of the present disclosure are directed towards a method of inhibiting the activity of POLRMT comprising administering a compound of any of the previous claims to a subject in need thereof. [0019] Other aspects and iterations of the present disclosure are detailed below. DETAILED DESCRIPTION OF THE INVENTION [0020] Modulators of POLRMT are useful in compositions and methods suitable for treating many disorders, such as cancer, neurodegenerative disorders, metabolic disorders, as well as diseases related to aging and mitochondrial diseases. Provided herein are novel compositions, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. Provided herein are compounds of Formulae (I), (IIa), (IIa-2), (IIb-1), (IIb-2)a, (IIc), (IIc-1), (IIc-2a), (IIc-2b), (IId), (IIe), (IIf), (III), (IIIa), (IIIb), (IV), (IVa), (IVb), (Va), (Va-1), (Vb), and (Vb-1) pharmaceutically acceptable salts thereof, prodrugs thereof, and pharmaceutical compositions comprising such compounds, their salts, or their prodrugs that are useful as inhibitors of POLRMT. (I) Definitions [0021] The term “alkyl” as used herein refers to both branched- and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms in a specified range. For example, the term “C1-C6 alkyl” means linear or branched chain alkyl groups, including all possible isomers, having 1, 2, 3, 4, 5, or 6 carbon atoms. Furthermore, alkyl groups allow for substituents to be located on any of the carbon atoms. For example, a substituted C3 alkyl group allows for the substituent to be located on any of the three carbon atoms. [0022] The term “alkoxy” or “alkoxyl” as used herein refers to an -O-alkyl group. For example, the term “ C1-C4 alkoxyl” means -O- C1-C4 alkyl. Examples of alkoxyl include methoxyl, ethoxyl, propoxyl (e.g., n-propoxyl and isopropoxyl), and the like. [0023] The term “haloalkoxy” or “haloalkoxyl” as used herein refers to an -O-alkyl group in which at least one of the hydrogen atoms of the alkyl group is replaced with a halogen atom. Examples of haloalkoxyl include trifluoromethoxyl, 2,2,2-trifluoroethoxyl, and the like.0027 The term “alkanoyl” or “acyl” as used herein refers to an -C(O)-alkyl group. For example, the term “C1-C6 alkanoyl” means -C(O)-C1-C6 alkyl. Examples of alkanoyl include acetyl, propionyl, butyryl, and the like. [0024] The term “bicyclic” as used herein refers to a saturated or unsaturated 6- to 12- membered ring consisting of two joined cyclic substructures, and includes fused, bridged, and spiro bicyclic rings. [0025] The term “heterobicyclic” as used herein refers to a bicyclic ring that contains 1 or more heteroatom(s) in one or more rings that are optionally substituted or oxidized, and may be selected from nitrogen (including N-oxides), oxygen, sulfur (including oxidized forms such as sulfones and sulfonates), phosphorus (including oxidized forms such as phosphates), boron, etc. Examples of heterobicyclic rings include, but are not limited to, 8-azabicyclo[3.2.1]octan-8- yl, 3-oxa-8-azabicyclo[3.2.1]octan-8-yl, 8-oxa-3- azabicyclo[3.2.1]octan-3-yl, and 5-methyl-2,5- diazabicyclo[2.2.1]heptan-2-yl. [0026] The term “cycloalkyl” as used herein refers to a cyclized alkyl ring having the indicated number of carbon atoms in a specified range. Thus, for example, “ C3-C6 cycloalkyl” encompasses each of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. [0027] The term “aryl” as used herein refers to a monocyclic or fused bicyclic ring system having the characteristics of aromaticity, wherein at least one ring contains a completely conjugated pi-electron system. Typically, aryl groups contain 6 to 14 carbon atoms (“C6- C14 aryl”) or preferably, 6 to 12 carbon atoms (“C6-C12 aryl”). Fused aryl groups may include an aryl ring (e.g., a phenyl ring) fused to another aryl ring, or fused to a saturated or partially unsaturated carbocyclic or heterocyclic ring. The point of attachment to the base molecule on such fused aryl ring systems may be a C atom of the aromatic portion or a C or N atom of the non-aromatic portion of the ring system. Examples, without limitation, of aryl groups include phenyl, biphenyl, naphthyl, anthracenyl, indanyl, indenyl, and tetrahydronaphthyl. [0028] The term “cycloaryl” herein refers to a polycyclic group wherein an aryl group is fused to a 5- or 6-membered aliphatic or heterocyclic ring. For example, “C6-C12 cycloaryl” means a C6- C12 aryl fused to a 5- or 6-membered aliphatic or heterocyclic ring. One example of C6 cycloaryl is 2,3-dihydrobenzo[b][1,4]dioxine. [0029] The term “heteroaryl” as used herein refers to (i) a 5- or 6-membered ring having the characteristics of aromaticity containing at least one heteroatom selected from N, O and S, wherein each N is optionally in the form of an oxide, and (ii) a 9- or 10- membered bicyclic fused ring system, wherein the fused ring system of (ii) contains at least one heteroatom independently selected from N, O and S, wherein each ring in the fused ring system contains zero, one or more than one heteroatoms, at least one ring is aromatic, each N is optionally in the form of an oxide, and each S in a ring which is not aromatic is optionally S(O) or S(O)2. Typically, heteroaryl groups contain 5 to 14 ring atoms (“5-14 membered heteroaryl”), and preferably 5 to 12 ring atoms (“5-12 membered heteroaryl”). Heteroaryl rings are attached to the base molecule via a ring atom of the heteroaromatic ring, such that aromaticity is maintained. Suitable 5- and 6-membered heteroaromatic rings include, for example, pyridyl, 3-fluroropyridyl, 4-fluoropyridyl, 3- methoxypyridyl, 4-methoxypyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, thienyl, furanyl, imidazolyl, pyrazolyl, triazolyl (i.e., 1,2,3-triazolyl or 1,2,4- triazolyl), tetrazolyl, oxazolyl, isooxazolyl, oxadiazolyl (i.e., the 1,2,3-, 1,2,4-, 1,2,5- (furazanyl), or 1,3,4- isomer), oxatriazolyl, thiazolyl, isothiazolyl, and thiadiazolyl. Suitable 9- and 10-membered heterobicyclic, fused ring systems include, for example, benzofuranyl, indolyl, indazolyl, naphthyridinyl, isobenzofuranyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, chromenyl, quinolinyl, isoquinolinyl, benzopiperidinyl, benzofuranyl, imidazo[1,2-a]pyridinyl, benzotriazolyl, indazolyl, indolinyl, and isoindolinyl. [0030] The term “heteroaryloxy” or “heteroaryloxyl” as used herein refers to an -O- heteroaryl group.0035 The term “heterocycle”, “heterocyclyl”, or “heterocyclic” as used herein represents a stable 3- to 10-membered monocyclic, non-aromatic ring that is either saturated or unsaturated, and that consists of carbon atoms and from one to two heteroatoms selected from the group consisting of N, O, and S. Examples include oxiranyl, aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, 1,4-dioxanyl, morpholinyl, piperazinyl, azepanyl, oxepanyl, and oxazepanyl. [0031] The term “oxo” as used herein refers to a group which consists of oxygen which is double bonded to carbon or any other element. [0032] The term “imine” as used herein refers to a group containing a carbon-nitrogen double bond. [0033] The term “carboxyl” as used herein refers to a combination of two functional groups attached to a single carbon atom, namely, hydroxyl (OH) and carbonyl (O). [0034] The term “optionally substituted” or “optional substituents” as used herein means that the groups are either unsubstituted or substituted with one or more of the substituents specified. When the groups are substituted with more than one substituent, the substituents may be the same or different. Furthermore, when using the terms “independently,” “independently are,” and “independently selected from” mean that the groups may be the same or different. [0035] The term “deuterium” as used herein refers to an isotope of hydrogen that has one proton and one neutron in its nucleus and that has twice the mass of ordinary hydrogen. Deuterium herein is represented by the symbol “D”. [0036] The term “deuterated” by itself or used to modify a compound or group as used herein refers to the presence of at least one deuterium atom attached to carbon. For example, the term “deuterated compound” refers to a compound which contains one or more carbon-bound deuterium(s). In a deuterated compound of the present invention, when a particular position is designated as having deuterium, it is understood that the abundance of deuterium at that position is substantially greater than the natural abundance of deuterium, which is about 0.015 %. [0037] The term “undeuterated” or “non-deuterated” as used herein refers to the ratio of deuterium atoms of which is not more than the natural isotopic deuterium content, which is about 0.015 %; in other words, all hydrogen are present at their natural isotopic percentages. Unless otherwise stated, when a position is designated specifically as “H” or “hydrogen”, the position is understood to have hydrogen at its natural abundance isotopic composition. [0038] The term “isotopic enrichment factor” as used herein refers to the ratio between the isotope abundance and the natural abundance of a specified isotope. [0039] The term “isotopologue” as used herein refers to a species in which the chemical structure differs from a specific compound of the invention only in the isotopic composition thereof. [0040] The term “substantially free of other stereoisomers” as used herein means less than 10 % of other stereoisomers, preferably less than 5 % of other stereoisomers, more preferably less than 2 % of other stereoisomers and most preferably less than 1 % of other stereoisomers are present. [0041] The term “pharmaceutically acceptable salt” as used herein refers to a salt that is not biologically or otherwise undesirable (e.g., not toxic or otherwise harmful). A salt of a compound of the invention is formed between an acid and a basic group of the compound, or a base and an acidic group of the compound. For example, when the compounds of the invention contain at least one basic group (i.e., groups that may be protonated), the invention includes the compounds in the form of their acid addition salts with organic or inorganic acids such as, for example, but not limited to salts with hydrogen chloride, hydrogen bromide, phosphoric acid, sulfuric acid, nitric acid, benzenesulfonic acid, acetic acid, citric acid, glutamic acid, lactic acid, and methanesulfonic acid. When compounds of the invention contain one or more acidic groups (e.g., a carboxylic acid), the invention includes the pharmaceutically acceptable salts of the compounds formed with but not limited to alkali metal salts, alkaline earth metal salts or ammonium salts. Examples of such salts include, but are not limited to, sodium salts, potassium salts, calcium salts, magnesium salts or salts with ammonia or organic amines such as, for example, ethylamine, ethanolamine, triethanolamine or amino acids. Additional examples of such salts may be found in Stahl, P. H. et al. Pharmaceutical Salts: Properties, Selection, and Use, 2nd Revised Edition, Wiley, 2011. [0042] The term “prodrug” as used herein refers to derivatives of compounds of the invention which may have reduced pharmacological activity, but can, when administered to a patient, be converted into the inventive compounds. Design and use of prodrugs may be found in “Pro- drugs as Novel Delivery Systems,” Vol.14, ACS Symposium Series (T Higuchi and W Stella) and “Bioreversible Carriers in Drug Design,” Pergamon Press, 1987 (ed. E B Roche, American Pharmaceutical Association), the disclosures of which are incorporated herein by reference in their entireties. The terms “treatment”, “treating” and “treat” as used herein, include their generally accepted meanings, i.e., the management and care of a patient for the purpose of preventing, reducing the risk in incurring or developing a given condition or disease, prohibiting, restraining, alleviating, ameliorating, slowing, stopping, delaying, or reversing the progression or severity, and holding in check existing characteristics of a disease, disorder, or pathological condition, including the alleviation or relief of symptoms or complications, or the cure or elimination of the disease, disorder, or condition. [0043] The term “therapeutically effective amount” as used herein refers to that amount of compound of the invention that will elicit the biological or medical response of a tissue, system, animal, or human that is being sought by a researcher, veterinarian, medical doctor or other. As will be recognized by a person of ordinary skill in the art, a therapeutically effective amount of the compounds of the invention will vary and will depend on the diseases treated, the severity of the disease, the route of administration, and the gender, age, and general health condition of the subject to whom the compound is being administered. The therapeutically effective amount may be administered as a single dose once a day, or as split doses administered multiple (e.g., two, three or four) times a day. The therapeutically effective amount may also be administered through continuous dosing, such as through infusion or with an implant. (II) Compounds A. General Structures [0044] The present disclosure is directed to a compound, or a pharmaceutically acceptable salt thereof, according to Formula (I):
Figure imgf000009_0001
wherein X1-X5 are each independently a hydrogen, a halogen, a hydroxy, a cyano, a C1-C6 alkyl, a substituted C1-C6 alkyl, a C3-C6 cycloalkyl, a substituted C3-C6 cycloalkyl, a C1-C6 alkoxy, optionally substituted with an aryl, a C3-C10 cycloalkyl, -C(O)NH2, -C(O)NHY1, - C(O)NY1Y2, -COOH, -C(O)OY1, -Y1COOH, or -Y1OY2; Y1 and Y2 are each independently a C1-C6 alkyl optionally substituted with one or more halogen or hydroxy; X6-X8 are each independently a C, N, S, or O; R3 is a halogen, a hydrogen, a C1-C6 alkyl, a C1-C6 alkyl substituted with one or more halogen, or a C3-C6 cycloalkyl; R4 is a hydrogen, a C1-C6 alkyl, or a C1-C6 alkyl substituted with one or more halogen; if R3 and R4 are optionally interconnected they form a C3-C6 cycloalkyl, a substituted C3-C6 cycloalkyl, 5-membered heterocyclic ring, a substituted 5-membered heterocyclic ring, 6-membered heterocyclic ring, a substituted 6-membered heterocyclic ring, a phenyl ring, or a substituted phenyl ring; A1 and A2 are each independently a hydrogen, a C1-C6 alkyl, a substituted C1-C6 alkyl, an aryl, substituted aryl, a C3-C6 cycloalkyl, a substituted C3-C6 cycloalkyl, a C3-C6 heterocyclyl, substituted C3-C6 heterocyclyl, or absent; wherein A1 and A2 may optionally be substituted with one or more members selected from the group consisting of halogen, ester, ether, carboxylic acid, -C(O)NH2, -CS(O)2Y3, a -CY1S(O)2Y3; Y3 is independently a hydrogen or a C1-C4 alkyl optionally substituted with one or more groups selected from the group consisting of a halogen, a hydroxyl, a C1-C4 haloalkoxyl, and a C1-C4 alkoxyl; with the proviso that formula (I) excludes the following compounds: 5-[5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl]-3-[1-(5-fluoro-2- methylphenyl)cyclopropyl]-1,2,4-oxadiazole; 3-[1-(3-methylphenyl)cyclopropyl]-5-(1-methyl-1H-pyrazol-5-yl)-1,2,4-oxadiazole; 3-[1-(3-Methoxyphenyl)cyclopropyl]-5-[5-(1-methylethyl)-1H-pyrazol-3-yl]-1,2,4- oxadiazole; 3-[1-(5-fluoro-2-methylphenyl)cyclopropyl]-5-(5-methoxy-1-methyl-1H-pyrazol-3-yl)- 1,2,4-oxadiazole; 5-(1-methyl-1H-pyrazol-3-yl)-3-(1-phenylcyclopropyl)-1,2,4-oxadiazole; 3-[1-(3,5-Dimethylphenyl)cyclopropyl]-5-(1-methyl-1H-pyrazol-5-yl)-1,2,4-oxadiazole; 1-methyl-5-(3-(1-(3-(trifluoromethyl)phenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-2,3-dihydro- 1H-pyrazol-3-ol, 1,2-Dihydro-1-methyl-5-[3-[1-[3-(trifluoromethyl)phenyl]cyclopropyl]-1,2,4- oxadiazol-5-yl]-3H-pyrazol-3-one; 5-(1-Methyl-1H-pyrazol-5-yl)-3-[1-[3-(trifluoromethyl)phenyl]cyclopropyl]-1,2,4- oxadiazole; 3-[1-(3-Methoxyphenyl)cyclopropyl]-5-(1-methyl-1H-pyrazol-5-yl)-1,2,4-oxadiazole; 3-[1-(3-Bromophenyl)cyclopropyl]-5-(1-methyl-1H-pyrazol-5-yl)-1,2,4-oxadiazole; and 5-(3-Ethyl-1-methyl-1H-pyrazol-5-yl)-3-[1-(3-methylphenyl)cyclopropyl]-1,2,4- oxadiazole. [0045] In some aspects, X1-X5 may each independently be a hydrogen, a halogen, a hydroxy, a cyano, a C1-C6 alkyl, a substituted C1-C6 alkyl, a C3-C6 cycloalkyl, a substituted C3-C6 cycloalkyl, a C1-C6 alkoxy, optionally substituted with an aryl, a C3-C10 cycloalkyl, -C(O)NH2, -C(O)NHY1, - C(O)NY1Y2, -COOH, -C(O)OY1, -Y1COOH, or -Y1OY2, wherein Y1 and Y2 are each independently a C1-C6 alkyl optionally substituted with one or more halogen or hydroxy. [0046] In some aspects, X6-X8 may each independently be a C, N, S, or O. [0047] In some aspects, R3 may be a halogen, a hydrogen, a C1-C6 alkyl, a C1-C6 alkyl substituted with one or more halogen, or a C3-C6 cycloalkyl. [0048] In some aspects, R4 may be a hydrogen, a C1-C6 alkyl, or a C1-C6 alkyl substituted with one or more halogen. [0049] In other aspects, R3 and R4 may optionally be interconnected to form a C3-C6 cycloalkyl, a substituted C3-C6 cycloalkyl, 5-membered heterocyclic ring, a substituted 5-membered heterocyclic ring, a phenyl ring, or a substituted phenyl ring. [0050] In some aspects, A1 and A2 may each independently be a hydrogen, a C1-C6 alkyl, a substituted C1-C6 alkyl, an aryl, substituted aryl, a C3-C6 cycloalkyl, a substituted C3-C6 cycloalkyl, a C3-C6 heterocyclyl, substituted C3-C6 heterocyclyl, or absent. [0051] In some aspects, A1 and A2 are each independently be one or more members selected from the group consisting of halogen, ester, ether, carboxylic acid, -C(O)NH2, -CS(O)2Y3, a - CY1S(O)2Y3, wherein Y3 may be independently a hydrogen or a C1-C4 alkyl optionally substituted with one or more groups selected from the group consisting of a halogen, a hydroxyl, a C1-C4 haloalkoxyl, and a C1-C4 alkoxyl. [0052] In some aspects, A1 and A2 may each independently be -C(O)NY3Y4, -CY1(O)NY3Y4, or - NY3Y4. In some aspects, Y3 is independently a hydrogen or a C1-C4 alkyl optionally substituted with one or more groups selected from the group consisting of a halogen, a hydroxyl, a C1-C4 haloalkoxyl, and a C1-C4 alkoxyl. In some asptects, Y4 is independently Y3, cyano, C3-C6 cycloheteroalkyl, C1-C6 amide, C1-C6 amine, C1-C6 carboxyl, aryl, C1-C6 alkyl optionally substituted with one or more halogen groups, 5- or 6-membered heterocyclyl, or C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 hydroxy, or -C(O)C1-C4 alkyl optionally substituted with one or more halogen groups. In yet other aspects, Y3and Y4are attached to the same nitrogen atom, Y3and Y4together with their connecting nitrogen form a 4- to 6-membered heterocyclic ring optionally containing one or more heteroatoms that is N, O, S, S(O), SO2, or S(O)NY3, and such heterocyclic ring is optionally substituted with one or more groups, each group independently selected from the group consisting of halogen, C1-C4alkyl, C1-C4alkoxyl, C1-C4haloalkoxyl, carboxyl, oxo, and C1-C4^alkylcarboxylate. B. Compounds with Formulae (IIa-1) and (IIa-2) [0053] The present disclosure is directed to a compound, or a pharmaceutically acceptable salt thereof, according to Formula (IIa-1):
Figure imgf000012_0001
[0054] In some aspects, X1-X5 may each independently be a hydrogen, a halogen, a hydroxy, a cyano, a C1-C6 alkyl, a substituted C1-C6 alkyl, a C3-C6 cycloalkyl, a substituted C3-C6 cycloalkyl, a C1-C6 alkoxy, optionally substituted with an aryl, a C3-C10 cycloalkyl, -C(O)NH2, -C(O)NHY1, - C(O)NY1Y2, -COOH, -C(O)OY1, -Y1COOH, or -Y1OY2, wherein Y1 and Y2 are each independently a C1-C6 alkyl optionally substituted with one or more halogen or hydroxy. [0055] In some aspects, R3 may be a halogen, a hydrogen, a C1-C6 alkyl, a C1-C6 alkyl substituted with one or more halogen, or a C3-C6 cycloalkyl. [0056] In some aspects, R4 may be a hydrogen, a C1-C6 alkyl, or a C1-C6 alkyl substituted with one or more halogen. [0057] In other aspects, R3 and R4 may optionally be interconnected to form a C3-C6 cycloalkyl, a substituted C3-C6 cycloalkyl, 5-membered heterocyclic ring, a substituted 5-membered heterocyclic ring, 6-membered heterocyclic ring, a substituted 6-membered heterocyclic ring, a phenyl ring, or a substituted phenyl ring. [0058] In some aspects, R10-R15 may each independently be a hydrogen, an alkoxy, a halogen, a C1-C6 alkyl, or a carboxylic acid. [0059] In some examples, X1 may be a C1-C6 alkyl or a halogen. [0060] In some examples, X2 may be a hydrogen or a halogen. [0061] In some examples, X3 may be a hydrogen, a halogen, or a C1-C6 alkyl. [0062] In some examples, X4 may be hydrogen. [0063] In some examples, X5 may be a hydrogen or a C1-C6 alkyl. [0064] In some examples, at least two of X2- X5 are hydrogen. [0065] In some examples, at least three of X2- X5 are hydrogen. [0066] In some examples, X2- X5 may be hydrogen. [0067] In some examples, X1 may be methyl or Cl. [0068] In some examples, X2 may be Cl or hydrogen and X3 may be methyl, F, Cl, or hydrogen. [0069] In some examples, R3 may be a hydrogen, a methyl or -CHF2. [0070] In some examples, R4 may be hydrogen. [0071] In some examples, R10-R15 may each independently be a hydrogen, a methyl, a methoxy, a halogen, a carboxylic acid, or an amide. [0072] In some examples, R3 may be -CHF2, methyl, or hydrogen, and R4 is hydrogen. [0073] In some examples, the X1 may be halogen or methyl and R3 may be methyl, -CHF2, or - CF3. [0074] In some examples, the X2 may be hydrogen or halogen and R3 may be methyl, -CHF2, or -CF3. [0075] In some examples, the X3 may be hydrogen or halogen and R3 may be methyl, -CHF2, or -CF3. [0076] In some examples, X1-X3 may each be independently hydrogen, halogen, or methyl, and R3 may be methyl, -CHF2, or -CF3. [0077] In some examples, X1-X3 may each be independently hydrogen, halogen, or methyl, and R3-R4 are independently hydrogen, methyl, -CHF2, or -CF3. [0078] In some examples, at least one of R10-R15 is carboxylic acid. [0079] In some examples, at least one of R10-R11 is carboxylic acid [0080] In some examples, at least one of R12-R13 is carboxylic acid [0081] In some examples, at least one of R14-R15 is carboxylic acid. [0082] In some examples, R12-R13 may each independently be hydrogen, fluorine, methyl, methoxy, or carboxylic acid. [0083] In some examples, R10-R11 and R14-R15 may be hydrogen and the compound may be represented by Formula (IIa-2):
Figure imgf000014_0001
[0084] In some embodiments of Formula (IIa-2), X1-X5 may each independently be hydrogen, halogen, or C1-C6 alkyl. [0085] In some embodiments of Formula (IIa-2), R3 may be halogen, hydrogen, C1-C6 alkyl, substituted C1-C6 alkyl, or C3-C6 cycloalkyl. [0086] In some embodiments of Formula (IIa-2), R4 may be hydrogen, C1-C6 alkyl, or substituted C1-C6 alkyl. [0087] In some embodiments of Formula (IIa-2), R12 and R13 are each independently a C1-C6 alkyl, a hydrogen, a halogen, a carboxylic acid, an alkoxy, or an amide. [0088] In some embodiments of Formula (IIa-2), X1 may be methyl. [0089] In some embodiments of Formula (IIa-2), X3 may be a halogen or a hydrogen. [0090] In some embodiments of Formula (IIa-2), X2, X4, and X5 may be hydrogen. [0091] In some embodiments of Formula (IIa-2), R3 may be hydrogen, C1-C6 alkyl, or substituted C1-C6 alkyl. [0092] In some embodiments of Formula (IIa-2), R4 may be hydrogen. [0093] In some embodiments of Formula (IIa-2), R12 and R13 may each independently be hydrogen, carboxylic acid, alkoxy, or amide. [0094] In some embodiments of Formula (IIa-2), X1 may be methyl, X2, X4, and X5 are hydrogen, X3 may be a halogen or a hydrogen, R3 may be hydrogen, C1-C6 alkyl, or substituted C1-C6 alkyl, R4 may be hydrogen, and R12 and R13 may each independently be hydrogen, carboxylic acid, alkoxy, or amide. [0095] In some embodiments of Formula (IIa-2), R3 may be difluoromethyl. [0096] In some embodiments of Formula (IIa-2), R10 may be carboxylic acid and R11 may be hydrogen. [0097] In some embodiments of Formula (IIa-2), R10 may be amide and R11 may be hydrogen. [0098] In some embodiments of Formula (IIa-2), X1 may be a halogen. [0099] In some embodiments of Formula (IIa-2), X2 may be hydrogen or halogen. [0100] In some embodiments of Formula (IIa-2), X3 may be methyl, halogen, or hydrogen. [0101] In some embodiments of Formula (IIa-2), X4 and X5 may be hydrogen [0102] In some embodiments of Formula (IIa-2), X1 may be a halogen, X2 is hydrogen or halogen, X3 is methyl, halogen, or hydrogen, and X4 and X5 are hydrogen. [0103] In some embodiments of Formula (IIa-2), R3 may be difluoromethyl and R4 may be hydrogen [0104] In some embodiments of Formula (IIa-2), R12 and R13 are each independently hydrogen or carboxylic acid. [0105] In some embodiments of Formula (IIa-2), R10 may be carboxylic acid and R11 may be methoxy. [0106] In some embodiments of Formula (IIa-2), R10 may be carboxylic acid and R11 may be methyl. C. Compounds with Formulae (IIb-1) & (IIb-2) [0107] The present disclosure is directed to a compound, or a pharmaceutically acceptable salt thereof, according to Formulae (IIb-1) & (IIb-2):
Figure imgf000015_0001
Formula (IIb-1); or
Figure imgf000016_0001
[0108] In some aspects, X1-X5 may each independently be a hydrogen, a halogen, a hydroxy, a cyano, a C1-C6 alkyl, a substituted C1-C6 alkyl, a C3-C6 cycloalkyl, a substituted C3-C6 cycloalkyl, a C1-C6 alkoxy, optionally substituted with an aryl, a C3-C10 cycloalkyl, -C(O)NH2, -C(O)NHY1, - C(O)NY1Y2, -COOH, -C(O)OY1, -Y1COOH, or -Y1OY2, wherein Y1 and Y2 are each independently a C1-C6 alkyl optionally substituted with one or more halogen or hydroxy. [0109] In some aspects, R3 may be a halogen, a hydrogen, a C1-C6 alkyl, a C1-C6 alkyl substituted with one or more halogen, or a C3-C6 cycloalkyl. [0110] In some aspects, R4 may be a hydrogen, a C1-C6 alkyl, or a C1-C6 alkyl substituted with one or more halogen. [0111] In other aspects, R3 and R4 may optionally be interconnected to form a C3-C6 cycloalkyl, a substituted C3-C6 cycloalkyl, 5-membered heterocyclic ring, a substituted 5-membered heterocyclic ring, 6-membered heterocyclic ring, a substituted 6-membered heterocyclic ring, a phenyl ring, or a substituted phenyl ring. [0112] In some aspects, R20-R29 may each independently be a hydrogen, a C1-C6 alkyl, a carboxylic acid, an amide, a substituted amide, an alkoxy, or a halogen. [0113] In some examples, X1 may be a C1-C6 alkyl. [0114] In some examples, X1 may be a methyl. [0115] In some examples, X2 and X4 may be hydrogen. [0116] In some examples, X3 may be a hydrogen or halogen. [0117] In some examples, X5 may be a hydrogen or a C1-C6 alkyl. [0118] In some examples, at least two of X2- X5 may be hydrogen. [0119] In some examples, at least three of X2- X5 may be hydrogen. [0120] In some examples, X2-X5 may be hydrogen. [0121] In some examples, R3 may be a hydrogen, a methyl, or -CHF2. [0122] In some examples, R4 may be hydrogen. [0123] In some examples, R20-R29 are each independently a hydrogen, a C1-C6 alkyl, an alkoxy, a halogen, a carboxylic acid, amide, or a substituted amide. [0124] In some examples, the substituted amide may be substituted with one or more C1-C6 alkyl. [0125] In some examples, at least one of R20-R29 may be carboxylic acid, amide, or substituted amide. [0126] In some examples, at least one of R20-R21 may be carboxylic acid, amide, or substituted amide. [0127] In some examples, at least one of R22-R23 may be carboxylic acid, amide, or substituted amide. [0128] In some examples, at least one of R24-R25 may be carboxylic acid, amide, or substituted amide. [0129] In some examples, at least one of R26-R27 may be carboxylic acid, amide, or substituted amide. [0130] In some examples, at least one of R28-R29 may be carboxylic acid, amide, or substituted amide. [0131] In some examples, X1 may be halogen or methyl and R3 may be hydrogen, methyl, CHF2, or CF3. [0132] In some examples, X2 may be hydrogen or halogen and R3 may be hydrogen, methyl, CHF2, or CF3. [0133] In some examples, X3 may be hydrogen or halogen and R3 may be hydrogen, methyl, CHF2, or CF3. [0134] In some examples, X1-X3 may each independently be hydrogen, halogen, or methyl, and R3 is H, methyl, CHF2, or CF3. [0135] In some examples, X1-X3 may each independently be hydrogen, halogen, or methyl, X4- X5 may each independently be hydrogen or halogen, and R3-R4 may independently be hydrogen, methyl, CHF2, or CF3. [0136] In some examples, X1-X3 may each independently be hydrogen, fluorine, chlorine, bromine, or methyl, X4-X5 are each independently hydrogen or halogen, and R3-R4 are independently hydrogen, methyl, CHF2, or CF3. [0137] In some examples, at least one of R20-R29 may be carboxylic acid. [0138] In some examples, at least one of R20-R23 may be carboxylic acid. [0139] In some examples, at least one of R24-R25 may be carboxylic acid. [0140] In some examples, at least one of R26-R29 may be carboxylic acid. [0141] In some examples, R24-R25 may each independently be hydrogen, fluorine, methyl, methoxy, or carboxylic acid. [0142] In some examples, R24-R25 may each independently be hydrogen or carboxylic acid. [0143] In some examples, wherein R3 and R4 may be interconnected to form a 5-membered cyclic ring. [0144] In some examples, R3 and R4 may be interconnected to form a phenyl ring. D. Compounds with Formulas (IIc), (IIc-1), (IIc-2a), and (IIc-2b) [0145] The present disclosure is directed to a compound, or a pharmaceutically acceptable salt thereof, according to Formula (IIc):
Figure imgf000018_0001
[0146] In some aspects, X1-X5 may each independently be a hydrogen, a halogen, a hydroxy, a cyano, a C1-C6 alkyl, a substituted C1-C6 alkyl, a C3-C6 cycloalkyl, a substituted C3-C6 cycloalkyl, a C1-C6 alkoxy, optionally substituted with an aryl, a C3-C10 cycloalkyl, -C(O)NH2, -C(O)NHY1, - C(O)NY1Y2, -COOH, -C(O)OY1, -Y1COOH, or -Y1OY2. Y1 and Y2 may each be independently a C1-C6 alkyl optionally substituted with one or more halogen or hydroxy. [0147] In some aspects, R3 may be a halogen, a hydrogen, a C1-C6 alkyl, a C1-C6 alkyl substituted with one or more halogen, or a C3-C6 cycloalkyl. [0148] In some aspects, R4 may be a hydrogen, a C1-C6 alkyl, or a C1-C6 alkyl substituted with one or more halogen. [0149] In other aspects, R3 and R4 may optionally be interconnected to form a C3-C6 cycloalkyl, a substituted C3-C6 cycloalkyl, 5-membered heterocyclic ring, a substituted 5-membered heterocyclic ring, 6-membered heterocyclic ring, a substituted 6-membered heterocyclic ring, a phenyl ring, or a substituted phenyl ring. [0150] In other aspects, A3 is a hydrogen, a C1-C6 alkyl, a C2-C6 branched alkyl, a C1-C6 alkyl substituted with heterocyclyl, a C1-C6 alkyl substituted with a substituted heterocyclyl, or a C1-C6 alkyl substituted C1-C6 alkoxy. [0151] In other aspects, B is -C(O)OH, -C(O)NH2, C(O)NHY3, C(O)NY3Y4, -CS(O)2Y3, - Y3CS(O)2Y3, or absent. Y3 and Y4 may each independently be a C1-C4 alkyl optionally substituted with one or more groups selected from the group consisting of a halogen, a hydroxyl, a C1-C4 haloalkoxyl, and a C1-C4 alkoxyl. [0152] In some examples, X1 is a hydrogen, a halogen, a cyano, a C1-C6 alkyl, a substituted C1- C6 alkyl, a C3-C6 cycloalkyl, a substituted C3-C6 cycloalkyl, a C1-C6 alkoxy, a C1-C6 cycloalkoxy, - COOH, -C(O)NH2, -C(O)NHY1, or -C(O)NY1Y2 and Y1 and Y2 are methyl. [0153] In some examples, X1 is a C1-C6 alkyl. For examples, the C1-C6 alkyl may be methyl or ethyl. [0154] In some examples, X1 is halogen. For example, the halogen may be fluorine, chlorine, or bromine. [0155] In some examples, the C3-C6 cycloalkyl may be cyclopropyl [0156] In some examples, X1 may be -CH2OCH3, -CH2OH, or -CF3. [0157] In some examples, X1 may be -C(O)NH2, -C(O)NHCH3, or -C(O)NCH3CH3. [0158] In some examples, X2 and X3 may be a hydrogen, a halogen, or a C1-C6 alkyl. [0159] In some examples, X4 may be a hydrogen, a halogen, a hydroxy, a methoxy, a C1-C6 alkyl, or a substituted C1-C6 alkyl. For example, the substituted C1-C6 alkyl may be -CH2OH. [0160] In some examples, X5 may be a hydrogen, halogen, hydroxy, methoxy, a C1-C6 alkyl, or a substituted C1-C6 alkyl. [0161] In some examples, A3 may be a C1-C6 alkyl or substituted C1-C6 alkyl and B is carboxylic acid. For example, A3 may be methyl, ethyl, 1-methyl-methyl, dimethyl-methyl, methyl ethyl, dimethyl ethyl, or methyl-cyclopropyl. Furthermore, the methyl may be connected to a thiazole via a carbon-carbon bond. The methyl may also be connected to a phenyl or a cyclopropyl. [0162] In some aspects, the substituted C1-C6 alkyl may be substituted methyl, substituted ethyl, or substituted propyl. For example, the substituted methyl may be -C(H)(CH3). Alternatively, the substituted ethyl may be -CH2CH(OCH3), -CH2CH(OH), - CH2C(CH3)H, or CH2C(CH3)2. [0163] In some examples, X1 may be C1-C6 alkyl or halogen. [0164] In some examples, X2 may be hydrogen or halogen. [0165] In some examples, X3 may be hydrogen, C1-C6 alkyl, or halogen. [0166] In some examples, X4 may be hydrogen. [0167] In some examples, X1 may be C1-C6 alkyl or hydrogen. [0168] In some examples, R3 may be C1-C6 alkyl substituted with one or more halogen. For example, R3 may be -CHF2 or -CF3. [0169] In some examples, R4 may be hydrogen. [0170] In some examples, X1-X5 may each independently be hydrogen, a halogen, or a C1-C6 alkyl. [0171] In some examples, X3-X4 may each independently be hydrogen, methyl, cyclopropyl, - CHF2, or -CF3. [0172] In some examples, A3 may be substituted with at least one halogen, ester, ether, or carboxylic acid. [0173] In some examples, A3 may be substituted with at least one -C(O)NH2, -CS(O)2Y3, or - CY1S(O)2Y3. [0174] In some examples, B may be carboxylic acid, amide, methanesulfonamide, methoxy, substituted amide, amine, substituted amine, or substituted sulfoxide. [0175] In some examples, B may be amine or substituted amine with Formula (IIc-1):
Figure imgf000020_0001
[0176] In some embodiments of Formula (IIc-1), X1 may be a C1-C6 alkyl. [0177] In some embodiments of Formula (IIc-1), X2-X5 may be hydrogen. [0178] In some embodiments of Formula (IIc-1), R3 may be -CHF2. [0179] In some embodiments of Formula (IIc-1), R4 may be hydrogen. [0180] In some embodiments of Formula (IIc-1), A3 may be a C1-C6 alkyl. [0181] In some embodiments of Formula (IIc-1), B3 and B4 may each independently be hydrogen or a C1-C6 alkyl. [0182] In some embodiments of Formula (IIc-1), X1 is a C1-C6 alkyl, X2-X5 are hydrogen, R3 is - CHF2, R4 is hydrogen, A3 is a C1-C6 alkyl; and B3 and B4 are each independently hydrogen or a C1-C6 alkyl. [0183] In some examples, B may be amide or substituted amide with Formula (IIc-2a) or Formula (IIc-2b):
Figure imgf000021_0001
Formula (IIc-2a); or
Figure imgf000022_0001
[0184] In some embodiments of Formulae (IIc-2a) and (IIc-2b), X1 may be C1-C6 alkyl or halogen. [0185] In some embodiments of Formulae (IIc-2a) and (IIc-2b), X2-X4 may be hydrogen or halogen. [0186] In some embodiments of Formulae (IIc-2a) and (IIc-2b), X5 may be hydrogen, halogen, or C1-C6 alkyl. [0187] In some embodiments of Formulae (IIc-2a) and (IIc-2b), R3 may be -CHF2, -CF3 or a C3- C6 cycloalkyl. [0188] In some embodiments of Formulae (IIc-2a) and (IIc-2b), R4 may be hydrogen. [0189] In some embodiments of Formulae (IIc-2a) and (IIc-2b), A3 may be a C1-C6 alkyl or branched C1-C6 alkyl. [0190] In some embodiments of Formulae (IIc-2a) and (IIc-2b), B3 and B4 may be each independently hydrogen, a C1-C6 alkyl, a substituted a C1-C6 alkyl, a C3-C6 cycloalkyl, a substituted a C3-C6 cycloalkyl, a C3-C6 heterocyclyl, a substituted a C3-C6 heterocyclyl, phenyl, substituted phenyl. [0191] In some embodiments of Formulae (IIc-2a) and (IIc-2b), if B3 and B4 are optionally interconnected they form a 4-membered, 5- membered, 6- membered cycloalkyl ring, substituted cycloalkyl ring, heterocyclyl ring, or substituted heterocyclyl ring. [0192] In some embodiments of Formulae (IIc-2a) and (IIc-2b), B5 and B6 may each independently be hydrogen or C1-C6 alkyl. [0193] In some embodiments of Formulae (IIc-2a) and (IIc-2b), the C1-C6 alkyl may be methyl of ethyl. [0194] In some embodiments of Formulae (IIc-2a) and (IIc-2b), the branched C1-C6 alkyl may be -CH2(CH3)-. [0195] In some embodiments of Formulae (IIc-2a) and (IIc-2b), the substituted C1-C6 alkyl may be - CH2CH2OCH3, -CH2C(CH3)2OH, -CH2CH2OH, -CH2COOH, -CH(CH3)COOH, - C(CH3)2COOH, methyl-pyridyl, methyl-methyl substituted-pyridyl, methyl cyclopropyl, methyl cyclobutyl, -CH2CONH2,CH2CONHCH3, -CH2CH2N(CH3)2, -CH(CH3)CONH2, or -CH2CF3. [0196] In some embodiments of Formulae (IIc-2a) and (IIc-2b), A3 may be ethyl and B may be methanesulfonamide [0197] In some embodiments of Formulae (IIc-2a) and (IIc-2b), A3 may be ethyl and B may be methoxy. [0198] In some embodiments of Formulae (IIc-2a) and (IIc-2b), A3 may be ethyl and B may be substituted sulfoxide. [0199] In some embodiments of Formulae (IIc-2a) and (IIc-2b), R3 may be -CHF2, halogen, cyclopropyl, or methyl. [0200] In some embodiments of Formulae (IIc-2a) and (IIc-2b), R4 may be hydrogen or methyl. [0201] In some embodiments of Formulae (IIc-2a) and (IIc-2b), R3 and R4 may be connected to form a 5-membered cycloalkyl ring. E. Compounds with Formula (IId) [0202] The present disclosure is directed to a compound, or a pharmaceutically acceptable salt thereof, according to Formula (IId):
Figure imgf000024_0001
[0203] In some aspects, X1-X5 may each independently be a hydrogen, a halogen, a hydroxy, a cyano, a C1-C6 alkyl, a substituted C1-C6 alkyl, a C3-C6 cycloalkyl, a substituted C3-C6 cycloalkyl, a C1-C6 alkoxy, optionally substituted with an aryl, a C3-C10 cycloalkyl, -C(O)NH2, -C(O)NHY1, - C(O)NY1Y2, -COOH, -C(O)OY1, -Y1COOH, or -Y1OY2. Y1 and Y2 may each be independently a C1-C6 alkyl optionally substituted with one or more halogen or hydroxy. [0204] In some aspects, R3 may be a halogen, a hydrogen, a C1-C6 alkyl, a C1-C6 alkyl substituted with one or more halogen, or a C3-C6 cycloalkyl. [0205] In some aspects, R4 may be a hydrogen, a C1-C6 alkyl, or a C1-C6 alkyl substituted with one or more halogen. [0206] In other aspects, R3 and R4 may optionally be interconnected to form a C3-C6 cycloalkyl, a substituted C3-C6 cycloalkyl, 5-membered heterocyclic ring, a substituted 5-membered heterocyclic ring, 6-membered heterocyclic ring, a substituted 6-membered heterocyclic ring, a phenyl ring, or a substituted phenyl ring. [0207] In some aspects, R30-R34 may each independently be a hydrogen, a carboxylic acid, an ester, a halogen, an amide, a substituted amide, a cyano, an ether, or a C1-C6 alkyl. [0208] In some examples, X1 may be a C1-C6 alkyl or a halogen. The C1-C6 alkyl may be methyl. The halogen may be chlorine. [0209] In some examples, X2 and X4 may each independently be a hydrogen or a halogen. [0210] In some examples, X3 may be a hydrogen, a C1-C6 alkyl or a halogen. The C1-C6 alkyl may be methyl. The halogen may be chlorine or fluorine [0211] In some examples, X5 may be a C1-C6 alkyl or a hydrogen. [0212] In some examples, at least two of X2- X5 may be hydrogen. [0213] In some examples, at least three of X2- X5 may be hydrogen. [0214] In some examples, X2- X5 may be hydrogen. [0215] In some examples, R3 may be C1-C6 alkyl or C1-C6 alkyl substituted with one or more halogen. The C1-C6 alkyl substituted with one or more halogen may be -CHF2. The C1-C6 alkyl may be methyl. [0216] In some examples, R4 may be hydrogen. [0217] In some examples, R30-R34 may be hydrogen. [0218] In some examples, R30 may be methyl, methoxy, carboxylic acid, -C(O)OCH3, cyano, amide, or substituted amide. [0219] In some examples, R31 may be methyl, methoxy, carboxylic acid, -C(O)OCH3, cyano, amide, or substituted amide. [0220] In some examples, R32 may be methyl, methoxy, carboxylic acid, -C(O)OCH3, cyano, amide, or substituted amide. [0221] In some examples, R33 may be methyl, methoxy, carboxylic acid, -C(O)OCH3, cyano, amide, or substituted amide. [0222] In some examples, R34 may be methyl, methoxy, carboxylic acid, -C(O)OCH3, cyano, amide, or substituted amide. [0223] In some examples, at least two of R30-R34 may be hydrogen, -OCH3, -COOH, -C(O)NH2, -C(O)NHCH3, cyano, methyl, - C(O)OCH3, or fluorine. [0224] In some examples, X1-X5 may each independently be hydrogen, halogen, Cl, F, or methyl, and R3-R4 are independently H, methyl, CHF2, or CF3. [0225] In some examples, at least one of R30-R34 may be carboxylic acid. [0226] In some examples, at least one of R30-R34 may be amide. [0227] In some examples, at least one of R30-R34 may be ester. [0228] In some examples, at least one of R30-R34 may be ether. [0229] In some examples, at least one of R30-R34 may be cyano. [0230] In some examples, at least one of R30-R34 may be methyl. [0231] In some examples, at least two of R30-R34 may be carboxylic acid, amide, ester, ether, cyano, or methyl. F. Compounds with Formula (IIe) [0232] The present disclosure is directed to a compound, or a pharmaceutically acceptable salt thereof, according to Formula (IIe):
Figure imgf000026_0001
wherein X1-X5 are each independently a hydrogen, a halogen, a hydroxy, a cyano, a C1-C6 alkyl, a substituted C1-C6 alkyl, a C3-C6 cycloalkyl, a substituted C3-C6 cycloalkyl, a C1-C6 alkoxy, optionally substituted with an aryl, a C3-C10 cycloalkyl, -C(O)NH2, -C(O)NHY1, - C(O)NY1Y2, -COOH, -C(O)OY1, -Y1COOH, or -Y1OY2; Y1 and Y2 are each independently a C1-C6 alkyl optionally substituted with one or more halogen or hydroxy; R3 is a halogen, a hydrogen, a C1-C6 alkyl, a C1-C6 alkyl substituted with one or more halogen, or a C3-C10 cycloalkyl; R4 is a hydrogen, a C1-C6 alkyl, or a C1-C6 alkyl substituted with one or more halogen; if R3 and R4 are optionally interconnected they form a C3-C10 cycloalkyl, a substituted C3-C10 cycloalkyl, 5-membered heterocyclic ring, a substituted 5-membered heterocyclic ring, 6-membered heterocyclic ring, a substituted 6-membered heterocyclic ring, a phenyl ring, or a substituted phenyl ring; and R40-R43 are independently hydrogen, a C1-C6 alkyl, or a substituted C1-C6 alkyl. [0233] In some embodiments, X1 may be a C1-C6 alkyl or a halogen. In some examples, X1 may be methyl. In some examples, X1 may be chlorine. [0234] In some embodiments, X2, X4, and X5 may be hydrogen. [0235] In some embodiments, X3 may be a hydrogen or halogen. [0236] In some embodiments, at least two of X2-X5 may be hydrogen. [0237] In some embodiments, at least three of X2-X5 may be hydrogen. [0238] In some embodiments, X2-X5 may be hydrogen. [0239] In some embodiments, R3 may be straight or branched C1-C6 alkyl optionally substituted with one or more halogen. For example, the straight or branched C1-C6 alkyl may be substituted with one or more fluorine. [0240] In some embodiments, R3 may be -CHF2 or -CF3. [0241] In some embodiments, R4 may be hydrogen. [0242] In some embodiments, X1-X3 may each independently be hydrogen, fluorine, chlorine, bromine, or methyl, X4-X5 may each independently be hydrogen or halogen, and R3-R4 may each independently be hydrogen, methyl, -CHF2, or -CF3. G. Compounds with Formula (IIf) [0243] The present disclosure is directed to a compound, or a pharmaceutically acceptable salt thereof, according to Formula (IIf):
Figure imgf000027_0001
wherein X1-X5 are each independently a hydrogen, a halogen, a hydroxy, a cyano, a C1-C6 alkyl, a substituted C1-C6 alkyl, a C3-C6 cycloalkyl, a substituted C3-C6 cycloalkyl, a C1-C6 alkoxy, optionally substituted with an aryl, a C3-C10 cycloalkyl, -C(O)NH2, -C(O)NHY1, - C(O)NY1Y2, -COOH, -C(O)OY1, -Y1COOH, or -Y1OY2; Y1 and Y2 are each independently a C1-C6 alkyl optionally substituted with one or more halogen or hydroxy; Y is carbon or nitrogen; R30-R34 are each independently a hydrogen, a carboxylic acid, a halogen, an amide, a substituted amide, a cyano, a C1-C6 alkyl, or absent; R3 is a halogen, a hydrogen, a C1-C6 alkyl, a C1-C6 alkyl substituted with one or more halogen, or a C3-C6 cycloalkyl; R4 is a hydrogen, a C1-C6 alkyl, or a C1-C6 alkyl substituted with one or more halogen; if R3 and R4 are optionally interconnected they form a C3-C6 cycloalkyl, a substituted C3-C6 cycloalkyl, 5-membered heterocyclic ring, a substituted 5-membered heterocyclic ring, 6-membered heterocyclic ring, a substituted 6-membered heterocyclic ring, a phenyl ring, or a substituted phenyl ring; and R30-R34 are each independently be a hydrogen, a carboxylic acid, an ester, a halogen, an amide, a substituted amide, a cyano, an ether, a C1-C6 alkyl, or absent. [0244] In some embodiments, X1 and X2 may be halogen. The halogen may be fluorine or chlorine. [0245] In some embodiments, X2, X3, and X5 may be hydrogen. [0246] In some embodiments, at least two of X2-X5 may be hydrogen. [0247] In some embodiments, at least three of X2-X5 may be hydrogen. [0248] In some embodiments, at least one Y may be nitrogen. [0249] In some embodiments, R30-R34 may each independently be a hydrogen or absent. [0250] In some embodiments, R3 may be -CH(CH3)2. H. Compounds with Formulae (III), (IIIa), (IIIb), (IV), (IVa), and (IVb) [0251] The present disclosure is directed to a compound, or a pharmaceutically acceptable salt thereof, according to Formula (III) or Formula (IV):
Figure imgf000029_0001
[0252] In some aspects, X1-X5 may each independently be a hydrogen, a halogen, a hydroxy, a cyano, a C1-C6 alkyl, a substituted C1-C6 alkyl, a C3-C6 cycloalkyl, a substituted C3-C6 cycloalkyl, a C1-C6 alkoxy, optionally substituted with an aryl, a C3-C10 cycloalkyl, -C(O)NH2, -C(O)NHY1, - C(O)NY1Y2, -COOH, -C(O)OY1, -Y1COOH, or -Y1OY2. Y1 and Y2 may each be independently a C1-C6 alkyl optionally substituted with one or more halogen or hydroxy. [0253] In some aspects, R3 may be a halogen, a hydrogen, a C1-C6 alkyl, a C1-C6 alkyl substituted with one or more halogen, or a C3-C6 cycloalkyl. [0254] In some aspects, R4 may be a hydrogen, a C1-C6 alkyl, or a C1-C6 alkyl substituted with one or more halogen. [0255] In other aspects, R3 and R4 may optionally be interconnected to form a C3-C6 cycloalkyl, a substituted C3-C6 cycloalkyl, 5-membered heterocyclic ring, a substituted 5-membered heterocyclic ring, 6-membered heterocyclic ring, a substituted 6-membered heterocyclic ring, a phenyl ring, or a substituted phenyl ring. [0256] In some aspects, A1 and A2 may each independently be a hydrogen, a C1-C6 alkyl, a substituted C1-C6 alkyl, an aryl, substituted aryl, a C3-C6 cycloalkyl, a substituted C3-C6 cycloalkyl, a C3-C6 heterocyclyl, substituted C3-C6 heterocyclyl, or absent. A1 and A2 may optionally be substituted with one or more members selected from the group consisting of halogen, ester, ether, carboxylic acid, -C(O)NH2, -CS(O)2Y3, a -CY1S(O)2Y3. Y3 may independently be a hydrogen or a C1-C4 alkyl optionally substituted with one or more groups selected from the group consisting of a halogen, a hydroxyl, a C1-C4 haloalkoxyl, and a C1-C4 alkoxyl. [0257] In some aspects, the present disclosure is directed to a compound with any one or Formulae (IIIa), (IIIb), (IVa), and (IVb):
Figure imgf000030_0001
Figure imgf000031_0001
[0258] In some embodiments, X1 may be C1-C6 alkyl. [0259] In some embodiments, X2, X3, and X5 may be hydrogen. [0260] In some embodiments, X4 may be hydrogen or fluorine. [0261] In some embodiments, A1 and A2 may each be independently a hydrogen, a C1-C6 alkyl, a substituted C1-C6 alkyl, an aryl, substituted aryl, a C3-C6 cycloalkyl, a substituted C3-C6 cycloalkyl, a C3-C6 heterocyclyl, or substituted C3-C6 heterocyclyl. A1 and A2 may optionally be substituted with one or more members selected from the group consisting of halogen, ester, ether, carboxylic acid, -C(O)NH2, -CS(O)2Y3, a -CY1S(O)2Y3. [0262] In some embodiments, R3 may be C1-C6 alkyl substituted with one or more halogen. [0263] In some embodiments, R4 may be a hydrogen. [0264] In some embodiments, X1 may be methyl. [0265] In some embodiments, X4 may behydrogen or fluorine. [0266] In some embodiments, at least two of X2-X5 may be hydrogen. [0267] In some embodiments, at least three of X2-X5 are hydrogen. [0268] In some embodiments, A1 and A2 may be substituted C1-C6 alkyl. A1 and A2 may be substituted ethyl. The ethyl may be substituted with carboxylic acid or amide. [0269] In some embodiments, A1 and A2 may be -CH(CH3)COOH. [0270] In some embodiments, A1 and A2 may be -CH2CH3COOH. [0271] In some embodiments, A1 and A2 may be -CH2CH3CONH2. [0272] In some embodiments, A1 and A2 may be substituted C3-C6 cycloalkyl. [0273] In some embodiments, the substituted C3-C6 cycloalkyl may be a cyclobutyl or cyclohexyl substituted with one or more carboxylic acid. [0274] In some embodiments, A1 and A2 may be substituted phenyl. The phenyl may be substituted with one or more carboxylic acid. [0275] In some embodiments, R3 may be -CHF2 or -CF3. [0276] In some embodiments, X1-X5 may each independently be hydrogen, halogen, or methyl. I. Compounds with Formulae (Va), (Va-1), (Vb), or (Vb-1) [0277] The present disclosure is directed to a compound, or a pharmaceutically acceptable salt thereof, according to Formula (III) or Formula (IV):
Figure imgf000032_0001
Formula (Vb); wherein X1-X5 are each independently a hydrogen, a halogen, a hydroxy, a cyano, a C1-C6 alkyl, a substituted C1-C6 alkyl, a C3-C6 cycloalkyl, a substituted C3-C6 cycloalkyl, a C1-C6 alkoxy, optionally substituted with an aryl, a C3-C10 cycloalkyl, -C(O)NH2, -C(O)NHY1, - C(O)NY1Y2, -COOH, -C(O)OY1, -Y1COOH, or -Y1OY2; Y1 and Y2 are each independently a C1-C6 alkyl optionally substituted with one or more halogen or hydroxy; A1 and A2 are each independently a hydrogen, a C1-C6 alkyl, a substituted C1-C6 alkyl, an aryl, substituted aryl, a C3-C6 cycloalkyl, a substituted C3-C6 cycloalkyl, a C3-C6 heterocyclyl, substituted C3-C6 heterocyclyl, or absent; wherein A1 and A2 may optionally be substituted with one or more members selected from the group consisting of halogen, ester, ether, carboxylic acid, -C(O)NH2, -CS(O)2Y3, a -CY1S(O)2Y3; Y3 is independently a hydrogen or a C1-C4 alkyl optionally substituted with one or more groups selected from the group consisting of a halogen, a hydroxyl, a C1-C4 haloalkoxyl, and a C1-C4 alkoxyl; R3 is a halogen, a hydrogen, a C1-C6 alkyl, a C1-C6 alkyl substituted with one or more halogen, or a C3-C6 cycloalkyl; and R4 is a hydrogen, a C1-C6 alkyl, or a C1-C6 alkyl substituted with one or more halogen; if R3 and R4 are optionally interconnected they form a C3-C6 cycloalkyl, a substituted C3-C6 cycloalkyl, 5-membered heterocyclic ring, a substituted 5-membered heterocyclic ring, 6-membered heterocyclic ring, a substituted 6-membered heterocyclic ring, a phenyl ring, or a substituted phenyl ring. [0278] In some embodiments, A1-A2 are independently hydrogen or methyl. [0279] In some embodiments, X1-X5 may be independently hydrogen, halogen, or methyl. [0280] In some embodiments, R3-R4 may be independently hydrogen, -CHF2 or -CF3. [0281] In some aspects, A1 may be absent and the compound is with Formula (Va-1) or Formula (Vb-1):
Figure imgf000034_0001
wherein: X1 is C1-C6 alkyl; X2, X3, and X5 are hydrogen; X4 is hydrogen or halogen; A2 is C1-C6 alkyl; R3 is hydrogen or C1-C6 alkyl substituted with one or more halogen; and R4 is hydrogen. [0282] In some embodiments, at least two of X2-X5 may be hydrogen. [0283] In some embodiments, at least three of X2-X5 may be hydrogen. [0284] In some embodiments, X2-X5 may be hydrogen. [0285] In some embodiments, the C1-C6 alkyl may be methyl. [0286] In some embodiments, the C1-C6 alkyl substituted with one or more halogen may be - CHF2 or -CF3. J. Compounds [0287] The disclosure is intended to encompass the compounds listed below and the non- stereochemistry and the alternative stereochemistry of the compounds listed below. [0288] In certain embodiments, the compound is Compound 1, or a pharmaceutically acceptable salt thereof:
Figure imgf000035_0001
[0289] In certain embodiments, the compound is Compound 2, or a pharmaceutically acceptable salt thereof:
Figure imgf000035_0002
[0290] In certain embodiments, the compound is Compound 3, or a pharmaceutically acceptable salt thereof:
Figure imgf000035_0003
[0291] In certain embodiments, the compound is Compound 4, or a pharmaceutically acceptable salt thereof:
Figure imgf000036_0002
[0292] In certain embodiments, the compound is Compound 5, or a pharmaceutically acceptable salt thereof:
Figure imgf000036_0003
[0293] In certain embodiments, the compound is Compound 6, or a pharmaceutically acceptable salt thereof:
Figure imgf000036_0004
[0294] In certain embodiments, the compound is Compound 7, or a pharmaceutically acceptable salt thereof:
Figure imgf000036_0001
[0295] In certain embodiments, the compound is Compound 8, or a pharmaceutically acceptable salt thereof:
Figure imgf000037_0001
[0296] In certain embodiments, the compound is Compound 9, or a pharmaceutically acceptable salt thereof:
Figure imgf000037_0004
[0297] In certain embodiments, the compound is Compound 10, or a pharmaceutically acceptable salt thereof:
Figure imgf000037_0002
[0298] In certain embodiments, the compound is Compound 11, or a pharmaceutically acceptable salt thereof:
Figure imgf000037_0003
[0299] In certain embodiments, the compound is Compound 12, or a pharmaceutically acceptable salt thereof:
Figure imgf000038_0001
[0300] In certain embodiments, the compound is Compound 13, or a pharmaceutically acceptable salt thereof:
Figure imgf000038_0002
[0301] In certain embodiments, the compound is Compound 14, or a pharmaceutically acceptable salt thereof:
Figure imgf000038_0003
[0302] In certain embodiments, the compound is Compound 15, or a pharmaceutically acceptable salt thereof:
Figure imgf000038_0004
[0303] In certain embodiments, the compound is Compound 16, or a pharmaceutically acceptable salt thereof:
Figure imgf000039_0001
[0304] In certain embodiments, the compound is Compound 17, or a pharmaceutically acceptable salt thereof:
Figure imgf000039_0002
[0305] In certain embodiments, the compound is Compound 18, or a pharmaceutically acceptable salt thereof:
Figure imgf000039_0003
[0306] In certain embodiments, the compound is Compound 19, or a pharmaceutically acceptable salt thereof:
Figure imgf000039_0004
[0307] In certain embodiments, the compound is Compound 20, or a pharmaceutically acceptable salt thereof:
Figure imgf000040_0001
[0308] In certain embodiments, the compound is Compound 21, or a pharmaceutically acceptable salt thereof:
Figure imgf000040_0002
[0309] In certain embodiments, the compound is Compound 22, or a pharmaceutically acceptable salt thereof:
Figure imgf000040_0003
[0310] In certain embodiments, the compound is Compound 23 or a pharmaceutically acceptable salt thereof:
Figure imgf000040_0004
[0311] In certain embodiments, the compound is Compound 24, or a pharmaceutically acceptable salt thereof:
Figure imgf000041_0001
[0312] In certain embodiments, the compound is Compound 25, or a pharmaceutically acceptable salt thereof:
Figure imgf000041_0002
[0313] In certain embodiments, the compound is Compound 26, or a pharmaceutically acceptable salt thereof:
Figure imgf000041_0003
[0314] In certain embodiments, the compound is Compound 27, or a pharmaceutically acceptable salt thereof:
Figure imgf000041_0004
[0315] In certain embodiments, the compound is Compound 28, or a pharmaceutically acceptable salt thereof:
Figure imgf000042_0001
[0316] In certain embodiments, the compound is Compound 29, or a pharmaceutically acceptable salt thereof:
Figure imgf000042_0002
[0317] In certain embodiments, the compound is Compound 30, or a pharmaceutically acceptable salt thereof:
Figure imgf000042_0003
[0318] In certain embodiments, the compound is Compound 31, or a pharmaceutically acceptable salt thereof:
Figure imgf000043_0001
[0319] In certain embodiments, the compound is Compound 32, or a pharmaceutically acceptable salt thereof:
Figure imgf000043_0002
[0320] In certain embodiments, the compound is Compound 33, or a pharmaceutically acceptable salt thereof:
Figure imgf000043_0003
[0321] In certain embodiments, the compound is Compound 34, or a pharmaceutically acceptable salt thereof:
Figure imgf000044_0001
[0322] In one embodiment, the compound is Compound 332, or a pharmaceutically acceptable salt thereof:
Figure imgf000044_0002
[0323] In one embodiment, the compound is Compound 333, or a pharmaceutically acceptable salt thereof:
Figure imgf000044_0003
[0324] In one embodiment, the compound is Compound 348, or a pharmaceutically acceptable salt thereof:
Figure imgf000044_0004
[0325] In one embodiment, the compound is Compound 349, or a pharmaceutically acceptable salt thereof:
Figure imgf000045_0001
[0326] In one embodiment, the compound is Compound 358, or a pharmaceutically acceptable salt thereof:
Figure imgf000045_0002
[0327] In one embodiment, the compound is Compound 359, or a pharmaceutically acceptable salt thereof:
Figure imgf000045_0003
[0328] In one embodiment, the compound is Compound 368, or a pharmaceutically acceptable salt thereof:
Figure imgf000045_0004
[0329] In one embodiment, the compound is Compound 369, or a pharmaceutically acceptable salt thereof:
Figure imgf000046_0001
[0330] In certain embodiments, the compound is Compound 35, or a pharmaceutically acceptable salt thereof:
Figure imgf000046_0004
[0331] In certain embodiments, the compound is Compound 36, or a pharmaceutically acceptable salt thereof:
Figure imgf000046_0002
. [0332] In certain embodiments, the compound is Compound 37, or a pharmaceutically acceptable salt thereof:
Figure imgf000046_0003
[0333] In certain embodiments, the compound is Compound 38, or a pharmaceutically acceptable salt thereof:
Figure imgf000047_0001
[0334] In certain embodiments, the compound is Compound 39, or a pharmaceutically acceptable salt thereof:
Figure imgf000047_0002
[0335] In certain embodiments, the compound is Compound 40, or a pharmaceutically acceptable salt thereof:
Figure imgf000047_0003
[0336] In certain embodiments, the compound is Compound 41, or a pharmaceutically acceptable salt thereof:
Figure imgf000047_0004
[0337] In certain embodiments, the compound is Compound 42, or a pharmaceutically acceptable salt thereof:
Figure imgf000048_0001
[0338] In certain embodiments, the compound is Compound 43, or a pharmaceutically acceptable salt thereof:
Figure imgf000048_0002
[0339] In certain embodiments, the compound is Compound 44, or a pharmaceutically acceptable salt thereof:
Figure imgf000048_0003
[0340] In certain embodiments, the compound is Compound 45, or a pharmaceutically acceptable salt thereof:
Figure imgf000049_0001
. [0341] In certain embodiments, the compound is Compound 46, or a pharmaceutically acceptable salt thereof:
Figure imgf000049_0002
[0342] In certain embodiments, the compound is Compound 47, or a pharmaceutically acceptable salt thereof:
Figure imgf000049_0003
. [0343] In certain embodiments, the compound is Compound 48, or a pharmaceutically acceptable salt thereof:
Figure imgf000049_0004
[0344] In certain embodiments, the compound is Compound 49, or a pharmaceutically acceptable salt thereof:
Figure imgf000050_0001
[0345] In certain embodiments, the compound is Compound 50, or a pharmaceutically acceptable salt thereof:
Figure imgf000050_0002
[0346] In certain embodiments, the compound is Compound 51, or a pharmaceutically acceptable salt thereof:
Figure imgf000050_0003
[0347] In certain embodiments, the compound is Compound 52, or a pharmaceutically acceptable salt thereof:
Figure imgf000050_0004
[0348] In one embodiment, the compound is Compound 316, or a pharmaceutically acceptable salt thereof:
Figure imgf000051_0001
[0349] In one embodiment, the compound is Compound 317, or a pharmaceutically acceptable salt thereof:
Figure imgf000051_0002
[0350] In one embodiment, the compound is Compound 335, or a pharmaceutically acceptable salt thereof:
Figure imgf000051_0003
[0351] In one embodiment, the compound is Compound 336, or a pharmaceutically acceptable salt thereof:
Figure imgf000051_0004
[0352] In one embodiment, the compound is Compound 346, or a pharmaceutically acceptable salt thereof:
Figure imgf000052_0001
[0353] In one embodiment, the compound is Compound 347, or a pharmaceutically acceptable salt thereof:
Figure imgf000052_0002
[0354] In one embodiment, the compound is Compound 355, or a pharmaceutically acceptable salt thereof:
Figure imgf000052_0003
[0355] In one embodiment, the compound is Compound 356, or a pharmaceutically acceptable salt thereof:
Figure imgf000053_0001
[0356] In one embodiment, the compound is Compound 366, or a pharmaceutically acceptable salt thereof:
Figure imgf000053_0002
[0357] In one embodiment, the compound is Compound 367, or a pharmaceutically acceptable salt thereof:
Figure imgf000053_0003
[0358] In certain embodiments, the compound is Compound 53, or a pharmaceutically acceptable salt thereof:
Figure imgf000053_0004
[0359] In certain embodiments, the compound is Compound 54, or a pharmaceutically acceptable salt thereof:
Figure imgf000054_0001
[0360] In certain embodiments, the compound is Compound 55, or a pharmaceutically acceptable salt thereof:
Figure imgf000054_0002
[0361] In certain embodiments, the compound is Compound 56, or a pharmaceutically acceptable salt thereof:
Figure imgf000054_0003
[0362] In certain embodiments, the compound is Compound 57, or a pharmaceutically acceptable salt thereof:
Figure imgf000055_0001
[0363] In certain embodiments, the compound is Compound 58, or a pharmaceutically acceptable salt thereof:
Figure imgf000055_0002
[0364] In certain embodiments, the compound is Compound 59, or a pharmaceutically acceptable salt thereof:
Figure imgf000055_0003
[0365] In certain embodiments, the compound is Compound 60, or a pharmaceutically acceptable salt thereof:
Figure imgf000056_0001
[0366] In certain embodiments, the compound is Compound 61, or a pharmaceutically acceptable salt thereof:
Figure imgf000056_0002
[0367] In certain embodiments, the compound is Compound 62, or a pharmaceutically acceptable salt thereof:
Figure imgf000056_0003
[0368] In certain embodiments, the compound is Compound 63, or a pharmaceutically acceptable salt thereof:
Figure imgf000056_0004
[0369] In certain embodiments, the compound is Compound 64, or a pharmaceutically acceptable salt thereof:
Figure imgf000057_0001
[0370] In certain embodiments, the compound is Compound 65, or a pharmaceutically acceptable salt thereof:
Figure imgf000057_0002
[0371] In certain embodiments, the compound is, Compound 66, or a pharmaceutically acceptable salt thereof:
Figure imgf000057_0003
[0372] In certain embodiments, the compound is, Compound 67, or a pharmaceutically acceptable salt thereof:
Figure imgf000058_0001
[0373] In certain embodiments, the compound is Compound 68, or a pharmaceutically acceptable salt thereof:
Figure imgf000058_0002
[0374] In certain embodiments, the compound is Compound 69, or a pharmaceutically acceptable salt thereof:
Figure imgf000058_0003
[0375] In certain embodiments, the compound is Compound 70, or a pharmaceutically acceptable salt thereof:
Figure imgf000059_0001
. [0376] In certain embodiments, the compound is Compound 71, or a pharmaceutically acceptable salt thereof:
Figure imgf000059_0002
. [0377] In certain embodiments, the compound is Compound 72, or a pharmaceutically acceptable salt thereof:
Figure imgf000059_0003
[0378] In certain embodiments, the compound is Compound 73, or a pharmaceutically acceptable salt thereof:
Figure imgf000060_0001
[0379] In certain embodiments, the compound is Compound 74, or a pharmaceutically acceptable salt thereof:
Figure imgf000060_0002
[0380] In certain embodiments, the compound is Compound 75, or a pharmaceutically acceptable salt thereof:
Figure imgf000060_0003
[0381] In one embodiment, the compound is Compound 319, or a pharmaceutically acceptable salt thereof:
Figure imgf000061_0001
[0382] In one embodiment, the compound is Compound 320, or a pharmaceutically acceptable salt thereof:
Figure imgf000061_0002
[0383] In one embodiment, the compound is Compound 324, or a pharmaceutically acceptable salt thereof:
Figure imgf000061_0003
[0384] In one embodiment, the compound is Compound 325, or a pharmaceutically acceptable salt thereof:
Figure imgf000061_0004
[0385] In one embodiment, the compound is Compound 326, or a pharmaceutically acceptable salt thereof:
Figure imgf000062_0001
[0386] In one embodiment, the compound is Compound 327, or a pharmaceutically acceptable salt thereof:
Figure imgf000062_0002
[0387] In one embodiment, the compound is Compound 328, or a pharmaceutically acceptable salt thereof:
Figure imgf000062_0003
[0388] In one embodiment, the compound is Compound 329, or a pharmaceutically acceptable salt thereof:
Figure imgf000062_0004
[0389] In one embodiment, the compound is Compound 330, or a pharmaceutically acceptable salt thereof:
Figure imgf000063_0001
[0390] In one embodiment, the compound is Compound 331, or a pharmaceutically acceptable salt thereof:
Figure imgf000063_0002
[0391] In one embodiment, the compound is Compound 334, or a pharmaceutically acceptable salt thereof:
Figure imgf000063_0003
[0392] In one embodiment, the compound is Compound 337, or a pharmaceutically acceptable salt thereof:
Figure imgf000063_0004
[0393] In one embodiment, the compound is Compound 338, or a pharmaceutically acceptable salt thereof:
Figure imgf000064_0004
[0394] In one embodiment, the compound is Compound 350, or a pharmaceutically acceptable salt thereof:
Figure imgf000064_0001
[0395] In one embodiment, the compound is Compound 351, or a pharmaceutically acceptable salt thereof:
Figure imgf000064_0002
[0396] In one embodiment, the compound is Compound 352, or a pharmaceutically acceptable salt thereof:
Figure imgf000064_0003
[0397] In one embodiment, the compound is Compound 353, or a pharmaceutically acceptable salt thereof:
Figure imgf000065_0001
[0398] In one embodiment, the compound is Compound 354, or a pharmaceutically acceptable salt thereof:
Figure imgf000065_0002
[0399] In one embodiment, the compound is Compound 357, or a pharmaceutically acceptable salt thereof:
Figure imgf000065_0003
[0400] In one embodiment, the compound is Compound 360, or a pharmaceutically acceptable salt thereof:
Figure imgf000066_0001
[0401] In one embodiment, the compound is Compound 361, or a pharmaceutically acceptable salt thereof:
Figure imgf000066_0002
[0402] In one embodiment, the compound is Compound 362, or a pharmaceutically acceptable salt thereof:
Figure imgf000066_0003
[0403] In one embodiment, the compound is Compound 363, or a pharmaceutically acceptable salt thereof:
Figure imgf000066_0004
[0404] In one embodiment, the compound is Compound 364, or a pharmaceutically acceptable salt thereof:
Figure imgf000067_0001
[0405] In one embodiment, the compound is Compound 365, or a pharmaceutically acceptable salt thereof:
Figure imgf000067_0002
[0406] In one embodiment, the compound is Compound 370, or a pharmaceutically acceptable salt thereof:
Figure imgf000067_0003
[0407] In one embodiment, the compound is Compound 371, or a pharmaceutically acceptable salt thereof:
Figure imgf000067_0004
[0408] In certain embodiments, the compound is Compound 76, or a pharmaceutically acceptable salt thereof:
Figure imgf000068_0001
[0409] In certain embodiments, the compound is Compound 77, or a pharmaceutically acceptable salt thereof:
Figure imgf000068_0002
[0410] In certain embodiments, the compound is Compound 78, or a pharmaceutically acceptable salt thereof:
Figure imgf000068_0003
[0411] In certain embodiments, the compound is Compound 79, or a pharmaceutically acceptable salt thereof:
Figure imgf000068_0004
[0412] In certain embodiments, the compound is Compound 80, or a pharmaceutically acceptable salt thereof:
Figure imgf000069_0001
[0413] In certain embodiments, the compound is Compound 81, or a pharmaceutically acceptable salt thereof:
Figure imgf000069_0002
[0414] In certain embodiments, the compound is Compound 82, or a pharmaceutically acceptable salt thereof:
Figure imgf000069_0003
[0415] In certain embodiments, the compound is Compound 83, or a pharmaceutically acceptable salt thereof:
Figure imgf000070_0001
[0416] In certain embodiments, the compound is Compound 84, or a pharmaceutically acceptable salt thereof:
Figure imgf000070_0002
[0417] In certain embodiments, the compound is Compound 85, or a pharmaceutically acceptable salt thereof:
Figure imgf000070_0003
[0418] In certain embodiments, the compound is Compound 86, or a pharmaceutically acceptable salt thereof:
Figure imgf000071_0001
[0419] In certain embodiments, the compound is Compound 87, or a pharmaceutically acceptable salt thereof:
Figure imgf000071_0002
[0420] In certain embodiments, the compound is Compound 88, or a pharmaceutically acceptable salt thereof:
Figure imgf000071_0003
[0421] In certain embodiments, the compound is Compound 89, or a pharmaceutically acceptable salt thereof:
Figure imgf000071_0004
[0422] In certain embodiments, the compound is Compound 90, or a pharmaceutically acceptable salt thereof:
Figure imgf000072_0001
[0423] In certain embodiments, the compound is Compound 91, or a pharmaceutically acceptable salt thereof:
Figure imgf000072_0002
[0424] In certain embodiments, the compound is Compound 92, or a pharmaceutically acceptable salt thereof:
Figure imgf000072_0003
[0425] In certain embodiments, the compound is Compound 93, or a pharmaceutically acceptable salt thereof:
Figure imgf000073_0001
[0426] In certain embodiments, the compound is Compound 94, or a pharmaceutically acceptable salt thereof:
Figure imgf000073_0002
[0427] In certain embodiments, the compound is Compound 95, or a pharmaceutically acceptable salt thereof:
Figure imgf000073_0003
[0428] In certain embodiments, the compound is Compound 96, or a pharmaceutically acceptable salt thereof:
Figure imgf000074_0001
[0429] In certain embodiments, the compound is Compound 97, or a pharmaceutically acceptable salt thereof:
Figure imgf000074_0002
[0430] In certain embodiments, the compound is Compound 98, or a pharmaceutically acceptable salt thereof:
Figure imgf000074_0003
[0431] In certain embodiments, the compound is Compound 99, or a pharmaceutically acceptable salt thereof:
Figure imgf000075_0001
[0432] In certain embodiments, the compound is Compound 100, or a pharmaceutically acceptable salt thereof:
Figure imgf000075_0002
[0433] In certain embodiments, the compound is Compound 101, or a pharmaceutically acceptable salt thereof:
Figure imgf000075_0003
[0434] In certain embodiments, the compound is Compound 102, or a pharmaceutically acceptable salt thereof:
Figure imgf000076_0001
[0435] In certain embodiments, the compound is Compound 103, or a pharmaceutically acceptable salt thereof:
Figure imgf000076_0002
[0436] In certain embodiments, the compound is Compound 104, or a pharmaceutically acceptable salt thereof:
Figure imgf000076_0003
[0437] In certain embodiments, the compound is Compound 105, or a pharmaceutically acceptable salt thereof:
Figure imgf000077_0001
[0438] In certain embodiments, the compound is Compound 106, or a pharmaceutically acceptable salt thereof:
Figure imgf000077_0002
[0439] In certain embodiments, the compound is Compound 107, or a pharmaceutically acceptable salt thereof:
Figure imgf000077_0003
[0440] In certain embodiments, the compound is Compound 108, or a pharmaceutically acceptable salt thereof:
Figure imgf000078_0001
[0441] In certain embodiments, the compound is Compound 109, or a pharmaceutically acceptable salt thereof:
Figure imgf000078_0002
[0442] In certain embodiments, the compound is Compound 110, or a pharmaceutically acceptable salt thereof:
Figure imgf000078_0003
[0443] In certain embodiments, the compound is Compound 111, or a pharmaceutically acceptable salt thereof:
Figure imgf000079_0001
[0444] In certain embodiments, the compound is Compound 112, or a pharmaceutically acceptable salt thereof:
Figure imgf000079_0002
[0445] In certain embodiments, the compound is Compound 113, or a pharmaceutically acceptable salt thereof:
Figure imgf000079_0003
[0446] In certain embodiments, the compound is Compound 114, or a pharmaceutically acceptable salt thereof:
Figure imgf000079_0004
[0447] In certain embodiments, the compound is Compound 115, or a pharmaceutically acceptable salt thereof:
Figure imgf000080_0001
. [0448] In certain embodiments, the compound is Compound 116, or a pharmaceutically acceptable salt thereof:
Figure imgf000080_0002
[0449] In certain embodiments, the compound is Compound 117, or a pharmaceutically acceptable salt thereof:
Figure imgf000080_0003
[0450] In certain embodiments, the compound is Compound 118, or a pharmaceutically acceptable salt thereof:
Figure imgf000081_0001
[0451] In certain embodiments, the compound is Compound 119, or a pharmaceutically acceptable salt thereof:
Figure imgf000081_0002
[0452] In certain embodiments, the compound is Compound 120, or a pharmaceutically acceptable salt thereof:
Figure imgf000081_0003
[0453] In certain embodiments, the compound is Compound 121, or a pharmaceutically acceptable salt thereof:
Figure imgf000082_0001
[0454] In certain embodiments, the compound is Compound 122, or a pharmaceutically acceptable salt thereof:
Figure imgf000082_0002
[0455] In certain embodiments, the compound is Compound 123, or a pharmaceutically acceptable salt thereof:
Figure imgf000082_0003
[0456] In certain embodiments, the compound is Compound 124, or a pharmaceutically acceptable salt thereof:
Figure imgf000083_0001
[0457] In certain embodiments, the compound is Compound 125, or a pharmaceutically acceptable salt thereof:
Figure imgf000083_0002
[0458] In certain embodiments, the compound is Compound 126, or a pharmaceutically acceptable salt thereof:
Figure imgf000083_0003
[0459] In certain embodiments, the compound is Compound 127, or a pharmaceutically acceptable salt thereof:
Figure imgf000084_0001
[0460] In certain embodiments, the compound is Compound 128, or a pharmaceutically acceptable salt thereof:
Figure imgf000084_0002
[0461] In certain embodiments, the compound is Compound 129, or a pharmaceutically acceptable salt thereof:
Figure imgf000084_0003
[0462] In certain embodiments, the compound is Compound 130, or a pharmaceutically acceptable salt thereof:
Figure imgf000085_0001
[0463] In certain embodiments, the compound is Compound 131, or a pharmaceutically acceptable salt thereof:
Figure imgf000085_0002
[0464] In certain embodiments, the compound is Compound 132, or a pharmaceutically acceptable salt thereof:
Figure imgf000085_0003
[0465] In certain embodiments, the compound is Compound 133, or a pharmaceutically acceptable salt thereof:
Figure imgf000086_0001
[0466] In certain embodiments, the compound is Compound 134, or a pharmaceutically acceptable salt thereof:
Figure imgf000086_0002
[0467] In certain embodiments, the compound is Compound 135, or a pharmaceutically acceptable salt thereof:
Figure imgf000086_0003
[0468] In certain embodiments, the compound is Compound 136, or a pharmaceutically acceptable salt thereof:
Figure imgf000087_0001
[0469] In certain embodiments, the compound is Compound 137, or a pharmaceutically acceptable salt thereof:
Figure imgf000087_0002
[0470] In certain embodiments, the compound is Compound 138, or a pharmaceutically acceptable salt thereof:
Figure imgf000087_0003
[0471] In certain embodiments, the compound is Compound 139, or a pharmaceutically acceptable salt thereof:
Figure imgf000088_0001
[0472] In certain embodiments, the compound is Compound 140, or a pharmaceutically acceptable salt thereof:
Figure imgf000088_0002
[0473] In certain embodiments, the compound is Compound 141, or a pharmaceutically acceptable salt thereof:
Figure imgf000088_0003
[0474] In certain embodiments, the compound is Compound 142, or a pharmaceutically acceptable salt thereof:
Figure imgf000089_0001
[0475] In certain embodiments, the compound is Compound 143, or a pharmaceutically acceptable salt thereof:
Figure imgf000089_0002
[0476] In certain embodiments, the compound is Compound 144, or a pharmaceutically acceptable salt thereof:
Figure imgf000089_0003
. [0477] In certain embodiments, the compound is Compound 145, or a pharmaceutically acceptable salt thereof:
Figure imgf000090_0001
[0478] In certain embodiments, the compound is Compound 146, or a pharmaceutically acceptable salt thereof:
Figure imgf000090_0002
[0479] In certain embodiments, the compound is Compound 147, or a pharmaceutically acceptable salt thereof:
Figure imgf000090_0003
[0480] In certain embodiments, the compound is Compound 148, or a pharmaceutically acceptable salt thereof:
Figure imgf000091_0001
[0481] In certain embodiments, the compound is Compound 149, or a pharmaceutically acceptable salt thereof:
Figure imgf000091_0002
[0482] In certain embodiments, the compound is Compound 150, or a pharmaceutically acceptable salt thereof:
Figure imgf000091_0003
[0483] In certain embodiments, the compound is Compound 151, or a pharmaceutically acceptable salt thereof:
Figure imgf000092_0001
[0484] In certain embodiments, the compound is Compound 152, or a pharmaceutically acceptable salt thereof:
Figure imgf000092_0002
. [0485] In certain embodiments, the compound is Compound 153, or a pharmaceutically acceptable salt thereof:
Figure imgf000092_0003
[0486] In certain embodiments, the compound is Compound 154, or a pharmaceutically acceptable salt thereof:
Figure imgf000093_0001
[0487] In certain embodiments, the compound is Compound 155, or a pharmaceutically acceptable salt thereof:
Figure imgf000093_0002
[0488] In certain embodiments, the compound is Compound 156, or a pharmaceutically acceptable salt thereof:
Figure imgf000093_0003
[0489] In certain embodiments, the compound is Compound 157, or a pharmaceutically acceptable salt thereof:
Figure imgf000094_0001
[0490] In certain embodiments, the compound is Compound 158, or a pharmaceutically acceptable salt thereof:
Figure imgf000094_0002
[0491] In certain embodiments, the compound is Compound 159, or a pharmaceutically acceptable salt thereof:
Figure imgf000094_0003
[0492] In certain embodiments, the compound is Compound 160, or a pharmaceutically acceptable salt thereof:
Figure imgf000095_0001
[0493] In certain embodiments, the compound is Compound 161, or a pharmaceutically acceptable salt thereof:
Figure imgf000095_0002
[0494] In one embodiment, the compound is Compound 162, or a pharmaceutically acceptable salt thereof:
Figure imgf000095_0003
[0495] In one embodiment, the compound is Compound 163, or a pharmaceutically acceptable salt thereof:
Figure imgf000096_0001
[0496] In one embodiment, the compound is Compound 164, or a pharmaceutically acceptable salt thereof:
Figure imgf000096_0002
[0497] In one embodiment, the compound is Compound 165, or a pharmaceutically acceptable salt thereof:
Figure imgf000096_0003
[0498] In one embodiment, the compound is Compound 166, or a pharmaceutically acceptable salt thereof:
Figure imgf000097_0001
[0499] In one embodiment, the compound is Compound 167, or a pharmaceutically acceptable salt thereof:
Figure imgf000097_0002
[0500] In one embodiment, the compound is Compound 168, or a pharmaceutically acceptable salt thereof:
Figure imgf000097_0003
[0501] In one embodiment, the compound is Compound 169, or a pharmaceutically acceptable salt thereof:
Figure imgf000098_0001
[0502] In one embodiment, the compound is Compound 170, or a pharmaceutically acceptable salt thereof.
Figure imgf000098_0002
[0503] In one embodiment, the compound is Compound 171, or a pharmaceutically acceptable salt thereof:
Figure imgf000098_0003
[0504] In one embodiment, the compound is Compound 172, or a pharmaceutically acceptable salt thereof:
Figure imgf000099_0001
[0505] In one embodiment, the compound is Compound 173, or a pharmaceutically acceptable salt thereof:
Figure imgf000099_0002
[0506] In one embodiment, the compound is Compound 174, or a pharmaceutically acceptable salt thereof:
Figure imgf000099_0003
[0507] In one embodiment, the compound is Compound 175, or a pharmaceutically acceptable salt thereof:
Figure imgf000100_0001
[0508] In one embodiment, the compound is Compound 176, or a pharmaceutically acceptable salt thereof:
Figure imgf000100_0002
[0509] In one embodiment, the compound is Compound 177, or a pharmaceutically acceptable salt thereof:
Figure imgf000100_0003
[0510] In one embodiment, the compound is Compound 178, or a pharmaceutically acceptable salt thereof:
Figure imgf000101_0001
[0511] In one embodiment, the compound is Compound 179, or a pharmaceutically acceptable salt thereof:
Figure imgf000101_0002
[0512] In one embodiment, the compound is Compound 180, or a pharmaceutically acceptable salt thereof:
Figure imgf000101_0003
[0513] In one embodiment, the compound is Compound 181, or a pharmaceutically acceptable salt thereof:
Figure imgf000102_0001
[0514] In one embodiment, the compound is Compound 182, or a pharmaceutically acceptable salt thereof:
Figure imgf000102_0002
[0515] In one embodiment, the compound is Compound 183, or a pharmaceutically acceptable salt thereof:
Figure imgf000102_0003
[0516] In one embodiment, the compound is Compound 184, or a pharmaceutically acceptable salt thereof:
Figure imgf000103_0001
[0517] In one embodiment, the compound is Compound 185, or a pharmaceutically acceptable salt thereof:
Figure imgf000103_0002
[0518] In one embodiment, the compound is Compound 186, or a pharmaceutically acceptable salt thereof:
Figure imgf000103_0003
[0519] In one embodiment, the compound is Compound 187, or a pharmaceutically acceptable salt thereof:
Figure imgf000104_0001
[0520] In one embodiment, the compound is Compound 188, or a pharmaceutically acceptable salt thereof:
Figure imgf000104_0002
[0521] In one embodiment, the compound is Compound 189, or a pharmaceutically acceptable salt thereof:
Figure imgf000104_0003
[0522] In one embodiment, the compound is Compound 190, or a pharmaceutically acceptable salt thereof:
Figure imgf000105_0001
[0523] In one embodiment, the compound is Compound 191, or a pharmaceutically acceptable salt thereof:
Figure imgf000105_0002
[0524] In one embodiment, the compound is Compound 192, or a pharmaceutically acceptable salt thereof:
Figure imgf000105_0003
[0525] In one embodiment, the compound is Compound 193, or a pharmaceutically acceptable salt thereof:
Figure imgf000106_0001
[0526] In one embodiment, the compound is Compound 194, or a pharmaceutically acceptable salt thereof:
Figure imgf000106_0002
[0527] In one embodiment, the compound is Compound 195, or a pharmaceutically acceptable salt thereof:
Figure imgf000106_0003
[0528] In one embodiment, the compound is Compound 196, or a pharmaceutically acceptable salt thereof:
Figure imgf000107_0001
[0529] In one embodiment, the compound is Compound 197, or a pharmaceutically acceptable salt thereof:
Figure imgf000107_0002
[0530] In one embodiment, the compound is Compound 198, or a pharmaceutically acceptable salt thereof:
Figure imgf000107_0003
[0531] In one embodiment, the compound is Compound 199, or a pharmaceutically acceptable salt thereof:
Figure imgf000108_0001
[0532] In one embodiment, the compound is Compound 200, or a pharmaceutically acceptable salt thereof:
Figure imgf000108_0002
[0533] In one embodiment, the compound is Compound 201, or a pharmaceutically acceptable salt thereof:
Figure imgf000108_0003
[0534] In one embodiment, the compound is Compound 202, or a pharmaceutically acceptable salt thereof:
Figure imgf000109_0001
[0535] In one embodiment, the compound is Compound 203, or a pharmaceutically acceptable salt thereof:
Figure imgf000109_0002
[0536] In one embodiment, the compound is Compound 204, or a pharmaceutically acceptable salt thereof:
Figure imgf000109_0003
[0537] In one embodiment, the compound is Compound 205, or a pharmaceutically acceptable salt thereof:
Figure imgf000110_0001
[0538] In one embodiment, the compound is Compound 206, or a pharmaceutically acceptable salt thereof:
Figure imgf000110_0002
[0539] In one embodiment, the compound is Compound 207, or a pharmaceutically acceptable salt thereof:
Figure imgf000110_0003
[0540] In one embodiment, the compound is Compound 208, or a pharmaceutically acceptable salt thereof:
Figure imgf000110_0004
[0541] In one embodiment, the compound is Compound 209, or a pharmaceutically acceptable salt thereof:
Figure imgf000111_0001
[0542] In one embodiment, the compound is Compound 210, or a pharmaceutically acceptable salt thereof:
Figure imgf000111_0002
[0543] In one embodiment, the compound is Compound 211, or a pharmaceutically acceptable salt thereof:
Figure imgf000111_0003
[0544] In one embodiment, the compound is Compound 212, or a pharmaceutically acceptable salt thereof:
Figure imgf000111_0004
[0545] In one embodiment, the compound is Compound 213, or a pharmaceutically acceptable salt thereof:
Figure imgf000112_0001
[0546] In one embodiment, the compound is Compound 214, or a pharmaceutically acceptable salt thereof:
Figure imgf000112_0002
[0547] In one embodiment, the compound is Compound 215, or a pharmaceutically acceptable salt thereof:
Figure imgf000112_0003
[0548] In one embodiment, the compound is Compound 216, or a pharmaceutically acceptable salt thereof:
Figure imgf000112_0004
[0549] In one embodiment, the compound is Compound 217, or a pharmaceutically acceptable salt thereof:
Figure imgf000113_0001
[0550] In one embodiment, the compound is Compound 218, or a pharmaceutically acceptable salt thereof:
Figure imgf000113_0002
[0551] In one embodiment, the compound is Compound 219, or a pharmaceutically acceptable salt thereof:
Figure imgf000113_0003
[0552] In one embodiment, the compound is Compound 220, or a pharmaceutically acceptable salt thereof:
Figure imgf000113_0004
[0553] In one embodiment, the compound is Compound 221, or a pharmaceutically acceptable salt thereof:
Figure imgf000114_0001
[0554] In one embodiment, the compound is Compound 222, or a pharmaceutically acceptable salt thereof:
Figure imgf000114_0002
[0555] In one embodiment, the compound is Compound 223, or a pharmaceutically acceptable salt thereof:
Figure imgf000114_0003
[0556] In one embodiment, the compound is Compound 224, or a pharmaceutically acceptable salt thereof:
Figure imgf000114_0004
[0557] In one embodiment, the compound is Compound 225, or a pharmaceutically acceptable salt thereof:
Figure imgf000115_0001
[0558] In one embodiment, the compound is Compound 226, or a pharmaceutically acceptable salt thereof:
Figure imgf000115_0002
[0559] In one embodiment, the compound is Compound 227, or a pharmaceutically acceptable salt thereof:
Figure imgf000115_0003
[0560] In one embodiment, the compound is Compound 228, or a pharmaceutically acceptable salt thereof:
Figure imgf000116_0001
[0561] In one embodiment, the compound is Compound 229, or a pharmaceutically acceptable salt thereof:
Figure imgf000116_0002
[0562] In one embodiment, the compound is Compound 230, or a pharmaceutically acceptable salt thereof:
Figure imgf000116_0003
[0563] In one embodiment, the compound is Compound 231, or a pharmaceutically acceptable salt thereof:
Figure imgf000117_0001
[0564] In one embodiment, the compound is Compound 232, or a pharmaceutically acceptable salt thereof:
Figure imgf000117_0002
[0565] In one embodiment, the compound is Compound 233, or a pharmaceutically acceptable salt thereof:
Figure imgf000117_0003
[0566] In one embodiment, the compound is Compound 234, or a pharmaceutically acceptable salt thereof:
Figure imgf000118_0001
[0567] In one embodiment, the compound is Compound 235, or a pharmaceutically acceptable salt thereof:
Figure imgf000118_0002
[0568] In one embodiment, the compound is Compound 236, or a pharmaceutically acceptable salt thereof:
Figure imgf000118_0003
[0569] In one embodiment, the compound is Compound 237, or a pharmaceutically acceptable salt thereof:
Figure imgf000118_0004
[0570] In one embodiment, the compound is Compound 238, or a pharmaceutically acceptable salt thereof:
Figure imgf000119_0001
[0571] In one embodiment, the compound is Compound 239, or a pharmaceutically acceptable salt thereof:
Figure imgf000119_0002
[0572] In one embodiment, the compound is Compound 240, or a pharmaceutically acceptable salt thereof:
Figure imgf000119_0003
[0573] In one embodiment, the compound is Compound 241, or a pharmaceutically acceptable salt thereof:
Figure imgf000120_0001
[0574] In one embodiment, the compound is Compound 242, or a pharmaceutically acceptable salt thereof:
Figure imgf000120_0002
[0575] In one embodiment, the compound is Compound 243, or a pharmaceutically acceptable salt thereof:
Figure imgf000120_0003
[0576] In one embodiment, the compound is Compound 244, or a pharmaceutically acceptable salt thereof:
Figure imgf000121_0001
[0577] In one embodiment, the compound is Compound 245, or a pharmaceutically acceptable salt thereof:
Figure imgf000121_0002
[0578] In one embodiment, the compound is Compound 246, or a pharmaceutically acceptable salt thereof:
Figure imgf000121_0003
[0579] In one embodiment, the compound is Compound 247, or a pharmaceutically acceptable salt thereof:
Figure imgf000122_0001
[0580] In one embodiment, the compound is Compound 248, or a pharmaceutically acceptable salt thereof:
Figure imgf000122_0002
[0581] In one embodiment, the compound is Compound 249, or a pharmaceutically acceptable salt thereof:
Figure imgf000122_0003
[0582] In one embodiment, the compound is Compound 250, or a pharmaceutically acceptable salt thereof:
Figure imgf000122_0004
[0583] In one embodiment, the compound is Compound 251, or a pharmaceutically acceptable salt thereof:
Figure imgf000123_0001
[0584] In one embodiment, the compound is Compound 252, or a pharmaceutically acceptable salt thereof:
Figure imgf000123_0002
[0585] In one embodiment, the compound is Compound 253, or a pharmaceutically acceptable salt thereof:
Figure imgf000123_0003
[0586] In one embodiment, the compound is Compound 254, or a pharmaceutically acceptable salt thereof:
Figure imgf000124_0001
[0587] In one embodiment, the compound is Compound 255, or a pharmaceutically acceptable salt thereof:
Figure imgf000124_0002
[0588] In one embodiment, the compound is Compound 256, or a pharmaceutically acceptable salt thereof:
Figure imgf000124_0003
[0589] In one embodiment, the compound is Compound 257, or a pharmaceutically acceptable salt thereof:
Figure imgf000125_0001
[0590] In one embodiment, the compound is Compound 258, or a pharmaceutically acceptable salt thereof:
Figure imgf000125_0002
[0591] In one embodiment, the compound is Compound 259, or a pharmaceutically acceptable salt thereof:
Figure imgf000125_0003
[0592] In one embodiment, the compound is Compound 260, or a pharmaceutically acceptable salt thereof:
Figure imgf000125_0004
[0593] In one embodiment, the compound is Compound 261, or a pharmaceutically acceptable salt thereof:
Figure imgf000126_0001
[0594] In one embodiment, the compound is Compound 262, or a pharmaceutically acceptable salt thereof:
Figure imgf000126_0002
[0595] In one embodiment, the compound is Compound 263, or a pharmaceutically acceptable salt thereof:
Figure imgf000126_0003
[0596] In one embodiment, the compound is Compound 264, or a pharmaceutically acceptable salt thereof:
Figure imgf000126_0004
[0597] In one embodiment, the compound is Compound 265, or a pharmaceutically acceptable salt thereof:
Figure imgf000127_0001
[0598] In one embodiment, the compound is Compound 266, or a pharmaceutically acceptable salt thereof:
Figure imgf000127_0002
[0599] In one embodiment, the compound is Compound 267, or a pharmaceutically acceptable salt thereof:
Figure imgf000127_0003
[0600] In one embodiment, the compound is Compound 268, or a pharmaceutically acceptable salt thereof:
Figure imgf000127_0004
[0601] In one embodiment, the compound is Compound 269, or a pharmaceutically acceptable salt thereof:
Figure imgf000128_0001
[0602] In one embodiment, the compound is Compound 270, or a pharmaceutically acceptable salt thereof:
Figure imgf000128_0002
[0603] In one embodiment, the compound is Compound 271, or a pharmaceutically acceptable salt thereof:
Figure imgf000128_0003
[0604] In one embodiment, the compound is Compound 272, or a pharmaceutically acceptable salt thereof:
Figure imgf000128_0004
[0605] In one embodiment, the compound is Compound 273, or a pharmaceutically acceptable salt thereof:
Figure imgf000129_0001
[0606] In one embodiment, the compound is Compound 274, or a pharmaceutically acceptable salt thereof:
Figure imgf000129_0002
[0607] In one embodiment, the compound is Compound 275, or a pharmaceutically acceptable salt thereof:
Figure imgf000129_0003
[0608] In one embodiment, the compound is Compound 276, or a pharmaceutically acceptable salt thereof:
Figure imgf000129_0004
[0609] In one embodiment, the compound is Compound 277, or a pharmaceutically acceptable salt thereof:
Figure imgf000130_0001
[0610] In one embodiment, the compound is Compound 278, or a pharmaceutically acceptable salt thereof:
Figure imgf000130_0002
[0611] In one embodiment, the compound is Compound 279, or a pharmaceutically acceptable salt thereof:
Figure imgf000130_0003
[0612] In one embodiment, the compound is Compound 280, or a pharmaceutically acceptable salt thereof:
Figure imgf000130_0004
[0613] In one embodiment, the compound is Compound 281, or a pharmaceutically acceptable salt thereof:
Figure imgf000131_0001
[0614] In one embodiment, the compound is Compound 282, or a pharmaceutically acceptable salt thereof:
Figure imgf000131_0002
[0615] In one embodiment, the compound is Compound 283, or a pharmaceutically acceptable salt thereof:
Figure imgf000131_0003
[0616] In one embodiment, the compound is Compound 284, or a pharmaceutically acceptable salt thereof:
Figure imgf000131_0004
[0617] In one embodiment, the compound is Compound 285, or a pharmaceutically acceptable salt thereof:
Figure imgf000132_0001
[0618] In one embodiment, the compound is Compound 286, or a pharmaceutically acceptable salt thereof:
Figure imgf000132_0002
[0619] In one embodiment, the compound is Compound 287, or a pharmaceutically acceptable salt thereof:
Figure imgf000132_0003
[0620] In one embodiment, the compound is Compound 288, or a pharmaceutically acceptable salt thereof:
Figure imgf000133_0001
[0621] In one embodiment, the compound is Compound 289, or a pharmaceutically acceptable salt thereof:
Figure imgf000133_0002
[0622] In one embodiment, the compound is Compound 290, or a pharmaceutically acceptable salt thereof:
Figure imgf000133_0003
[0623] In one embodiment, the compound is Compound 291, or a pharmaceutically acceptable salt thereof:
Figure imgf000133_0004
[0624] In one embodiment, the compound is Compound 292, or a pharmaceutically acceptable salt thereof:
Figure imgf000134_0001
[0625] In one embodiment, the compound is Compound 293, or a pharmaceutically acceptable salt thereof:
Figure imgf000134_0002
[0626] In one embodiment, the compound is Compound 294, or a pharmaceutically acceptable salt thereof:
Figure imgf000134_0003
[0627] In one embodiment, the compound is Compound 295, or a pharmaceutically acceptable salt thereof:
Figure imgf000134_0004
[0628] In one embodiment, the compound is Compound 296, or a pharmaceutically acceptable salt thereof:
Figure imgf000135_0001
[0629] In one embodiment, the compound is Compound 297, or a pharmaceutically acceptable salt thereof:
Figure imgf000135_0002
[0630] In one embodiment, the compound is Compound 298, or a pharmaceutically acceptable salt thereof:
Figure imgf000135_0003
[0631] In one embodiment, the compound is Compound 299, or a pharmaceutically acceptable salt thereof:
Figure imgf000135_0004
[0632] In one embodiment, the compound is Compound 300, or a pharmaceutically acceptable salt thereof:
Figure imgf000136_0001
[0633] In one embodiment, the compound is Compound 301, or a pharmaceutically acceptable salt thereof:
Figure imgf000136_0002
[0634] In one embodiment, the compound is Compound 302, or a pharmaceutically acceptable salt thereof:
Figure imgf000136_0003
[0635] In one embodiment, the compound is Compound 303, or a pharmaceutically acceptable salt thereof:
Figure imgf000136_0004
[0636] In one embodiment, the compound is Compound 304, or a pharmaceutically acceptable salt thereof:
Figure imgf000137_0001
[0637] In one embodiment, the compound is Compound 305, or a pharmaceutically acceptable salt thereof:
Figure imgf000137_0002
[0638] In one embodiment, the compound is Compound 306, or a pharmaceutically acceptable salt thereof:
Figure imgf000137_0003
[0639] In one embodiment, the compound is Compound 307, or a pharmaceutically acceptable salt thereof:
Figure imgf000137_0004
[0640] In one embodiment, the compound is Compound 308, or a pharmaceutically acceptable salt thereof:
Figure imgf000138_0001
[0641] In one embodiment, the compound is Compound 309, or a pharmaceutically acceptable salt thereof:
Figure imgf000138_0002
[0642] In one embodiment, the compound is Compound 310, or a pharmaceutically acceptable salt thereof:
Figure imgf000138_0003
[0643] In one embodiment, the compound is Compound 311, or a pharmaceutically acceptable salt thereof:
Figure imgf000138_0004
[0644] In one embodiment, the compound is Compound 312, or a pharmaceutically acceptable salt thereof:
Figure imgf000139_0001
[0645] In one embodiment, the compound is Compound 313, or a pharmaceutically acceptable salt thereof:
Figure imgf000139_0002
[0646] In one embodiment, the compound is Compound 314, or a pharmaceutically acceptable salt thereof:
Figure imgf000139_0003
[0647] In one embodiment, the compound is Compound 315, or a pharmaceutically acceptable salt thereof:
Figure imgf000140_0001
[0648] In one embodiment, the compound is Compound 318, or a pharmaceutically acceptable salt thereof:
Figure imgf000140_0002
[0649] In one embodiment, the compound is Compound 321, or a pharmaceutically acceptable salt thereof:
Figure imgf000140_0003
[0650] In one embodiment, the compound is Compound 322, or a pharmaceutically acceptable salt thereof:
Figure imgf000140_0004
[0651] In one embodiment, the compound is Compound 323, or a pharmaceutically acceptable salt thereof:
Figure imgf000141_0001
[0652] In one embodiment, the compound is Compound 339, or a pharmaceutically acceptable salt thereof:
Figure imgf000141_0003
[0653] In one embodiment, the compound is Compound 340, or a pharmaceutically acceptable salt thereof:
Figure imgf000141_0002
[0654] In one embodiment, the compound is Compound 341, or a pharmaceutically acceptable salt thereof:
Figure imgf000142_0001
[0655] In one embodiment, the compound is Compound 342, or a pharmaceutically acceptable salt thereof:
Figure imgf000142_0002
[0656] In one embodiment, the compound is Compound 343, or a pharmaceutically acceptable salt thereof:
Figure imgf000142_0003
[0657] In one embodiment, the compound is Compound 344, or a pharmaceutically acceptable salt thereof:
Figure imgf000142_0004
[0658] In one embodiment, the compound is Compound 345, or a pharmaceutically acceptable salt thereof:
Figure imgf000143_0001
[0659] In one embodiment, the compound is Compound 372, or a pharmaceutically acceptable salt thereof:
Figure imgf000143_0002
[0660] In one embodiment, the compound is Compound 373, or a pharmaceutically acceptable salt thereof:
Figure imgf000143_0003
[0661] In one embodiment, the compound is Compound 374, or a pharmaceutically acceptable salt thereof:
Figure imgf000143_0004
[0662] In one embodiment, the compound is Compound 375, or a pharmaceutically acceptable salt thereof:
Figure imgf000144_0001
[0663] In certain embodiments, the compounds inhibits POLRMT. [0664] In certain embodiments, the compounds promote POLRMT. [0665] The compounds of the present invention may contain asymmetric carbon atoms (sometimes as the result of a deuterium atom) and thereby may exist as either individual stereoisomers or mixtures of the enantiomers or mixtures of diastereomers. Accordingly, a compound of the present invention may exist as either a racemic mixture, a mixture of diastereomers, or as individual stereoisomers that are substantially free of other stereoisomers. Synthetic, separation, or purification methods to be used to obtain an enantiomer of a given compound are known in the art and are applicable for obtaining the compounds identified herein. [0666] Unless otherwise indicated, when a disclosed compound is named or depicted by a structure without specifying the stereochemistry and has one or more chiral centers, it is understood to represent all possible stereoisomers of the compound. Carbon atoms labelled with * or ** refer to a compound that is chiral but the absolute stereochemistry has not been determined. [0667] The compounds of the present invention may contain double bonds that may exist in more than one geometric isomer. Examples of such double bonds are carbon- carbon double bonds which form alkenes. In the case of carbon-carbon double bonds, the geometric isomers may be E or Z isomers. [0668] Unless otherwise indicated, when a disclosed compound is named or depicted by a structure without specifying the geometric isomerism and has one or more possible geometric isomers, it is understood to represent all possible geometric isomers of the compound. [0669] Certain compounds of the present invention may be able to exist as tautomers. All tautomeric forms of these compounds, whether isolated individually or in mixtures, are within the scope of the present invention. For example, in instances where an —OH substituent is permitted on a heteroaromatic ring and ketoenol tautomerism is possible, it is understood that the substituent might in fact be present, in whole or in part, in the oxo (═O) form. [0670] Compounds of the present invention may exist in amorphous form and/or one or more crystalline forms. As such all amorphous and crystalline forms and mixtures thereof of the compounds of the invention are intended to be included within the scope of the present invention. In addition, some of the compounds of the present invention may form solvates with water (i.e., a hydrate) or common organic solvents. Such solvates and hydrates, particularly the pharmaceutically acceptable solvates and hydrates, of the compounds of this invention are likewise encompassed within the scope of the compounds of the invention and the pharmaceutically acceptable salts thereof, along with un-solvated and anhydrous forms of such compounds. [0671] In one embodiment, deuterium isotope content at the deuterium substituted position is greater than the natural isotopic deuterium content (0.015%), more preferably greater than 50%, more preferably greater than 60%, more preferably greater than 75%, more preferably greater than 90%, more preferably greater than 95%, more preferably greater than 97%, more preferably greater than 99%. It will be understood that some variation of natural isotopic abundance may occur in any compound depending upon the source of the reagents used in the synthesis. Thus, a preparation of undeuterated compounds may inherently contain small amounts of deuterated isotopologues, such amounts being insignificant as compared to the degree of stable isotopic substitution of the deuterated compounds of the invention. See, e.g., Gannes, L Z et al., Comp Biochem Physiol Mol Integr Physiol, 119, 725 (1998). Replacement of hydrogen with deuterium may affect the activity, toxicity, and pharmacokinetics (e.g., absorption, distribution, metabolism, and excretion (“ADME”)) of some drugs. For instance, such replacement may alter the chemical stability and biochemical reactivity of a compound through kinetic isotope effects. Because of the increased mass of deuterium relative to hydrogen, epimerization at stereogenic carbons may be slowed down when hydrogen is replaced with deuterium. See Pirali et al, J. Med. Chem.62, 5276-97 (2019). Additionally, the presence of deuterium may affect how a molecule interacts with enzymes, thereby impacting enzyme kinetics. While in certain cases the increased mass of deuterium as compared to hydrogen may stabilize a compound and thereby improve activity, toxicity, or half-life, such impact is not predictable. In other instances deuteration may have little to no impact on these properties, or may affect them in an undesirable manner. Whether and/or how such replacement will impact drug properties may only be determined if the drug is synthesized, evaluated, and compared to its non-deuterated counterpart. Because some drugs have multiple sites of metabolism or more than one active sites for binding to a target, it is unpredictable as to which sites may benefit by deuterium replacement or to what extent isotope enrichment is necessary to produce a beneficial effect. (III) Methods of making of compounds [0672] The starting materials and reagents used in each step in the preparation are known and may be readily prepared or purchased from commercial sources. [0673] The compound obtained in each step may also be used for the next reaction as a reaction mixture thereof or after obtaining a crude product thereof. Alternatively, the compound obtained in each step may be isolated and/or purified from the reaction mixture by a separation means such as concentration, crystallization, recrystallization, distillation, solvent extraction, fractionation, chromatography and the like according to a conventional method. [0674] In each reaction step, while the reaction time varies depending on the reagents and solvents to be used, unless otherwise specified, it is generally 1 min. to 48 h., preferably 10 min. to 8 h. In the reaction of each step, while the reaction temperature varies depending on the reagents and solvents to be used, unless otherwise specified, it is generally -78 °C to 300 °C, preferably -78 °C to 150 °C. In the reaction of each step, unless otherwise specified, a reagent is used in 0.5 equivalent to 20 equivalents, preferably 0.8 equivalent to 5 equivalents, relative to the substrate. When a reagent is used as a catalyst, the reagent is used in 0.001 equivalent to 1 equivalent, preferably 0.01 equivalent to 0.2 equivalent, relative to the substrate. When the reagent is also a reaction solvent, the reagent is used in a solvent amount. [0675] In the reaction of each step, unless otherwise specified, it is performed without solvent or by dissolving or suspending in a suitable solvent. Specific examples of the solvent include the following. Alcohols: methanol, ethanol, tert-butyl alcohol, 2- methoxyethanol and the like; ethers: diethyl ether, diphenyl ether, tetrahydrofuran, 1,2- dimethoxyethane and the like; aromatic hydrocarbons: chlorobenzene, toluene, xylene and the like; saturated hydrocarbons: cyclohexane, hexane and the like; amides: N,N- dimethylformamide, N-methylpyrrolidone and the like; halogenated hydrocarbons: dichloromethane, carbon tetrachloride and the like; nitriles: acetonitrile and the like; sulfoxides: dimethyl sulfoxide and the like; aromatic organic bases: pyridine and the like; acid anhydrides: acetic anhydride and the like; organic acids: formic acid, acetic acid, trifluoroacetic acid and the like; inorganic acids: hydrochloric acid, sulfuric acid and the like; esters: ethyl acetate and the like; ketones: acetone, methyl ethyl ketone and the like; and water. [0676] Two or more kinds of the above-mentioned solvents may be used by mixing at an appropriate ratio. [0677] Unless otherwise specified, the reaction of each step is performed according to a known method, for example, the methods described in “Reactions and Syntheses: In the Organic Chemistry Laboratory 2nd Edition” (Lutz F. Tietze, Theophil Eicher, Ulf Diederichsen, Andreas Speicher, Nina Schützenmeister) Wiley, 2015; “Organic Syntheses Collective Volumes 1 – 12” (John Wiley & Sons Inc); “Comprehensive Organic Transformations, Third Edition” (Richard C. Larock) Wiley, 2018 and the like. [0678] In each step, protection or deprotection of a functional group is performed by a known method, for example, the methods described in “Protective Groups in Organic Synthesis, 4th Ed.” (Theodora W. Greene, Peter G. M. Wuts) Wiley-Interscience, 2007; “Protecting Groups 3rd Ed.” (P. J. Kocienski) Thieme, 2004 and the like. [0679] Deuterated POLRMT modulators of the present invention may be prepared using chemical reactions known to a person of ordinary skill in the art using deuterated starting materials or reagents. Deuterium-containing reagents are well known in the art and may be prepared using known procedures or purchased from commercial sources. The deuterated compounds obtained may be characterized by analytical techniques known to persons of ordinary skill in the art. For example, nuclear magnetic resonance (“NMR”) may be used to determine a compound’s structure while mass spectroscopy (“MS”) may be used to determine the amount of deuterium atom in the compound by comparison to its non-deuterated form. (IV) Compositions [0680] The present invention further includes pharmaceutical compositions of the compounds or a pharmaceutically acceptable salt of said compounds. In addition to the compound of the invention or a salt thereof, the pharmaceutical compositions comprise one or more pharmaceutically acceptable excipients, such excipients being compatible with other ingredients in the composition and also being not toxic or otherwise harmful. Examples of excipients include carriers, lubricants, binders, disintegrants, solvents, solubilizing agents, suspending agents, isotonic agents, buffers, soothing agents, preservatives, antioxidants, colorants, taste-modifying agents, absorbents, and/or wetting agents. [0681] The pharmaceutical compositions of the invention include those suitable for oral, rectal, nasal, topical, buccal, sublingual, vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration. Such compositions may be prepared by any methods well known in the art of pharmaceutical formulations and pharmacy. See, e.g., Remington: The Science and Practice of Pharmacy, Elsevier Science, 23rd ed. (2020). [0682] Formulations for parenteral administration include sterile aqueous or non- aqueous solutions, suspensions, or emulsions. A variety of aqueous carriers may be used, e.g., water, buffered water, saline, and the like. Examples of other suitable vehicles include polypropylene glycol, polyethylene glycol, vegetable oils, hydrogels, gelatin, hydrogenated naphthalenes, and injectable organic esters, such as ethyl oleate. Such formulations may also contain auxiliary substances, such as preserving, wetting, buffering, emulsifying, and/or dispersing agents. Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene- polyoxypropylene copolymers may be used to control the release of the active ingredients. Alternatively, the compositions may be administered by oral ingestion. Compositions intended for oral use may be prepared in solid or liquid forms, according to any method known to a person of ordinary skill in the art for the manufacture of pharmaceutical compositions. Solid dosage forms for oral administration include capsules (both soft and hard gelatin capsules), tablets, powders, and granules. Generally, these pharmaceutical preparations contain active ingredients admixed with pharmaceutically acceptable excipients. These excipients include, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, sucrose, glucose, mannitol, cellulose, starch, calcium phosphate, sodium phosphate, kaolin and the like; binding agents, buffering agents, and/or lubricating agents (e.g., magnesium stearate) may also be used. Tablets and capsules may additionally be prepared with release-controlling coatings such as enteric coatings. The compositions may optionally contain sweetening, flavoring, coloring, perfuming, and preserving agents in order to provide a more palatable preparation. [0683] In another embodiment, a pharmaceutical composition of this invention further comprises a second therapeutic agent. The second therapeutic agent may be selected from any pharmaceutically active compound; preferably the second therapeutic agent is known to correct mitochondrial dysfunction. Alternatively, the compounds of the invention and second therapeutic agent may be administered together (within less than 24 hours of one another, consecutively or simultaneously) but in separate pharmaceutical compositions. In certain embodiments, the compounds on the invention and second therapeutic agent may be administered separately (e.g., more than 24 hours of one another.) If the second therapeutic agent acts synergistically with the compounds of this invention, the therapeutically effective amount of such compounds and/or the second therapeutic agent may be less that such amount required when either is administered alone. [0684] For the treatment of cancer, the compounds described herein may be administered in combination with a chemotherapeutic agent. Therapeutically effective amounts of the additional chemotherapeutic agent(s) are well known to those skilled in the art. However, it is well within the attending physician to determine the amount of other chemotherapeutic agent(s) to be delivered. Examples of these chemotherapeutic agents include, but are not limited to, Abitrexate (Methotrexate Injection), Abraxane (Paclitaxel Injection), Actemra (Tocilizumab), Adcetris (Brentuximab Vedotin Injection), Adriamycin (Doxorubicin), Adrucil Injection (5-FU (fluorouracil)), Afinitor (Everolimus), Afinitor Disperz (Everolimus), Aldara (Imiquimod), Alimta (PEMET EXED), Alkeran Injection (Melphalan Injection), Alkeran Tablets (Melphalan), Aredia (Pamidronate), Arimidex (Anastrozole), Aromasin (Exemestane), Arranon (Nelarabine), Arzerra (Ofatumumab Injection), Avastin (Bevacizumab), Avelumab, Bexxar (Tositumomab), BiCNU (Carmustine), Blenoxane (Bleomycin), Blincyto (Blinatumomab), Bosulif (Bosutinib), Busulfex Injection (Busulfan Injection), Campath (Alemtuzumab), Camptosar (Irinotecan), Caprelsa (Vandetanib), Casodex (Bicalutamide), CeeNU (Lomustine), CeeNU Dose Pack (Lomustine), Cerubidine (Daunorubicin), Clolar (Clofarabine Injection), Cometriq (Cabozantinib), Cosmegen (Dactinomycin), CytosarU (Cytarabine), Cytoxan (Cytoxan), Cytoxan Injection (Cyclophosphamide Injection), Cyramza (Ramucirumab), Dacogen (Decitabine), Darzalex (Daratumumab), DaunoXome (Daunorubicin Lipid Complex Injection), Decadron (Dexamethasone), DepoCyt (Cytarabine Lipid Complex Injection), Dexamethasone Intensol (Dexamethasone), Dexpak Taperpak (Dexamethasone), Docefrez (Docetaxel), Doxil (Doxorubicin Lipid Complex Injection), Droxia (Hydroxyurea), DTIC (Decarbazine), Durvalumab, Eligard (Leuprolide), Ellence (Ellence (epirubicin)), Eloxatin (Eloxatin (oxaliplatin)), Elspar (Asparaginase), Emcyt (Estramustine), Empliciti (Elotuzumab), Enhertu (fam- trastuzumab deruxtecan-nxki), Erbitux (Cetuximab), Erivedge (Vismodegib), Erwinaze (Asparaginase Erwinia chrysanthemi), Ethyol (Amifostine), Etopophos (Etoposide Injection), Eulexin (Flutamide), Fareston (Toremifene), Faslodex (Fulvestrant), Femara (Letrozole), Firmagon (Degarelix Injection), Fludara (Fludarabine), Folex (Methotrexate Injection), Folotyn (Pralatrexate Injection), FUDR (FUDR (floxuridine)), Gazyva (Obinutuzumab), Gemzar (Gemcitabine), Gilotrif (Afatinib), Gleevec (Imatinib Mesylate), Gliadel Wafer (Carmustine wafer), Halaven (Eribulin Injection), Herceptin (Trastuzumab), Hexalen (Altretamine), Hycamtin (Topotecan), Hycamtin (Topotecan), Hydrea (Hydroxyurea), Iclusig (Ponatinib), Idamycin PFS (Idarubicin), Ifex (Ifosfamide), Inlyta (Axitinib), Intron A alfab (Interferon alfa-2a), Iressa (Gefitinib), Istodax (Romidepsin Injection), Ixempra (Ixabepilone Injection), Jakafi (Ruxolitinib), Jevtana (Cabazitaxel Injection), Kadcyla (Ado-trastuzumab Emtansine), Kyprolis (Carfilzomib), Leflunomide (SU101), Lartruvo (Olaratumab), Leukeran (Chlorambucil), Leukine (Sargramostim), Leustatin (Cladribine), Libtayo (Cemiplimab), Lupron (Leuprolide), Lupron Depot (Leuprolide), Lupron DepotPED (Leuprolide), Lysodren (Mitotane), Marqibo Kit (Vincristine Lipid Complex Injection), Matulane (Procarbazine), Megace (Megestrol), Mekinist (Trametinib), Mesnex (Mesna), Mesnex (Mesna Injection), Metastron (Strontium-89 Chloride), Mexate (Methotrexate Injection), Mustargen (Mechlorethamine), Mutamycin (Mitomycin), Myleran (Busulfan), Mylotarg (Gemtuzumab Ozogamicin), Navelbine (Vinorelbine), Neosar Injection (Cyclophosphamide Injection), Neulasta (filgrastim), Neulasta (pegfilgrastim), Neupogen (filgrastim), Nexavar (Sorafenib), Nilandron (Nilandron (nilutamide)), Nipent (Pentostatin), Nolvadex (Tamoxifen), Novantrone (Mitoxantrone), Oncaspar (Pegaspargase), Oncovin (Vincristine), Ontak (Denileukin Diftitox), Onxol (Paclitaxel Injection), Panretin (Alitretinoin), Paraplatin (Carboplatin), Perjeta (Pertuzumab Injection), Platinol (Cisplatin), Platinol (Cisplatin Injection), PlatinolAQ (Cisplatin), PlatinolAQ (Cisplatin Injection), Pomalyst (Pomalidomide), Portrazza (Necitumumab), Prednisone Intensol (Prednisone), Proleukin (Aldesleukin), Purinethol (Mercaptopurine), Reclast (Zoledronic acid), Revlimid (Lenalidomide), Removab (Catumaxomab), Rheumatrex (Methotrexate), Rituxan (Rituximab), RoferonA alfaa (Interferon alfa-2a), Rubex (Doxorubicin), Sandostatin (Octreotide), Sandostatin LAR Depot (Octreotide), Sarclisa (Isatuximab-irfc), Soltamox (Tamoxifen), Sprycel (Dasatinib), Sterapred (Prednisone), Sterapred DS (Prednisone), Stivarga (Regorafenib), Supprelin LA (Histrelin Implant), Sutent (Sunitinib), Sylatron (Peginterferon Alfa-2b Injection (Sylatron)), Synribo (Omacetaxine Injection), Tabloid (Thioguanine), Taflinar (Dabrafenib), Tarceva (Erlotinib), Targretin Capsules (Bexarotene), Tasigna (Decarbazine), Taxol (Paclitaxel Injection), Taxotere (Docetaxel), Tecentriq (Atezolizumab), Temodar (Temozolomide), Temodar (Temozolomide Injection), Tepadina (Thiotepa), Thalomid (Thalidomide), TheraCys BCG (BCG), Thioplex (Thiotepa), TICE BCG (BCG), Toposar (Etoposide Injection), Torisel (Temsirolimus), Treanda (Bendamustine hydrochloride), Tremelimumab, Trelstar (Triptorelin Injection), Trexall (Methotrexate), Trisenox (Arsenic trioxide), Tykerb (lapatinib), Unituxin (Dinutuximab), Valstar (Valrubicin Intravesical), Vantas (Histrelin Implant), Vectibix (Panitumumab), Velban (Vinblastine), Velcade (Bortezomib), Vepesid (Etoposide), Vepesid (Etoposide Injection), Vesanoid (Tretinoin), Vidaza (Azacitidine), Vincasar PFS (Vincristine), Vincrex (Vincristine), Votrient (Pazopanib), Vumon (Teniposide), Wellcovorin IV (Leucovorin Injection), Xalkori (Crizotinib), Xeloda (Capecitabine), Xtandi (Enzalutamide), Yervoy (Ipilimumab Injection), Zaltrap (Ziv-aflibercept Injection), Zanosar (Streptozocin), Zelboraf (Vemurafenib), Zevalin (lbritumomab Tiuxetan), Zoladex (Goserelin), Zolinza (Vorinostat), Zometa (Zoledronic acid), Zortress (Everolimus), Zytiga (Abiraterone), Nimotuzumab and immune checkpoint inhibitors such as nivolumab, pembrolizumab/MK-3475, pidilizumab and AMP-224 targeting PD-1; and BMS-935559, MEDI4736, MPDL3280A and MSB0010718C targeting. EXAMPLES [0685] The examples and preparations provided below further illustrate and exemplify the compounds of the present invention and methods of preparing such compounds. It is to be understood that the scope of the present invention is not limited in any way by the scope of the following examples and preparations. [0686] The structures of the compounds are confirmed by either mass spectrometry or nuclear magnetic resonance spectroscopy (NMR), where peaks assigned to the characteristic protons in the title compound are presented where appropriate.1H NMR shift (δH) are given in parts per million (ppm) down field from an internal reference standard. Acceptable 1H NMR shifts and masses are within 5% of the reported values (i.e., all reported measurement values herein also include ± 5%, ± 4%, ± 3%, ± 2%, and/or ± 1%). All reported LCMS values herein also include ± 5%, ± 4%, ± 3%, ± 2%, and/or ± 1%. [0687] The abbreviations used herein are known to a person of ordinary skill in the art. A partial list of abbreviations that may be used herein include: acetonitrile (MeCN), ammonium carbonate (NH4)2CO3, ammonium chloride (NH4Cl), aqueous (aq.), 1,1’- bis(diphenylphosphino)ferrocene (dppf), 1,3-bis(diphenylphosphino)propane (dppp), bis(pinacolato)diboron (B2pin2), N- bromosuccinimide (NBS), bromo-tris-pyrrolidino- phosphonium hexafluorophosphate (PyBroP),boron tribromide (BBr3), butyl lithium (BuLi), calculated (Calcd.), cesium carbonate (Cs2CO3), dichloromethane (DCM, CH2Cl2), N,N-dicyclohexylcarbodiimide (DCC), dichloroethane (DCE), diethyl azodicarboxylate (DEAD), diisopropyl azodicarboxylate (DIAD), N,N- diisopropylethylamine (DIPEA), 4-dimethylaminopyridine (DMAP), dimethylformamide (DMF), dimethyl sulfoxide (DMSO), di-tert-butyl decarbonate (Boc2O), 1-ethyl-3-(3- dimethylaminopropyl)carbodiimide (EDC), electrospray ionization (ESI), enantiomeric excess (ee), ethyl acetate (EtOAc), hour (h.), N-[(dimethylamino)-1H-1,2,3-triazolo-[4,5- b]pyridin-1- ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide (HATU), high performance liquid chromatography (HPLC), hydroxybenzotriazole (HOBt), isopropyl alcohol (IPA), lithium hydroxide monohydrate (LiOH HHO), methanol (MeOH), methyl iodide (MeI), minutes (min.), potassium carbonate (K2CO3), liquid chromatography-mass spectrometry (LCMS), phenyliodide(III) diacetate (PIDA), propylphosphonic anhydride (T3P), reverse phase (RP), room/ambient temperature (rt, RT), silver oxide (Ag2O), sodium hydride (NaH), sodium sulfate (Na2SO3), supercritical fluid chromatography (SFC), tetrahydrofuran (THF), triethylamine (Et3N), thionyl chloride (SOCl2), triphenylphosphine (PPh3), dicyclohexyl[2′,4′,6′-tris(propan-2-yl)[1,1′- biphenyl]-2-yl]phosphane (XPhos). Table 1 provides a listing of example compounds of the present invention and IC50 values for inhibition of POLRMT. [0688] The following examples illustrate various non-limiting embodiments of the present disclosure. [0689] Table 1 correlates Example number with Compound number.
Figure imgf000152_0001
Figure imgf000153_0001
Figure imgf000154_0001
Figure imgf000155_0001
Figure imgf000156_0001
Figure imgf000157_0002
Example 1: Synthesis of 3-(1-(5-fluoro-2-methylphenyl)cyclopropyl)-5-(1-methyl-5- (trifluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Compound 301)
Figure imgf000157_0001
[0690] Synthesis of 1-(5-fluoro-2-methylphenyl)cyclopropane-1-carbonitrile, 2 [Step 1]: To a stirred solution of KOH (2.3 g, 40.2 mmol) in water (10 mL), 2-(5-fluoro-2- methylphenyl)acetonitrile (1, 500 mg, 3.4 mmol) and TBAB (216 mg, 0.67 mmol) were added at 0 °C. After 5 min, 1,2-dibromoethane (1.5 mL, 16.8 mmol) was added dropwise and the resulting reaction mixture was heated at 60 °C for 12 h. After completion, the reaction mixture was poured into cold water and extracted with ethyl acetate (thrice). Combined organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to afford 1-(5- fluoro-2-methylphenyl)cyclopropane-1-carbonitrile (2, 450 mg).1H NMR (400 MHz, DMSO-d6) δ 7.33-7.29 (m, 1H), 7.22-7.11 (m, 1H), 7.06-7.02(m, 1H), 2.44 (s, 3H), 2.29 (s, 3H), 1.69 (s, 2H), 1.41 (s, 2H) [Note: HNMR showed extra peaks.] [0691] Synthesis of (Z)-1-(5-fluoro-2-methylphenyl)-N'-hydroxycyclopropane-1- carboximidamide, 3 [Step 2]: To a stirred solution of 1-(5-fluoro-2-methylphenyl)cyclopropane-1- carbonitrile (2, 450 mg, 2.6 mmol) in ethanol (2 mL), Na2CO3 (545 mg, 5.1 mmol) was added followed by NH2OH.HCl (355 g, 5.1 mmol) and the reaction mixture was heated to reflux at 70 °C for 12h. After completion, the volatiles were evaporated under reduced pressure. The reduced mass was diluted with water and extracted with ethyl acetate (thrice). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by column chromatography to afford (Z)-1-(5-fluoro-2- methylphenyl)-N'-hydroxycyclopropane-1-carboximidamide (3, 450 mg). LCMS (ESI) Calcd for C11H13FN2O: 208.1, found [M+H]+ = 209.1. [0692] Synthesis of (Z)-1-(5-fluoro-2-methylphenyl)-N'-((1-methyl-5-(trifluoromethyl)-1H- pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide, 4, [Step 3]: To a stirred solution of 1- methyl-5-(trifluoromethyl)-1H-pyrazole-3-carboxylic acid (100 mg, 0.5 mmol) and (Z)-1-(5-fluoro- 2-methylphenyl)-N'-hydroxycyclopropane-1-carboximidamide (3, 160 mg, 0.8 mmol) in dichloromethane (3 mL), N,N-Diisopropylethylamine (0.2 mL, 1.03 mmol), EDCI.HCl (128 mg, 0.7 mmol) and HOAt (15 mg, 0.1 mmol) were added at 0 °C and the reaction mixture was stirred at ambient temperature for 16h. After completion, the reaction mixture was concentrated under reduced pressure, dissolved with ethyl acetate, washed with water (twice) and brine. The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by column chromatography to afford (Z)-1-(5-fluoro- 2-methylphenyl)-N'-((1-methyl-5-(trifluoromethyl)-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1- carboximidamide (4, 150 mg). LCMS (ESI) Calcd for C17H16F4N4O2: 384.1, found [M+H]+ = 385.1. [0693] Synthesis of 3-(1-(5-fluoro-2-methylphenyl)cyclopropyl)-5-(1-methyl-5-(trifluoromethyl)- 1H-pyrazol-3-yl)-1,2,4-oxadiazole, Example 1 [Step 4]: To a stirred solution of (Z)-1-(5-fluoro-2- methylphenyl)-N'-((1-methyl-5-(trifluoromethyl)-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1- carboximidamide (4, 150 mg, 0.4 mmol) in THF (2 mL), tetrabutylammonium hydroxide (25 mg, 0.04 mmol, 1M in methanol) was added and the resulting reaction mixture was stirred at ambient temperature for 60 min. After completion, the reaction mixture was concentrated under reduced pressure, dissolved in ethyl acetate, washed with water (twice), dried over anhydrous Na2SO4, filtered and concentrated again under reduced pressure. The product was purified through reverse phase prep-HPLC and lyophilized to afford 3-(1-(5-fluoro-2- methylphenyl)cyclopropyl)-5-(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 1, 25 mg). LCMS (ESI) Calcd for C17H14F4N4O: 366.1, found [M+H]+ = 367.1.1HNMR (400 MHz, DMSO-d6) δH 7.65 (s, 1H), 7.27-7.20 (m, 2H), 7.10-7.06 (m, 1H), 4.10 (s, 3H), 2.22 (s, 3H), 1.67-1.65 (m, 2H), 1.46-1.44 (m, 2H). Example 2: Synthesis of 5-(1,5-dimethyl-1H-pyrazol-3-yl)-3-(1-(5-fluoro-2- methylphenyl)cyclopropyl)-1,2,4-oxadiazole (Example 2): [0694] 5-(1,5-dimethyl-1H-pyrazol-3-yl)-3-(1-(5-fluoro-2-methylphenyl)cyclopropyl)-1,2,4- oxadiazole was synthesized Scheme 1 using 1,5-dimethyl-1H-pyrazole-3-carboxylic acid. LCMS (ESI) Calcd for C17H17FN4O: 312.1, found [M+H]+ = 313.2.1HNMR (400 MHz, DMSO-d6) δH 7.26-7.19 (m, 2H), 7.09-7.04 (m, 1H), 6.71 (s, 1H), 3.84 (s, 3H), 2.31 (s, 3H), 2.22 (s, 3H), 1.65-1.63 (m, 2H), 1.42-1.39 (m, 2H). Example 3: Synthesis of 3-(1-(5-fluoro-2-methylphenyl)cyclopropyl)-5-(1-methyl-1H- pyrazol-3-yl)-1,2,4-oxadiazole (Example 3): [0695] 3-(1-(5-fluoro-2-methylphenyl)cyclopropyl)-5-(1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole was synthesized following Scheme 1 using 1-methyl-1H-pyrazole-3-carboxylic acid. LCMS (ESI) Calcd for C16H15FN4O: 298.1, found [M+H]+ = 299.2.1HNMR (400 MHz, DMSO-d6) δH 7.96 (s, 1H), 7.27-7.20 (m, 2H), 7.09-7.06 (m, 1H), 6.91 (s, 1H), 3.97 (s, 3H), 2.22 (s, 3H), 1.65 (m, 2H), 1.42 (m, 2H). Example 4: Synthesis of 5-(5-cyclopropyl-1-methyl-1H-pyrazol-3-yl)-3-(1-(5-fluoro-2- methylphenyl)cyclopropyl)-1,2,4-oxadiazole (Example 4): [0696] 5-(5-cyclopropyl-1-methyl-1H-pyrazol-3-yl)-3-(1-(5-fluoro-2-methylphenyl)cyclopropyl)- 1,2,4-oxadiazole was synthesized following Scheme 1 using 5-cyclopropyl-1-methyl-1H- pyrazole-3-carboxylic acid. LCMS (ESI) Calcd for C19H19FN4O: 338.2, found [M+H]+ = 339.2. 1HNMR (400 MHz, DMSO-d6) δH 7.26-7.19 (m, 2H), 7.09-7.05 (m, 1H), 6.58 (s, 1H), 3.95 (s, 3H), 2.20 (s, 3H), 1.99-1.92 (m, 1H), 1.64-1.61 (m, 2H), 1.42-1.39 (m, 2H), 1.00-0.93 (m, 2H), 0.75-0.72 (m, 2H). Example 5: Synthesis of 3-(1-(5-fluoro-2-methylphenyl)cyclopropyl)-5-(5-isopropyl-1- methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 5) [0697] 3-(1-(5-fluoro-2-methylphenyl)cyclopropyl)-5-(5-isopropyl-1-methyl-1H-pyrazol-3-yl)- 1,2,4-oxadiazole was synthesized following Scheme 1 using 5-isopropyl-1-methyl-1H-pyrazole- 3-carboxylic acid. LCMS (ESI) Calcd for C19H21FN4O: 340.2, found [M+H]+ = 341.2.1HNMR (400 MHz, DMSO-d6, at 100 °C) δH 7.24-7.17 (m, 2H), 7.05-7.01 (m, 1H), 6.67 (s, 1H), 3.89 (s, 3H), 3.11-3.08 (m,1H), 2.25 (s, 3H), 1.67 (brs, 2H), 1.40 (brs, 2H), 1.26-1.25 (d, 6H). Example 6: Synthesis of 3-(1-(5-fluoro-2-methylphenyl)cyclopropyl)-5-(1-phenyl-1H- pyrazol-3-yl)-1,2,4-oxadiazole (Example 6) [0698] 3-(1-(5-fluoro-2-methylphenyl)cyclopropyl)-5-(1-phenyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole was synthesized following Scheme 1 using 1-phenyl-1H-pyrazole-3-carboxylic acid. LCMS (ESI) Calcd for C21H17FN4O: 360.3, found [M+H]+ = 361.2.1HNMR (400MHz,DMSO-d6):δ 8.78 (d,1H), 7.39 (d, 2H), 7.56 (t, 2H), 7.42 (t,1H), 7.27-7.22 (m,3H), 7.11-7.06 (m,1H), 2.24 (s,3H), 1.68 (s, 2H), 1.46-1.43 (m, 2H). Example 7: Synthesis of 3-(1-(5-fluoro-2-methylphenyl)cyclopropyl)-5-(5-isopropyl-1- (pyridin-2-yl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 7) [0699] 3-(1-(5-fluoro-2-methylphenyl)cyclopropyl)-5-(5-isopropyl-1-(pyridin-2-yl)-1H-pyrazol-3- yl)-1,2,4-oxadiazole was synthesized following Scheme 1 using 5-isopropyl-1-(pyridin-2-yl)-1H- pyrazole-3-carboxylic acid. LCMS (ESI) Calcd for C23H22FN5O: 403.2, found [M+H]+ = 404.2.1H NMR (400 MHz, DMSO-d6) δH 8.59-8.58 (m, 1H), 8.10-8.07 (m, 1H), 7.86-7.84 (m, 1H), 7.55- 7.52 (m, 1H), 7.27-7.21 (m, 2H), 7.10-7.04 (m, 2H), 3.82-3.75 (m, 1H), 2.23 (s, 3H), 1.68 (m, 2H), 1.45 (m, 2H), 1.24-1.22(m, 6H). Example 8: Synthesis of 3-(1-(5-fluoro-2-methylphenyl)cyclopropyl)-5-(1-(2- fluorophenyl)-5-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 8) [0700] 3-(1-(5-fluoro-2-methylphenyl)cyclopropyl)-5-(1-(2-fluorophenyl)-5-methyl-1H-pyrazol-3- yl)-1,2,4-oxadiazole was synthesized following Scheme 1 using 1-(2-fluorophenyl)-5-methyl-1H- pyrazole-3-carboxylic acid. LCMS (ESI) Calcd for C22H18F2N4O: 392.4, found [M+H]+ = 393.2.1H NMR (400 MHz, DMSO-d6) δH 7.67-7.63 (m, 2H), 7.57 (t, 1H), 7.45 (t, 1H), 7.27-7.20 (m, 2H), 7.10-7.05 (m, 1H), 7.00 (s, 1H), 2.23 (s, 6H), 1.67 (t, 2H), 1.45 (t, 2H). Example 9: Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(3- fluorophenyl)cyclopropyl)-1,2,4-oxadiazole (Example 9)
Figure imgf000160_0001
[0701] Synthesis of 1-(3-fluorophenyl)cyclopropane-1-carbonitrile, 6 [Step 1]: To a stirred solution of KOH (3.7 g, 66.6 mmol) in water(10 mL), 2-(3-fluorophenyl)acetonitrile (5, 750 mg, 5.6 mmol) and TBAB (360 mg, 1.1 mmol) were added at 0 °C. After 5 min, 1,2-dibromoethane (2.4 mL, 27.7 mmol) was added dropwise and the resulting reaction mixture was heated at 60 °C for 12 h. After completion, the reaction mixture was poured into cold water and extracted with ethyl acetate (thrice). Combined organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to afford 1-(3-fluorophenyl)cyclopropane-1-carbonitrile (6, 710 mg).1H NMR (400 MHz, CDCl3) δH 7.35-7.25 (m, 1H), 7.08 (d, 1H), 6.99-6.95 (m, 2H), 1.59-1.24 (m, 4H). [Note: 1HNMR contain extra peak.] [0702] Synthesis of (Z)-1-(3-fluorophenyl)-N'-hydroxycyclopropane-1-carboximidamide, 7 [Step 2]: To a stirred solution of 1-(3-fluorophenyl)cyclopropane-1-carbonitrile (6, 700 mg, 4.3 mmol) in ethanol (10 mL), Na2CO3 (920 mg, 8.7 mmol) was added followed by NH2OH.HCl (605 g, 8.7 mmol) and the reaction mixture was heated to reflux at 70 °C for 12 h. After completion, the volatiles were evaporated under reduced pressure, diluted with water and extracted with ethyl acetate (thrice). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by column chromatography to afford (Z)-1-(3-fluorophenyl)-N'-hydroxycyclopropane-1-carboximidamide (7, 450 mg). LCMS (ESI) Calcd for C10H11FN2O: 194.1, found [M+H]+ = 195.0. [0703] Synthesis of (Z)-N'-((5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)-1-(3- fluorophenyl)cyclopropane-1-carboximidamide, 8 [Step 3]: To a stirred solution of 5- (difluoromethyl)-1-methyl-1H-pyrazole-3-carboxylic acid (120 mg, 0.7 mmol) and (Z)-1-(3- fluorophenyl)-N'-hydroxycyclopropane-1-carboximidamide (7, 200 mg, 1.0 mmol) in dichloromethane (3 mL), N,N-Diisopropylethylamine (0.2 mL, 1.4 mmol), EDCI.HCl (170 mg, 0.9 mmol) and HOAt (20 mg, 0.1 mmol) were added at 0 °C and reaction mixture was stirred at ambient temperature for 16h. After completion, the reaction mixture was concentrated under reduced pressure, dissolved with ethyl acetate, washed with water (twice) and brine. The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by column chromatography to afford (Z)-N'-((5- (difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)-1-(3-fluorophenyl)cyclopropane-1- carboximidamide (8, 180 mg). LCMS (ESI) calculated for C16H15F3N4O2: 352.1, found [M+H]+ = 353.3. [0704] Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(3- fluorophenyl)cyclopropyl)-1,2,4-oxadiazole, Example 9 [Step 4]: To a stirred solution of (Z)-N'- ((5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)-1-(3-fluorophenyl)cyclopropane-1- carboximidamide (8, 180 mg, 0.5 mmol) in THF (2 mL), tetrabutylammonium hydroxide(33 mg, 0.05 mmol, 1M in methanol) was added and resulting reaction mixture was stirred at ambient temperature for 60 min. After completion, the reaction mixture was concentrated under reduced pressure, dissolved in ethyl acetate, washed with water (twice), dried over anhydrous Na2SO4, filtered and concentrated again under reduced pressure. The product was purified through reverse phase prep-HPLC and lyophilized to afford 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3- yl)-3-(1-(3-fluorophenyl)cyclopropyl)-1,2,4-oxadiazole (Example 9, 80 mg). LCMS (ESI) Calcd for C16H13F3N4O: 334.1, found [M+H]+ = 335.1.1HNMR (400 MHz, DMSO-d6) δH 7.5-7.24 (t, 1H), 7.43-7.39 (m, 1H), 7.29-7.27 (m, 3H), 7.17-7.11 (m, 1H), 4.05 (s, 3H), 1.60-1.57 (m, 2H), 1.49- 1.46 (m, 2H). Example 10: Synthesis of 3-(1-(3-fluorophenyl)cyclopropyl)-5-(1-methyl-5- (trifluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 10) [0705] 3-(1-(3-fluorophenyl)cyclopropyl)-5-(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-1,2,4- oxadiazole was synthesized following Scheme 2 using 1-methyl-5-(trifluoromethyl)-1H- pyrazole-3-carboxylic acid. LCMS (ESI) Calcd for C16H12F4N4O: 352.1, found [M+H]+: = 353.2. 1HNMR (400 MHz, DMSO-d6) δH 7.66(s, 1H), 7.44-7.38 (m, 1H), 7.29 (d, 2H), 7.17-7.12 (m, 1H), 4.11 (s, 3H), 1.61-1.59 (m, 2H), 1.50-1.48 (m, 2H). Example 11: Synthesis of 5-(1,5-dimethyl-1H-pyrazol-3-yl)-3-(1-(3- fluorophenyl)cyclopropyl)-1,2,4-oxadiazole [0706] 5-(1,5-dimethyl-1H-pyrazol-3-yl)-3-(1-(3-fluorophenyl)cyclopropyl)-1,2,4-oxadiazole was synthesized following Scheme 2 using 1,5-dimethyl-1H-pyrazole-3-carboxylic acid. LCMS (ESI) Calcd for C16H15FN4O: 298.1, found [M+H]+ = 299.2.1HNMR (400 MHz, DMSO-d6) δH 7.42-7.37 (m, 1H), 7.28 (d, 2H), 7.15-7.11 (t, 1H), 6.72 (s, 1H), 3.84 (s, 3H), 2.31 (s, 3H), 1.58-1.55 (m, 2H), 1.46-1.43 (m, 2H). Example 12: Synthesis of 5-(1,5-dimethyl-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazole
Figure imgf000162_0001
[0707] Synthesis of 1-(o-tolyl)cyclopropane-1-carbonitrile, 10 [Step 1]: To a stirred solution of NaOH (31.79 g, 457 mmol) in water (50 mL), 2-(o-tolyl)acetonitrile (9, 5 g, 38.1 mmol) and TBAB (2.46 g, 7.62 mmol) were added at 0 °C. After 5 min 1,2-dibromoethane (29 mL, 191 mmol) was added dropwise and the resulting reaction mixture was heated at 600C for 12 hr. After completion, reaction mixture was poured into cold water and extracted with ethyl acetate (thrice). Combined organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to afford 1-(o-tolyl)cyclopropane-1-carbonitrile (10, 5 g).1H NMR (400 MHz, DMSO-d6) δ 7.35-7.20 (m, 6H), 2.47 (s, 3H), 2.29 (s, 3H), 1.70-1.67 (m, 2H), 1.36-1.33 (m.2H) [Note: HNMR contain extra peak.] [0708] Synthesis of (Z)-N'-hydroxy-1-(o-tolyl)cyclopropane-1-carboximidamide, 11 [Step 2]: To a stirred solution of 1-(o-tolyl)cyclopropane-1-carbonitrile (10, 2.00 g, 12.7 mmol) in ethanol (10mL), Na2CO3 (2.7 g, 25.4 mmol) was added followed by NH2OH.HCl (177 g, 25.4 mmol) and the reaction mixture was refluxed at 70 °C for 12h. After completion, volatiles are evaporated under reduced pressure, diluted with water and extracted with ethyl acetate (thrice). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by column chromatography to afford (Z)-N'-hydroxy- 1-(o-tolyl)cyclopropane-1-carboximidamide (11, 900 mg). LCMS (ESI) calculated for C11H14N2O [M]: 190.1, found [M+H]+: 190.7. [0709] Synthesis of (Z)-N'-((1,5-dimethyl-1H-pyrazole-3-carbonyl)oxy)-1-(o-tolyl)cyclopropane- 1-carboximidamide, 12, [Step 3]: To a stirred solution of 1,5-dimethyl-1H-pyrazole-3-carboxylic acid (50 mg, 0.4 mmol) and (Z)-N'-hydroxy-1-(o-tolyl)cyclopropane-1-carboximidamide (11, 100 mg, 0.5 mmol) in dichloromethane (2 mL), N,N-Diisopropylethylamine (0.1 mL, 0.7 mmol), EDCI.HCl (90 mg, 0.5 mmol) and HOAt (9.7 mg, 0.1 mmol) were added at 0 °C and reaction mixture was stirred at ambient temperature for 16h. After completion the reaction mixture was concentrated under reduced pressure, dissolved with ethyl acetate, washed with water (twice) and brine. The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by column chromatography to afford (Z)-N'-((1,5-dimethyl-1H-pyrazole-3-carbonyl)oxy)-1-(o-tolyl)cyclopropane-1- carboximidamide (12, 100 mg). LCMS (ESI) Calcd for C17H20N4O2: 312.2, found [M+H]+ = 313.2. [0710] Synthesis of 5-(1,5-dimethyl-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole, Example 12 [Step 4]: To a stirred solution of (Z)-N'-((1,5-dimethyl-1H-pyrazole-3-carbonyl)oxy)- 1-(o-tolyl)cyclopropane-1-carboximidamide (12, 100 mg, 0.3 mmol) in THF (2 mL), tetrabutylammonium hydroxide(105 mg, 0.2 mmol, 1M in methanol) was added and resulting reaction mixture was stirred at ambient temperature for 60 min. After completion, the reaction mixture was concentrated under reduced pressure, dissolved in ethyl acetate, washed with water (twice), dried over anhydrous Na2SO4, filtered and concentrated again under reduced pressure. The product was purified through reverse phase prep-HPLC and lyophilized to afford 5-(1,5-dimethyl-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 12, 50 mg). LCMS (ESI) Calcd for C17H18N4O: 294.1 , found [M+H]+ = 295.2.1HNMR (400 MHz, DMSO-d6) δH 7.37 (d, 1H), 7.23-7.18 (m, 3H), 6.70 (s, 1H), 3.84 (s, 3H), 2.31 (s, 3H), 2.26 (s, 3H), 1.63 (m, 2H), 1.36 (m, 2H). Example 13: Synthesis of 5-(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 13) [0711] 5-(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazole was synthesized following Scheme 3 using 1-methyl-5-(trifluoromethyl)-1H-pyrazole- 3-carboxylic acid. [0712] LCMS (ESI) Calcd for C17H15F3N4O: 348.1, found [M+H]+ = 349.2.1HNMR (400 MHz, DMSO-d6) δH 1H NMR (400 MHz, DMSO-d6) δH 7.63 (s, 1H), 7.38 (d, 1H), 7.24-7.19 (m, 3H), 4.10 (s, 3H), 2.32 (d, 3H), 1.66 (brs, 2H), 1.40 (brs, 2H). Example 14: Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 14) [0713] 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazole was synthesized following Scheme 3 using 5-(difluoromethyl)-1-methyl-1H-pyrazole- 3-carboxylic acid. [0714] LCMS (ESI) Calcd for C17H16F2N4O: 330.1, found [M+H]+ = 331.2.1HNMR (400 MHz, DMSO-d6) δH 7.50-7.19 (m, 6H), 4.04 (s, 3H), 2.26 (s, 3H), 1.66 (brs, 2H), 1.39 (brs, 2H). Example 15: Synthesis of 5-(1-methyl-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazole (Example 15) [0715] 5-(1-methyl-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole was synthesized following Scheme 3 using 1-methyl-1H-pyrazole-3-carboxylic acid. [0716] LCMS (ESI) Calcd for C16H16N4O: 280.1, found [M+H]+: = 281.1.1H NMR (400 MHz, DMSO-d6) δH 7.95 (s, 1H), 7.37 (d, 1H), 7.26-7.18 (m, 3H), 6.91 (brs, 1H), 3.97 (s, 3H), 2.26 (s, 3H), 1.65 (brs, 2H), 1.37 (brs, 2H). Example 16: Synthesis of 5-(1,4-dimethyl-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazole (Example 16) [0717] 5-(1,4-dimethyl-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole was synthesized following Scheme 3 using 1,4-dimethyl-1H-pyrazole-3-carboxylic acid. [0718] LCMS (ESI) Calcd. for C17H18N4O: 294.2, found [M+H]+ = 295.1.1H NMR (400 MHz, DMSO-d6) δH 7.75 (s, 1H), 7.37 (d, 1H), 7.25-7.19 (m, 3H), 3.89 (s, 3H), 2.26 (d, 6H), 1.65 (s, 2H), 1.37 (s, 2H). Example 17: Synthesis of 5-(5-(difluoromethyl)-1-(2-methoxyethyl)-1H-pyrazol-3-yl)-3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 17)
Figure imgf000165_0001
[0719] Synthesis of ethyl 5-(difluoromethyl)-1-(2-methoxyethyl)-1H-pyrazole-3-carboxylate, 15 [Step 1]: To a stirred solution of ethyl 5-(difluoromethyl)-1H-pyrazole-3-carboxylate (13, 2.0 g, 10.5 mmol) in DMF (50 mL) at 0°C, sodium hydride (505 mg, 12.6 mmol) was added at 0 oC. The reaction mixture was stirred at ambient temperature for 1 h and 1-bromo-2-methoxy-ethane (1.5 g, 10.5 mmol) was added. The reaction mixture was stirred at ambient temperature for 16 h and quenched with crushed ice. The resulting mixture was extracted ethyl acetate and washed with ice cold water and brine. The combined organic extract was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by column chromatography to afford ethyl 5-(difluoromethyl)-1-(2-methoxyethyl)-1H-pyrazole-3- carboxylate (15, 400 mg). LCMS (ESI) Calcd. C10H14F2N2O3: 248.1, found [M+H]+ = 249.2.1H NMR (400 MHz, DMSO-d6) δH 7.43-7.05 (m, 2H), 4.46 (t, 2H), 4.31-4.26 (m, 2H), 3.70 (t, 2H), 3.21 (s, 3H), 1.29 (t, 3H). Note: Isolated 900 mg other isomer 14 and the structure was confirmed by NOE experiment. [0720] Ethyl 3-(difluoromethyl)-1-(2-methoxyethyl)-1H-pyrazole-5-carboxylate, 14: LCMS (ESI) Calcd. C10H14F2N2O3: 248.1, found [M+H]+ = 249.2.1H NMR (400 MHz, DMSO-d6) δH 7.19-6.92 (m, 2H), 4.70 (t, 2H), 4.34-4.29 (m, 2H), 3.69 (t, 2H), 3.19 (s, 3H), 1.31 (t, 3H). [0721] Synthesis of 5-(difluoromethyl)-1-(2-methoxyethyl)-1H-pyrazole-3-carboxylic acid, 16 [Step 2]: To an ice cold solution of ethyl 5-(difluoromethyl)-1-(2-methoxyethyl)-1H-pyrazole-3- carboxylate (15, 420 mg, 1.4 mmol) in THF (4 mL) and methanol (1 mL), an aqueous solution of lithium hydroxide (135 mg, 3.2 mmol) in water (2 mL) was added dropwise. The reaction mixture was stirred at ambient temperature for 2 h and volatiles were evaporated under reduced pressure. The aqueous phase was acidified with 1 N aqueous solution of hydrochloric acid to ~pH-5 and extracted with a mixture of dichloromethane and isopropyl alcohol (9:1). Combined organic extract was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford 5-(difluoromethyl)-1-(2-methoxyethyl)-1H-pyrazole-3-carboxylic acid (16, 320 mg). LCMS (ESI) Calcd. for C18H10F2N2O2: 220.1, found [M+H]+ = 221.2. [0722] Synthesis of (Z)-N'-((5-(difluoromethyl)-1-(2-methoxyethyl)-1H-pyrazole-3-carbonyl)oxy)- 1-(o-tolyl)cyclopropane-1-carboximidamide, 17 [Step 3]: To a stirred solution of 5- (difluoromethyl)-1-(2-methoxyethyl)-1H-pyrazole-3-carboxylic acid (16, 320 mg, 1.5 mmol), and (Z)-N'-hydroxy-1-(o-tolyl)cyclopropane-1-carboximidamide (11, 275 mg, 1.5 mmol) in dichloromethane (15 mL), N,N-diisopropylethylamine (0.6 mL, 4.4 mmol), 1-hydroxy-7- azabenzotriazole (40 mg, 0.3 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (360 mg, 1.9 mmol) were added. The reaction mixture was stirred at ambient temperature for 16 h, diluted with ethyl acetate and washed with water and brine. Combined organic extract was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford (Z)-N'-((5-(difluoromethyl)-1-(2-methoxyethyl)-1H-pyrazole-3- carbonyl)oxy)-1-(o-tolyl)cyclopropane-1-carboximidamide (17, 540 mg). LCMS (ESI) Calcd. for C19H22F2N4O3: 392.2, found [M+H] = 393.2. [0723] Synthesis of 5-(5-(difluoromethyl)-1-(2-methoxyethyl)-1H-pyrazol-3-yl)-3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazole, Example 17 [Step 4]: To a stirred solution of (Z)-N'-((5- (difluoromethyl)-1-(2-methoxyethyl)-1H-pyrazole-3-carbonyl)oxy)-1-(o-tolyl)cyclopropane-1- carboximidamide (17, 540 mg, 1.4 mmol) in tetrahydrofuran (10 mL), tetra butyl ammonium hydroxide (39.6 mg, 0.2 mmol) was added. The resulting reaction mixture was stirred at ambient temperature for 12 h and concentrated under reduced pressure. The residue was diluted with ethyl acetate and washed with water and brine. Combined organic extract was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by reverse phase prep HPLC to afford 5-(5-(difluoromethyl)-1-(2-methoxyethyl)-1H- pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 17, 287 mg). LCMS (ESI) Calcd. for C19H20F2N4O2: 374.2, found [M+H]+ = 375.3.1H NMR (400 MHz, DMSO-d6) δH 7.47- 7.24 (m, 3H), 7.23-7.20 (m, 3H), 4.52 (t, 2H), 3.72 (t, 2H), 3.22 (s, 3H), 2.27 (s, 3H), 1.68-1.65 (m, 2H), 1.41-1.38 (m, 2H). Note: Another isomer was formed during alkylation. Example 18: Synthesis of 3-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5- yl)-1H-pyrazol-1-yl)propenamide (Example 18)
Figure imgf000167_0001
[0724] Synthesis of ethyl 1-(3-amino-3-oxo-propyl)-5-(difluoromethyl)pyrazole-3-carboxylate, 18 and ethyl 2-(3-amino-3-oxo-propyl)-5-(difluoromethyl)pyrazole-3-carboxylate, 18a [Step 1]: To a stirred solution of ethyl 5-(difluoromethyl)-1H-pyrazole-3-carboxylate (13, 500 mg, 2.6 mmol) in dimethylformamide (25 mL), potassium carbonate (1.8 g, 13.1 mmol) was added. After 1 h, 3- bromopropanamide (600 mg, 3.9 mmol) was added and the reaction mixture was stirred at ambient temperature for 16 h. The reaction mixture was diluted with ethyl acetate and washed with ice-cold water and brine. Combined organic extracts was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by column chromatography to afford a mixture of ethyl 1-(3-amino-3-oxo-propyl)-5- (difluoromethyl)pyrazole-3-carboxylate and ethyl 2-(3-amino-3-oxo-propyl)-5- (difluoromethyl)pyrazole-3-carboxylate (18 and 18a, 470 mg). LCMS (ESI) Calcd. for C10H13F2N3O3: 261.1, found [M+H]+ = 262.2. [0725] Synthesis of 1-(3-amino-3-oxo-propyl)-5-(difluoromethyl)pyrazole-3-carboxylic acid, 19 and 1-(3-amino-3-oxopropyl)-3-(difluoromethyl)-1H-pyrazole-5-carboxylic acid, 19a [Step 2]: To a cold solution mixture of ethyl 1-(3-amino-3-oxopropyl)-5-(difluoromethyl)-1H-pyrazole-3- carboxylate and ethyl 1-(3-amino-3-oxopropyl)-3-(difluoromethyl)-1H-pyrazole-5-carboxylate (18 and 18a, 300 mg, 1.2 mmol) in tetrahydrofuran (4 mL) and methanol (1 mL), a solution of lithium hydroxide (95 mg, 2.3 mmol) in water (2 mL) was added drop-wise. The reaction mixture was stirred at ambient temperature for 3 h. After completion, the volatiles were evaporated under reduced pressure. The aqueous phase was acidified with 1 N aqueous solution of hydrochloric acid to ~pH-5 and extracted with a mixture of ethyl acetate and isopropyl alcohol (1:9). Combined organic extracts was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The products were purified by column chromatography to afford a mixture of 1-(3-amino-3-oxo-propyl)-5-(difluoromethyl)pyrazole-3-carboxylic acid and 1- (3-amino-3-oxopropyl)-3-(difluoromethyl)-1H-pyrazole-5-carboxylic acid (19 and 19a, 240 mg). LCMS (ESI) Calcd. for C8H9F2N3O3: 405.2, found [M+H]+ = 406.4. [0726] Synthesis of (Z)-3-(3-((((amino(1-(o-tolyl)cyclopropyl)methylene)amino)oxy)carbonyl)-5- (difluoromethyl)-1H-pyrazol-1-yl)propanamide, 20 and (Z)-3-(5-((((amino(1-(o- tolyl)cyclopropyl)methylene)amino)oxy)carbonyl)-3-(difluoromethyl)-1H-pyrazol-1- yl)propanamide, 20a [Step 3]: To a stirred solution mixture of 1-(3-amino-3-oxo-propyl)-5- (difluoromethyl)pyrazole-3-carboxylic acid and 1-(3-amino-3-oxopropyl)-3-(difluoromethyl)-1H- pyrazole-5-carboxylic acid (19 and 19a, 240 mg, 1.0 mmol) in dichloromethane (10 mL), N,N- Diisopropylethylamine (330 mg, 2.6 mmol), 1-hydroxy-7-azabenzotriazole (30 mg, 0.2 mmol), 1- ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (255 mg, 1.3 mmol) and (Z)-N'- hydroxy-1-(o-tolyl)cyclopropane-1-carboximidamide (11, 235 mg, 1.2 mmol) were added. The reaction mixture was stirred at ambient temperature for 16 h. After completion, the reaction mixture was diluted with ethyl acetate and washed with water and brine. Combined organic extracts was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The products were purified by combi-flash chromatography to afford the first product as (Z)-3-(5-((((amino(1-(o-tolyl)cyclopropyl)methylene)amino)oxy)carbonyl)-3-(difluoromethyl)- 1H-pyrazol-1-yl)propanamide (20a, 120 mg) and the second product as (Z)-3-(3-((((amino(1-(o- tolyl)cyclopropyl)methylene)amino)oxy)carbonyl)-5-(difluoromethyl)-1H-pyrazol-1- yl)propanamide (20, 90 mg). LCMS (ESI) Calcd. for C19H21F2N5O3: 405.2, found [M+H]+ = 406.4. Note: Structure of both the isomers were confirmed based on NOE experiments of the final products. [0727] Synthesis of 3-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)propanamide, Example 171 [Step 4]: To a stirred solution of (Z)-3-(5-((((amino(1-(o- tolyl)cyclopropyl)methylene)amino)oxy)carbonyl)-3-(difluoromethyl)-1H-pyrazol-1- yl)propanamide (20a, 60 mg, 0.2 mmol) in tetrahydrofuran (5 mL), tetra butyl ammonium hydroxide (0.03 mL, 0.03 mmol, 1M in methanol) was added. The resulting reaction mixture was stirred at ambient temperature for 2 h and concentrated under reduced pressure. The residue was diluted with ethyl acetate and washed with water and brine. Combined organic extracts was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by reverse phase prep HPLC to afford 3-(5-(difluoromethyl)-3-(3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)propanamide (Example 171, 9 mg). LCMS (ESI) Calcd. for C19H19F2N5O2: 387.2, found [M+H]+ = 388.3.1H NMR (400 MHz, DMSO- d6) δH 7.56-7.18 (m, 7H), 6.98 (brs, 1H), 4.48 (t, 2H), 2.74 (t, 2H), 2.26 (s, 3H), 1.65 (brs, 2H), 1.39 (brs, 2H). [0728] Synthesis of 3-(3-(difluoromethyl)-5-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)propanamide, Example 18 [Step 5]: To a stirred solution of (Z)-3-(3-((((amino(1-(o- tolyl)cyclopropyl)methylene)amino)oxy)carbonyl)-5-(difluoromethyl)-1H-pyrazol-1- yl)propanamide (20, 80 mg, 0.2 mmol) in tetrahydrofuran (2 mL), tetra butyl ammonium hydroxide (10 mg, 0.04 mmol) was added. The resulting reaction mixture was stirred at ambient temperature for 2 h and concentrated under reduced pressure. The residue was diluted with ethyl acetate and washed with water followed by brine wash. Combined organic extracts was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by reverse phase prep HPLC to afford 3-(3-(difluoromethyl)-5-(3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)propanamide (Example 18, 22 mg). LCMS (ESI) Calcd. for C19H19F2N5O2: 387.2, found [M+H]+ = 388.3.1H NMR (400 MHz, DMSO- d6) δH 7.39-6.90 (m, 8H), 4.79 (t, 2H), 2.68 (t, 2H), 2.29 (s, 3H), 1.71 (brs, 2H), 1.42 (brs, 2H). Note: Structure was confirmed based on NOE experiment. Example 19: Synthesis of 5-(1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 19)
Figure imgf000169_0001
[0729] Synthesis of 5-(1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole, 25 [Step 1]: To a suspension of methyl 1H-pyrazole-3-carboxylate (265 mg, 2.1 mmol) and (Z)-N'-hydroxy-1- (o-tolyl)cyclopropane-1-carboximidamide (11, 400 mg, 2.1 mmol) in toluene (4 mL) was added potassium carbonate (581 mg, 4.2 mmol), and the reaction mixture was heated to reflux. After 16 h, the reaction mixture was filtered through a pad of celite, and the filtrate was concentrated under reduced pressure. The compound was purified by column chromatography to afford 5- (1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (25, 360 mg). LCMS calcd. for C15H14N4O: 266.12, found [M+H]+ = 267.3.1H NMR (400 MHz, DMSO-d6): δH 13.75 (brs, 1H), 8.00 (d, 1H), 7.39-7.37 (m, 1H), 7.24-7.20 (m, 3H), 6.92 (d, 1H), 2.27 (s, 3H), 1.66-1.65 (m, 2H), 1.38-1.37 (m, 2H) [0730] Synthesis of 5-(1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)- 1,2,4-oxadiazole, Example 19 [Step 2]: To an ice-cold solution of 5-(1H-pyrazol-3-yl)-3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazole (25, 150 mg, 0.6 mmol) in THF (6 mL) was added NaH (27 mg, 60% in mineral oil, 0.7 mmol). After 15 min, 1-bromo-2-(methylsulfonyl)ethane (126 mg, 0.7 mmol) was added, and the reaction mixture was allowed to warm to ambient temperature. After 16 h, the reaction mixture was quenched with cold water, and extracted with ethyl acetate. The organic phase was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The compound was purified by column chromatography using 0-50% ethyl acetate in hexanes to afford 5-(1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazole (Example 19, 125 mg). LCMS calcd. for C18H20N4O3S: 372.13, found [M+H]+ = 373.1. 1H NMR (400 MHz, DMSO-d6): δH 8.09 (d, 1H), 7.38-7.36 (m, 1H), 7.26-7.17 (m, 3H), 6.95 (d, 1H), 4.70 (t, 2H), 3.77 (t, 2H), 2.96 (s, 3H), 2.26 (s, 3H), 1.67-1.64 (m, 2H), 1.39-1.36 (m, 2H). Structure of the compound was supported by NOE data. Example 20: Synthesis of 5-(5-cyclopropyl-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-3- (1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 20)
Figure imgf000170_0001
[0731] Synthesis of 5-(5-cyclopropyl-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazole, 26 [Step 1]: To a suspension of methyl 5-cyclopropyl-1H-pyrazole-3-carboxylate (349 mg, 2.1 mmol) and (Z)-N'-hydroxy-1-(o-tolyl)cyclopropane-1-carboximidamide (11, 400 mg, 2.1 mmol) in toluene (4 mL) was added potassium carbonate (581 mg, 4.2 mmol), and the reaction mixture was heated to reflux. After 16 h, the reaction mixture was filtered through a pad of celite, and the filtrate was concentrated under reduced pressure. Purification on a silica gel column afforded 5-(5-cyclopropyl-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (26, 350 mg). LCMS calcd. for C18H18N4O: 306.15, found [M+H]+ = 307.3.1H NMR (400 MHz, DMSO-d6): δH 13.49 (brs, 1H), 7.38-7.36 (m, 1H), 7.25-7.18 (m, 3H), 6.57-6.56 (m, 1H), 2.26 (s, 3H), 1.99-1.93 (m, 1H), 1.63 (brs, 2H), 1.37-1.36 (m, 2H), 1.00-0.96 (m, 2H), 0.80-0.77 (m, 2H). [0732] Synthesis of 5-(5-cyclopropyl-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazole, Example 20 [Step 2]: To an ice-cold solution of 5-(5- cyclopropyl-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (26, 150 mg, 0.5 mmol) in THF (5 mL) was added NaH (24 mg, 60% in mineral oil, 0.6 mmol). After 15 min, 1-bromo-2- (methylsulfonyl)ethane (110 mg, 0.6 mmol) was added, and the reaction mixture was allowed to warm to ambient temperature. After 16 h, the reaction mixture was quenched with cold water, and extracted with ethyl acetate. The organic phase was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The compound was purified by column chromatography using 0-50% ethyl acetate in hexanes to afford 5-(5-cyclopropyl-1-(2- (methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 20, 110 mg). LCMS calcd. for C21H24N4O3S: 412.16, found [M+H]+ = 413.2.1H NMR (400 MHz, DMSO-d6): δH 7.37-7.36 (m, 1H), 7.25-7.17 (m, 3H), 6.63 (s, 1H), 4.70 (t, 2H), 3.77 (t, 2H), 3.00 (s, 3H), 2.25 (s, 3H), 2.07-2.00 (m, 1H), 1.63 (brs, 2H), 1.37 (brs, 2H), 1.03-0.99 (m, 2H), 0.79- 0.78 (m, 2H). Protons of one cyclopropyl ring appeared as two broad singlets. Structure of the compound was supported by NOE data. Example 21: Synthesis of 5-(5-methyl-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 21)
Figure imgf000171_0001
[0733] Synthesis of 5-(5-methyl-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole, 27 [Step 1]: To a suspension of methyl 5-methyl-1H-pyrazole-3-carboxylate ( 295 mg, 2.1 mmol) and (Z)-N'-hydroxy-1-(o-tolyl)cyclopropane-1-carboximidamide (11, 400 mg, 2.1 mmol) in toluene (4 mL) was added potassium carbonate (581 mg, 4.2 mmol), and the reaction mixture was heated to reflux. After 16 h, the reaction mixture was filtered through a celite pad, and the filtrate concentrated under reduced pressure. The compound was purified by column chromatography to afford 5-(5-methyl-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazole (27, 450 mg). LCMS calcd. for C16H16N4O: 280.13, found [M+H]+ = 281.3.1H NMR (400 MHz, DMSO-d6): δH 13.43 (brs, 1H), 7.38-7.36 (m, 1H), 7.26-7.17 (m, 3H), 6.65 (s, 1H), 2.30 (s, 3H), 2.26 (s, 3H), 1.65-1.63 (m, 2H), 1.38-1.35 (m, 2H). [0734] Synthesis of 5-(5-methyl-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazole, Example 21 [Step 2]: To an ice-cold solution of 5-(5-methyl- 1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (27, 100 mg, 0.4 mmol) in THF (4 mL) was added NaH (17 mg, 60% in mineral oil, 0.4 mmol). After 15 min, 1-bromo-2- (methylsulfonyl)ethane (80 mg, 0.4 mmol) was added, and the reaction mixture was allowed to warm to ambient temperature. After 16 h, the reaction mixture was quenched with cold water, and extracted with ethyl acetate. The organic phase was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The compound was purified by column chromatography using 0-50% ethyl acetate in hexanes to afford 5-(5-methyl-1-(2- (methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 21, 68 mg). LCMS calcd. for C19H22N4O3S: 386.14, found [M+H]+ = 387.1.1H NMR (400 MHz, DMSO-d6): δH 7.38-7.36 (m, 1H), 7.22-7.19 (m, 3H), 6.74 (s, 1H), 4.56 (t, 2H), 3.74 (t, 2H), 2.96 (s, 3H), 2.38 (s, 3H), 2.26 (s, 3H), 1.64 (brs, 2H), 1.37 (brs, 2H). Protons of the cyclopropyl ring appeared as two broad singlets. Structure of the compound was supported by NOE experiment. Example 22: Synthesis of 5-(5-isopropyl-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-3-(1- (o-tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 22) Scheme 9 [0735] Synthesis of (Z)-N'-((5-isopropyl-1H-pyrazole-3-carbonyl)oxy)-1-(o-tolyl)cyclopropane-1- carboximidamide, 28 [Step 1]: To a stirred solution of 5-isopropyl-1H-pyrazole-3-carboxylic acid (220 mg, 1.4 mmol) and (Z)-N'-hydroxy-1-(o-tolyl)cyclopropane-1-carboximidamide (11, 407 mg, 2.1 mmol) in dichloromethane (5 mL), N,N-diisopropylethylamine (1.2 mL, 7.1 mmol), EDCI.HCl (545 mg, 2.8 mmol) and HOAt (40 mg, 0.3 mmol) were added at 0 °C. The reaction mixture was stirred at ambient temperature for 16 h. After completion, the reaction mixture was diluted with water and extracted with dichloromethane. The organic extract was washed with brine and dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford (Z)-N'-((5- isopropyl-1H-pyrazole-3-carbonyl)oxy)-1-(o-tolyl)cyclopropane-1-carboximidamide (28, 500 mg). LCMS (ESI) calcd. for C18H22N4O2: 326.1, [M+H]+ = 327.4. [0736] Synthesis of 5-(5-isopropyl-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole, 29 [Step 2]: To a stirred solution of (Z)-N'-((5-isopropyl-1H-pyrazole-3-carbonyl)oxy)-1-(o- tolyl)cyclopropane-1-carboximidamide (28, 465 mg, 1.4 mmol) in THF (5 mL), tetrabutylammonium hydroxide (0.1 mL, 0.1 mmol, 1M in methanol) was added at ambient temperature. The reaction was stirred at ambient temperature for 2 h. After completion, the reaction mixture was concentrated under reduced pressure, diluted with ethyl acetate and washed with water. The organic extract was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by combiflash chromatography to afford 5-(5-isopropyl-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (29, 156 mg). LCMS (ESI) calcd. for C18H20N4O: 308.1, [M+H]+ = 309.4. [0737] Synthesis of 5-(5-isopropyl-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazole and 5-(3-isopropyl-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-5- yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole, Example 22 & Example 172 [Step 3]: To a stirred solution of 5-(5-isopropyl-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (29, 155 mg, 0.5 mmol) in THF (5 mL), NaH (25 mg, 0.6 mmol, 60% in oil) was added at 0 °C under nitrogen atmosphere and the reaction mixture was stirred for 10 min. Into the reaction mixture, 1-bromo-2-(methylsulfonyl)ethane ( 114 mg, 0.6 mmol) was added and stirred at ambient temperature for 16 h. After completion, the reaction mixture was diluted with ice cold water and extracted with ethyl acetate. The organic extract was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by combiflash chromatography to afford 5-(5-isopropyl-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)- 1,2,4-oxadiazole (Example 22, 100 mg) as Peak-1 and 5-(3-isopropyl-1-(2- (methylsulfonyl)ethyl)-1H-pyrazol-5-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 172, 20 mg) as peak-2. NOTE: The exact structure was confirmed by NOE of peak 1 and Peak-2. [0738] Analytical data of 5-(5-isopropyl-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazole, Example 22 (Peak-1): LCMS (ESI) calcd. for C21H26N4O3S: 414.1, [M+H]+ = 415.2.1H NMR (400 MHz, DMSO-d6) δH 7.38-7.36 (m, 1H), 7.21-7.13 (m, 3H), 6.78 (s, 1H), 4.57 (t, 2H), 3.76 (t, 2H), 3.18-3.15 (m, 1H), 2.98 (s, 3H), 2.25 (s, 3H), 1.70-1.64 (m, 2H), 1.45-1.37 (m, 2H), 1.25-1.23 (m, 6H). Example 23: Synthesis of 3-(3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (trifluoromethyl)-1H-pyrazol-1-yl)propanoic acid (Example 23)
Figure imgf000174_0001
[0739] Synthesis of methyl 5-(trifluoromethyl)-1H-pyrazole-3-carboxylate, 31 [Step 1]: To a stirred solution of 5-(trifluoromethyl)-1H-pyrazole-3-carboxylic acid (30, 900 mg, 5.0 mmol) in methanol (20 mL) at 0 °C was added thionyl chloride (0.73 mL, 10.0 mmol) dropwise. The reaction mixture was allowed to stir at ambient temperature for 14 h and volatiles were evaporated. The residue was diluted with ethyl acetate and washed with saturated solution of sodium bicarbonate followed by brine wash. Combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford methyl 5-(trifluoromethyl)-1H-pyrazole-3-carboxylate (31, 550 mg). LCMS (ESI) Calcd. for C6H5F3N2O2: 194.0, found [M-H]- = 193.1. [0740] Synthesis of 3-(1-(o-tolyl)cyclopropyl)-5-(5-(trifluoromethyl)-1H-pyrazol-3-yl)-1,2,4- oxadiazole, 32 [Step 2]: To a stirred solution of (Z)-N'-hydroxy-1-(o-tolyl)cyclopropane-1- carboximidamide (11, 600 mg, 3.2 mmol) in toluene (15 mL) was added potassium carbonate (872 mg, 6.3 mmol) and methyl 5-(trifluoromethyl)-1H-pyrazole-3-carboxylate (31, 612 mg, 3.2 mmol). Resulting reaction mixture was refluxed for 16 h and filtered through a celite bed. Combined filtrate was concentrated and the product was purified by column chromatography to afford 3-(1-(o-tolyl)cyclopropyl)-5-(5-(trifluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (32, 400 mg). LCMS (ESI) Calcd. for C16H13F3N4O: 334.1, found [M+H]+ = 335.0. [0741] Synthesis of tert-butyl 3-(3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (trifluoromethyl)-1H-pyrazol-1-yl)propanoate, 33 and tert-butyl 3-(5-(3-(1-(o-tolyl)cyclopropyl)- 1,2,4-oxadiazol-5-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)propanoate, 33a [Step 3]: To a stirred solution of 3-(1-(o-tolyl)cyclopropyl)-5-(5-(trifluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (32, 300 mg, 1.0 mmol) in THF (10 mL) was added potassium carbonate (186 mg, 1.4 mmol). After 10 min., tert-butyl 3-bromopropanoate (281 mg, 1.4 mmol) was added. The reaction mixture was refluxed for 14 h, filtered and combined filtrate was concentrated under reduced pressure. The products were purified by reverse phase preparative HPLC to afford the first product as tert- butyl 3-(3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(trifluoromethyl)-1H-pyrazol-1- yl)propanoate, Peak 1 (33, 50 mg) and the second product as tert-butyl 3-(5-(3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)propanoate, Peak-2 (33a, 75 mg). The structure of the regiomers were confirmed by 2D NMR analyses. [0742] tert-butyl 3-(3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(trifluoromethyl)-1H- pyrazol-1-yl)propanoate, Peak 1 (33): LCMS (ESI) Calcd. for C23H25F3N4O3: 462.19, found [M+H]+ = 463.10. [0743] tert-butyl 3-(5-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-3-(trifluoromethyl)-1H- pyrazol-1-yl)propanoate, Peak-2 (33a): LCMS (ESI) Calcd. for C23H25F3N4O3: 462.19, found [M+H]+ = 463.10. [0744] Synthesis of 3-(3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(trifluoromethyl)-1H- pyrazol-1-yl)propanoic acid, Example 23 [Step 4]: To a stirred solution of tert-butyl 3-(3-(3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)propanoate (33, 50 mg, 0.1 mmol) in dichloromethane (4 mL) was added trifluoroacetic acid (0.08 mL, 1.1 mmol). The reaction mixture was allowed to stir at ambient temperature for 16 h and volatiles were evaporated under reduced pressure. The product was purified by reverse phase preparative HPLC to afford 3-(3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(trifluoromethyl)-1H- pyrazol-1-yl)propanoic acid (Example 23, 15 mg). LCMS (ESI) Calcd. for C19H17F3N4O3: 406.13, found [M+H]+ = 407.10.1H NMR (400 MHz, DMSO-d6): δH 7.63 (s, 1H), 7.38 (d, 1H), 7.24-7.19 (m, 3H), 4.53 (t, 2H), 2.92 (t, 2H), 2.26 (s, 3H), 1.68-1.65 (m, 2H), 1.41-1.39 (m, 2H). One acid proton was exchangeable. [0745] Synthesis of 3-(5-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-3-(trifluoromethyl)-1H- pyrazol-1-yl)propanoic acid, Example 173 [Step 5]: To a stirred solution of tert-butyl 3-(5-(3-(1- (o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)propanoate (33a, 75 mg, 0.2 mmol) in dichloromethane (4 mL) was added trifluoroacetic acid (0.12 mL, 1.6 mmol). The reaction mixture was allowed to stir at ambient temperature for 16 h and volatiles were evaporated under reduced pressure. The product was purified by reverse phase preparative HPLC to afford 3-(5-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-3- (trifluoromethyl)-1H-pyrazol-1-yl)propanoic acid (Example 173, 30 mg). LCMS (ESI) Calcd. for C19H17F3N4O3: 406.13, found [M+H]+ = 407.10.1H NMR (400 MHz, DMSO-d6): δH 7.64 (s, 1H), 7.38 (d, 1H), 7.25-7.18 (m, 3H), 4.84 (t, 2H), 2.85 (t, 2H), 2.29 (s, 3H), 1.71-168 (m, 2H), 1.45- 1.42 (m, 2H). One acid proton was exchangeable. Example 24: Synthesis of 3-(3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (trifluoromethyl)-1H-pyrazol-1-yl)propanamide (Example 24)
Figure imgf000176_0001
[0746] Synthesis of 1-(o-tolyl)-N'-((5-(trifluoromethyl)-1H-pyrazole-3-carbonyl)oxy)cyclopropane- 1-carboximidamide, 35 [Step 1]: To a stirred solution of N'-hydroxy-1-(o-tolyl)cyclopropane-1- carboximidamide (11, 500 mg, 2.6 mmol) and 5-(trifluoromethyl)-1H-pyrazole-3-carboxylic acid (520 mg, 2.9 mmol) in dichloromethane (8 mL) were added DIPEA (1.4 mL, 7.9 mmol), EDC.HCl (1.0 g, 5.3 mmol) and HOAt (55 mg, 0.5 mmol) at 0 °C and the reaction mixture was stirred at ambient temperature for 16 h. The reaction mixture was diluted with dichloromethane and washed with water. Organic extract was collected, washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduce pressure to afford 1-(o-tolyl)-N'-((5- (trifluoromethyl)-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide (35, 500 mg). LCMS (ESI) Calcd for C16H15F3N4O2: 352.3, found [M+H]+ = 353.1. [0747] Synthesis of 3-(1-(o-tolyl)cyclopropyl)-5-(5-(trifluoromethyl)-1H-pyrazol-3-yl)-1,2,4- oxadiazole, 32 [Step 2]: To a stirred solution of 1-(o-tolyl)-N'-((5-(trifluoromethyl)-1H-pyrazole-3- carbonyl)oxy)cyclopropane-1-carboximidamide (35, 500 mg, 1.4 mmol) in THF (4 mL) was added tetrabutylammonium hydroxide (185 mg, 0.3 mmol) and the reaction mixture was stirred at ambient temperature for 2 h. After completion, the reaction mixture was diluted with ethyl acetate and washed with water. The combined organic extract was collected, washed with brine, dried over anhydrous Na2SO4 and, concentrated under reduced pressure. The product was purified by column chromatography to afford 3-(1-(o-tolyl)cyclopropyl)-5-(5-(trifluoromethyl)- 1H-pyrazol-3-yl)-1,2,4-oxadiazole (32, 300 mg). LCMS (ESI) Calcd for C16H13F3N4O: 334.3, found [M+H]+ = 335.3. [0748] Synthesis of 3-(3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(trifluoromethyl)-1H- pyrazol-1-yl)propanamide & 3-(5-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-3- (trifluoromethyl)-1H-pyrazol-1-yl)propanamide, Example 24 & Example 174 [Step 3]: To a stirred solution of 3-(1-(o-tolyl)cyclopropyl)-5-(5-(trifluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (32, 280 mg, 0.8 mmol) in THF (5mL) was added K2CO3 (462 mg, 3.4 mmol) at 0 °C. After 15 min 3- bromopropanamide (255 mg, 1.7 mmol) was added to the reaction mixture and stirred at ambient temperature for 16 h. After completion, the reaction mixture was diluted with ethyl acetate and washed with water. The combined organic extract was collected, washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The product was purified by column chromatography and isolated compound was lyophilized to afford 3-(3- (3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)propanamide (Example 24, 62 mg) and 3-(5-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-3- (trifluoromethyl)-1H-pyrazol-1-yl)propanamide (Example 174, 62 mg). Note: Structure was confirmed by HMBC & HSQC. [0749] Analytical data of 3-(3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(trifluoromethyl)- 1H-pyrazol-1-yl)propanamide, Example 24: LCMS (ESI) Calcd for C19H18F3N5O2: 405.3, found [M+H]+ = 406.3.1H NMR (400 MHz, DMSO-d6) δH 7.62 (s, 1H), 7.49 (brs, 1H), 7.38 (d, 1H), 7.24-7.20 (m, 3H), 6.90 (brs, 1H), 4.52 (t, 2H), 2.78 (t, 2H), 2.26 (s, 3H), 1.66 (s, 2H), 1.40 (s, 2H). Example 25: Synthesis of 3-(5-cyclopropyl-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5- yl)-1H-pyrazol-1-yl)propanoic acid (Example 25)
Figure imgf000177_0001
[0750] Synthesis of methyl 5-cyclopropyl-1H-pyrazole-3-carboxylate, 38 [Step 1]: To a stirred solution of 5-cyclopropyl-1H-pyrazole-3-carboxylic acid (37, 1.5 g, 9.8 mmol) in methanol (30 mL) at 0 °C was added thionyl chloride (1.4 mL, 19.7 mmol) dropwise. The reaction mixture was allowed to stir at ambient temperature for 14 h, quenched with saturated aqueous solution of sodium bicarbonate and extracted with ethyl acetate. Combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated to afford methyl 5-cyclopropyl-1H- pyrazole-3-carboxylate (38, 720 mg). LCMS (ESI) Calcd. for C8H10N2O2: 166.0, found [M+H]+ = 167.2. [0751] Synthesis of 5-(5-cyclopropyl-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazole, 26 [Step 2]: To a stirred solution of (Z)-N'-hydroxy-1-(o-tolyl)cyclopropane-1- carboximidamide (11, 700 mg, 3.7 mmol) in toluene (15 mL) were added potassium carbonate (1.0 g, 7.4 mmol) and methyl 5-cyclopropyl-1H-pyrazole-3-carboxylate (38, 611 mg, 3.7 mmol). Resulting reaction mixture was heated at 110 °C for 16 h, filtered through a celite bed and concentrated under reduced pressure. The product was purified by column chromatography to afford 5-(5-cyclopropyl-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (26, 500 mg). LCMS (ESI) Calcd. for C18H18N4O: 306.1, found [M+H]+ = 360.8. [0752] Synthesis of tert-butyl 3-(5-cyclopropyl-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 1H-pyrazol-1-yl)propanoate, 40 [Step 3]: To a stirred solution of 5-(5-cyclopropyl-1H-pyrazol-3- yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (26, 250 mg, 0.8 mmol) in acetonitrile (10 mL) was added Cs2CO3 (399 mg, 1.2 mmol) and tert-butyl 3-bromopropanoate ( 205 mg, 0.9 mmol). The reaction mixture was stirred at 70 °C for 14 h, filtered, the filtrate was concentrated under reduced pressure. The product was purified by column chromatography to afford tert-butyl 3-(5- cyclopropyl-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)propanoate (40, 175 mg). LCMS (ESI) Calcd. for C25H30N4O3: 434.2, found [M+H]+ = 435.4. [0753] Synthesis of 3-(5-cyclopropyl-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)propanoic acid, Example 25 [Step 4]: To a stirred solution of tert-butyl 3-(5- cyclopropyl-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)propanoate (40, 175 mg, 0.4 mmol) in dichloromethane (8 mL) at 0 °C was added trifluoroacetic acid (0.31 mL, 4.0 mmol). The reaction mixture was allowed to stir at ambient temperature for 16 h and volatiles were evaporated under reduced pressure. The product was purified by reverse phase preparative HPLC to afford [0754] 3-(5-cyclopropyl-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1- yl)propanoic acid (Example 25, 95 mg). LCMS (ESI) Calcd. for C21H22N4O3: 378.1, found [M+H]+ = 379.2.1H NMR (400 MHz, DMSO-d6): δH 7.36 (d, 1H), 7.21-7.19 (m, 3H), 6.55 (s, 1H), 4.43 (t, 2H), 2.77 (t, 2H), 2.24 (s, 3H), 2.07-2.03 (m, 1H), 1.62 (brs, 2H), 1.35 (brs, 2H), 0.98-0.96 (m, 2H), 0.74-0.73 (m, 2H). Structure was confirmed by 2D NMR analysis. Example 26: Synthesis of 5-(1-(2-(methylsulfonyl)ethyl)-5-(trifluoromethyl)-1H-pyrazol-3- yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 26)
Figure imgf000179_0001
[0755] Synthesis of 3-(1-(o-tolyl)cyclopropyl)-5-(5-(trifluoromethyl)-1H-pyrazol-3-yl)-1,2,4- oxadiazole, 32 [Step 1]: To a stirred solution of (Z)-N'-hydroxy-1-(o-tolyl)cyclopropane-1- carboximidamide (11, 410 mg, 2.2 mmol) and ethyl 5-(trifluoromethyl)-1H-pyrazole-3- carboxylate (450 mg, 2.2 mmol) in toluene (6 mL) was added potassium carbonate (600 mg, 4.3 mmol) at ambient temperature and reaction mixture was allowed to stir at 110 °C for 16 h. After completion, the reaction mixture was cooled to ambient temperature and diluted with water and extracted with dichloromethane. The organic extract was washed with brine and dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by combiflash chromatography to afford 3-(1-(o-tolyl)cyclopropyl)-5-(5-(trifluoromethyl)-1H- pyrazol-3-yl)-1,2,4-oxadiazole (32, 450 mg). LCMS (ESI) Calcd. for C16H13F3N4O: 334.1, [M+H]+ = 335.3. [0756] Synthesis of 5-(1-(2-(methylsulfonyl)ethyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)-3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazole, Example 175 [Step 2]: To a stirred solution of 3-(1-(o- tolyl)cyclopropyl)-5-(5-(trifluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (32, 250 mg, 0.7 mmol) in THF (5 mL) was added NaH (60% in oil suspension) (35 mg, 0.9 mmol) at 0 °C under nitrogen atmosphere and the reaction mixture was stirred for 10 min at same condition. To this reaction mixture was added 1-bromo-2-(methylsulfonyl)ethane (170 mg, 0.9 mmol) and the reaction mixture was stirred for 16 h at ambient temperature. After completion, the reaction mixture was diluted with ice cold water and extracted with ethyl acetate. The organic extract was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by combiflash chromatography to afford 5-(1-(2-(methylsulfonyl)ethyl)-3- (trifluoromethyl)-1H-pyrazol-5-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 175, 80 mg). LCMS (ESI) calcd. for C19H19F3N4O3S: 440.1, [M+H]+ = 441.0.1H NMR (400 MHz, DMSO- d6) δH 7.72 (s, 1H), 7.38-7.37 (m, 1H), 7.23-7.20 (m, 3H), 5.12 (t, 2H), 3.78 (t, 2H), 3.00 (s, 3H), 2.29 (s, 3H), 1.75 (s, 2H), 1.43 (s, 2H). NOTE: The exact structure was confirmed by HMBC. [0757] Synthesis of 5-(1-(2-(methylsulfonyl)ethyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl)-3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazole, Example 26 [Step 3]: To a stirred solution of 3-(1-(o- tolyl)cyclopropyl)-5-(5-(trifluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (32, 220 mg, 0.7 mmol) in THF (5 mL) was added K2CO3 (182 mg, 1.3 mmol) at 0 °C under nitrogen atmosphere and the reaction mixture was stirred for 10 min at same condition. To this reaction mixture was added 1-bromo-2-(methylsulfonyl)ethane (185 mg, 1 mmol) and the reaction mixture was stirred for 16 h at ambient temperature. After completion, the reaction mixture was diluted with ice cold water and extracted with ethyl acetate. The organic extract was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by combiflash chromatography to afford 5-(1-(2-(methylsulfonyl)ethyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl)-3-(1- (o-tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 26, 25 mg). LCMS (ESI) calcd. for C19H19F3N4O3S: 440.11, [M+H]+ = 441.0, 1H NMR (400 MHz, DMSO-d6) δH 7.69 (s, 1H), 7.39- 7.37 (m, 1H), 7.26-7.18 (m, 3H), 4.77 (t, 2H), 3.85 (t, 2H), 3.08 (s, 3H), 2.26 (s, 3H), 1.66 (s, 2H), 1.41 (s, 2H). NOTE: The exact structure was confirmed by HMBC. Example 27: Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)-N-methylacetamide (Example 27)
Figure imgf000181_0001
[0758] Synthesis of ethyl 1-(2-(tert-butoxy)-2-oxoethyl)-5-(difluoromethyl)-1H-pyrazole-3- carboxylate, 43 [Step 1]: To a stirred solution of ethyl 5-(difluoro methyl)-1H-pyrazole-3- carboxylate (42, 800 mg, 4.2 mmol) in dimethylformamide (5 mL) at 0 °C, sodium hydride (200 mg, 5.1 mmol, 60% dispersion in mineral oil) was added at 0 °C. The reaction mixture was stirred at ambient temperature for 1 h and tert-butyl 2-bromoacetate (985 mg, 5.1 mmol) was added. The resulting reaction mixture was stirred at ambient temperature for 16 h. After completion, the reaction mixture was quenched with crushed ice, extracted with ethyl acetate. The organic extract was washed with ice cold water and brine. Combined organic extract was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by column chromatography to afford ethyl 1-(2-(tert-butoxy)-2-oxoethyl)-5- (difluoromethyl)-1H-pyrazole-3-carboxylate (43, 500 mg).1H NMR (400 MHz, DMSO-d6) δH 7.41-7.11 (m, 2H), 5.19 (s, 2H), 4.32-4.27 (m, 2H), 1.41 (s, 9H), 1.30 (t, 3H). Note: Isolated 300 mg of ethyl 1-(2-(tert-butoxy)-2-oxoethyl)-3-(difluoromethyl)-1H-pyrazole-5-carboxylate (43a) and the structure of desired isomer was confirmed by NOE experiment.1H NMR (400 MHz, DMSO-d6) δH 7.20-6.93 (m, 2H), 5.25 (s, 2H), 4.32-4.27 (m, 2H), 1.41 (s, 9H), 1.29 (t, 3H). [0759] Synthesis of 2-(5-(difluoromethyl)-3-(ethoxycarbonyl)-1H-pyrazol-1-yl)acetic acid, 44 [Step 2]: To a stirred solution of ethyl 1-(2-(tert-butoxy)-2-oxoethyl)-5-(difluoromethyl)-1H- pyrazole-3-carboxylate (43, 200 mg, 0.7 mmol) in dichloromethane (1 mL), trifluoroacetic acid (1.0 mL, 13.5 mmol) was added dropwise at 0 °C. The reaction mixture was stirred at ambient temperature for 3 h. After completion the volatiles were evaporated under reduced pressure to afford 2-(5-(difluoromethyl)-3-(ethoxycarbonyl)-1H-pyrazol-1-yl)acetic acid (44, 120 mg). LCMS (ESI) Calcd. for C9H10F2N2O4: 248.0, found [M+H]+ = 249.2. [0760] Synthesis of ethyl 5-(difluoromethyl)-1-(2-(methylamino)-2-oxoethyl)-1H-pyrazole-3- carboxylate, 45 [Step 3]: To a stirred solution of 2-(5-(difluoromethyl)-3-(ethoxycarbonyl)-1H- pyrazol-1-yl)acetic acid (44, 400 mg, 1.6 mmol) in dry tetrahydrofuran (3 mL), 4- methylmorpholine (0.6 mL, 5.6 mmol) and isobutyl chloroformate (0.3 mL, 2.4 mmol) were added. The reaction mixture was stirred at -15 °C for 15 min and methanamine hydrochloride (545 mg, 8.1 mmol) was added. The resulting reaction mixture was stirred at ambient temperature for additional 16 h. After completion, the reaction mixture was diluted with ethyl acetate and washed with water. Combined organic extracts was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford ethyl 5-(difluoromethyl)-1- (2-(methylamino)-2-oxoethyl)-1H-pyrazole-3-carboxylate (45, 110 mg). LCMS (ESI) Calcd. C10H13F2N3O3: 261.1, found [M+H]+ = 262.2. [0761] Synthesis of 5-(difluoromethyl)-1-(2-(methylamino)-2-oxoethyl)-1H-pyrazole-3-carboxylic acid, 46 [Step 4]: To a cold solution of ethyl 5-(difluoromethyl)-1-(2-(methylamino)-2-oxoethyl)- 1H-pyrazole-3-carboxylate (45, 110 mg, 0.4 mmol) in tetrahydrofuran (4 mL) and methanol (1 mL), a solution of lithium hydroxide (26.5 mg, 0.6 mmol) in water (2 mL) was added drop-wise. The reaction mixture was stirred at ambient temperature for 16 h and volatiles were evaporated under reduced pressure. The aqueous phase was acidified with 1 N aqueous solution of hydrochloric acid to ~pH-5 and extracted with a mixture of ethyl acetate and isopropyl alcohol (9:1). Combined organic extracts was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford 5-(difluoromethyl)-1-(2-(methylamino)-2- oxoethyl)-1H-pyrazole-3-carboxylic acid (46, 80 mg).1H NMR (400 MHz, DMSO-d6) δH 13.03 (brs, 1H), 8.19 (d, 1H), 7.23 (t, 1H), 7.01 (s, 1H), 4.97 (s, 2H), 2.62 (d, 3H). [0762] Synthesis of (Z)-2-(3-((((amino(1-(o-tolyl)cyclopropyl)methylene)amino)oxy)carbonyl)-5- (difluoromethyl)-1H-pyrazol-1-yl)-N-methylacetamide, 47 [Step 5]: To a stirred solution of 5- (difluoromethyl)-1-(2-(methylamino)-2-oxoethyl)-1H-pyrazole-3-carboxylic acid (46, 80 mg, 0.3 mmol) and (Z)-N'-hydroxy-1-(o-tolyl)cyclopropane-1-carboximidamide (11, 105 mg, 0.6 mmol) in dichloromethane (5 mL), N,N-diisopropylethylamine (0.3 mL, 1.7 mmol), 1-Hydroxy-7- azabenzotriazole (9.3 mg, 0.1 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (98.7 mg, 0.5 mmol) were added. The reaction mixture was stirred at ambient temperature for 16 h. After completion, the reaction mixture was diluted with ethyl acetate and washed with water and brine. Combined organic extracts was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford (Z)-2-(3-((((amino(1-(o- tolyl)cyclopropyl)methylene)amino)oxy)carbonyl)-5-(difluoromethyl)-1H-pyrazol-1-yl)-N- methylacetamide (47, 130 mg). LCMS (ESI) Calcd. for C19H21F2N5O3: 405.2, found [M+H]+ = 406.4. [0763] Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)-N-methylacetamide, Example 27 [Step 6]: To a stirred solution of (Z)-2-(3- ((((amino(1-(o-tolyl)cyclopropyl)methylene)amino)oxy)carbonyl)-5-(difluoromethyl)-1H-pyrazol-1- yl)-N-methylacetamide (47, 130 mg, 0.3 mmol) in tetrahydrofuran (2 mL), tetra butyl ammonium hydroxide (41.6 mg, 0.1 mmol) was added. The resulting reaction mixture was stirred at ambient temperature for 16 h and concentrated under reduced pressure. The residue was diluted with ethyl acetate and washed with water and brine. Combined organic extract was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by reverse phase prep-HPLC purification to afford 2-(5-(difluoromethyl)-3-(3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)-N-methylacetamide (Example 27, 15 mg). LCMS Calcd. for C19H19F2N5O2: 387.2, found [M+H]+ = 388.3.1H NMR (400 MHz, DMSO- d6) δH 8.22-8.21 (m, 1H), 7.42-7.15 (m, 6H), 5.06 (s, 2H), 2.62 (d, 3H), 2.26 (s, 3H), 1.67-1.65 (m, 2H), 1.41-1.38 (m, 2H). Example 28: Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)-N,N-dimethylacetamide (Example 28)
Figure imgf000183_0001
[0764] Synthesis of ethyl 5-(difluoromethyl)-1-(2-(dimethylamino)-2-oxoethyl)-1H-pyrazole-3- carboxylate, 48 [Step 1]: To a stirred solution of 2-(5-(difluoromethyl)-3-(ethoxycarbonyl)-1H- pyrazol-1-yl)acetic acid (44, 350 mg, 1.4 mmol) in dry dimethylformamide (5 mL), N,N- diisopropylethylamine (0.9 mL, 4.9 mmol) and N-methylmethanamine hydrochloride (1.2 g, 14.1 mmol) were added. After 10 min, T3P (1.3 mL, 4.2 mmol, 50 % in ethyl acetate) was added. The reaction mixture was stirred at ambient temperature for 16 h. After completion, the reaction mixture was quenched with ice-cold water and extracted with ethyl acetate. Combined organic extract was washed with ice-cold water, dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford ethyl 5-(difluoromethyl)-1-(2-(dimethylamino)-2- oxoethyl)-1H-pyrazole-3-carboxylate (48, 180 mg). LCMS (ESI) Calcd. C11H15F2N3O3: 275.1, found [M+H]+ = 276.2. [0765] Synthesis of 5-(difluoromethyl)-1-(2-(dimethylamino)-2-oxoethyl)-1H-pyrazole-3- carboxylic acid, 49 [Step 2]: To a cold solution of ethyl 5-(difluoromethyl)-1-(2-(dimethylamino)- 2-oxoethyl)-1H-pyrazole-3-carboxylate (48, 180 mg, 0.7 mmol) in tetrahydrofuran (4 mL) and methanol (1 mL) mixture, a solution of lithium hydroxide monohydrate (40 mg, 1.0 mmol) in water (1 mL) was added dropwise. The reaction mixture was stirred at ambient temperature for 16 h. After completion, the volatiles were evaporated under reduced pressure. The aqueous phase was acidified with 1 N aqueous solution of hydrochloric acid to ~pH-5 and extracted with a mixture of ethyl acetate and isopropyl alcohol (9:1). Combined organic extracts was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford 5- (difluoromethyl)-1-(2-(dimethylamino)-2-oxoethyl)-1H-pyrazole-3-carboxylic acid (49, 110 mg). 1H NMR (400 MHz, DMSO-d6) δH 13.05 (brs, 1H), 7.41-7.00 (m, 2H), 5.34-5.16 (s, 1H), 3.04- 2.89 (m, 3H), 2.85-2.73 (s, 3H).1H NMR indicated the product as mixture of rotamers. [0766] Synthesis of (Z)-2-(3-((((amino(1-(o-tolyl)cyclopropyl)methylene)amino)oxy)carbonyl)-5- (difluoromethyl)-1H-pyrazol-1-yl)-N,N-dimethylacetamide, 50 [Step 3]: To a stirred solution of 5- (difluoromethyl)-1-(2-(dimethylamino)-2-oxoethyl)-1H-pyrazole-3-carboxylic acid (49, 110 mg, 0.5 mmol) and (Z)-N'-hydroxy-1-(o-tolyl)cyclopropane-1-carboximidamide (11, 85.5 mg, 0.5 mmol) in dichloromethane (2 mL), N,N-diisopropylethylamine (0.3 mL, 1.6 mmol), 1-Hydroxy-7- azabenzotriazole (12.3 mg, 0.1 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (112.1 mg, 0.6 mmol) were added. The reaction mixture was stirred at ambient temperature for 16 h, diluted with ethyl acetate and washed with water and brine. Combined organic extracts was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford (Z)-2-(3-((((amino(1-(o- tolyl)cyclopropyl)methylene)amino)oxy)carbonyl)-5-(difluoromethyl)-1H-pyrazol-1-yl)-N,N- dimethylacetamide (50, 160 mg). LCMS (ESI) Calcd. for C20H23F2N5O3: 419.2 found [M+H]+ = 420.4. [0767] Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)-N,N-dimethylacetamide, Example 28 [Step 4]: To a stirred solution of (Z)-2-(3- ((((amino(1-(o-tolyl)cyclopropyl)methylene)amino)oxy)carbonyl)-5-(difluoromethyl)-1H-pyrazol-1- yl)-N,N-dimethylacetamide (50, 130 mg, 0.3 mmol) in tetrahydrofuran (2 mL), tetra butyl ammonium hydroxide (41.6 mg, 0.1 mmol) was added. The resulting reaction mixture was stirred at ambient temperature for 16h. After completion, the reaction mixture was concentrated under reduced pressure. The residue was diluted with ethyl acetate and washed with water and brine. Combined organic extracts was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by reverse phase prep-HPLC purification to afford 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)-N-methylacetamide (Example 28, 25 mg). LCMS (ESI) Calcd. for C20H21F2N5O2: 401.1, found [M+H]+ = 402.3.1H NMR (400 MHz, DMSO-d6) δH 7.38 (d, 1H), 7.34-7.08 (m, 5H), 5.44 (s, 2H), 3.05 (s, 3H), 2.85 (s, 3H), 2.26 (s, 3H), 1.67-1.66 (m, 2H), 1.41-1.38 (m, 2H). Example 29: Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)-N,N-dimethylacetamide (Example 29)
Figure imgf000185_0001
[0768] Synthesis of ethyl 5-(difluoromethyl)-1-(2-(oxetan-3-ylamino)-2-oxoethyl)-1H-pyrazole-3- carboxylate, 3 [Step 1]: To a stirred solution of 2-(5-(difluoromethyl)-3-(ethoxycarbonyl)-1H- pyrazol-1-yl)acetic acid (44, 300 mg, 1.2 mmol) in dry tetrahydrofuran (10 mL), n-methyl morpholine (245 mg, 2.4 mmol) and isobutyl chloroformate (165 mg, 1.2 mmol) were added at - 15 °C. After 15 min, oxetan-3-amine (105 mg, 1.5 mmol) was added at -15 °C and the reaction mixture was stirred at same temperature for additional 2 h. After completion, the reaction mixture was diluted with ethyl acetate and washed with water and brine. Combined organic extracts was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by combi flash chromatography to afford ethyl 5- (difluoromethyl)-1-(2-(oxetan-3-ylamino)-2-oxoethyl)-1H-pyrazole-3-carboxylate (51, 340 mg). 1H NMR (400 MHz, DMSO-d6) δH 9.11 (d, 1H), 7.36-7.07 (m, 2H), 5.06 (s, 2H), 4.82-4.77 (m, 1H), 4.75-4.70 (m, 2H), 4.43 (t, 2H), 4.31-4.26 (m, 2H), 1.29 (t, 3H). [0769] Synthesis of 5-(difluoromethyl)-1-(2-(oxetan-3-ylamino)-2-oxoethyl)-1H-pyrazole-3- carboxylic acid, 52 [Step 2]: To a cold solution of ethyl 5-(difluoromethyl)-1-(2-(oxetan-3- ylamino)-2-oxoethyl)-1H-pyrazole-3-carboxylate (51, 170 mg, 0.6 mmol) in tetrahydrofuran (3 mL), a solution of lithium hydroxide (45 mg, 1.1 mmol) in water (1 mL) was added drop-wise. The reaction mixture was stirred at ambient temperature for 3 h. After completion, the volatiles were evaporated under reduced pressure. The aqueous phase was acidified with 1 N aqueous solution of hydrochloric acid to ~pH-5 and extracted with ethyl acetate (twice). Combined organic extracts was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford 5-(difluoromethyl)-1-(2-(oxetan-3-ylamino)-2-oxoethyl)-1H-pyrazole- 3-carboxylic acid (52, 140 mg). LCMS (ESI) Calcd. for C10H11F2N3O4: 275.1 found [M+H]+ = 276.2. [0770] Synthesis of (Z)-2-(3-((((amino(1-(o-tolyl)cyclopropyl)methylene)amino)oxy)carbonyl)-5- (difluoromethyl)-1H-pyrazol-1-yl)-N-(oxetan-3-yl)acetamide, 53 [Step 3]: To a stirred solution of 5-(difluoromethyl)-1-(2-(oxetan-3-ylamino)-2-oxoethyl)-1H-pyrazole-3-carboxylic acid (52, 160 mg, 0.6 mmol) in dichloromethane (10 mL), N,N-diisopropylethylamine (185 mg, 1.5 mmol), 1- hydroxy-7-azabenzotriazole (15.8 mg, 0.1 mmol), 1-ethyl-3-(3- dimethylaminopropyl)carbodiimide hydrochloride (145 mg, 0.8 mmol) and (Z)-N'-hydroxy-1-(o- tolyl)cyclopropane-1-carboximidamide (11, 135 mg, 0.7 mmol) were added at 30 °C. The reaction mixture was stirred at ambient temperature for 16 h, diluted with ethyl acetate and washed with water and brine. Combined organic extract was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford (Z)-2-(3-((((amino(1-(o- tolyl)cyclopropyl)methylene)amino)oxy)carbonyl)-5-(difluoromethyl)-1H-pyrazol-1-yl)-N-(oxetan- 3-yl)acetamide (53, 260 mg). LCMS (ESI) Calcd. for C21H23F2N5O4: 447.2, found [M+H]+ = 448.4. [0771] Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)-N-(oxetan-3-yl)acetamide, Example 29 [Step 4]: To a stirred solution of (Z)-2-(3- ((((amino(1-(o-tolyl)cyclopropyl)methylene)amino)oxy)carbonyl)-5-(difluoromethyl)-1H-pyrazol-1- yl)-N-(oxetan-3-yl)acetamide (53, 260 mg, 0.6 mmol) in tetrahydrofuran (5 mL), tetra butyl ammonium hydroxide (30 mg, 0.1 mmol) was added. The resulting reaction mixture was stirred at ambient temperature for 2 h and concentrated under reduced pressure. The residue was diluted with ethyl acetate and washed with water and brine. Combined organic extracts was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by reverse phase prep HPLC to afford 2-(5-(difluoromethyl)-3-(3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)-N-(oxetan-3-yl)acetamide (Example 29, 75 mg). LCMS (ESI) Calcd. for C21H21F2N5O3: 429.1, found [M+H]+ = 430.35.1H NMR (400 MHz, DMSO-d6) δH 9.15 (d, 1H), 7.41-7.38 (m, 1H), 7.31-7.14 (m, 5H), 5.29 (s, 2H), 4.82-4.77 (m, 1H), 4.74-4.70 (m, 2H), 4.45-4.42 (m, 2H), 2.26 (s, 3H), 1.60 (brs, 2H), 1.31 (brs, 2H). Example 30: Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)-1-(piperazin-1-yl)ethan-1-one (Example 30)
Figure imgf000187_0001
[0772] Synthesis of tert-butyl 4-(2-(5-(difluoromethyl)-3-(ethoxycarbonyl)-1H-pyrazol-1- yl)acetyl)piperazine-1-carboxylate, 55 [Step 1]: To a stirred solution of 2-(5-(difluoromethyl)-3- (ethoxycarbonyl)-1H-pyrazol-1-yl)acetic acid (44, 300 mg, 1.2 mmol) in dichloromethane (5 mL), N,N-diisopropylethylamine (0.04 mL, 0.2 mmol) and propane phosphonic acid anhydride (0.06 mL, 0.20 mmol, 50% in ethyl acetate) were added. After 15 min, tert-butyl piperazine-1- carboxylate (54, 225 mg, 1.2 mmol) was added and the reaction mixture was stirred at ambient temperature for 16 h. After completion, the reaction mixture was diluted with dichloromethane, washed with saturated solution of aqueous sodium bicarbonate followed by brine. Combined organic extracts was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by flash column chromatography to afford tert-butyl 4-(2-(5-(difluoromethyl)-3-(ethoxycarbonyl)-1H-pyrazol-1-yl)acetyl)piperazine-1-carboxylate (55, 450 mg). LCMS (ESI) Calcd. for C18H26F2N4O5: 416.2, found [M+H]+ = 417.1.1H NMR (400 MHz, DMSO-d6) δH 7.30-7.03 (m, 2H), 5.43 (s, 2H), 4.31-4.26 (m, 2H), 3.49-3.47 (m, 2H), 3.43- 3.42 (m, 4H), 3.32-3.30 (m, 2H), 1.42 (s, 9H), 1.29 (t, 3H). [0773] Synthesis of 1-(2-(4-(tert-butoxycarbonyl)piperazin-1-yl)-2-oxoethyl)-5-(difluoromethyl)- 1H-pyrazole-3-carboxylic acid, 56 [Step 2]: To an ice cold solution of tert-butyl 4-(2-(5- (difluoromethyl)-3-(ethoxycarbonyl)-1H-pyrazol-1-yl)acetyl)piperazine-1-carboxylate (55, 100 mg, 0.2 mmol) in tetrahydrofuran (1 mL) and methanol (1 mL), a solution of lithium hydroxide (10 mg, 0.2 mmol) in water (1 mL) was added drop-wise. The reaction mixture was stirred at ambient temperature for 3 h. After completion, the volatiles were evaporated under reduced pressure. The aqueous phase was acidified with 1 N aqueous solution of hydrochloric acid to ~pH-5 and extracted with a mixture of ethyl acetate and isopropyl alcohol (9:1). Combined organic extracts was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford 1-(2-(4-(tert-butoxycarbonyl)piperazin-1-yl)-2-oxoethyl)-5- (difluoromethyl)-1H-pyrazole-3-carboxylic acid (56, 90 mg). LCMS (ESI) Calcd. for C16H22F2N4O5: 388.2, found [M-H]- = 387.1.1H NMR (400 MHz, DMSO-d6) δH 7.16-7.01 (m, 2H), 5.40 (s, 2H), 3.49-3.42 (m, 8H), 1.42 (s, 9H). [0774] Synthesis of tert-butyl (Z)-4-(2-(3-((((amino(1-(o- tolyl)cyclopropyl)methylene)amino)oxy)carbonyl)-5-(difluoromethyl)-1H-pyrazol-1- yl)acetyl)piperazine-1-carboxylate, 57 [Step 3]: To a stirred solution of 1-(2-(4-(tert- butoxycarbonyl)piperazin-1-yl)-2-oxoethyl)-5-(difluoromethyl)-1H-pyrazole-3-carboxylic acid (56, 40 mg, 0.10 mmol), and (Z)-N'-hydroxy-1-(o-tolyl)cyclopropane-1-carboximidamide (11, 20 mg, 0.1 mmol) in dichloromethane (2 mL), N,N-diisopropylethylamine (0.05 mL, 0.3 mmol), 1- Hydroxy-7-azabenzotriazole (2.8 mg, 0.02 mmol) and 1-ethyl-3-(3- dimethylaminopropyl)carbodiimide hydrochloride (23.7 mg, 0.1 mmol) were added. The reaction mixture was stirred at ambient temperature for 16 h. After completion, the reaction mixture was diluted with ethyl acetate and washed with water and brine. Combined organic extracts was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford tert-butyl (Z)-4-(2-(3-((((amino(1-(o-tolyl)cyclopropyl)methylene)amino)oxy)carbonyl)-5- (difluoromethyl)-1H-pyrazol-1-yl)acetyl)piperazine-1-carboxylate (57, 80 mg). LCMS (ESI) Calcd. for C27H34F2N6O5: 560.3, found [M+H]+ = 561.5. [0775] Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)-1-(piperazin-1-yl)ethan-1-one, Example 30 [Step 4]: To a stirred solution of tert- butyl (Z)-4-(2-(3-((((amino(1-(o-tolyl)cyclopropyl)methylene)amino)oxy)carbonyl)-5- (difluoromethyl)-1H-pyrazol-1-yl)acetyl)piperazine-1-carboxylate (57, 80 mg, 0.1 mmol) in toluene (2 mL), propane phosphonic acid anhydride (0.05 mL, 0.2 mmol, 50% in ethyl acetate) was added. The resulting reaction mixture was heated at 90 °C for 12 h and concentrated under reduced pressure. The product was purified by reverse phase prep-HPLC purification to afford 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)-1- (piperazin-1-yl)ethan-1-one (Example 30, 12 mg). LCMS (ESI) Calcd. for C22H24F2N6O2: 442.1, found [M+H]+ = 443.2.1H NMR (400 MHz, DMSO-d6 and two drops of D2O) δH 7.37-7.05 (m, 6H), 5.41 (s, 2H), 3.41-3.35 (m, 4H), 2.74-2.72 (m, 2H), 2.65-2.63 (m, 2H), 2.24 (s, 3H), 1.66- 1.63 (m, 2H), 1.39-1.36 (m, 2H). Example 31: Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)-N-(2-(dimethylamino)ethyl)acetamide (Example 31)
Figure imgf000189_0001
[0776] Synthesis of ethyl 5-(difluoromethyl)-1-(2-((2-(dimethylamino)ethyl)amino)-2-oxoethyl)- 1H-pyrazole-3-carboxylate, 58 [Step 1]: To a stirred solution of 2-(5-(difluoromethyl)-3- (ethoxycarbonyl)-1H-pyrazol-1-yl)acetic acid (44, 300 mg, 1.2 mmol) in dichloromethane (5 mL) were added DIPEA (0.6 mL, 3.6 mmol) and propyl phosphonic anhydride (50% in ethyl acetate) (0.9 mL, 3.02 mmol). After 15 min, N,N-dimethylethane-1,2-diamine (106 mg, 1.2 mmol) was added and the resulting reaction mixture was allowed to stir at ambient temperature for 16 h. The reaction mixture was diluted with dichloromethane, washed with saturated solution of sodium bicarbonate followed by brine wash. Combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by combiflash chromatography to afford ethyl 5-(difluoromethyl)-1-(2-((2- (dimethylamino)ethyl)amino)-2-oxoethyl)-1H-pyrazole-3-carboxylate (58, 200 mg). LCMS (ESI) Calcd. for C13H20F2N4O3: 318.1, found [M+H]+ = 319.1 [0777] Synthesis of 5-(difluoromethyl)-1-(2-((2-(dimethylamino)ethyl)amino)-2-oxoethyl)-1H- pyrazole-3-carboxylic acid, 59 [Step 2]: To a stirred solution of ethyl 5-(difluoromethyl)-1-(2-((2- (dimethylamino)ethyl)amino)-2-oxoethyl)-1H-pyrazole-3-carboxylate (58, 200 mg, 1.5 mmol) in a mixture of THF (3 mL) and methanol (1 mL), was added a solution of lithium hydroxide monohydrate (52 mg, 1.2 mmol) in water (2 mL). The reaction mixture was stirred at ambient temperature for 2 h and volatiles were evaporated under reduced pressure. The residue was acidified with 1 (N) HCl and white precipitate was filtered and dried under reduced pressure to afford 5-(difluoromethyl)-1-(2-((2-(dimethylamino)ethyl)amino)-2-oxoethyl)-1H-pyrazole-3- carboxylic acid (59, 160 mg). The product was carried to next step without further purification. [0778] Synthesis of (Z)-2-(3-((((amino(1-(o-tolyl)cyclopropyl)methylene)amino)oxy)carbonyl)-5- (difluoromethyl)-1H-pyrazol-1-yl)-N-(2-(dimethylamino)ethyl)acetamide, 60 [Step 3]: To a stirred solution of 5-(difluoromethyl)-1-(2-((2-(dimethylamino)ethyl)amino)-2-oxoethyl)-1H-pyrazole-3- carboxylic acid (59, 160 mg, 0.5 mmol) in DMF (3 mL), DIPEA (0.3 mL, 1.65 mmol), EDC.HCl (158 mg, 0.8 mmol) and HOAt (15 mg, 0.1 mmol) were added at ambient temperature. After 15 min, (Z)-N'-hydroxy-1-(o-tolyl)cyclopropane-1-carboximidamide (11, 105 mg, 0.5 mmol) was added. Resulting reaction mixture was stirred at ambient temperature for 16 h, diluted with ethyl acetate and washed with water followed by brine wash. Combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford (Z)-N'-((5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)-1-(5-methoxy-2- methylphenyl)cyclopropane-1-carboximidamide (60, 220 mg). LCMS (ESI) Calcd. for C22H28F2N6O3: 462.2, found [M+H]+ = 462.8. The product was carried to next step without further purification. [0779] Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)-N-(2-(dimethylamino)ethyl)acetamide, Example 31 [Step 4]: A solution of (Z)-N'- ((5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)-1-(5-methoxy-2- methylphenyl)cyclopropane-1-carboximidamide (60, 100 mg, 0.2 mmol) in toluene (2 mL), was added propyl phosphonic anhydride (50% in ethyl acetate) ( 0.1 mL,0.3 mmol). Resulting reaction mixture was stirred at 90 °C for 16 h, diluted with ethyl acetate and washed with saturated solution of sodium bicarbonate followed by brine wash. Combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by reverse phase preparative HPLC to give 2-(5-(difluoromethyl)-3-(3- (1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)-N-(2- (dimethylamino)ethyl)acetamide (Example 31, 16 mg). LCMS (ESI) Calcd. for C22H26F2N6O2: 444.2, found [M+H]+ = 445.2.1H NMR (400 MHz, DMSO-d6 at HT): δH 8.17 (brs, 1H), 7.39-7.12 (m, 6H), 5.10 (s, 2H), 3.31 (t, 2H), 2.67 (brs, 2H), 2.43 (s, 6H), 2.30 (s, 3H), 1.70-1.67 (m, 2H), 1.41-1.38 (m, 2H). Example 32: Synthesis of N-(2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)ethyl)acetamide (Example 32)
Figure imgf000191_0001
[0780] Synthesis of ethyl 1-(2-((tert-butoxycarbonyl)amino)ethyl)-5-(difluoromethyl)-1H- pyrazole-3-carboxylate, 61 [Step 1]: To a stirred solution of ethyl 5-(difluoromethyl)-1H-pyrazole- 3-carboxylate (13, 200 mg, 1.0 mmol) in tetrahydrofuran (5 mL), potassium tert-butoxide (355 mg, 3.1 mmol) was added. The reaction mixture was heated at 80 °C for 30 min and tert-butyl N-(2-bromoethyl)carbamate (235 mg, 1.0 mmol) was added. The resulting reaction mixture was heated at 80 °C for 6 h. After completion, the reaction mixture was quenched with crushed ice, extracted with ethyl acetate and washed with ice cold water and brine. Combined organic extracts was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by column chromatography to afford ethyl 1-(2-((tert- butoxycarbonyl)amino)ethyl)-5-(difluoromethyl)-1H-pyrazole-3-carboxylate (61, 50 mg). LCMS (ESI) Calcd. for C14H21F2N3O4: 333.1, found [M+H]+ = 334.1.1H NMR (400 MHz, DMSO-d6) δH 7.27 (t, 1H), 7.03 (s, 1H), 6.97-6.94 (m, 1H), 4.30-4.25 (m, 4H), 3.36-3.34 (m, 2H), 1.32 (s, 9H), 1.30 (t, 3H). Note: Structure of desired regio-isomer was confirmed by NOE experiment. [0781] Synthesis of ethyl 1-(2-aminoethyl)-5-(difluoromethyl)-1H-pyrazole-3-carboxylate 2,2,2- trifluoroacetate, 62 [Step 2]: To a stirred solution of ethyl 1-(2-((tert- butoxycarbonyl)amino)ethyl)-5-(difluoromethyl)-1H-pyrazole-3-carboxylate (61, 200 mg, 0.6 mmol) in dichloromethane (2 mL), trifluoroacetic acid (0.1 mL, 1.2 mmol) was added dropwise at 0 °C. The reaction mixture was stirred at ambient temperature for 2 h. After completion, the volatiles were evaporated under reduced pressure to afford ethyl 1-(2-aminoethyl)-5- (difluoromethyl)-1H-pyrazole-3-carboxylate 2,2,2-trifluoroacetate (62, 150 mg). LCMS (ESI) Calcd. for C14H21F2N3O4: 233.1 found [M+H]+ = 234.1. [0782] Synthesis of ethyl 5-(difluoromethyl)-1-(2-(methylamino)-2-oxoethyl)-1H-pyrazole-3- carboxylate, 63 [Step 3]: To a stirred solution of ethyl 1-(2-aminoethyl)-5-(difluoromethyl)-1H- pyrazole-3-carboxylate 2,2,2-trifluoroacetate (62, 250 mg, 0.8 mmol) in tetrahydrofuran at 0 oC, triethyl amine (0.3 mL, 2.3 mmol) and acetyl chloride (0.1 mL, 2.3 mmol) were added. The reaction mixture was stirred at ambient temperature for 2 h. After completion, the reaction mixture was diluted with ethyl acetate and washed with water and brine. Combined organic extracts was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford ethyl 5-(difluoromethyl)-1-(2-(methylamino)-2-oxoethyl)-1H-pyrazole-3- carboxylate (63, 150 mg). LCMS (ESI) Calcd. for C11H15F2N3O3: 275.1, found [M+H]+ = 276.3. [0783] Synthesis of 1-(2-acetamidoethyl)-5-(difluoromethyl)-1H-pyrazole-3-carboxylic acid, 64 [Step 4]: To a cold solution of ethyl 5-(difluoromethyl)-1-(2-(methylamino)-2-oxoethyl)-1H- pyrazole-3-carboxylate (63, 250 mg, 0.9 mmol) in tetrahydrofuran (4 mL), a solution of lithium hydroxide monohydrate (76.3 mg, 1.8 mmol) in water (2 mL) was added drop-wise. The reaction mixture was stirred at ambient temperature for 3 h. After completion, the volatiles were evaporated under reduced pressure. The aqueous phase was acidified with 1 N aqueous solution of hydrochloric acid to ~pH-5 and extracted with a mixture of dichloromethane and isopropyl alcohol (9:1). Combined organic extracts was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford 1-(2-acetamidoethyl)-5- (difluoromethyl)-1H-pyrazole-3-carboxylic acid (64, 140 mg). LCMS (ESI) Calcd. for C9H11F2N3O3: 247.1, found [M+H]+ = 248.0. [0784] Synthesis of (Z)-N-(2-(3-((((amino(1-(o-tolyl)cyclopropyl)methylene)amino)oxy)carbonyl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)ethyl)acetamide, 65 [Step 5]: To a stirred solution of 1-(2- acetamidoethyl)-5-(difluoromethyl)-1H-pyrazole-3-carboxylic acid (64, 130 mg, 0.5 mmol), and (Z)-N'-hydroxy-1-(o-tolyl)cyclopropane-1-carboximidamide (120 mg, 0.6 mmol) in dichloromethane (15 mL), N,N-diisopropylethylamine (0.3 mL, 1.6 mmol), 1-Hydroxy-7- azabenzotriazole (15 mg, 0.1 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (130 mg, 0.7 mmol) were added. The reaction mixture was stirred at ambient temperature for 16 h. After completion, the reaction mixture was diluted with ethyl acetate and washed with water and brine. Combined organic extracts was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford (Z)-N-(2-(3-((((amino(1-(o- tolyl)cyclopropyl)methylene)amino)oxy)carbonyl)-5-(difluoromethyl)-1H-pyrazol-1- yl)ethyl)acetamide (65, 120 mg). LCMS (ESI) Calcd. for C20H23F2N5O3: 419.2, found [M+H]+ = 420.2. [0785] Synthesis of N-(2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 1H-pyrazol-1-yl)ethyl)acetamide, Example 32 [Step 6]: A solution of (Z)-N-(2-(3-((((amino(1-(o- tolyl)cyclopropyl)methylene)amino)oxy)carbonyl)-5-(difluoromethyl)-1H-pyrazol-1- yl)ethyl)acetamide (65, 100 mg, 0.2 mmol) in toluene (3 mL) was heated at 80 °C for 16 h After completion, the reaction mixture was concentrated under reduced pressure. The product was purified by reverse phase prep HPLC to afford N-(2-(5-(difluoromethyl)-3-(3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)ethyl)acetamide (Example 32, 71 mg). LCMS (ESI) Calcd. for C20H21F2N5O2: 401.1, found [M+H]+ = 402.3.1H NMR (400 MHz, DMSO- d6) δH 7.97-7.96 (m, 1H), 7.45-7.19 (m, 6H), 4.36 (t, 2H), 3.49 (t, 2H), 2.27 (s, 3H), 1.74 (s, 3H), 1.66-1.65 (m, 2H), 1.40-1.39 (m, 2H). Example 33: Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)-1-(4-methylpiperazin-1-yl)ethan-1-one (Example 33)
Figure imgf000194_0001
[0786] Synthesis of ethyl 5-(difluoromethyl)-1-(2-(4-methylpiperazin-1-yl)-2-oxoethyl)-1H- pyrazole-3-carboxylate, 66 [Step 1]: To a stirred solution of 2-(5-(difluoromethyl)-3- (ethoxycarbonyl)-1H-pyrazol-1-yl)acetic acid (44, 200 mg, 0.8 mmol) in dichloromethane (5 mL), N,N-Diisopropylethylamine (0.4 mL, 2.4 mmol) and propane phosphonic acid anhydride (0.4 mL, 1.2 mmol, 50% in ethyl acetate) were added. After 15 min, 1-methylpiperazine (95 mg, 1.0 mmol) was added and the reaction mixture was stirred at ambient temperature for 16 h. After completion, the reaction mixture was diluted with dichloromethane, washed with saturated solution of aqueous sodium bicarbonate followed by brine wash. Combined organic extracts was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by flash column chromatography to afford 5-(difluoromethyl)-1-(2-(4- methylpiperazin-1-yl)-2-oxoethyl)-1H-pyrazole-3-carboxylate (66, 280 mg). LCMS (ESI) Calcd. for C14H20F2N4O3: 330.2, found [M+H]+ = 331.2.1H NMR (400 MHz, DMSO-d6) δH 7.30-7.03 (m, 2H), 5.40 (s, 2H), 4.33-4.26 (m, 2H), 3.48-3.34 (m, 4H), 2.37 (brs, 2H), 2.27 (brs, 2H), 2.20 (s, 3H), 1.29 (t, 3H). [0787] Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)-1-(4-methylpiperazin-1-yl)ethan-1-one, Example 33 [Step 2]: To a stirred solution of ethyl 5-(difluoromethyl)-1-(2-(4-methylpiperazin-1-yl)-2-oxoethyl)-1H-pyrazole-3-carboxylate (66, 280 mg, 0.9 mmol) in toluene (8 mL), potassium carbonate (140 mg, 1.0 mmol) and (Z)-N'- hydroxy-1-(o-tolyl)cyclopropane-1-carboximidamide (160 mg, 0.8 mmol) were added. The reaction mixture was stirred at 90 °C for 16 h and concentrated under reduced pressure. The resultant residue was diluted with ethyl acetate and washed with water and brine. Combined organic extracts was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The product was purified by reverse phase prep-HPLC purification to afford 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)-1-(4- methylpiperazin-1-yl)ethan-1-one (Example 33, 51 mg). LCMS (ESI) Calcd. for C23H26F2N6O2: 456.2, found [M+H]+ = 457.3.1H NMR (400 MHz, methanol-d4) δH 7.38 (d, 1H), 7.23-6.90 (m, 5H), 5.42 (s, 2H), 3.68 (brs, 4H), 2.75-2.67 (m, 4H), 2.49 (s, 3H), 2.31 (s, 3H), 1.75-1.74 (m, 2H), 1.40-1.38 (m, 2H). Example 34: Synthesis of 5-(5-(difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-3- yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 34)
Figure imgf000195_0001
[0788] Synthesis of ethyl 5-(difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazole-3- carboxylate, 67 [Step 1]: To a stirred suspension of ethyl 5-(difluoromethyl)-1H-pyrazole-3- carboxylate (13, 1.0 g, 5.3 mmol) and potassium carbonate (2.9 g, 21.0 mmol) in DMF (60 mL) at 0 °C, 1-bromo-2-(methylsulfonyl)ethane (1.5 g, 7.9 mmol) was added. The resulting reaction mixture was stirred at ambient temperature for 16 h. After completion, the reaction mixture was diluted with ethyl acetate and washed with ice cold water and brine. Combined organic extract was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by flash column chromatography to afford ethyl 5-(difluoromethyl)-1-(2- (methylsulfonyl)ethyl)-1H-pyrazole-3-carboxylate (67, 420 mg). LCMS (ESI) calcd. for C10H14F2N2O4S: 296.0, found [M+H]+ = 297.0.1H NMR (400 MHz, DMSO-d6) δH 7.38 (t, 1H), 7.09 (s, 1H), 4.70 (t, 2H), 4.32-4.27 (m, 2H), 3.78-3.74 (m, 2H), 3.07 (s, 3H), 1.29 (t, 3H). Note: Structure was confirmed based on NOE experiment of compounds 67 and 67a. [0789] Synthesis of 5-(difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazole-3-carboxylic acid, 68 [Step 2]: To an ice cold solution of ethyl 5-(difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H- pyrazole-3-carboxylate (67, 420 mg, 1.4 mmol) in tetrahydrofuran (6 mL) and methanol (1 mL), an aqueous solution (2 mL) of lithium hydroxide (120 mg, 2.8 mmol) was added dropwise. The reaction mixture was stirred at ambient temperature for 16 h. After completion, the volatiles were evaporated under reduced pressure. The aqueous phase was acidified with 1 N aqueous solution of hydrochloric acid to ~pH-5 and extracted with a mixture of dichloromethane and isopropyl alcohol (9:1). Combined organic extract was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford 5-(difluoromethyl)-1-(2- (methylsulfonyl)ethyl)-1H-pyrazole-3-carboxylic acid (68, 350 mg). LCMS (ESI) Calcd. for C8H10F2N2O4S: 268.0, found [M+H]+ = 269.0. [0790] Synthesis of (Z)-N'-((5-(difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazole-3- carbonyl)oxy)-1-(o-tolyl)cyclopropane-1-carboximidamide, 69 [Step 3]: To a stirred solution of 5- (difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazole-3-carboxylic acid (68, 350 mg, 1.3 mmol), and (Z)-N'-hydroxy-1-(o-tolyl)cyclopropane-1-carboximidamide (11, 248.2 mg, 1.3 mmol) in dichloromethane (10 mL), N,N-diisopropylethylamine (335 mg, 2.6 mmol), 1-hydroxy-7- azabenzotriazole (36 mg, 0.3 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (325 mg, 1.7 mmol) were added. The reaction mixture was stirred at ambient temperature for 16 h. After completion, the reaction mixture was diluted with ethyl acetate and washed with water and brine. Combined organic extract was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford (Z)-N'-((5-(difluoromethyl)- 1-(2-(methylsulfonyl)ethyl)-1H-pyrazole-3-carbonyl)oxy)-1-(o-tolyl)cyclopropane-1- carboximidamide (69, 300 mg). LCMS (ESI) Calcd. for C19H22F2N4O4S: 440.1, found [M+H]+ = 441.4.1H NMR (400 MHz, DMSO-d6) δH 7.51-7.24 (m, 4H), 7.17-7.16 (m, 2H), 6.12 (brs, 2H), 4.68 (t, 2H), 3.76 (t, 2H), 3.04 (s, 3H), 2.40 (s, 3H), 1.43 (brs, 2H), 1.00 (brs, 2H). [0791] Synthesis of 5-(5-(difluoromethyl)-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazole, 70 [Step 4]: To a stirred solution of (Z)-N'-((5-(difluoromethyl)-1-(2- (methylsulfonyl)ethyl)-1H-pyrazole-3-carbonyl)oxy)-1-(o-tolyl)cyclopropane-1-carboximidamide (69, 300 mg, 0.7 mmol) in tetrahydrofuran (10 mL), tetra butyl ammonium hydroxide (35 mg, 0.1 mmol) was added. The resulting reaction mixture was stirred at ambient temperature for 12 h and concentrated under reduced pressure. The residue was diluted with ethyl acetate and washed with water and brine. Combined organic extract was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford 5-(5-(difluoromethyl)-1H- pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (70, 200 mg). LCMS (ESI) Calcd. for C16H14F2N4O: 316.1, found [M+H]+ = 317.2. [0792] Synthesis 5-(5-(difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazole, Example 34 and 5-(3-(difluoromethyl)-1-(2- (methylsulfonyl)ethyl)-1H-pyrazol-5-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole, Example 176 [Step 5]: To a stirred suspension of 5-(5-(difluoromethyl)-1H-pyrazol-3-yl)-3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazole (70, 200 mg, 0.6 mmol) and potassium carbonate (350 mg, 2.5 mmol) in DMF (10 mL) at 0 °C, 1-bromo-2-(methylsulfonyl)ethane (175 mg, 1.0 mmol) was added. The resulting reaction mixture was stirred at ambient temperature for 16 h. After completion, the reaction mixture was diluted with ethyl acetate and washed with ice-cold water and brine. Combined organic extract was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product were purified by reverse phase preparative HPLC to afford the first product as 5-(5-(difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol- 3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 34, 46 mg) as Peak-1 and the second product as 5-(3-(difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-5-yl)-3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 176, 30 mg) as Peak-2. [0793] 5-(5-(difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazole, Example 34 (Peak-1): LCMS (ESI) Calcd. for C19H20F2N4O3S: 422.1, found [M+H]+ = 423.3.1H NMR (400 MHz, DMSO-d6) δH 7.55-7.29 (m, 3H), 7.24-7.20 (m, 3H), 4.76 (t, 2H), 3.80 (t, 2H), 3.07 (s, 3H), 2.26 (s, 3H), 1.66-1.65 (m, 2H), 1.41-1.39 (m, 2H). Note: The structure of the final oxadiazoles was confirmed by NOE experiments and another isomer was formed during alkylation. Example 35: Synthesis of 3-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)propanoic acid (Example 35)
Figure imgf000197_0001
[0794] Synthesis of tert-butyl 3-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol- 5-yl)-1H-pyrazol-1-yl)propanoate, 71 [Step 1]: To a stirred suspension of 5-(5-(difluoromethyl)- 1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (70, 400 mg, 1.3 mmol) and potassium carbonate (1.2 g, 8.9 mmol) in dimethylformamide (10 mL) at 0 °C, tert-butyl 3- bromopropanoate (395 mg, 1.9 mmol) was added. The resulting reaction mixture was allowed to stir at ambient temperature for 16 h. After completion, the reaction mixture was diluted with ethyl acetate and washed with ice-cold water and brine. Combined organic extracts was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by flash column chromatography to afford tert-butyl 3-(5-(difluoromethyl)-3-(3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)propanoate (71, 130 mg). LCMS (ESI) Calcd. for C23H26F2N4O3: 444.2, found [M+H]+ = 445.4.1H NMR (400 MHz, DMSO-d6) δH 7.37- 7.22 (m, 5H), 4.51 (t, 2H), 2.86 (t, 2H), 2.26 (s, 3H), 1.65 (brs, 2H), 1.39 (brs, 3H), 1.35 (s, 9H). Note: Structure was confirmed based on NOE experiment. [0795] Synthesis of 3-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)propanoic acid, Example 35 [Step 2]: To a stirred solution of tert-butyl 3-(5- (difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)propanoate (71, 120 mg, 0.3 mmol) in dichloromethane (15 mL), trifluoroacetic acid (0.4 mL, 5.4 mmol) was added at 0 °C. The reaction mixture was stirred at ambient temperature for 6 h. After completion, the volatiles were removed under reduced pressure. The product was purified by reverse phase prep HPLC to afford 3-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)propanoic acid (Example 35, 35 mg). LCMS (ESI) Calcd. for C19H18F2N4O3: 388.1, found [M+H]+ = 389.3.1H NMR (400 MHz, DMSO-d6) δH 12.54 (brs, 1H), 7.56-7.29 (m, 2H), 7.26-7.18 (m, 4H), 4.52 (t, 2H), 2.90 (t, 2H), 2.26 (s, 3H), 1.66 (brs, 2H), 1.39 (brs, 2H). Note: Another isomer was formed during alkylation. Examples 36a & 36b: 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5- yl)-1H-pyrazol-1-yl)-N,N-dimethylethan-1-amine (Example 36a) & 2-(3-(difluoromethyl)-5- (3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)-N,N-dimethylethan-1- amine (Example 36b)
Figure imgf000199_0001
[0796] Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)-N,N-dimethylethan-1-amine, 36a & 2-(3-(difluoromethyl)-5-(3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)-N,N-dimethylethan-1-amine, 36b [Step 1]: To a stirred solution of 5-(5-(difluoromethyl)-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazole (70, 120 mg, 0.38 mmol) in dimethylformamide (3 mL), potassium carbonate (105 mg, 0.76 mmol) and 2-bromo-N,N-dimethyl-ethanamine hydrobromide (106 mg, 0.46 mmol) were added. The resulting reaction mixture was allowed to stir at ambient temperature for 16 h, diluted with ethyl acetate, washed with ice-cold water and brine. Combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The products were purified by reverse phase preparative HPLC to afford peak-1 as 2-(5- (difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)-N,N- dimethylethan-1-amine (36a, 14 mg) and peak-2 as 2-(3-(difluoromethyl)-5-(3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)-N,N-dimethylethan-1-amine (36b, 25 mg). [0797] 2-(5-(Difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)- N,N-dimethylethan-1-amine, Example 36a: LCMS (ESI) Calcd. for C20H23F2N5O: 387.1, found [M + H]+ = 388.2, 1H NMR (400 MHz, DMSO-d6): δH 7.51-7.20 (m, 6H), 4.42 (t, 2H), 2.70-2.68 (m, 2H), 2.27 (s, 3H), 2.18 (s, 6H), 1.66 (brs, 2H), 1.39 (brs, 2H). [0798] 2-(3-(Difluoromethyl)-5-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)- N,N-dimethylethan-1-amine, 36b: LCMS (ESI) Calcd. for C20H23F2N5O: 387.1, found [M + H]+ = 388.2, 1H NMR (400 MHz, DMSO-d6): δH 7.39-7.36 (m, 2H), 7.25-6.97(m, 4H), 4.68 (t, 2H), 2.65 (t, 2H), 2.28 (s, 3H), 2.11 (s, 6H), 1.70-1.67 (m, 2H), 1.45-1.43 (m, 2H). Example 37: Synthesis of N-(2-amino-2-oxoethyl)-2-(5-(difluoromethyl)-3-(3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)acetamide (Example 37)
Figure imgf000200_0001
[0799] Synthesis of tert-butyl-2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol- 5-yl)-1H-pyrazol-1-yl)acetate, 72 [Step 1]: To a stirred suspension of 5-(5-(difluoromethyl)-1H- pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (70, 600 mg, 1.9 mmol) and potassium carbonate (265 mg, 1.9 mmol) in dimethylformamide (20 mL) at 0 °C, tert-butyl 2-bromoacetate (72, 555 mg, 2.9 mmol) was added. The resulting reaction mixture was allowed to stir at ambient temperature for 16 h, diluted with ethyl acetate and washed with ice-cold water and brine. Combined organic extracts was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by flash column chromatography to afford tert-butyl-2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)acetate (70, 120 mg) and tert-butyl 2-(3-(difluoromethyl)-5-(3-(1- (o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)acetate (72a, 200 mg). [0800] Analytical data of tert-butyl-2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)acetate, 72: LCMS (ESI) Calcd. for C22H24F2N4O3: 430.2, found [M+H]+ = 431.2.1H NMR (400 MHz, DMSO-d6) δH 7.46-7.19 (m, 6H), 5.26 (s, 2H), 2.27 (s, 3H), 1.67 (brs, 2H), 1.41 (s, 9H), 1.25 (brs, 2H). Note: Structure was confirmed based NOE experiment. [0801] Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)acetic acid, 73 [Step 2]: To a stirred solution of tert-butyl 2-(5-(difluoromethyl)-3-(3- (1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)acetate (72, 120 mg, 0.3 mmol) in dichloromethane (15 mL), trifluoroacetic acid (317.9 mg, 2.8 mmol) was added at 0 oC. The reaction mixture was stirred at ambient temperature for 6 h and the volatiles were reduced under reduced pressure to afford 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)acetic acid (73, 100 mg). LCMS (ESI) Calcd. for C18H16F2N4O3: 374.1, found [M+H]+ = 375.2. [0802] Synthesis of N-(2-amino-2-oxoethyl)-2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)- 1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)acetamide, Example 37 [Step 3]: To a stirred solution of 2- (5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)acetic acid (73, 90 mg, 0.2 mmol) and 2-aminoacetamide hydrochloride (35 mg, 0.3 mmol) in dichloromethane (10 mL) and dimethylformamide (0.5 mL), N,N-Diisopropylethylamine (155 mg, 1.2 mmol) and propane phosphonic acid anhydride (0.1 mL, 0.4 mmol, 50% in ethyl acetate) were added. The resulting reaction mixture was allowed to stir at ambient temperature for 16 h, diluted with dichloromethane and washed with water and brine. Combined organic extracts was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by reverse phase prep HPLC to afford N-(2-amino-2-oxoethyl)-2-(5- (difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)acetamide (Example 37, 26 mg). LCMS (ESI) Calcd. for C20H20F2N6O3: 430.2, found [M+H]+ = 431.3.1H NMR (400 MHz, DMSO-d6) δH 8.55 (t, 1H), 7.41-7.37 (m, 2H), 7.30-7.28 (m, 2H), 7.24-7.20 (m, 3H), 7.14-7.12 (m, 1H), 5.18 (s, 2H), 3.70 (d, 2H), 2.26 (s, 3H), 1.66 (brs, 2H), 1.39 (brs, 2H). Note: Another isomer was formed during alkylation. Example 38: Synthesis of 1-((5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)cyclopropane-1-carboxylic acid (Example 38)
Figure imgf000201_0001
[0803] Synthesis of ethyl 1-((5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5- yl)-1H-pyrazol-1-yl)methyl)cyclopropane-1-carboxylate, 74 [Step 1]: To a stirred solution of 5-[5- (difluoromethyl)-1H-pyrazol-3-yl]-3-[1-(o-tolyl)cyclopropyl]-1,2,4-oxadiazole (70, 200 mg, 0.632 mmol) in acetonitrile (6 mL) was added Cs2CO3 (515 mg, 1.6 mmol). After 5 min, ethyl 1- (bromomethyl)cyclopropanecarboxylate (262 mg, 1.3 mmol) was added and the reaction mixture was stirred at 90 °C for 16 h. The reaction mixture was diluted ethyl acetate and washed with water followed by brine wash. Combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by column chromatography to give ethyl 1-((5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)cyclopropane-1-carboxylate (74, 130 mg). Structure of regiomers were confirmed by NOE experiment. LCMS (ESI) Calcd. for C23H24F2N4O3: 422.18, found [M+H] + = 443.4. Note: Other regio-isomer was also formed. [0804] Synthesis of 1-((5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)methyl)cyclopropane-1-carboxylic acid, Example 38 [Step 2]: To a solution of ethyl 1-((5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1- yl)methyl)cyclopropane-1-carboxylate (74, 110 mg, 0.3 mmol) in THF (2 mL) and water (2 mL), lithium hydroxide monohydrate (32 mg, 0.770 mmol) was added. The reaction mixture was stirred at 70 °C for 4 h and volatiles were evaporated under reduced pressure. The residual aqueous phase was acidified with 1(N) HCl and extracted with ethyl acetate (thrice). Combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by reverse phase preparative HPLC to give 1-((5- (difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1- yl)methyl)cyclopropane-1-carboxylic acid (Example 38, 37 mg). LCMS (ESI) Calcd. for C21H20F2N4O2: 414.2, found [M+H]+ = 415.3.1H NMR (400 MHz, DMSO-d6): δH 12.62 (brs, 1H), 7.64-7.20 (m, 6H), 4.52 (s, 2H), 2.27 (s, 3H), 1.66 (brs, 2H), 1.39 (brs, 2H), 1.23 (brs, 2H),1.14 (brs, 2H). Example 39: Synthesis of 3-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)-2,2-dimethylpropanoic acid (Example 39)
Figure imgf000202_0001
Scheme 26 [0805] Synthesis of 3-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)-2,2-dimethylpropanoic acid, Example 39 and 3-(3-(difluoromethyl)-5-(3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)-2,2-dimethylpropanoic acid, Example 178 [Step 1]: To a stirred solution of 5-[5-(difluoromethyl)-1H-pyrazol-3-yl]-3-[1-(o- tolyl)cyclopropyl]-1,2,4-oxadiazole (220 mg, 0.7 mmol) in DMA (2 mL), Cs2CO3 ( 680 mg, 2.09 mmol) and 3-bromo-2,2-dimethylpropanoic acid (227 mg, 1.25 mmol) were added. Resulting reaction mixture was stirred at 90 °C for 16 h, diluted with ethyl acetate and washed with water followed by brine. Combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by reverse phase preparative HPLC to give the first product as 3-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)- 1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)-2,2-dimethylpropanoic acid, Peak 1 (Example 39, 29 mg) and the second product as 3-(3-(difluoromethyl)-5-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5- yl)-1H-pyrazol-1-yl)-2,2-dimethylpropanoic acid, Peak 2 (Example 178, 38 mg). [0806] 3-(5-(Difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)- 2,2-dimethylpropanoic acid (Example 39): LCMS (ESI) Calcd. for C21H22F2N4O3: 416.2, found [M+H]+ = 417.3.1H NMR (400 MHz, DMSO-d6): δH 12.67 (brs, 1H),7.54-7.19 (m, 6H), 4.46 (s, 2H), 2.27 (s, 3H), 1.67- 1.65 (m, 2H), 1.40-1.37 (m, 2H), 1.13 (s, 6H). Examples 40a & 40b: Synthesis of 3-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)thietane 1,1-dioxide (Example 40a) and 3-(3- (difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)thietane 1,1-dioxide (Example 40b)
Figure imgf000203_0001
Scheme 27 [0807] Synthesis of 3-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)thietane 1,1-dioxide, Example 40a & 3-(3-(difluoromethyl)-5-(3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)thietane 1,1-dioxide, Example 40b [Step 1]: 5-(5-(difluoromethyl)-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (70, 200 mg, 0.6 mmol) in acetontrile (2 mL), cesium carbonate (410 mg, 1.3 mmol) was added at 0 °C. After 15 min, 3-bromothietane 1,1-dioxide (290 mg, 1.6 mmol) was added to the reaction mixture and the reaction mixture was heated at 100 °C for 16 h. After completion, the mixture was diluted with water and partitioned with ethyl acetate. The combined organic layer was collected, washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by reverse phase prep-HPLC to afford 3-(5-(difluoromethyl)- 3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)thietane 1,1-dioxide (Example 40a, 25 mg) as peak 1 and 3-(3-(difluoromethyl)-5-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5- yl)-1H-pyrazol-1-yl)thietane 1,1-dioxide (Example 40b, 20 mg) as peak 2. [0808] 3-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1- yl)thietane 1,1-dioxide, Example 40a [Peak-1]: LCMS (ESI) Calcd for C19H18F2N4O3S: 420.1, found [M+H]+ = 421.1.1H NMR (400 MHz, DMSO-d6) δH 7.53-7.20 (m, 6H), 5.65-5.61 (m, 1H), 4.84-4.82 (m, 4H), 2.27 (s, 3H), 1.68-1.67 (brs, 2H), 1.42-1.39 (brs, 2H). [0809] 3-(3-(difluoromethyl)-5-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1- yl)thietane 1,1-dioxide, Example 40b [Peak-2]: LCMS (ESI) Calcd for C19H18F2N4O3S: 420.1, found [M+H]+ = 421.3.1H NMR (400 MHz, DMSO-d6 at 100 °C): δH 7.43-7.10 (m, 6H), 5.97 (brs, 1H), 4.85-4.74 (m, 4H), 2.33 (s, 3H), 1.77 (s, 2H), 1.45 (s, 2H). Example 41: Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)-N-methylethan-1-amine (Example 41)
Figure imgf000204_0001
[0810] Synthesis of tert-butyl (2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol- 5-yl)-1H-pyrazol-1-yl)ethyl)(methyl)carbamate, 75 [Step 1]: To a stirred solution of triphenylphosphine (1.2g , 1.9 mmol) in THF (15 mL) and DIAD (383.6 mg, 1.9 mmol) at 0 °C, 5-(5-(difluoromethyl)-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (70, 400 mg, 1.3 mmol) and tert-butyl (2-hydroxyethyl)(methyl)carbamate (332 mg, 1.9 mmol) were added. Resulting reaction mixture was allowed to stir at ambient temperature for 16 h and filtered through a celite pad. Combined filtrate was evaporated under reduced pressure. The product was purified by flash column chromatography to afford first product as tert-butyl (2-(3- (difluoromethyl)-5-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1- yl)ethyl)(methyl)carbamate (75a, 230 mg) and second product was tert-butyl (2-(5- (difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1- yl)ethyl)(methyl)carbamate (75, 230 mg). LCMS (ESI) Calcd. for C24H29F2N5O3: 473.2 found [M+H] + = 474.2. The structure of these regio-isomer was determined in the next step. [0811] Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)-N-methylethan-1-amine, Example 41 [Step 2]: To a stirred solution of tert-butyl (2- (5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1- yl)ethyl)(methyl)carbamate (75, 230 mg, 0.5 mmol) in dichloromethane (10 mL), trifluoroacetic acid (114.0 mg, 2.4 mmol) was added at 0 °C. The reaction mixture was stirred at ambient temperature for 12 h and volatiles were reduced under reduced pressure. The product was purified by reverse phase preparative HPLC to give 2-(5-(difluoro methyl)-3-(3-(1-(o-tolyl) cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)-N-methylethan-1-amine, (Example 41, 15 mg). LCMS (ESI) Calcd. for C19H21F2N5O: 373.17, found [M+H] + = 374.2, 1H NMR (400 MHz, DMSO-d6) δH 7.52-7.720 (m, 6H), 4.37 (t, 2H), 2.91 (t, 2H), 2.26 (s, 6H), 1.66 (brs, 2H), 1. (brs, 2H). The structure was confirmed based on NOE experiment. Example 42: Synthesis of 3-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)cyclobutane-1-carboxylic acid (Example 42)
Figure imgf000205_0001
[0812] Synthesis of methyl 3-(3-(difluoromethyl)-5-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5- yl)-1H-pyrazol-1-yl)cyclobutane-1-carboxylate, 76a and methyl 3-(5-(difluoromethyl)-3-(3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)cyclobutane-1-carboxylate, 76 [Step 1]: To a stirred solution of DIAD (330 mg, 1.9 mmol) in THF (15 mL) at 0 °C, triphenylphosphine (1.1 g, 1.9 mmol) was added. After 5 min., methyl 3-hydroxycyclobutanecarboxylate (247 mg, 1.9 mmol) and 5-[5-(difluoromethyl)-1H-pyrazol-3-yl]-3-[1-(o-tolyl)cyclopropyl]-1,2,4-oxadiazole (70, 400 mg, 1.3 mmol) was added and the resulting reaction mixture was stirred at ambient temperature for 12 h, filtered through a celite bed and combined filtrate was concentrated under reduced pressure. The products were purified by column chromatography to give the first product as methyl 3-(3-(difluoromethyl)-5-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)cyclobutane-1-carboxylate, Peak 1 (76a, 220 mg) and the second product as methyl 3-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1- yl)cyclobutane-1-carboxylate, Peak 2 (76, 110 mg). The structure of regiomers were confirmed by NOE experiment. [0813] Methyl 3-(3-(difluoromethyl)-5-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)cyclobutane-1-carboxylate, Peak 1 (76a): LCMS (ESI) Calcd. for C22H22F2N4O3: 428.2, found [M+H]+ = 429.4. [0814] Methyl 3-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)cyclobutane-1-carboxylate, Peak 2 (76): LCMS (ESI) Calcd. for C22H22F2N4O3: 428.2, found [M+H]+ = 429.4. [0815] Synthesis of 3-(3-(difluoromethyl)-5-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)cyclobutane-1-carboxylic acid, Example 180 [Step 2]: To a solution of methyl 3-(3- (difluoromethyl)-5-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)cyclobutane- 1-carboxylate (76a, 220 mg, 0.5 mmol) in THF (2 mL), a solution of lithium hydroxide monohydrate (65 mg, 1.5 mmol) in water (2 mL) was added. The reaction mixture was stirred at 70 °C for 4 h and volatiles were evaporated under reduced pressure, acidified with 1(N) HCl, and extracted with ethyl acetate. Combined organic extracts were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by reverse phase preparative HPLC to give 3-(3-(difluoromethyl)-5-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)cyclobutane-1-carboxylic acid (Example 180, 45 mg). LCMS (ESI) Calcd. for C21H20F2N4O3: 414.1, found [M+H] + = 415.2.1H NMR (400 MHz, DMSO-d6): δH 7.39-7.00 (m, 6H), 5.79 (t, 1H), 3.11-3.07 (d, 1H), 2.85-2.78 (m, 2H), 2.67-2.63 (m, 2H), 2.30 (s, 3H), 1.71 (brs, 2H), 1.44 (brs, 2H). One acid proton is exchangeable. [0816] Synthesis of 3-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)cyclobutane-1-carboxylic acid, Example 42 [Step 3]: To a solution of methyl 3-(5- (difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)cyclobutane- 1-carboxylate (76, 100 mg, 0.2 mmol) in THF (2 mL), a solution of lithium hydroxide monohydrate (29 mg, 0.7 mmol) in water (2 mL) was added. The reaction mixture was stirred at 70 °C for 4 h and volatiles were evaporated under reduced pressure, acidified with 1(N) HCl, and extracted with ethyl acetate. Combined organic extracts were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by reverse phase preparative HPLC to give 3-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)cyclobutane-1-carboxylic acid (Example 42, 25 mg). LCMS (ESI) Calcd. for C21H20F2N4O3: 414.15, found [M+H] + = 415.25.1H NMR (400 MHz, DMSO-d6): δH 7.53-7.20 (m, 6H), 5.24-5.20 (m, 1H), 3.13-3.10 (m, 1H), 2.89-2.81 (m, 2H), 2.67-2.62 (m, 2H), 2.27 (s, 3H), 1.67 (brs, 2H), 1.40 (brs, 2H). One acid proton is exchangeable. Example 43: Synthesis of N-(2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)ethyl)methanesulfonamide (Example 43)
Figure imgf000207_0001
[0817] Synthesis of ethyl tert-butyl (2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)ethyl)carbamate, 77 [Step 1]: To a stirred solution of 5-(5- (difluoromethyl)-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (70, 340 mg, 1.0 mmol) in acetonitrile (15 mL) was added Cs2CO3 (1.0 g, 3.2 mmol) and tert-butyl (2- bromoethyl)carbamate (482 mg, 2.1 mmol). Resulting reaction mixture was allowed to stir at 80 °C for 16 h. The reaction mixture was diluted with ethyl acetate and washed with water followed by brine wash. Combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by flash chromatography to afford ethyl tert-butyl (2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)ethyl)carbamate (77, 170 mg). LCMS (ESI) Calcd. for C23H27F2N5O3: 459.2, found [M+H]+ = 460.4. Note: Other regio-isomer (77a) was also formed. [0818] Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)ethan-1-amine, 78 [Step 2]: To a stirred solution of ethyl tert-butyl (2-(5- (difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1- yl)ethyl)carbamate (77, 170 mg, 0.37 mmol) in dichloromethane (5 mL), was added TFA (0.2 mL, 2.6 mmol). Resulting reaction mixture was stirred at ambient temperature for 16 h and volatiles were evaporated under reduced pressure to afford 2-(5-(difluoromethyl)-3-(3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)ethan-1-amine (78, 120 mg). The product was carried to next step without further purification. LCMS (ESI) Calcd. for C18H19F2N5O: 359.1, found [M+H]+ = 360.1 [0819] Synthesis of N-(2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 1H-pyrazol-1-yl)ethyl)methanesulfonamide, Example 43 [Step 3]: To a stirred solution of 2-(5- (difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)ethan-1-amine (78, 120 mg, 0.3 mmol) in THF (5 mL), triethylamine (0.13 mL, 19.7 mmol) and methanesulfonyl chloride (0.04 mL, 0.5 mmol )were added at 0 °C. Resulting reaction mixture was stirred at ambient temperature for 16 h, diluted with ethyl acetate and washed with saturated solution of sodium bicarbonate followed by brine. Combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by reverse phase preparative HPLC to afford N-(2-(5-(difluoromethyl)-3-(3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)ethyl)methanesulfonamide (Example 43, 50 mg). LCMS (ESI) Calcd. for C19H21F2N5O3S: 437.1, found [M+H]+ = 438.1.1H NMR (400 MHz, DMSO-d6): δH 7.49-7.20 (m, 7H), 4.21(t, 2H), 3.44-3.42 (m, 2H), 2.87 (s, 3H), 2.32 (s, 3H), 1.67 (brs, 2H), 1.40 (brs, 2H). Example 44: Synthesis of 2-[5-(difluoromethyl)-3-[3-[1-(o-tolyl)cyclopropyl]-1,2,4-oxadiazol-5-yl]- 1H-pyrazol-1-yl]acetic acid (Example 44)
Figure imgf000208_0001
Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol- 1-yl)acetic acid, Example 44 [Step 1]: To a stirred solution of tert-butyl 2-(5-(difluoromethyl)-3- (3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)acetate (72, 200 mg, 0.5 mmol) in dichloromethane (10 mL), trifluoroacetic acid (0.36 mL, 4.7 mmol) was added at 0 °C. The reaction mixture was stirred at ambient temperature for 12 h and volatiles were reduced under reduced pressure. The product was purified by reverse phase preparative HPLC to give 2-[5- (difluoromethyl)-3-[3-[1-(o-tolyl)cyclopropyl]-1,2,4-oxadiazol-5-yl]-1H-pyrazol-1-yl]acetic acid (Example 44, 176 mg). LCMS (ESI) Calcd. For C18H16F2N4O3: 374.1, found [M+H] + = 375.2, 1H NMR (400 MHz, DMSO-d6): δH 7.39-7.12 (m, 6H), 4.83 (brs, 2H), 2.27 (s, 3H), 1.67-1.65 (m, 2H), 1.39 (brs, 2H). One acid proton is exchangeable. Example 45: Synthesis of N-(2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)ethyl)-N-methylacetamide (Example 45)
Figure imgf000209_0001
Sc e e 3 [0820] Synthesis of tert-butyl (2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol- 5-yl)-1H-pyrazol-1-yl)ethyl)(methyl)carbamate, 79 [Step 1]: To a stirred solution of triphenylphosphine (1.2g , 1.9 mmol) in THF (15 mL) and DIAD (383.6 mg, 1.9 mmol) at 0 °C, 5-(5-(difluoromethyl)-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (70, 400 mg, 1.3 mmol) and tert-butyl (2-hydroxyethyl)(methyl)carbamate (332 mg, 1.9 mmol) were added. Resulting reaction mixture was allowed to stir at ambient temperature for 16 h and filtered through a celite pad. Combined filtrate was evaporated under reduced pressure. The product was purified by flash column chromatography to afford first product as tert-butyl (2-(3- (difluoromethyl)-5-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1- yl)ethyl)(methyl)carbamate (79a, 230 mg) and second product was tert-butyl (2-(5- (difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1- yl)ethyl)(methyl)carbamate (79, 230 mg). LCMS (ESI) Calcd. for C24H29F2N5O3: 473.2 found [M+H] + = 474.2. The structure of these regio-isomer was determined in the next step. [0821] Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)-N-methylethan-1-amine, 80 [Step 2]: To a stirred solution of tert-butyl (2-(5- (difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1- yl)ethyl)(methyl)carbamate (79, 230 mg, 0.5 mmol) in dichloromethane (10 mL), trifluoroacetic acid (114.0 mg, 2.4 mmol) was added at 0 °C. The reaction mixture was stirred at ambient temperature for 12 h and volatiles were reduced under reduced pressure. The product was purified by reverse phase preparative HPLC to give 2-(5-(difluoro methyl)-3-(3-(1-(o-tolyl) cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)-N-methylethan-1-amine, (80, 15 mg). LCMS (ESI) Calcd. for C19H21F2N5O: 373.17, found [M+H] + = 374.2, 1H NMR (400 MHz, DMSO-d6) δH 7.52-7.720 (m, 6H), 4.37 (t, 2H), 2.91 (t, 2H), 2.26 (s, 6H), 1.66 (brs, 2H), 1. (brs, 2H). The structure was confirmed based on NOE experiment. [0822] Synthesis of N-(2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 1H-pyrazol-1-yl)ethyl)-N-methylacetamide, Example 45 [Step 3]: To a stirred solution of 2-(5- (difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)-N- methylethan-1-amine (80, 250 mg, 0.7 mmol) in dichloromethane (10 mL) were added triethylamine (0.5 mL, 3.4 mmol) and acetyl chloride (0.14 mL, 2.0 mmol) was added at 0 °C. The reaction mixture was stirred at 25 °C for 6 h and volatiles were evaporated under reduced pressure. The product was purified by reverse phase preparative HPLC to give N-(2-(5- (difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)ethyl)-N- methylacetamide (Example 45, 24 mg). LCMS (ESI) Calcd. for C21H23F2N5O2: 415.18, found [M+H] + = 416.29.1H NMR (400 MHz, DMSO-d6 at 100 °C) δH 7.44-7.17 (m, 6H), 4.48 (brs, 2H), 3.75 (brs, 2H), 2.82 (brs, 3H), 2.31 (s, 3H), 1.90 (s, 3H), 1.71-1.68 (m, 2H), 1.40-1.37 (m, 2H). Example 46: Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)-1-morpholinoethan-1-one (Example 46)
Figure imgf000211_0001
[0823] Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)-1-morpholinoethan-1-one, Example 46 [Step 1]: To a stirred solution of 2-[5- (difluoromethyl)-3-[3-[1-(o-tolyl)cyclopropyl]-1,2,4-oxadiazol-5-yl]-1H-pyrazol-1-yl]acetic acid (Example 44, 120 mg, 0.321 mmol) in dichloromethane (10 mL) were added DIPEA (0.6 mL, 3.6 mmol) and propyl phosphonic anhydride (50% in ethyl acetate) (0.16 mL, 0.962 mmol). After 15 min, morpholine (2, 34.4 mg, 0.4 mmol) was added and the resulting reaction mixture was allowed to stir at ambient temperature for 16 h, diluted with dichloromethane and washed with saturated solution of sodium bicarbonate followed by brine wash. Combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by prep HPLC to give 2-[5-(difluoromethyl)-3-[3-[1-(o-tolyl)cyclopropyl]- 1,2,4-oxadiazol-5-yl]pyrazol-1-yl]-1-morpholinoethanone (Example 46, 42 mg). LCMS (ESI) Calcd. for C22H23F2N5O3: 443.2 found [M+H] + = 444.3.1H NMR (400 MHz, DMSO-d6): δH 7.39- 7.06 (m, 6H), 5.49 (s, 2H), 3.66 (t, 2H), 3.58 (t, 2H), 3.51 (t, 2H), 3.44 (t, 2H), 2.27 (s, 3H), 1.67- 1.66 (m, 2H), 1.41-1.38 (brs, 2H). Example 47: Synthesis of (2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)acetyl)glycine (Example 47)
Figure imgf000211_0002
[0824] Synthesis of tert-butyl (2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol- 5-yl)-1H-pyrazol-1-yl)acetyl)glycinate, 81 [Step 1]: To a stirred solution of 2-[5-(difluoromethyl)- 3-[3-[1-(o-tolyl)cyclopropyl]-1,2,4-oxadiazol-5-yl]-1H-pyrazol-1-yl]acetic acid (Example 44, 220 mg, 0.6 mmol) in dichloromethane (15 mL) were added DIPEA ( 227 mg, 1.8 mmol) and propyl phosphonic anhydride (50% in ethyl acetate) (0.45 mL, 1.5 mmol). After 15 min, tert-butyl glycinate (157 mg, 1.2 mmol) was added and the resulting reaction mixture was allowed to stir at ambient temperature for 16 h. The reaction mixture was diluted with dichloromethane, washed with saturated solution of sodium bicarbonate followed by brine wash. Combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by reverse phase preparative HPLC to give tert- butyl (2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1- yl)acetyl)glycinate (81, 76 mg). LCMS (ESI) Calcd. for C24H27F2N5O4: 487.2, found [M+H] + = 488.4. [0825] Synthesis of (2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)acetyl)glycine, Example 47 [Step 2]: To a stirred solution of tert-butyl (2-(5- (difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1- yl)acetyl)glycinate (81, 60 mg, 0.1 mmol) in dichloromethane (5 mL), trifluoroacetic acid (1 mL, 13.0 mmol) was added at 0 °C. The reaction mixture was stirred at ambient temperature for 12 h and volatiles were reduced under reduced pressure. The product was purified by reverse phase preparative HPLC to give 2-[[2-[5-(difluoromethyl)-3-[3-[1-(o-tolyl)cyclopropyl]-1,2,4-oxadiazol-5- yl]pyrazol-1-yl]acetyl]amino]acetic acid (Example 47, 37 mg,). LCMS (ESI) Calcd. for C20H19F2N5O4: 431.1, found [M+H] + = 432.2.1H NMR (400 MHz, DMSO-d6): δH 12.80 (brs, 1H), 8.64 (brs, 1H) 7.41-7.14 (m, 6H), 5.17 (s, 2H), 3.81 (s, 2H), 2.26 (s, 3H), 1.66 (brs, 2H), 1.39 (brs, 2H). Example 48: Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)-N-(2-methoxyethyl)acetamide (Example 48)
Figure imgf000212_0001
[0826] Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)-N-(2-methoxyethyl)acetamide, Example 48 [Step 1]: To a stirred solution of 2-(5- (difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)acetic acid (Example 44, 70 mg, 0.18 mmol) in dichloromethane (3 mL), N,N-diisopropylethylamine (0.10 mL, 0.56 mmol) and propane phosphonic acid anhydride (50% in ethyl acetate) (0.08 mL, 0.28 mmol) were added. After 15 min, 2-methoxyethan-1-amine (17 mg, 0.22 mmol) was added and the reaction mixture was stirred at ambient temperature for 16 h, diluted with dichloromethane, washed with saturated solution of aqueous sodium bicarbonate followed by brine wash. Combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by reverse phase preparative HPLC to afford 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)-N-(2-methoxyethyl)acetamide (Example 48, 20 mg). LCMS (ESI) Calcd. for C21H23F2N5O3: 431.2, found [M + H]+ = 432.3, , 1H NMR (400 MHz, DMSO-d6): δH 8.44 (t, 1H), 7.41-7.14 (m, 6H), 5.09 (s, 2H), 3.38-3.35 (m, 2H), 3.32-3.26 (m, 5H), 2.26 (s, 3H), 1.66 (brs, 2H), 1.39 (brs, 2H). Example 49: Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)-N-(2-hydroxyethyl)acetamide (Example 49)
Figure imgf000213_0001
Scheme 36 [0827] Synthesis of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)-N-(2-hydroxyethyl)acetamide, Example 49 [Step 1]: To a stirred solution of 2-(5- (difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)acetic acid (Example 44, 120 mg, 0.3 mmol) in N,N-dimethylformamide (2 mL), N,N-diisopropylethylamine (0.2 mL, 1.0 mmol) and T3P (0.1 mL, 0.5 mmol, 50% in ethyl acetate) were added. After 15 min, 2-aminoethan-1-ol (0.04 mL, 0.6 mmol) was added and the reaction mixture was stirred at ambient temperature for 16 h, diluted with ethyl acetate, washed with ice cold water followed by brine. Combined organic extracts was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by reverse phase prep HPLC to afford 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)-N- (2-hydroxyethyl)acetamide (Example 49, 20 mg). LCMS (ESI) Calcd. for C20H21F2N5O3: 417.2, found [M+H]+ = 418.3.1H NMR (400 MHz, DMSO-d6) δH 8.36 (t, 1H), 7.41-7.14 (m, 6H), 5.09 (s, 2H), 4.75 (t, 1H), 3.45-3.40 (m, 2H), 3.18-3.14 (m, 2H), 2.26 (s, 3H) 1.68-1.65 (m, 2H), 1.41- 1.38 (m, 2H). Example 50: Synthesis of (S)-2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)-1-(3-(dimethylamino)pyrrolidin-1-yl)ethan-1-one (Example 50)
Figure imgf000214_0001
[0828] Synthesis of (S)-2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 1H-pyrazol-1-yl)-N-(2-hydroxyethyl)acetamide, Example 50 [Step 1]: To a stirred solution of 2- (5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)acetic acid (Example 44, 100 mg, 0.3 mmol) in N,N-dimethylformamide (2 mL), N,N-diisopropylethylamine (0.1 mL, 0.8 mmol) and T3P (0.1 mL, 0.4 mmol, 50% in ethyl acetate) were added. After 15 min, (S)-N,N-dimethylpyrrolidin-3-amine (60 mg, 0.5 mmol) was added and the reaction mixture was stirred at ambient temperature for 16 h, diluted with ethylacetate, washed with ice cold water followed by brine. Combined organic extract were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by reverse phase prep HPLC to afford (S)-2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 1H-pyrazol-1-yl)-1-(3-(dimethylamino)pyrrolidin-1-yl)ethan-1-one (Example 50, 36 mg). LCMS (ESI) Calcd. for C24H28F2N6O2: 470.2, found [M+H]+ = 471.2.1H NMR (400 MHz, DMSO-d6, 100 °C) δH 7.40-7.38 (m, 1H), 7.32-7.06 (m, 5H), 5.31 (brs, 2H), 3.78-3.71 (m, 1H), 3.56-3.52 (m, 1H), 3.32 (m, 1H), 2.88-2.86 (m, 1H), 2.76 (m, 1H), 2.30 (m, 3H), 2.22-2.13 (m, 6H), 2.03-2.00 (m, 1H), 1.87 (m, 1H), 1.69 (m, 2H), 1.39 (m, 2H). Example 51: Synthesis of (R)-2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)-1-(3-(dimethylamino)pyrrolidin-1-yl)ethan-1-one (Example 51)
Figure imgf000215_0001
[0829] Synthesis of (R)-2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 1H-pyrazol-1-yl)-1-(3-(dimethylamino)pyrrolidin-1-yl)ethan-1-one, Example 51 [Step 1]: To a stirred solution of 2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)acetic acid (Example 44, 100 mg, 0.3 mmol) in DMF (2 mL), DIPEA (0.13 mL, 0.8 mmol) and propane phosphonic acid anhydride (50% in ethyl acetate) (0.12 mL, 0.40 mmol) were added. After 15 mins, (R)-N,N-dimethylpyrrolidin-3-amine (30 mg, 0.3 mmol) was added and the reaction mixture was stirred at ambient temperature for 16 h, diluted with dichloromethane, washed with saturated solution of sodium bicarbonate followed by brine wash. Combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by reverse phase prep-HPLC method to afford (R)-2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)-1-(3-(dimethylamino)pyrrolidin-1-yl)ethan-1-one (Example 51, 38 mg). LCMS (ESI) Calcd. for C24H28F2N6O2: 470.2, found [M+H]+ = 471.2.1H NMR (400 MHz, DMSO-d6 at 100 °C): 7.40-7.05 (m, 6H), 5.34-5.31 (m, 2H), 3.78-3.72 (m, 1H), 3.55-3.50 (m, 1H), 3.36-3.31 (m, 1H), 2.91-2.87 (m, 1H), 2.76-2.72 (m, 1H), 2.30 (m, 3H), 2.22-2.12 (m, 6H), 2.02 (m, 1H), 1.89-1.86 (m, 1H), 1.69 (m, 2H), 1.39 (m, 2H). Example 52 & Example 53: Synthesis of (S)-1-(3-aminopyrrolidin-1-yl)-2-(5- (difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)ethan-1- one (Example 52 & Example 53)
Figure imgf000216_0001
[0830] Synthesis of tert-butyl (S)-(1-(2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)acetyl)pyrrolidin-3-yl)carbamate, 83 and tert-butyl (S)-(1-(2-(5- (difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1- yl)acetyl)pyrrolidin-3-yl)carbamate, 83 [Step 1]: To a stirred solution of 2-(5-(difluoromethyl)-3- (3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)acetic acid (Example 44, 300 mg, 0.8 mmol) in DMF (5 mL), DIPEA (0.42 mL, 2.4 mmol) and propane phosphonic acid anhydride (50% in ethyl acetate) (0.48 mL, 1.6 mmol) were added. After 15 min, tert-butyl pyrrolidin-3-ylcarbamate (299 mg, 1.6 mmol) was added and the reaction mixture was stirred at ambient temperature for 16 h, diluted with ethyl acetate, washed with ice cold water followed by brine wash. Combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by reverse phase preparative HPLC to afford tert-butyl (1-(2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5- yl)-1H-pyrazol-1-yl)acetyl)pyrrolidin-3-yl)carbamate (380 mg). The enantiomers were separated by normal phase chiral HPLC to afford the first product as tert-butyl (S)-(1-(2-(5-(difluoromethyl)- 3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)acetyl)pyrrolidin-3- yl)carbamate, Peak 1 (82, 150 mg) and the second product as tert-butyl (R)-(1-(2-(5- (difluoromethyl)-3-(3-(1-phenylcyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1- yl)acetyl)pyrrolidin-3-yl)carbamate, Peak 2 (83, 150 mg). The absolute stereochemistries of these compounds were not determined. [0831] tert-butyl (S)-(1-(2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 1H-pyrazol-1-yl)acetyl)pyrrolidin-3-yl)carbamate, Peak 1 (82): LCMS (ESI) Calcd. for C27H32F2N6O4: 542.2, found [M+H]+ = 543.3, [0832] tert-butyl (R)-(1-(2-(5-(difluoromethyl)-3-(3-(1-phenylcyclopropyl)-1,2,4-oxadiazol-5-yl)- 1H-pyrazol-1-yl)acetyl)pyrrolidin-3-yl)carbamate, Peak 2 (83): LCMS (ESI) Calcd. for C27H32F2N6O4: 542.2, found [M+H]+ = 543.4. [0833] Chiral HPLC method: Chiral separation was performed on an Agilent 1200 series instrument. Column: CHIRALPAK IC (250 X 20 mm) 5µ, operating at ambient temperature with a flow rate of 18.0 mL/min. Mobile phase: 70% Hexane, 15% EtOH and 15% dichloromethane, held isocratic mixture up to 16 min at a wavelength of 250 nm. [0834] Synthesis of (S)-1-(3-aminopyrrolidin-1-yl)-2-(5-(difluoromethyl)-3-(3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)ethan-1-one, Example 52, [Step 3]: To a stirred solution of tert-butyl (S)-(1-(2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)acetyl)pyrrolidin-3-yl)carbamate (82, 150 mg, 0.3 mmol) in dichloromethane (3 mL) was added trifluoroacetic acid ( 1.0 mL, 13.1 mmol) at 0 °C. The resulting reaction mixture was allowed to stir at ambient temperature for 2 h and volatiles were evaporated under reduced pressure. The product was purified by reverse phase preparative HPLC to afford (S)-1-(3-aminopyrrolidin-1-yl)-2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)- 1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)ethan-1-one (Example 52, 47 mg). LCMS (ESI) Calcd. for C22H24F2N6O2: 442.19, found [M+H]+ = 443.20.1H NMR (400 MHz, DMSO-d6 and 2 drops of D2O): δH 7.37-7.35 (m, 1H), 7.32-7.05 (m, 5H), 5.30-5.27 (m, 2H), 3.62-3.31 (m, 4H), 3.15-3.06 (m, 1H), 2.24 (s, 3H), 2.08-1.97 (m, 1H), 1.72-1.60 (m, 3H), 1.39-1.36 (m, 2H). Two amine protons are exchangeable. [0835] Synthesis of (R)-1-(3-aminopyrrolidin-1-yl)-2-(5-(difluoromethyl)-3-(3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)ethan-1-one, Example 53 [Step 4]: To a stirred solution of tert-butyl (R)-(1-(2-(5-(difluoromethyl)-3-(3-(1-phenylcyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)acetyl)pyrrolidin-3-yl)carbamate (83, 150 mg, 0.3 mmol) in dichloromethane (3 mL) was added trifluoroacetic acid ( 1.0 mL, 13.1 mmol) at 0 °C. The resulting reaction mixture was allowed to stir at ambient temperature for 2 h and volatiles were evaporated under reduced pressure. The product was purified by reverse phase preparative HPLC to afford (R)-1-(3-aminopyrrolidin-1-yl)-2-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)- 1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)ethan-1-one (Example 53, 48 mg). LCMS (ESI) Calcd. for C22H24F2N6O2: 442.19, found [M+H]+ = 443.20.7.37-7.35 (m, 1H), 7.32-7.05 (m, 5H), 5.30-5.27 (m, 2H), 3.62-3.31 (m, 4H), 3.15-3.06 (m, 1H), 2.24 (s, 3H), 2.08-1.97 (m, 1H), 1.72-1.60 (m, 3H), 1.39-1.36 (m, 2H). Two amine protons are exchangeable. Example 54: Synthesis of 3-(5-cyclopropyl-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5- yl)-1H-pyrazol-1-yl)propenamide (Example 54)
Figure imgf000218_0001
[0836] Synthesis of 3-(5-cyclopropyl-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)propenamide, Example 54 [Step 5]: To a stirred solution of 3-(5-cyclopropyl-3-(3-(1- (o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)propanoic acid (Example 22, 60 mg, 0.16 mmol) in DMF (3 mL), were added HATU (90 mg, 0.24 mmol), DIPEA (0.14 mL, 0.8 mmol) and ammonium chloride (25 mg, 0.5 mmol). The reaction mixture was stirred at ambient temperature for 14 h, diluted ethyl acetate and washed with water followed by brine. Combined organic extracts were dried over anhydrous sodium sulphate and concentrated under reduced pressure. The product was purified by reverse phase preparative HPLC to afford 3-(5- cyclopropyl-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)propenamide (Example 54, 47 mg). LCMS (ESI) Calcd. for C21H23N5O2: 377.19, found [M+H]+ = 378.10.1H NMR (400 MHz, DMSO-d6): δH 7.44 (brs, 1H), 7.37 (d, 1H), 7.23-7.19 (m, 3H), 6.92 (brs,1H), 6.55 (s, 1H), 4.44 (t, 2H), 2.70 (t, 2H), 2.25 (s, 3H), 2.04 (brs,1H), 1.64-1.61 (m, 2H), 1.37-1.35 (m, 2H), 0.99-0.96 (m, 2H), 0.76-0.73 (m, 2H). Examples 55a & 55b: Synthesis of 5-(4-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 55a) and 5-(4-(difluoromethyl)-1-methyl-1H- pyrazol-5-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 55b)
Figure imgf000219_0001
[0837] Synthesis of 5-(4-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)- 1,2,4-oxadiazole & 5-(4-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)-3-(1-(o-tolyl)cyclopropyl)- 1,2,4-oxadiazole, Example 55a and Example 55b [Step 1]: To a stirred solution of methyl 4- (difluoromethyl)-1-methyl-1H-pyrazole-3-carboxylate (86, 200 mg, 1 mmol) (along with other regioisomer) in toluene (2 mL), K2CO3 (270 mg, 2.0 mmol) and N'-hydroxy-1-(o- tolyl)cyclopropanecarboxamidine (180 mg, 1.0 mmol) were added and reaction mixture was allowed to stir at 90 °C for 16 h. After completion the reaction mixture was diluted with ethyl acetate and partitioned with water. Combined organic layer was dried over anhydrous Na2SO4, filtered, concentrated under reduced pressure. The product was purified and separated by reverse phase prep-HPLC to afford 5-(4-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 55a, 65 mg) as peak 1 and 5-(4-(difluoromethyl)-1- methyl-1H-pyrazol-5-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 55b, 90 mg) as peak 2. [0838] Analytical data of 5-(4-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazole, Example 55a: LCMS (ESI) Calcd for C17H16F2N4O: 330.3, found [M+H]+ = 331.0.1H NMR (400 MHz, DMSO-d6) δH 8.39 (s, 1H), 7.41-7.13 (m, 5H), 4.00 (s, 3H), 2.27 (s, 3H), 1.69-1.66 (m, 2H), 1.41-1.38 (m, 2H). [0839] Analytical data of 5-(4-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)-3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazole, Example 55b: LCMS (ESI) Calcd for C17H16F2N4O: 330.3, found [M+H]+ = 331.0.1H NMR (400 MHz, DMSO-d6) δH 7.97 (s, 1H), 7.38 (d, 1H), 7.27-7.11 (m, 4H), 4.18 (s, 3H), 2.30 (s, 3H), 1.73-1.70 (m, 2H), 1.45-1.42 (s, 2H). Note: The exact structure of peak 1 & peak 2 was confirmed by NOE experiments. Example 56: Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-2-(1-(o- tolyl)cyclopropyl)oxazole (Example 56)
Figure imgf000220_0001
[0840] Synthesis of 5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl chloride, 88 [Step 1]: To a stirred solution of 5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carboxylic acid (87, 140 mg, 0.8 mmol) in SOCl2 (5.0 mL, 70 mmol) was heated at 60 °C added and stirred for 2 h. After completion volatiles was evaporated under reduced pressure to afford 5-(difluoromethyl)-1- methyl-1H-pyrazole-3-carbonyl chloride (88, 150 mg) which was confirmed in next step. [0841] Synthesis of 2-diazo-1-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)ethan-1-one, 89 [Step 2]: To a solution of 5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl chloride (88, 150 mg, 0.8 mmol) in Toluene (2 mL), (Trimethylsilyl)diazomethane (2M in hexane) (2.0 mL, 4 mmol) was added dropwise at 0 °C. The reaction was stirred at ambient temperature for 16 h. Reaction mixture was directly forwarded to next step. LCMS Calcd. for C7H6F2N4O: [M] = 200.15, found [M+H]+= 201.2. [0842] Synthesis of 2-bromo-1-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)ethan-1-one, 90 [Step 3]: To a stirred solution of 2-diazo-1-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)ethan-1- one (150 mg, 0.8 mmol) in 1,4-Dioxane (2mL), HBr in H2O (48%) (1.0 mL, 20 mmol) was added slowly at 0 °C and stirred for 1 h at ambient temperature. The reaction was concentrated to dryness and the residue was taken up in EtOAc and the organic extracts were washed with water then saturated brine solution. The organic ectracts were then separated and dried (MgSO4) under reduced pressure which was purified by flash column chromatography to afford 2-bromo-1-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)ethan-1-one (90, 190 mg). LCMS Calcd. for C7H7BrF2N2O: [M] = 253, found [M+H]+= 255. Synthesis of 2-amino-1-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)ethan-1-one, 91 [Step 4]: To a solution of 2-bromo-1-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)ethan-1-one (150 mg, 0.6 mmol) in Chloroform (2 mL), Hexamethylentetramine (0.06 mL, 1 mmol) was added and stirred for 4 hours at ambient temperature. The reaction mixture was filtered through celite bed to afford the precipitated hexamine adduct. The adduct was then heated with Methanol (4 mL) and Conc. HCl (0.40 mL) for 16 h under reflux. The reaction mixture was cooled, fitered and concentrated under reduced pressure. The product was purified by flash column chromatography to afford 2-amino-1-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)ethan-1-one (91, 200 mg). LCMS Calcd. For C7H9F2N3O: [M] = 189.16, found [M+H]+= 190.1. Example 56: Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-2-(1-(o- tolyl)cyclopropyl)oxazole (Example 56)
Figure imgf000221_0001
[0843] Synthesis of 1-(o-tolyl)cyclopropane-1-carboxylic acid, 92 [Step 1]: To a stirred solution of 1-(o-tolyl)cyclopropane-1-carbonitrile (10, 1.00 g, 6 mmol) in 4M LiOH.H2O aq. solution (8.0 mL, 25 mmol) was refluxed at 100 °C for 24h with continue stirring. Reaction mixture was cooled at 0 °C, washed with ethyl acetate and aqueous layer was acidified by 5N HCl solution and extracted with ethyl acetate (thrice). Organic layer was washed with water, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford 1-(o- tolyl)cyclopropane-1-carboxylic acid (92, 600 mg).1H NMR (400 MHz, DMSO-d6) δH 12.19 (brs, 1H), 7.21-7.08 (m, 4H), 2.27 (s, 3H), 1.50 (d, 2H), 1.10-1.08 (m, 2H). Notes: Extra peak present in 1H NMR. [0844] Synthesis of 1-(o-tolyl)cyclopropane-1-carboxylic chloride, 93 [Step 2]: A stirred solution of 1-(o-tolyl)cyclopropane-1-carboxylic acid (92, 350 mg, 2 mmol) in SOCl2 (6 mL, 80 mmol) was heated at 60 °C added and stirred for 2 h. After completion volatiles was evaporated under reduced pressure to afford 1-(o-tolyl)cyclopropanecarbonyl chloride (93, 350 mg) which was confirmed in next step. [0845] Synthesis of N-(2-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-2-oxoethyl)-1-(o- tolyl)cyclopropane-1-carboxamide, 94 [Step 3]: To a stirred solution of 1-(o-tolyl)cyclopropane-1- carboxylic chloride (200 mg, 1.2 mmol) in 1,2 dichloromethane (4mL), triethyl amine (0.4 mL, 3 mmol) in 1,2 dichloromethane (2 ml) and 2-amino-1-[5-(difluoromethyl)-1-methyl-pyrazol-3- yl]ethanone (230 mg, 1.2 mmol) in 1,2 dichloromethane(2 ml) was added portionwise at 0 °C. The reaction mixture was stirred at ambient temperature for 1 h. The reaction mixture was concentrated under reduced pressure, diluted with water and extracted with 1,2 dichloromethane. The organic extracts were then separated and under reduced pressure. The product was purified by reverse phase prep HPLC purification to afford N-(2-(5-(difluoromethyl)- 1-methyl-1H-pyrazol-3-yl)-2-oxoethyl)-1-(o-tolyl)cyclopropane-1-carboxamide (94, 120 mg).1H NMR (400 MHz, DMSO-d6) δH 7.44-6.81 (m, 7H), 4.39 (d, 2H), 3.99 (s, 3H), 2.39 (s, 3H), 1.42 (d, 2H), 0.97 (d, 2H). LC/MS: calculated for C18H19F2N3O2 [M]: 347.36, found [M+H]+: 348. Notes: 15mg of compound shipped. Rest amount were forwarded to next step. [0846] Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-2-(1-(o- tolyl)cyclopropyl)oxazole, Example 56 [Step 4]: In a round buttom flask, POCl3 (1.5 mL, 15 mmol) was added in a stirred solution of N-(2-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-2- oxoethyl)-1-(o-tolyl)cyclopropane-1-carboxamide (94, 100 mg, 0.3 mmol) at 0 °C. The resulting reaction mixture was stirred for 16 h at 100 °C. The reaction mixture was concentrated under reduced pressure, diluted with water and extracted with ethyl acetate. The organic extracts were then separated and dried under reduced pressure. The product was purified by reverse phase prep HPLC purification to afford 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-2-(1-(o- tolyl)cyclopropyl)oxazole (Example 56, 30 mg).1H NMR (400 MHz, DMSO-d6) δH 7.44-6.81 (m, 7H), 3.90 (s, 3H), 2.24 (s, 3H), 1.67-1.65 (m, 2H), 1.36-1.33 (m, 2H). LC/MS: calculated for C18H17F2N3O [M]: 329.34, found [M+H]+: 330.2. Examples 57-64: Synthesis of (Z)-1-(2-chloro-5-fluorophenyl)-N'-hydroxycyclopropane-1-carboximidamide, 97
Figure imgf000222_0001
[0847] Synthesis of 1-(2-chloro-5-fluorophenyl)cyclopropane-1-carbonitrile, 96 [Step 1]: To a stirred solution of NaOH (1.4 g, 35.4 mmol) in water (5 mL), 2-(2-chloro-5-fluoro- phenyl)acetonitrile (95, 500 mg, 3.0 mmol), TBAB (190 mg, 0.6 mmol) and 1,2-dibromoethane (2.2 mL, 14.7 mmol) were added and the reaction mixture was heated at 60 °C for 12h. After completion, the reaction mixture was poured into cold water and extracted with ethyl acetate (thrice). Combined organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford 1-(2-chloro-5-fluorophenyl)cyclopropane-1- carbonitrile (96, 510 mg ).1H NMR (400 MHz, DMSO-d6) δH 7.63-7.59 (m, 1H), 7.50-7.47 (m, 1H), 7.34-7.29 (m, 1H), 1.99-1.69 (m, 2H), 1.52-1.41 (m, 2H). [0848] Synthesis of (Z)-1-(2-chloro-5-fluorophenyl)-N'-hydroxycyclopropane-1-carboximidamide, 97 [Step 2]: To a stirred solution of 1-(2-chloro-5-fluorophenyl)cyclopropane-1-carbonitrile (96, 500 mg, 2.6 mmol) in ethanol (25mL), sodium carbonate (540 mg, 5.1 mmol) and hydroxylamine hydrochloride (355 mg, 5.1 mmol) were added and the reaction was heated at 70 °C for 12h. After completion, the volatiles were evaporated under reduced pressure, diluted with ethyl acetate and washed with water and brine. Combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by column chromatography to afford (Z)-1-(2-chloro-5-fluorophenyl)-N'-hydroxycyclopropane-1- carboximidamide (97, 550 mg). LCMS (ESI) Calcd for C10H10ClFN2O: 228.6, found [M+H]+ = 229.2. Examples 57a & 57b: Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(5- (difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 57a)
Figure imgf000223_0001
[0849] Synthesis of ethyl 5-(difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazole-3- carboxylate, 67 [Step 1]: To a stirred suspension of ethyl 5-(difluoromethyl)-1H-pyrazole-3- carboxylate (13, 1 g, 5.3 mmol) and potassium carbonate (2.9 g, 21.03 mmol) in dimethylformamide (60 mL) at 0 °C, 1-bromo-2-(methylsulfonyl)ethane (1.48 g, 7.89 mmol) was added. The resulting reaction mixture was allowed to stir at ambient temperature for 16 h, diluted with ethyl acetate and washed with ice-cold water followed by brine wash. Combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by flash column chromatography to afford ethyl 5- (difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazole-3-carboxylate (67, 420 mg). LCMS (ESI) calcd. for C10H14F2N2O4S: 296.0 found [M+H]+ = 297.0, 1H NMR (400 MHz, DMSO- d6): δH 7.38 (t, 1H), 7.09 (s, 1H), 4.70 (t, 2H), 4.32-4.27 (m, 2H), 3.78-3.74 (m, 2H), 3.07 (s, 3H), 1.29 (t, 3H). Note: Structure was confirmed based NOE experiment on compound 67a. [0850] Synthesis of 5-(difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazole-3-carboxylic acid, 68 [Step 2]: To a cold solution of ethyl 5-(difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H- pyrazole-3-carboxylate (67, 420 mg, 1.42 mmol) in tetrahydrofuran (6 mL) and methanol (1 mL), a solution of lithium hydroxide (119 mg, 2.84 mmol) in water (2 mL) was added drop-wise. The reaction mixture was stirred at ambient temperature for 16 h and volatiles were evaporated under reduced pressure. The aqueous phase was acidified with 1 N aqueous solution of hydrochloric acid to ~pH-5 and extracted with a mixture of dichloromethane and isopropyl alcohol (9:1). Combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to give 5-(difluoromethyl)-1-(2-(methylsulfonyl)ethyl)- 1H-pyrazole-3-carboxylic acid (68, 350 mg). The product was carried to next step without further purification. LCMS (ESI) Calcd. for C8H10F2N2O4S: 268.03 found [M+H]+ = 269.09. [0851] Synthesis of (Z)-1-(4-chloro-2-fluorophenyl)-N'-((5-(difluoromethyl)-1-(2- (methylsulfonyl)ethyl)-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide, 98 [Step 3]: To a stirred solution of 5-(difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazole-3- carboxylic acid (68, 600 mg, 2.2 mmol), and (Z)-1-(2-chloro-4-fluorophenyl)-N'- hydroxycyclopropane-1-carboximidamide (565 mg, 2.5 mmol) in dichloromethane (10 mL), N,N- diisopropylethylamine (1.9 mL, 11.2 mmol), 1-hydroxy-7-azabenzotriazole (60 mg, 0.5 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (645 mg, 3.4 mmol) were added. The reaction mixture was stirred at ambient temperature for 16 h. After completion, the reaction mixture was diluted with ethyl acetate and washed with water and brine. Combined organic extract was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford (Z)-1-(4-chloro-2-fluorophenyl)-N'-((5-(difluoromethyl)-1-(2- (methylsulfonyl)ethyl)-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide (98, 500 mg). LCMS (ESI) Calcd. for C18H18ClF3N4O4S: 478.1, found [M+H]+ = 479.1. [0852] Synthesis of 3-(1-(4-chloro-2-fluorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1H-pyrazol- 3-yl)-1,2,4-oxadiazole, 99 [Step 4]: To a stirred solution of (Z)-1-(4-chloro-2-fluorophenyl)-N'-((5- (difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1- carboximidamide (98, 450 mg, 0.9 mmol) in tetrahydrofuran (8 mL), tetra butyl ammonium hydroxide (1.9 mL, 1.9 mmol) was added. The resulting reaction mixture was stirred at ambient temperature for 12 h and concentrated under reduced pressure. The residue was diluted with ethyl acetate and washed with water and brine. Combined organic extract was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford 3-(1-(4- chloro-2-fluorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (99, 250 mg). LCMS (ESI) Calcd. for C15H10ClF3N4O: 354.1, found [M+H]+ = 354.8. [0853] Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)-N,N-dimethylacetamide, Example 57a [Step 5]: To a stirred suspension of 3-(1-(4-chloro-2-fluorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1H-pyrazol-3-yl)- 1,2,4-oxadiazole (99, 130 mg, 0.4 mmol) and potassium carbonate (100 mg, 0.7 mmol) in THF (2 mL) at 0 °C, 2-bromo-N,N-dimethylacetamide (73 mg, 0.4 mmol) was added. The resulting reaction mixture was stirred at ambient temperature for 16 h. After completion, the reaction mixture was diluted with ethyl acetate and washed with ice-cold water and brine. Combined organic extract was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product were purified by reverse phase prep HPLC to afford 2-(3-(3-(1- (2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)- N,N-dimethylacetamide (Example 57a, 35 mg). LCMS (ESI) Calcd. for C19H17ClF3N5O2: 439.1, found [M+H]+ = 440.1.1H NMR (400 MHz, DMSO-d6) δH 7.65-7.61 (m, 1H), 7.51-7.48 (dd, 1H), 7.34-7.08 (m, 3H), 5.44 (s, 2H), 3.05 (s, 3H), 2.86 (s, 3H), 1.73-1.70 (m, 2H), 1.49-1.46(m, 2H). Note: Example 57b was isolated as other regio-isomer. [0854] Examples 58-64 were synthesized in a manner similar to Example 57 from the corresponding pyrazole carboxylic acid. Example 58: Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-(2- (methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Examples 58) [0855] 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-(2- (methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole was synthesized following Scheme 45 using 1-bromo-2-(methylsulfonyl)ethane. LCMS (ESI) Calcd. for C18H16ClF3N4O3S: 460.1, found [M+H]+ = 461.0.1H NMR (400 MHz, DMSO-d6) δH 7.65-7.61 (m, 1H), 7.55-7.42 (m, 2H), 7.32 (s, 1H), 7.29-7.23 (m, 1H), 4.78-4.74 (m, 2H), 3.82-3.78 (m, 2H), 3.06 (s, 3H), 1.71 (s, 2H), 1.48 (s, 2H). Examples 59 & 60: Synthesis of (S)-2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)propanamide, (Example 59) and (R)-2-(3-(3- (1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1- yl)propenamide (Example 60) [0856] (S)-2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)propenamide and (R)-2-(3-(3-(1-(2-chloro-4- fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)propenamide were synthesized following Scheme 45 using 2-bromopropanamide. The absolute stereochemistries were not determined and was arbitrarily assigned. [0857] (S)-2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)propanamide, Example 59 (Peak 1): LCMS (ESI) Calcd. for C18H15ClF3N5O2: 425.7, found [M+H]+ = 426.2.1H NMR (400 MHz, DMSO-d6): δH 7.63-7.25 (m, 7H), 5.26 (s, 1H), 1.73 (d, 5H), 1.47 (s, 2H). [0858] (R)-2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)propenamide, Example 60 (Peak 2): LCMS (ESI) Calcd. for C18H15ClF3N5O2: 425.7, found [M+H]+ = 426.2.1H NMR (400 MHz, DMSO-d6): δH 7.65-7.61 (m, 1H), 7.50-7.25 (m, 6H), 5.26 (d, 1H), 1.73 (d, 5H), 1.47 (s, 2H). [0859] Chiral Prep HPLC method: HPLC SFC prep purification was performed on Pic Solution 175 instrument equipped with Knauer UV Detector 40D by using Chiralcel-OX-H (21.0 mm x 250 mm), 5µ Column operating at 35 ºC temperature, maintaining flow rate of 70 ml/min, using 80% CO2 in super critical state & 20% of 100% methanol as mobile phase. Run this isocratic mixture up to 10 minutes and also maintained the isobaric condition of 100 bar at 254 nm wavelength. Example 61: Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-(3- (methylsulfonyl)propyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 61) [0860] 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-(3- (methylsulfonyl)propyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 61)was synthesized following Scheme 45 using 1-bromo-3-(methylsulfonyl)propane. LCMS (ESI) Calcd. for C19H18ClF3N4O3S: 474.1, found [M+H]+ = 475.1.1H NMR (400 MHz, DMSO-d6): δH 7.64-7.61 (m, 1H), 7.53-7.48 (m, 1H), 7.40-7.23 (m, 3H), 4.49-4.45 (t, 2H), 3.20- 3.17 (t, 2H), 2.99 (s, 3H), 2.33-2.22 (m, 2H), 1.72 (brs, 2H), 1.47 (brs, 2H). Example 62: Synthesis of 3-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)thietane 1,1-dioxide (Example 62) [0861] 3-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)thietane 1,1-dioxide (Example 62) was synthesized following Scheme 45 using 3-bromothietane 1,1-dioxide. LCMS (ESI) Calcd for C18H14ClF3N4O3S: 458.0, found [M+H]+ = 459.0.1H NMR (400 MHz, DMSO-d6): δH 7.65-7.61 (m, 1H), 7.53-7.24 (m, 4H), 5.65-5.61 (m,1H), 4.84-4.82 (m, 4H), 1.73 (s, 2H), 1.48 (s, 2H). Example 63: Synthesis of 3-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)propenamide (Example 63) [0862] 3-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)propenamide (Example 63) was synthesized following Scheme 45 using 3- bromopropanamide. LCMS (ESI) Calcd for C18H15ClF3N5O2: 425.7; found [M+H]+ = 426.3.1H NMR (400 MHz, DMSO-d6): δH 7.64-7.60 (m, 1H), 7.56-7.24 (m, 5H), 6.97 (brs, 1H), 4.48 (t, 2H), 2.73 (t, 2H), 1.72-1.70 (m, 2H), 1.48-1.45 (m, 2H). Example 64: Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)acetamide (Example 64) [0863] 2-(5-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-3-(difluoromethyl)- 1H-pyrazol-1-yl)acetamide (Example 64) was synthesized following Scheme 45 using 3-2- bromoacetamide. LCMS (ESI) Calcd. for C17H13ClF3N5O2: 411.1, found [M+H]+ = 412.0.1H NMR (400 MHz, DMSO-d6): δH 7.71 (s, 1H), 7.64-7.60 (m, 1H), 7.51-7.49 (dd, 1H), 7.42 (s, 1H), 7.34(s, 1H), 7.26-6.97 (m, 2H), 5.25 (s, 2H), 1.74-1.72 (m, 2H), 1.50-1.47 (m, 2H). Example 65: Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol- 5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)-N-phenylacetamide (Example 65)
Figure imgf000227_0001
[0864] Synthesis of tert-butyl 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5- yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)acetate, 100 [step 1]: tert-Butyl 2-(3-(3-(1-(2-chloro-4- fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)99-5-(difluoromethyl)-1H-pyrazol-1-yl)acetate was synthesized following Scheme 45 using tert-butyl 2-bromoacetate. LCMS (ESI) Calcd. for C21H20ClF3N4O3: 468.1, found [M+H]+ = 469.2.1H NMR (400 MHz, DMSO-d6): δH 7.65-7.61 (m, 1H), 7.51-7.48 (m, 1H), 7.46-7.19 (m, 3H) 5.26 (s, 2H), 1.74-1.71 (m, 2H), 1.49-1.46 (m, 2H), 1.40 (s, 9H). [0865] Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)acetic acid, Example 109 [Step 2]: To a stirred solution of tert- butyl 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)acetate (100, 100 mg, 0.2 mmol) in dichloromethane (2 mL), trifluoroacetic acid (16 equiv.0.3 mL, 3.2 mmol) was added at 0 °C. The reaction mixture was stirred at ambient temperature for 6 h and the volatiles were removed under reduced pressure and purified by reverse phase prep-HPLC to afford 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)acetic acid (Example 109, 23 mg). Structure was confirmed by NOE experiment. LCMS (ESI) Calcd for C17H12ClF3N4O3: 412.1, found [M+H]+ = 413.0.1HNMR (400 MHz, DMSO-d6) δH 7.65-7.61 (m, 1H), 7.50-7.47 (dd, 1H), 7.27-7.10 (m, 3H), 4.79 (s, 2H), 1.77-1.74 (m, 2H), 1.47-1.44 (m, 2H). [0866] Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)-N-phenylacetamide, Example 65: [Step 3]: To a stirred solution of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H- pyrazol-1-yl)acetic acid (Example 109, 70 mg, 0.2 mmol) in dichloromethane ( 2 mL), aniline (0.023 mL, 0.3 mmol ) and DIPEA ( 0.089 mL, 0.5 mmol) were added followed by addition of T3P (50% in ethyl acetate) (3 equiv.). Resulting reaction mixture was stirred for 16 h at ambient temperature, diluted with dichloromethane and washed with water. Combined organic extracts were dried over anhydrous Na2SO4, filtered, concentrated under reduced pressure. The product was purified by reverse phase preparative HPLC to afford 2-(3-(3-(1-(2-chloro-4- fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)-N- phenylacetamide (Example 65, 40 mg ). LCMS (ESI) Calcd for C23H17ClF3N5O2: 487.1, found [M-H]-: 486.2.1H NMR (400 MHz, DMSO-d6,100 °C): δH 10.13 (s, 1H), 7.64-7.60 (t, 1H), 7.55 (d, 2H), 7.42-16 (m, 6H), 7.11-7.09 (m, 1H), 5.29 (s, 2H), 1.75 (brs, 2H), 1.47 (brs, 2H). [0867] Examples 66-92 were synthesized in a manner similar to Example 65. Example 66: Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-N-(2,2,2 trifluoroethyl)acetamide (Example 66) [0868] 2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-N-(2,2,2-trifluoroethyl)acetamid (Example 66) was synthesized following Scheme 46 using 2,2,2-trifluoroethan-1-amine. LCMS Calcd. for C19H14ClF6N5O2:493.7, found [M+H]+ = 494.1HNMR (400 MHz, DMSO-d6): δH 9.03-8.99 (m, 1H), 7.64-7.61 (m, 1H),7.51-7.48 (m, 1H),7.33-7.15(m, 3H), 5.21 (s, 2H), 4.02-3.92 (brs, 2H), 1.73-1.70 (brs, 2H), 1.49-1.46 (brs, 2H). Example 67: Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-N-(2-hydroxyethyl)acetamide (Example 67) [0869] 2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-N-(2-hydroxyethyl)acetamide (Example 67) was synthesized following Scheme 46 using 2-aminoethan-1-ol. LCMS (ESI) Calcd for C19H17ClF3N5O3: 455.1, found [M+H]+ = 456.1.1H NMR (400 MHz, DMSO-d6 at 100 °C): δH 8.01 (brs, 1H), 7.62 (t, 1H), 7.39 (d, 1H), 7.23-7.19 (m, 2H), 5.07 (s, 2H), 4.39 (brs, 1H), 3.48-3.46 (m, 2H), 3.21 (q, 2H), 1.75 (s, 2H), 1.47-1.45 (m, 2H). Example 68: Synthesis of N-(2-amino-2-oxoethyl)-2-(3-(3-(1-(2-chloro-4- fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)acetamide (Example 68) [0870] N-(2-Amino-2-oxoethyl)-2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol- 5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)acetamide (Example 68) was synthesized following Scheme 46 using 2-aminoacetamide. LCMS (ESI) Calcd for C19H16ClF3N6O3: 468.1, found [M+H]+ = 469.1.1H NMR (400 MHz, DMSO-d6 at 100 °C): δH 8.24 (s, 1H), 7.64-7.60 (t, 1H), 7.39 (d, 1H), 7.24-6.96 (m, 5H), 5.16 (s, 2H), 3.73-3.72 (brs, 2H), 1.75 (s, 2H), 1.47 (s, 2H). Example 69: Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-N-(2-hydroxyethyl)-N-methylacetamide (Example 69) [0871] 2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-N-(2-hydroxyethyl)-N-methylacetamide (Example 69) was synthesized following Scheme 46 using 2-(methylamino)ethan-1-ol. LCMS (ESI) Calcd for C20H19ClF3N5O3: 469.1, found [M+H]+ = 470.1.1H NMR (400 MHz, DMSO-d6): δH 7.62 (d, 1H), 7.46 (d, 1H), 7.24- 7.19 (m, 3H), 5.50 (s, 2H), 5.38 (s, 1H), 3.65 (d, 1H), 3.48-3.40 (m, 2H), 3.35-3.21 (m, 1H), 3.05 (s, 1H), 2.83 (s, 2H), 1.79 (t, 2H), 1.46 (t, 2H). Example 70: Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-N-(2-(dimethylamino)ethyl)acetamide (Example 70) [0872] 2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-N-(2-(dimethylamino)ethyl)acetamide Example 70 was synthesized following Scheme 46 using N1,N1-dimethylethane-1,2-diamine. LCMS (ESI) Calcd. for C21H22ClF3N6O2: 482.1, found [M+H]+ = 483.1.1HNMR (400 MHz, DMSO-d6 at 100 °C): δH 7.88 (s, 1H), 7.64-7.60 (t, 1H), 7.39-7.10 (m, 4H), 5.06 (s, 2H), 3.22-3.19 (brs, 2H), 2.37-2.34 (brs, 2H), 2.18 (s, 6H), 1.75 (s, 2H), 1.47 (s, 2H). Example 71: Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-N-(2-methoxyethyl)acetamide (Example 71) [0873] 2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-N-(2-methoxyethyl)acetamide (Example 71) was synthesized following Scheme 3 using 2-methoxyethan-1-amine. LCMS (ESI) Calcd for C20H19ClF3N5O3: 469.1, found [M+H]+ = 470.1.1H NMR (400 MHz, DMSO-d6): δH 8.43 (t, 1H), 7.62 (q, 1H), 7.49 (dd, 1H), 7.41-7.14 (m, 3H), 5.10 (s, 2H), 3.38-3.24 (m, 7H), 1.73-1.70 (m, 2H), 1.48-1.46 (m, 2H). Example 72: Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (Example 72) [0874] 2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-N-methyl-N-(2,2,2-trifluoroethyl)acetamide (Example 72) was synthesized following Scheme 46 using 2,2,2-trifluoro-N-methylethan-1-amine. LCMS (ESI) Calcd. for C20H16ClF6N5O2: 507.1, found [M+H]+ = 508.1.1H NMR (400 MHz, DMSO-d6 at 100 °C): δH 7.64- 7.60 (t, 1H), 7.40 (d, 1H), 7.31-7.04 (m, 3H), 5.53 (s, 2H), 4.18 (s, 2H), 3.20 (s, 3H), 1.75 (s, 2H), 1.47 (s, 2H). Example 73: Synthesis of (R)-2-(2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)acetamido)propenamide (Example 73) [0875] (R)-2-(2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)acetamido)propanamide (Example 73) was synthesized following Scheme 46 using (R)-2-aminopropanamide. LCMS (ESI) Calcd for C20H18ClF3N6O3: 482.1, found [M+H]+ = 483.0.1H NMR (400 MHz, DMSO-d6 at 100 °C): δH 8.20 (s, 1H), 7.63- 7.62 (t, 1H), 7.40-7.37 (m, 1H), 7.22-6.93 (m, 5H), 5.14 (s, 2H), 4.27(s, 1H), 1.75 (s, 2H), 1.47 (s, 2H), 1.27 (d, 3H). Example 74: Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-N-(2-(dimethylamino)ethyl)-N-methylacetamide (Example 74) [0876] 2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-N-(2-(dimethylamino)ethyl)-N-methylacetamide (Example 74) was synthesized following Scheme 46 using N1,N1,N2-trimethylethane-1,2-diamine. LCMS (ESI) Calcd for C22H24ClF3N6O2: 496.1, found [M+H]+ = 497.1.1H NMR (400 MHz, DMSO-d6): δH 7.61 (t, 1H), 7.39-7.37 (m, 1H), 7.28-7.01 (m, 3H), 3.48-3.43 (m, 2H), 2.44 (brs, 1H), 2.21 (brs, 5H), 1.92 (s, 3H), 1.78-1.74 (m, 2H), 1.47-1.45 (m, 2H). Example 75: Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-N-(2-methoxyethyl)-N-methylacetamide (Example 75) [0877] 2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-N-(2-methoxyethyl)-N-methylacetamide (Example 75) was synthesized following Scheme 46 using 2-methoxy-N-methylethan-1-amine. LCMS (ESI) Calcd for C21H21ClF3N5O3: 483.2, found [M+H]+ = 484.1.1H NMR (400 MHz, DMSO-d6 at 100 °C): δH 7.63- 7.60 (m, 1H), 7.37 (dd, 1H), 7.27-7.00 (m, 3H), 5.40 (s, 2H), 3.53 (brs, 4H), 3.31 (brs, 3H), 3.04- 2.93 (m, 2H), 1.83-1.70 (m, 2H), 1.52-1.45 (m, 2H). Example 76: Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-N-(2-hydroxy-2-methylpropyl)acetamide (Example 76) [0878] 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-N-(2-hydroxy-2-methylpropyl)acetamide (Example 76) was synthesized following Scheme 46 using 1-amino-2-methylpropan-2-ol. LCMS (ESI) Calcd for C21H21ClF3N5O3: 483.1, found [M+H]+ = 484.1.1H NMR (400 MHz, DMSO-d6): δH 7.82 (brs, 1H),7.63-7.60 (m, 1H), 7.39-7.36 (m, 1H), 7.23-7.09 (m, 3H), 5.13 (s, 2H), 4.10 (s, 1H), 3.11 - 3.10 (brs, 2H), 1.77-1.75 (brs, 2H), 1.48-1.45 (brs, 2H), 1.10 (s, 6H). Example 77: Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-N-((1-methylpiperidin-4-yl)methyl)acetamide (Example 77) [0879] 2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-N-((1-methylpiperidin-4-yl)methyl)acetamide (Example 77) was synthesized following Scheme 46 using (1-methylpiperidin-4-yl)methanamine. LCMS (ESI) Calcd for C24H26ClF3N6O2: 522.1, found [M+H]+ = 523.1.1HNMR (400 MHz, DMSO-d6 at 100 °C): δH 7.97 (brs, 1H), 7.63-7.60 (t, 1H), 7.39-7.09 (m, 4H), 5.06 (s, 2H), 3.04-3.01 (m, 2H), 2.73-2.67 (m, 2H), 2.15 (s, 3H), 1.88-1.82 (t, 2H), 1.76-1.75 (brs, 2H), 1.63-1.59 (m, 2H), 1.52-1.47 (brs, 2H), 1.43-1.38 (brs, 1H), 1.28-1.14 (m, 2H). Example 78: Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-N-(1-cyanocyclopropyl)acetamide (Example 78) [0880] 2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-N-(1-cyanocyclopropyl)acetamide (Example 78) was synthesized following Scheme 46 using 1-aminocyclopropane-1-carbonitrile. LCMS (ESI) Calcd for C21H16ClF3N6O2: 476.1, found [M+H]+ = 477.2.1H NMR (400 MHz, DMSO-d6): δH 9.27 (s, 1H), 7.65-7.61 (m, 1H), 7.50-7.48 (m, 1H), 7.40-7.14 (m, 3H), 5.12 (s, 2H), 1.73-1.71 (m, 2H),1.52-1.46 (m, 4H), 1.18- 1.14 (m, 2H). Example 79: Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-N-(2-(methylamino)-2-oxoethyl)acetamide (Example 79) [0881] 2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-N-(2-(methylamino)-2-oxoethyl)acetamide (Example 79) was synthesized following Scheme 46 using 2-amino-N-methylacetamide. LCMS (ESI) Calcd. for C20H18ClF3N6O2: 482.1, found [M-H]- = 481.2.1H NMR (400 MHz, DMSO-d6): δH 8.61 (t, 1H), 7.86 (d, 1H), 7.64-7.60 (m, 1H), 7.50-7.47 (m, 1H), 7.31-7.14 (m, 3H), 5.17 (s, 2H), 3.72 (d, 2H), 2.60 (d, 3H), 1.71 (s, 2H), 1.47 (s, 2H). Example 80: Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-N-(cyclopropylmethyl)acetamide (Example 80) [0882] 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-N-(cyclopropylmethyl)acetamide (Example 80) was synthesized following Scheme 46 using cyclopropylmethanamine. LCMS (ESI) Calcd. For C21H19ClF3N5O2: 465.2, found [M+H]+ = 466.2.1H NMR (400 MHz, DMSO-d6): δH 8.42 (t, 1H), 7.64 (t, 1H), 7.50-7.48 (m, 1H), 7.41-7.14 (m, 3H), 5.08 (s, 2H), 2.99 (t, 2H), 1.71 (s, 2H), 1.47 (s, 2H), 0.90 (s, 1H), 0.43 (d, 2H), 0.17 (d, 2H). Example 81: Synthesis of N-(2-amino-2-oxoethyl)-2-(3-(3-(1-(2-chloro-4- fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)-N- methylacetamide (Example 81) [0883] N-(2-Amino-2-oxoethyl)-2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol- 5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)-N-methylacetamide (Example 81) was synthesized following Scheme 46 using 2-(methylamino)acetamide. LCMS (ESI) Calcd. for C20H18ClF3N6O3: 482.1, found [M+H]+ = 483.0.1H NMR (400 MHz, DMSO-d6 at 100 °C): δH 7.63-7.60 (m, 1H), 7.40-7.37 (m, 1H), 7.27-7.0 (m, 5H), 5.43 (brs, 2H), 4.04-3.91 (m, 2H), 3.09 (brs, 2H), 2.86 (brs, 1H), 1.76-1.73 (m, 2H), 1.48-1.45 (m, 2H). Example 82: Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-N-(cyclobutylmethyl)acetamide (Example 82) [0884] 2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-N-(cyclobutylmethyl)acetamide was synthesized following Scheme 46 using cyclobutylmethanamine. LCMS (ESI) Calcd. for C22H21ClF3N5O2: 479.1, found [M+H]+ = 480.1. 1H NMR (400 MHz, DMSO-d6 at 100 °C): δH 7.93 (brs, 1H), 7.63-7.59 (m, 1H), 7.39-7.36 (m, 1H), 7.22-7.09 (m, 3H), 5.05 (s, 2H), 3.18-3.15 (m, 2H), 2.44-2.41 (m, 1H), 2.04-1.97 (m, 2H), 1.85-1.66 (m, 6H), 1.47-1.45 (m, 2H). Example 83: Synthesis of (S)-2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5- yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)-1-(3-methoxypyrrolidin-1-yl)ethan-1-one (Example 83) [0885] (S)-2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)-1-(3-methoxypyrrolidin-1-yl)ethan-1-one (Example 83) was synthesized following Scheme 46 using (S)-3-methoxypyrrolidine. LCMS (ESI) Calcd. for C22H21ClF3N5O3: 495.1, found [M+H]+ = 496.1.1H NMR (400 MHz, DMSO-d6): δH 7.64-7.60 (t, 1H), 7.39 (d, 1H), 7.33-7.06 (m, 3H), 5.36-5.28 (brs, 2H), 4.09-3.99 (m, 1H), 3.67-3.58 (m, 2H), 3.44 (s, 2H), 3.35-3.27 (m, 3H), 2.07 (s, 1H),1.95 (s, 1H), 1.75 (s, 2H), 1.47-1.45 (brs, 2H). Example 84: Synthesis of (R)-2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5- yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)-1-(3-methoxypyrrolidin-1-yl)ethan-1-one (Example 84) [0886] (R)-2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)-1-(3-methoxypyrrolidin-1-yl)ethan-1-one (Example 84) was synthesized following Scheme 46 using (R)-3-methoxypyrrolidine. LCMS (ESI) Calcd. for C22H21ClF3N5O3: 495.2, found [M+H]+ = 496.2.1H NMR (400 MHz, DMSO-d6 at 100 °C): δH 7.63-7.59 (m, 1H), 7.39-7.32 (m, 1H), 7.22-7.06 (m, 3H), 5.36-5.28 (m, 2H), 4.09-3.99 (m, 1H), 3.66-3.59 (m, 2H), 3.43-3.36 (m, 2H), 3.30-3.27 (m, 3H), 2.06-1.94 (m, 2H), 1.76-1.73 (m, 2H), 1.48-1.45 (m, 2H). Example 85: Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-1-(3-methoxyazetidin-1-yl)ethan-1-one (Example 85) [0887] 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-1-(3-methoxyazetidin-1-yl)ethan-1-one (Example 85) was synthesized following Scheme 46 using 3-methoxyazetidine. LCMS (ESI) Calcd. for C21H19ClF3N5O3: 481.8, found [M+H]+ = 482.2.1H NMR (400 MHz, DMSO-d6 at 100 °C): δH 7.62 (t, 1H), 7.40 (d, 1H), 7.35- 7.08 (m, 3H), 5.16 (s, 2H), 4.39-4.28 (m, 3H), 4.09 (brs, 1H), 3.76 (brs, 1H), 3.26 (s, 3H), 1.74 (s, 2H), 1.47 (s, 2H). Example 86: Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-1-(3,3-difluoropyrrolidin-1-yl)ethan-1-one (Example 86) [0888] 2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-1-(3,3-difluoropyrrolidin-1-yl)ethan-1-one (Example 86) was synthesized following Scheme 46 using 3,3-difluoropyrrolidine. LCMS (ESI) Calcd. for C21H17ClF5N5O2: 501.8, found [M+H]+ = 502.4.1H NMR (400 MHz, DMSO-d6 at 100 °C): δH 7.62 (t, 1H), 7.39 (d, 1H), 7.32-7.06 (m, 3H), 5.36 (s, 2H), 4.07-3.62 (m, 4H), 2.32 (brs, 1H), 1.75-1.69 (m, 2H), 1.52- 1.47 (m, 2H). Example 87: Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-1-(pyrrolidin-1-yl)ethan-1-one (Example 87) [0889] 2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-1-(pyrrolidin-1-yl)ethan-1-one (Example 87) was synthesized following Scheme 46 using pyrrolidine. LCMS (ESI) Calcd. for C21H19ClF3N5O2: 465.1, found [M+H]+ = 466.1.1H NMR (400 MHz, DMSO-d6): δH 7.65-7.61 (m, 1H), 7.51-7.48 (m, 1H), 7.36-7.09 (m, 3H), 5.35 (s, 2H), 3.54-3.51 (m, 2H), 3.31 (d, 2H), 1.96-1.90 (m, 2H), 1.83-1.76 (m, 2H), 1.71 (s, 2H), 1.47 (s, 2H). Example 88: Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-1-(3,3-difluoroazetidin-1-yl)ethan-1-one (Example 88) [0890] 2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-1-(3,3-difluoroazetidin-1-yl)ethan-1-one (Example 88) was synthesized following Scheme 46 using 3,3-difluoroazetidine. LCMS (ESI) Calcd. for C20H15ClF5N5O2: 487.1, found [M+H]+ = 488.0.1H NMR (400 MHz, DMSO-d6): δH 7.65-7.61 (m, 1H), 7.51-7.48 (m, 1H), 7.38-7.11 (m, 3H), 5.33 (s, 2H), 4.78-4.72 (m, 2H), 4.42-4.36 (m, 2H), 1.71 (s, 2H), 1.47 (brs, 2H). Example 89: Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-N-(2-hydroxy-2-methylpropyl)-N-methylacetamide (Example 89) [0891] 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-N-(2-hydroxy-2-methylpropyl)-N-methylacetamide (Example 89) was synthesized following Scheme 46 using 2-methyl-1-(methylamino)propan-2-ol. LCMS (ESI) Calcd. for C22H23ClF3N5O3: 497.1, found [M+H]+ = 498.1.1H NMR (400 MHz, DMSO-d6): δH 7.63-7.60 (t, 1H), 7.38 (d, 1H), 7.27-7.00 (m, 3H), 5.46 (s, 2H), 4.55-4.16 (brs, 1H), 3.34 (s, 2H), 3.17 (brs, 3H), 1.75 (s, 2H), 1.47 (s, 2H), 1.12 (s, 6H). Examples 90 & 91: Synthesis of (S)-2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)-N-(tetrahydrofuran-3-yl)acetamide (Example 90) & (R)-2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)-N-(tetrahydrofuran-3-yl)acetamide (Example 91) [0892] (S)-2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)-N-(tetrahydrofuran-3-yl)acetamide (Example 90) and (R)-2-(3- (3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol- 1-yl)-N-(tetrahydrofuran-3-yl)acetamide (Example 91) were synthesized following Scheme 46 using tetrahydrofuran-3-amine. The absolute stereochemistries were assigned by matching the chiral HPLC SFC data of both peaks with the compound synthesized using chiral amine (S- isomer) with known absolute stereochemistry. [0893] (S)-2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)-N-(tetrahydrofuran-3-yl)acetamide (Example 90) (Peak 1): 1H NMR (400 MHz, DMSO-d6): δH 8.63 (d, 1H), 7.64-7.61 (m, 1H), 7.49 (dd, 1H), 7.31 (s, 1H), 7.27-7.23 (m, 2H), 5.08 (s, 2H), 4.24 (brs, 1H), 3.81-3.67 (m, 3H), 3.51-3.47 (m, 1H), 2.13-2.08 (m, 1H), 1.73 (d, 3H), 1.47 (s, 2H). LCMS (ESI) Calcd for C21H19ClF3N5O3: 481.8, found [M+H]+ = 482.1. [0894] (R)-2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)-N-(tetrahydrofuran-3-yl)acetamide (Example 91) (Peak 2): LCMS (ESI) Calcd. for C21H19ClF3N5O3: 481.8, found [M+H]+ = 482.1.1H NMR (400 MHz, DMSO-d6): δH 8.63 (d, 1H), 7.64-7.61 (m, 1H), 7.49 (dd, 1H), 7.41-7.14 (m, 3H), 5.08 (s, 2H), 4.24 (brs, 1H), 3.81-3.67 (m, 3H), 3.51-3.47 (m, 1H), 2.13-2.08 (m, 1H), 1.73 (d, 3H), 1.47 (s, 2H). [0895] Preparative chiral HPLC method: SFC preparative purification was performed on Pic Solution 175 instrument equipped with Knauer UV Detector 40D by using C Amylose A (30.0 mm x 250mm ), 5µ Column operating at 35 ºC temperature, maintaining flow rate of 110 ml/min, using 75 % CO2 in super critical state & 25% of methanol as mobile phase, Run this isocratic mixture up to 14.0 minutes and also maintained the isobaric condition of 100 bar at 254 nm wavelength. Example 92: Synthesis of (S)-2-(2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)acetamido)propenamide (Example 92) [0896] (S)-2-(2-(3-(3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)acetamido) propanamide (Example 92) was synthesized following Scheme 46 using 2-aminopropanamide. LCMS (ESI) Calcd for C20H18ClF3N6O3: 482.1, found [M+H]+ = 483.1.1H NMR (400 MHz, DMSO-d6): δH 8.53 (d, 1H), 7.65-7.61 (t, 1H), 7.51- 7.50 (m,1H), 7.48 (s, 1H), 7.43-7.13 (m, 3H), 7.06 (s, 1H), 5.21-5.11 (m, 2H), 4.24-4.21 (m, 1H), 1.72 (s, 2H), 1.47 (brs, 2H), 1.24-1.22(m, 3H). [0897] Preparative chiral HPLC method: SFC preaparative purification was performed on Pic Solution 175 instrument equipped with Knauer UV Detector 40D by using I Cullulose J (30.0 mm x 250 mm), 5 min column operating at 35 °C temperature, maintaining flow rate of 90 mL/min, using 85% CO2 in super critical state and 15% of MeOH mobile phase. Run this isocratic mixture up to 14 min and also maintained the isobaric condition of 100 bar at 220 nm. Note: Reaction with (2R)-2-aminopropanamide was performed to obtain (R)-2-(2-(3-(3-(1- (2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1- yl)acetamido)propenamide (Example 92) with known absolute configuration. After comparing the chiral HPLC of both isomers (Peak 1 & Peak 2) with this R-isomer, it is confirmed that Peak 1 is R-isomer and Peak 2 is S-isomer. Example 93: Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-N-(piperidin-4-ylmethyl)acetamide (Example 93)
Figure imgf000236_0001
Scheme 47 [0898] Synthesis of tert-butyl 4-((2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)acetamido)methyl)piperidine-1-carboxylate, 101 [Step 1]: tert-Butyl 4-((2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)acetamido)methyl)piperidine-1-carboxylate 101 was synthesized following Scheme 46 using tert-butyl 4-(aminomethyl)piperidine-1-carboxylate. LCMS (ESI) Calcd. for C28H32ClF3N6O4: 608.2, found [M+H]+ = 609.1. [0899] Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)-N-(piperidin-4-ylmethyl)acetamide, Example 93 [Step 2]: To a stirred solution of tert-butyl 4-((2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol- 5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)acetamido)methyl)piperidine-1-carboxylate (101, 150 mg, 0.2 mmol) in dichloromethane (4 mL), HCl (2.0 mL, 4M in Dioxane) was added dropwise at 0 °C and stirred at ambient temperature for 2h. After completion, the reaction mixture was concentrated under reduced pressure. The product was purified by reverse phase prep-HPLC to afford 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-N-(piperidin-4-ylmethyl)acetamide (Example 93, 80 mg). LCMS (ESI) Calcd. for C23H24ClF3N6O2: 508.1, found [M+H]+ = 509.4.1H NMR (400 MHz, DMSO-d6): δH 8.28 (s, 1H), 7.65-7.61 (m, 1H), 7.51-7.48 (m, 1H), 7.41-7.14 (m, 4H), 5.08 (s, 2H), 2.97-2.94 (m, 2H), 2.91- 2.88 (m, 2H), 2.41-2.35 (m, 2H), 1.71 (s, 2H), 1.56-1.47 (m, 5H), 1.00-0.95 (m, 2H). Example 94: Synthesis of (2-(3-(3-(1-(2-chloro-4-fluorophenyl) cyclopropyl)-1,2,4-oxadiazol-5- yl)-5-(difluoromethyl)-1H-pyrazol-1-yl) acetyl) glycine (Example 94)
Figure imgf000237_0001
Scheme 48 [0900] Synthesis of tert-butyl (2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol- 5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)acetyl)glycinate, 102 [Step 1]: tert-Butyl (2-(3-(3-(1-(2- chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1- yl)acetyl)glycinate 102 was synthesized following Scheme 46 using tert-butyl glycinate. The product was carried to next step without further purification. LCMS (ESI) Calcd. for C23H23ClF3N5O4: 525.1, found [M+H] + = 526.4. [0901] Synthesis of (2-(3-(3-(1-(2-chloro-4-fluorophenyl) cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl) acetyl) glycine, Example 94 [Step 2]: To a stirred solution of tert-butyl (2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)acetyl)glycinate (102, 170 mg, 0.3 mmol) in dichloromethane (4 mL), trifluoroacetic acid (0.3 mL, 3.9 mmol) was added dropwise at 0 °C and stirred at ambient temperature for 2h. After completion, the reaction mixture was concentrated under reduced pressure. The product was purified by reverse phase preparative HPLC to afford (2-(3-(3-(1-(2- chloro-4-fluorophenyl) cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl) acetyl) glycine (Example 94, 20 mg). LCMS (ESI) Calcd. for C19H15ClF3N5O4: 469.1, found [M+H]+ = 470.0.1H NMR (400 MHz, DMSO-d6): δH 8.59 (s, 1H), 7.63 (t, 1H), 7.49 (d, 1H), 7.41-7.14 (m, 3H), 5.17 (s, 2H), 3.78 (s, 2H), 1.71 (s, 2H), 1.47(s, 2H). Example 95: Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-1-(piperazin-1-yl)ethan-1-one (Example 95)
Figure imgf000238_0001
Scheme 49 [0902] Synthesis of tert-butyl 4-(2-(5-(difluoromethyl)-3-(ethoxycarbonyl)-1H-pyrazol-1- yl)acetyl)piperazine-1-carboxylate, 104 [Step 1]: tert-Butyl 4-(2-(5-(difluoromethyl)-3- (ethoxycarbonyl)-1H-pyrazol-1-yl)acetyl)piperazine-1-carboxylate was synthesized following Scheme 46 using tert-butyl piperazine-1-carboxylate. LCMS (ESI) Calcd. for C18H26F2N4O5: 416.2, found [M+H]+ = 417.1. [0903] Synthesis of tert-Butyl 4-(2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)acetyl)piperazine-1-carboxylate, 105 [Step 2]: To a stirred solution of tert-butyl 4-(2-(5-(difluoromethyl)-3-(ethoxycarbonyl)-1H-pyrazol-1- yl)acetyl)piperazine-1-carboxylate (55, 200 mg, 0.5 mmol) in toluene (5 mL), K2CO3 (172.5 mg, 1.2 mmol) and (Z)-1-(2-chloro-4-fluorophenyl)-N'-hydroxycyclopropane-1-carboximidamide (228.6 mg, 0.6 mmol) were added and the resulting reaction mixture was allowed to stir at 90 °C for 16 h. After completion, volatiles were evaporated under reduced pressure, diluted with ethyl acetate and washed with water (twice). The combined organic layer was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by column chromatography to afford tert-butyl 4-(2-(3-(3-(1-(2-chloro-4- fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1- yl)acetyl)piperazine-1-carboxylate (105, 140 mg). LCMS (ESI) Calcd. for C26H28ClF3N6O4: 580.2, found [M+H]+ = 581.4. [0904] Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)-1-(piperazin-1-yl)ethan-1-one, Example 95 [Step-3]: To a solution of tert-Butyl 4-(2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)acetyl)piperazine-1-carboxylate (105, 140 mg, 0.24 mmol) in dichloromethane (2 mL), 4M HCl in 1,4-dioxane (2 mL) was added at 0 °C and stirred for 2 h at ambient temperature. After completion, volatiles were evaporated under reduced pressure and the product was purified by reverse phase preparative HPLC to afford 2-(3-(3-(1-(2-chloro-4- fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)-1-(piperazin- 1-yl)ethan-1-one (Example 95, 65 mg). LCMS (ESI) Calcd. for C21H20ClF3N6O2: 480.1, found [M+H]+ = 481.1.1H NMR (400 MHz, DMSO-d6): δH 7.65-7.61 (m, 1H), 7.51-7.49 (m, 1H), 7.35- 7.08 (m, 3H), 5.45 (s, 2H), 3.40-3.31 (m, 4H), 2.74 (s, 2H), 2.65 (s, 2H), 1.71 (s, 2H), 1.47 (s, 2H). Example 96: Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-(piperazin-1-yl)ethan-1-one (Example 96)
Figure imgf000239_0001
Scheme 50 [0905] Synthesis of tert-butyl 4-(2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)acetyl)piperazine-1-carboxylate, 106 [Step 1]: tert-Butyl 4-(2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (trifluoromethyl)-1H-pyrazol-1-yl)acetyl)piperazine-1-carboxylate was synthesized following Scheme 49 using tert-butyl 4-(2-(3-(methoxycarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1- yl)acetyl)piperazine-1-carboxylate. LCMS (ESI) Calcd for C26H27ClF4N6O4: 598.1, found [M+H]+ = 599.3. [0906] Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (trifluoromethyl)-1H-pyrazol-1-yl)-1-(piperazin-1-yl)ethan-1-one, Example 96 [Step 2]: 2-(3-(3-(1- (2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)- 1-(piperazin-1-yl)ethan-1-one (Example 96) was synthesized following Scheme 49 using tert- Butyl 4-(2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(trifluoromethyl)- 1H-pyrazol-1-yl)acetyl)piperazine-1-carboxylate. LCMS (ESI) Calcd for C21H19ClF4N6O2: 498.1, found [M+H]+ = 499.2.1H NMR (400 MHz, DMSO-d6 at 100 °C): δH 7.64-7.60 (t, 1H), 7.53 (s, 1H), 7.39 (d, 1H), 7.23-7.19 (t, 1H), 5.43 (s,2H), 3.42(s, 4H), 2.73 -2.64 (brs,4H), 1.76 (s, 2H), 1.48-1.47 (brs,2H). Examples 97 & 98: Synthesis of (R)-2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)propanoic acid (Example 97) and (S)-2-(3-(3- (1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1- yl)propanoic acid (Example 98)
Figure imgf000240_0001
Scheme 51 [0907] Synthesis of tert-butyl 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5- yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)propanoate, 109 [Step 1]: tert-Butyl 2-(3-(3-(1-(2-chloro-4- fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)propanoate was synthesized following Scheme 45 using tert-butyl 2-bromopropanoate. LCMS (ESI) Calcd for C22H22ClF3N4O3: 482.8, found [M-H]- = 481.2. [0908] Synthesis of chiral tert-butyl 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)propanoate, 110 and 111(Step 2): Tert-butyl 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H- pyrazol-1-yl)propanoate (109, 130 mg) was used for SFC chiral separation to afford chiral tert- butyl 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)propanoate (60 mg) as peak-1 and chiral tert-butyl 2-(3-(3-(1-(2-chloro-4- fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)propanoate (60 mg) as peak 2. LCMS (ESI) Calcd for C22H22ClF3N4O3: 482.8, found [M-H]- = 481.2. The absolute stereochemistry was not determined and was arbitrarily assigned. [0909] Chiral HPLC method: SFC PREP PURIFICATION was performed on Pic Solution 175 instrument equipped with Knauer UV Detector 40D by using Chiralpak IG (30.0mm x 250mm ), 5µ Column operating at 35 °C temperature, maintaining flow rate of 70 ml/min ,using 60% CO2 in super critical state & 40% MeOH as mobile phase, Run this isocratic mixture up to 5.0 minutes and also maintained the isobaric condition of 100 bar at 249 nm wavelength. [0910] Synthesis of (R)-2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)propanoic acid, Example 97 (Step 3): To a stirred solution of tert-butyl (R)-2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)propanoate (111, 60 mg, 0.1 mmol) in dichloromethane (2 mL), trifluoroacetic acid (0.2 mL, 2.5 mmol) was added drop wise under cold condition and the reaction mixture was stirred at ambient temperature for 4 h. After completion, the volatiles were removed under reduced pressure. The product was purified by reverse phase prep HPLC and lyophilized to afford (R)-2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)propanoic acid (Example 97, 25 mg). LCMS (ESI) Calcd for C18H14ClF3N4O3: 426.7, found [M+H]+ = 427.2.1H NMR (400 MHz, DMSO-d6) δH 7.64-7.61 (m, 1H), 7.50-7.21 (m, 4H), 5.13 (t, 1H), 2.97 (s, 1H), 1.72 (s, 2H), 1.67 (d, 3H),1.46 (s, 2H). [0911] Synthesis of (S)-2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)propanoic acid, Example 98 (Step 4): To a stirred solution of tert-butyl (S)-2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)propanoate (110, 60 mg, 0.1 mmol) in dichloromethane (2 mL), trifluoroacetic acid (0.2 mL, 2.5 mmol) was added drop wise under cold condition and the reaction mixture was stirred at ambient temperature for 12h. After completion, the volatiles were removed under reduced pressure. The product was purified by reverse phase prep HPLC and lyophilized to afford (S)-2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)propanoic acid (Example 98, 35 mg). LCMS (ESI) Calcd for C18H14ClF3N4O3: 426.7, found [M+H]+ = 427.2.1H NMR (400 MHz, DMSO-d6): δH 7.64-7.61 (m, 1H), 7.50-7.21 (m, 4H), 5.13 (t, 1H), 2.97 (s, 1H), 1.72 (s, 2H), 1.67 (d, 3H), 1.46 (s, 2H). Example 99: Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(5-methyl-1-(2- (methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 99)
Figure imgf000241_0001
[0912] Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(5-methyl-1H-pyrazol-3-yl)- 1,2,4-oxadiazole, 113 [Step 1]: 3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-5-(5-methyl-1H- pyrazol-3-yl)-1,2,4-oxadiazole 113 was synthesized following Scheme 49 using methyl 5- methyl-1H-pyrazole-3-carboxylate. LCMS (ESI) Calcd. for C15H12ClFN4O: 318.7, found [M+H]+ = 319.3. 1H NMR (400 MHz, DMSO-d6): δH 13.44 (brs, 1H), 7.61 (t, 1H), 7.48 (d, 1H), 7.24 (t, 1H), 6.65 (s, 1H), 2.29 (s, 3H), 1.69 (s, 2H), 1.43 (s, 2H). [0913] Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(5-methyl-1-(2- (methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole, Example 99 [Step 2]: 3-(1-(2-Chloro-4- fluorophenyl)cyclopropyl)-5-(5-methyl-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-1,2,4- oxadiazole (Example 99) was synthesized following Scheme 45 using 1-bromo-2- (methylsulfonyl)ethane. LCMS (ESI) Calcd. for C18H18ClFN4O3S: 424.8; found [M+H]+ = 425.2. 1H NMR (400 MHz, DMSO-d6): δH 7.63-7.59 (m, 1H), 7.50-7.47 (m, 1H), 7.27-7.21 (m, 1H), 6.74 (s, 1H), 4.56 (t, 2H), 3.74 (t, 2H), 2.96 (s, 3H), 2.38 (s, 3H), 1.68 (s, 2H), 1.46 (s, 2H). Note: Structure of regio-isomer was confirmed by NOE. Example 100: Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(1-(2- (methylsulfonyl)ethyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 100)
Figure imgf000242_0001
[0914] Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(5-(trifluoromethyl)-1H-pyrazol- 3-yl)-1,2,4-oxadiazole, 115 [Step 1]: 3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-5-(5- (trifluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole 115 was synthesized following Scheme 49 using methyl 5-(trifluoromethyl)-1H-pyrazole-3-carboxylate. LCMS (ESI) Calcd for C15H9ClF4N4O: 372.7, found [M-H]- = 371.1. [0915] Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(1-(2-(methylsulfonyl)ethyl)-5- (trifluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole, Example 100 [Step 2]: 3-(1-(2-Chloro-4- fluorophenyl)cyclopropyl)-5-(1-(2-(methylsulfonyl)ethyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl)- 1,2,4-oxadiazole (Example 100) was synthesized following Scheme 45 using 1-bromo-2- (methylsulfonyl)ethane. LCMS (ESI) Calcd for C18H15ClF4N4O3S: 478.8; found [M+H]+ = 479.2. 1H NMR (400 MHz, DMSO-d6): δH 7.71 (s, 1H), 7.64-7.61 (m, 1H), 7.52-7.49 (m, 1H), 7.28-7.23 (s, 1H), 4.77 (t, 2H), 3.85 (t, 2H), 3.08 (s, 3H), 1.68 (s, 2H), 1.46 (s, 2H). Note: Structure was confirmed by HMBC & HSQC. Example 101: Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)-N-(oxetan-3-yl)acetamide (Example 101)
Figure imgf000243_0001
Scheme 54 [0916] Synthesis of ethyl 5-(difluoromethyl)-1-(2-(oxetan-3-ylamino)-2-oxoethyl)-1H-pyrazole-3- carboxylate, 116 (Step-1): Ethyl 5-(difluoromethyl)-1-(2-(oxetan-3-ylamino)-2-oxoethyl)-1H- pyrazole-3-carboxylate (116) was synthesized following Scheme 49 using oxetan-3-amine. LCMS (ESI) Calcd. for C12H15F2N3O4: 303.1, found [M+H]+ = 304.0. [0917] Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)-N-(oxetan-3-yl)acetamide, Example 101 [Step-2]: 2-(3-(3-(1- (2-Chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)- N-(oxetan-3-yl)acetamide (Example 101) was synthesized following Scheme 49. LCMS (ESI) Calcd. for C20H17ClF3N5O3: 467.1, found [M+H]+: 468.0.1H NMR (400 MHz, DMSO-d6): δH 9.13 (d, 1H), 7.64-7.61 (m, 1H), 7.51-7.48 (m, 1H), 7.32-7.14 (m, 3H), 5.12 (s, 2H), 4.79-4.70 (m, 3H), 4.45-4.41 (t, 2H), 1.72-1.70 (m, 2H), 1.49-1.46 (m, 2H). Example 102: Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(1-(2- (methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 102)
Figure imgf000244_0001
Scheme 55 [0918] Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(1H-pyrazol-3-yl)-1,2,4- oxadiazole, 118 [Step 1]: 3-(1-(2-Chloro-4-fluorophenyl)cyclopropyl)-5-(1H-pyrazol-3-yl)-1,2,4- oxadiazole (118) was synthesized following Scheme 49 using methyl 1H-pyrazole-3- carboxylate. LCMS (ESI) Calcd. for C14H10ClFN4O: 304.7, found [M+H]+ = 305.2.1H NMR (400 MHz, DMSO-d6): δH 13.76 (brs, 1H), 8.01 (s, 1H), 7.62 (t, 1H), 7.48 (d, 1H), 7.25 (t, 1H), 6.92 (s, 1H), 1.70 (s, 2H), 1.45 (s, 2H). [0919] Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(1-(2-(methylsulfonyl)ethyl)-1H- pyrazol-3-yl)-1,2,4-oxadiazole, Example 102 [Step 2]: 3-(1-(2-Chloro-4- fluorophenyl)cyclopropyl)-5-(1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 102) was synthesized following Scheme 45 using 1-bromo-2-(methylsulfonyl)ethane. LCMS (ESI) Calcd. for C17H16ClFN4O3S: 410.8; found [M+H]+ = 411.1.1H NMR (400 MHz, DMSO-d6): δH 8.09 (d, 1H), 7.63-7.60 (m, 1H), 7.50-7.47 (m, 1H), 7.27-7.22 (m, 1H), 6.95 (d, 1H), 4.70 (t, 2H), 3.77 (t, 2H), 2.96 (s, 3H), 1.71-1.69 (m, 2H), 1.46-1.44 (m, 2H). Note: Structure was confirmed by NOE. Examples 103a & 103b: Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(4- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 103a)
Figure imgf000244_0002
[0920] Synthesis of methyl 4-formyl-1-methyl-1H-pyrazole-3-carboxylate, 120 & 120a [Step 1]: To a solution of methyl 4-formyl-1H-pyrazole-3-carboxylate (119, 700 mg, 4.5 mmol) in DMF (5 mL), K2CO3 (1.2 g, 9.0 mmol) was added and the reaction mixture was stirred for 15 minutes under nitrogen atmosphere. Iodomethane (0.5 mL, 8 mmol) was added and the reaction mixture was stirred at ambient temperature for 12 h. Ethyl acetate was added to the reaction mixture and washed with ice cold water. The organic extract was washed with brine for several times, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford methyl 4-formyl-1-methyl-1H-pyrazole-3-carboxylate as mixture of regioisomer (120 & 120a, 500 mg). LCMS (ESI) Calcd. For C7H8N2O3: 168.1, found [M+H]+ = 169.2. [0921] Synthesis of methyl 4-(difluoromethyl)-1-methyl-1H-pyrazole-3-carboxylate, 86 [Step 2]: To a stirred solution of methyl 4-formyl-1-methyl-1H-pyrazole-3-carboxylate (along with other regioisomer) (120 & 120a, 350 mg, 2.0 mmol) in dichloromethane (5 mL), DAST (0.5 mL, 4.0 mmol) was added at 0 °C and stirred for 16 h. Dichloromethane was added to the reaction mixture and washed with water. Organic extracts were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford methyl 4-(difluoromethyl)-1- methyl-1H-pyrazole-3-carboxylate (along with other regioisomer) (86, 300 mg).1HNMR (400 MHz, DMSO-d6) δH 8.24 (s, 1H), 7.84 (s, 1H), 7.33-7.05 (m, 2H), 4.10-4.07 (m, 3H), 3.94-3.88 (m, 6H), 3.82-3.77 (m, 3H). Notes: Extra peak present in 1H NMR. [0922] Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(4-(difluoromethyl)-1-methyl- 1H-pyrazol-3-yl)-1,2,4-oxadiazole, Example 103a [Step 3]: 3-(1-(2-Chloro-4- fluorophenyl)cyclopropyl)-5-(4-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole was synthesized following Scheme 49 using methyl 4-(difluoromethyl)-1-methyl-1H-pyrazole-3- carboxylate (86). LCMS (ESI) Calcd. for C16H12ClF3N4O: 368.7, found [M+H]+ = 369.1.1H NMR (400 MHz, DMSO-d6): δH 8.39 (s, 1H), 7.62 (t, 1H), 7.49 (dd, 1H), 7.41-7.14 (m, 2H), 4.00 (s, 3H), 1.73 (s, 2H), 1.47 (s, 2H). Note: The exact structure of both the regioisomers was confirmed by NOE experiments. Example 104: Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(4,5-dimethyl-1- (2-(methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 104)
Figure imgf000245_0001
Scheme 57 [0923] Synthesis of (Z)-1-(2-chloro-4-fluorophenyl)-N'-((4,5-dimethyl-1H-pyrazole-3- carbonyl)oxy)cyclopropane-1-carboximidamide, 123 [Step-1]: To a stirred solution of 4,5- dimethyl-1H-pyrazole-3-carboxylic acid (122, 120 mg, 0.9 mmol) and (Z)-1-(2-chloro-4- fluorophenyl)-N'-hydroxycyclopropane-1-carboximidamide (215 mg, 0.9 mmol) in dichloromethane (2 mL), DIPEA (0.45 mL, 2.6 mmol), EDCI.HCl (245 mg, 1.3 mmol) and HOAt (24 mg, 0.2 mmol) were added and the reaction mixture was stirred at ambient temperature for 16 h. After completion, the reaction mixture was diluted with dichloromethane and partitioned with water. Combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford (Z)-1-(2-chloro-4-fluorophenyl)-N'-((4,5-dimethyl- 1H-pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide (123, 270 mg). LCMS (ESI) Calcd. for C16H16ClFN4O2: 350.1, found [M+H]+ = 351.0. [0924] Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(4,5-dimethyl-1H-pyrazol-3-yl)- 1,2,4-oxadiazole, 124 [Step-2]: To a stirred solution of (Z)-1-(2-chloro-4-fluorophenyl)-N'-((4,5- dimethyl-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide (123, 250 mg, 0.7 mmol) in THF (2 mL), tetrabutylammonium hydroxide(0.1 mL, 0.1 mmol, 1M in methanol) was added and the resulting reaction mixture was stirred at ambient temperature for 60 min. After completion, the reaction mixture was concentrated under reduced pressure, dissolved in ethyl acetate, washed with water and dried over anhydrous Na2SO4, filtered and concentrated again under reduced pressure. The product was purified by reverse phase prep-HPLC and lyophilized to afford 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(4,5-dimethyl-1H-pyrazol-3-yl)-1,2,4- oxadiazole (124, 160 mg). LCMS (ESI) Calcd. for C16H14ClFN4O: 332.1, found [M+H]+ = 333.2. 1H NMR (400 MHz, DMSO-d6 at 100 °C): δH 13.01 (brs, 1H), 7.63-7.59 (t, 1H), 7.38 (d, 1H), 7.22-7.18 (t, 1H), 2.22 (s, 3H), 2.18 (s, 3H), 1.74 (s, 2H), 1.45 (s, 2H). [0925] Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(4,5-dimethyl-1-(2- (methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole, Example 104 [Step-3]: 3-(1-(2-Chloro- 4-fluorophenyl)cyclopropyl)-5-(4,5-dimethyl-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-1,2,4- oxadiazole was synthesized following Scheme 2 using 1-bromo-2-(methylsulfonyl)ethane. LCMS (ESI) Calcd. for C19H20ClFN4O3S: 438.1, found [M+H]+ = 439.1.1H NMR (400 MHz, DMSO-d6): δH 7.64-7.60 (t, 1H), 7.50-7.47 (dd, 1H), 7.27-7.22 (m, 1H), 4.57-4.53 (m, 2H), 3.73- 3.70 (m, 2H), 2.96 (s, 3H), 2.30 (s, 3H), 2.19 (s, 3H), 1.71 (brs, 2H), 1.45 (brs, 2H). Note: The structure of the final compound was confirmed by NOE experiments. Example 105: Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(1-(2- (methylsulfonyl)ethyl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-1,2,4-oxadiazole (Example 105)
Figure imgf000247_0001
[0926] Synthesis of (Z)-1-(2-chloro-4-fluorophenyl)-N'-((1,4,5,6-tetrahydrocyclopenta[c]pyrazole- 3-carbonyl)oxy)cyclopropane-1-carboximidamide, 126 [Step-1]: To a stirred solution of 1,4,5,6- tetrahydrocyclopenta[c]pyrazole-3-carboxylic acid (125, 110 mg, 0.7 mmol) and (Z)-1-(2-chloro- 4-fluorophenyl)-N'-hydroxycyclopropane-1-carboximidamide (180 mg, 0.8 mmol) in dichloromethane (2 mL), DIPEA (0.4 mL, 2.2 mmol), EDCI.HCl (210 mg, 1.1 mmol) and HOAt (20 mg, 0.15 mmol) were added and the reaction mixture was stirred at ambient temperature for 16h. After completion, the reaction mixture was diluted with dichloromethane and partitioned with water. Combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford (Z)-1-(2-chloro-4-fluorophenyl)-N'-((1,4,5,6- tetrahydrocyclopenta[c]pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide (126, 220 mg). LCMS (ESI) Calcd. for C17H16ClFN4O2: 362.1, found [M+H]+ = 363.2. [0927] Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(1,4,5,6- tetrahydrocyclopenta[c]pyrazol-3-yl)-1,2,4-oxadiazole, 127 [Step-2]: To a stirred solution of (Z)- 1-(2-chloro-4-fluorophenyl)-N'-((1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3- carbonyl)oxy)cyclopropane-1-carboximidamide (126, 200 mg, 0.5 mmol) in THF (2 mL), tetrabutylammonium hydroxide(0.1 mL, 0.1 mmol, 1M in methanol) was added and the resulting reaction mixture was stirred at ambient temperature for 60 min. After completion, the reaction mixture was concentrated under reduced pressure, dissolved in ethyl acetate, washed with water, dried over anhydrous Na2SO4, filtered and concentrated again under reduced pressure. The product was purified by reverse phase prep-HPLC and lyophilized to afford 3-(1-(2-chloro- 4-fluorophenyl)cyclopropyl)-5-(1,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-1,2,4-oxadiazole (127, 114 mg). LCMS (ESI) Calcd. for C17H14ClFN4O: 344.1, found [M-H]-: 343.1.1H NMR (400 MHz, DMSO-d6, at 100 °C): δH 13.11 (brs, 1H), 7.62-7.59 (t, 1H), 7.38 (d, 1H), 7.22-7.18 (t, 1H), 2.74-2.67 (m, 4H), 2.50 (m, 2H), 1.73 (s, 2H), 1.44 (s, 2H). [0928] Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(1-(2-(methylsulfonyl)ethyl)- 1,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-1,2,4-oxadiazole, Example 105 [Step-3]: 3-(1-(2- Chloro-4-fluorophenyl)cyclopropyl)-5-(1-(2-(methylsulfonyl)ethyl)-1,4,5,6- tetrahydrocyclopenta[c]pyrazol-3-yl)-1,2,4-oxadiazole was synthesized following Scheme 45 using 1-bromo-2-(methylsulfonyl)ethane. LCMS (ESI) Calcd. for C20H20ClFN4O3S: 450.1, found [M+H]+ = 451.1.1H NMR (400 MHz, DMSO-d6): δH 7.63-7.59 (m, 1H), 7.50-7.47 (m, 1H), 7.27- 7.22 (m, 1H), 4.54-4.50 (t, 2H), 3.74-3.71(t, 2H), 2.94 (s, 3H), 2.85- 2.81 (m, 2H), 2.74-2.71 (m, 2H), 2.55-2.50 (m, 2H), 1.68 (brs, 2H), 1.44 (brs, 2H). Note: The structure of the final oxadiazoles were confirmed by NOE experiments. Examples 106a & 106b: Synthesis of 5-(5-Bromo-4-methyl-1-(2-(methylsulfonyl)ethyl)-1H- pyrazol-3-yl)-3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazole (Example 106a) and 5-(3-bromo-4-methyl-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-5-yl)-3-(1-(2-chloro-4- fluorophenyl)cyclopropyl)-1,2,4-oxadiazole (Example 106b)
Figure imgf000248_0001
[0929] Synthesis of methyl 5-bromo-4-methyl-1H-pyrazole-3-carboxylate, 129 [Step 1]: To a solution of methyl 4-methyl-1H-pyrazole-3-carboxylate (128, 100 mg, 0.7 mmol) in water (1 mL), bromine (0.04 mL, 0.7 mmol) was added dropwise at 0 °C and reaction mixture was stirred for 3h at ambient temperature. After completion the reaction mixture was diluted with dichloromethane and partitioned with water. Combined organic layer was dried over anhydrous Na2SO4, filtered, concentrated and purified via column chromatography to afford methyl 5- bromo-4-methyl-1H-pyrazole-3-carboxylate (129, 100 mg). LCMS (ESI) Calcd. for C6H7BrN2O2 [M]: 217.97, found [M+H]+: 219.09 [0930] Synthesis of 5-(5-bromo-4-methyl-1H-pyrazol-3-yl)-3-(1-(2-chloro-4- fluorophenyl)cyclopropyl)-1,2,4-oxadiazole, 130 [Step-2]: To a stirred solution of 1-(2-chloro-4- fluoro-phenyl)-N'-hydroxy-cyclopropanecarboxamidine (100 mg, 0.438 mmol) in toluene (4mL), K2CO3 (126 mg, 0.9 mmol) was added and stirred for 10 min. at ambient temperature. Methyl 5- bromo-4-methyl-1H-pyrazole-3-carboxylate (129, 80 mg, 0.37 mmol) was added to the reaction mixture and the resulting reaction mixture was heated at 100 °C for 16 h. After completion, volatiles were evaporated, diluted with ethyl acetate and washed with water (twice). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by prep-HPLC (reverse phase) to afford 5-(5- bromo-4-methyl-1H-pyrazol-3-yl)-3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazole (130, 21 mg). LCMS (ESI) Calcd. for C15H11BrClFN4O: 395.98, found [M-H]-: 395.0.1H NMR (400 MHz, DMSO-d6): δH 14.44 (brs, 1H), 7.64-7.61 (m, 1H), 7.51-7.48 (m, 1H), 7.28-7.24 (m, 1H), 2.22 (s, 3H), 1.73 (brs, 2H), 1.48 (brs, 2H). [0931] Synthesis of 5-(5-bromo-4-methyl-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-3-(1-(2- chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazole, Example 106a & 5-(3-bromo-4-methyl-1-(2- (methylsulfonyl)ethyl)-1H-pyrazol-5-yl)-3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4- oxadiazole, Example 106b [Step-3]: To a stirred suspension of 5-(5-bromo-4-methyl-1H-pyrazol- 3-yl)-3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazole (130, 100 mg, 0.25 mmol) in THF(3 mL), potassium carbonate (69 mg, 0.5 mmol) was added. After 15 min, 1-bromo-2- (methylsulfonyl)ethane (71 mg, 0.38 mmol)was added and the resulting reaction mixture was stirred at ambient temperature for 16 h. After completion, the reaction mixture was diluted with ethyl acetate and washed with ice-cold water and brine. Combined organic extract was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product were purified by reverse phase preparative HPLC to afford 5-(5-bromo-4-methyl-1-(2- (methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4- oxadiazole (106a, 21 mg) as Peak-1 and 5-(3-bromo-4-methyl-1-(2-(methylsulfonyl)ethyl)-1H- pyrazol-5-yl)-3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazole (106b, 15 mg) as Peak-2. [0932] Analytical data of 5-(5-bromo-4-methyl-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-3-(1- (2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazole, 106a (Peak-1): LCMS (ESI) Calcd. for C18H17BrClFN4O3S: 501.99, found [M+H]+ = 503.2.1H NMR (400 MHz, DMSO-d6) δH 7.64-7.60 (m, 1H), 7.51-7.48 (dd, 1H), 7.28-7.23 (m, 1H), 4.69-4.66 (t, 2H), 3.77-3.74 (t, 2H), 3.03 (s, 3H), 2.23 (s, 3H), 1.73-1.71 (m, 2H), 1.49-1.46 (m, 2H). [0933] Analytical data of 5-(3-bromo-4-methyl-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-5-yl)-3-(1- (2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazole, 106b (Peak-2): LCMS (ESI) Calcd. for C18H17BrClFN4O3S: 501.99, found [M+H]+ = 503.0.1HNMR (400 MHz, DMSO-d6) δH 7.64-7.60 (m, 1H), 7.52-7.49 (dd, 1H), 7.28-7.24 (m, 1H), 4.99-4.96 (t, 2H), 3.71-3.68 (t, 2H), 3.00 (s, 3H), 2.22 (s, 3H), 1.81-1.79 (m, 2H), 1.51-1.48 (m, 2H). Example 107: Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(1,4-dimethyl-1H- pyrazol-3-yl)-1,2,4-oxadiazole (Example 107)
Figure imgf000250_0001
[0934] Synthesis of (Z)-1-(2-chloro-4-fluorophenyl)-N'-((1,4-dimethyl-1H-pyrazole-3- carbonyl)oxy)cyclopropane-1-carboximidamide, 132 [Step 1]: To a solution of (Z)-1-(2-chloro-4- fluorophenyl)-N'-hydroxycyclopropane-1-carboximidamide (185 mg, 0.811 mmol) and 1,4- dimethyl-1H-pyrazole-3-carboxylic acid ( 131, 125 mg, 0.89 mmol) in dichloromethane (1 mL), DIPEA ( 0.39 mL, 2.21 mmol ), EDCI.HCl ( 212 mg, 1.11 mmol) and HOAt ( 20 mg, 0.15 mmol) were added and reaction mixture was stirred for 16h at ambient temperature. The reaction mixture was diluted with dichloromethane and partitioned with water. Combined organic extracts were dried over anhydrous Na2SO4, filtered, concentrated. The product was purified by combiflash column chromatography to afford (Z)-1-(2-chloro-4-fluorophenyl)-N'-((1,4-dimethyl- 1H-pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide (132, 130 mg ). LCMS (ESI) Calcd. for C16H16ClFN4O2: 350.7, found [M+H]: 351.2. [0935] Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(1,4-dimethyl-1H-pyrazol-3-yl)- 1,2,4-oxadiazole, Example 107 [Step 2]: To a stirred solution of (Z)-1-(2-chloro-4-fluorophenyl)- N'-((1,4-dimethyl-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide (132, 130 mg, 0.371 mmol) in THF (2 mL), tetrabutylammonium hydroxide (1M in methanol) ( 0.10 mL, 0.11 mmol ) was added and the resulting reaction mixture was stirred for 60 min at ambient temperature. The reaction mixture was concentrated under reduced pressure, dissolved in ethyl acetate and washed with water (twice). Combined organic extracts were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by reverse phase preparative HPLC to afford 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(1,4-dimethyl-1H- pyrazol-3-yl)-1,2,4-oxadiazole (Example 107, 20 mg). LCMS (ESI) Calcd for C16H14ClFN4O: 332.1, found [M+H]+: 333.1.1H NMR (400 MHz, DMSO-d6): δH 7.75 (s, 1H), 7.64-7.60 (m, 1H), 7.50-7.47 (dd, 1H), 7.27-7.22 (m, 1H), 3.90(s, 3H), 2.24 (s, 3H), 1.72-1.69 (m, 2H), 1.46-1.43 (m, 2H). Example 108: Synthesis of 3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol- 5-yl)-4-methyl-1-(2-(methylsulfonyl)ethyl)-1H-pyrazole-5-carbaldehyde (Example 108)
Figure imgf000251_0001
[0936] Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(4-methyl-1-(2- (methylsulfonyl)ethyl)-5-vinyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole, 133 [Step 1]: To a stirred solution of 5-(5-bromo-4-methyl-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-3-(1-(2-chloro-4- fluorophenyl)cyclopropyl)-1,2,4-oxadiazole (Example 106, 300 mg, 0.6 mmol) in 1,4-Dioxane (4 mL) and water (1 mL), K3PO4 (379 mg, 1.8 mmol) and potassium vinyltrifluoroborate (80 mg, 0.6 mmol) were added and degassed for 10 min. Pd-118 (39 mg, 0.06 mmol) was added and the reaction mixture and heated at 100 °C for 12 h with continuous stirring. The reaction mixture was filtered through celite bed, washed with ethyl acetate, dried over anhydrous Na2SO4, concentrated under reduced pressure. The product was purified by column chromatography to afford 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(4-methyl-1-(2-(methylsulfonyl)ethyl)-5-vinyl- 1H-pyrazol-3-yl)-1,2,4-oxadiazole (133, 2, 200 mg). LCMS (ESI) Calcd. for C20H20ClFN4O3S: 450.1, found [M+H]+ = 451.2. [0937] Synthesis of 3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-4-methyl- 1-(2-(methylsulfonyl)ethyl)-1H-pyrazole-5-carbaldehyde, 134 [Step 2]: To a solution of 3-(1-(2- chloro-4-fluorophenyl)cyclopropyl)-5-(4-methyl-1-(2-(methylsulfonyl)ethyl)-5-vinyl-1H-pyrazol-3- yl)-1,2,4-oxadiazole (133, 180 mg, 0.4 mmol) in acetone (5 mL) and water (1 mL) was added NMO (94 mg, 0.8 mmol) followed by the addition of OsO4 (4% in water) ( 0.05 mL, 0.04 mmol) and stirred the reaction mixture at ambient temperature. After 4 h, NaIO4 (128 mg, 0.6 mmol) was added, and the reaction mixture was stirred for another 16 h at ambient temperature. After completion, reaction mixture was concentrated under reduced pressure and dissolved in ethyl acetate. The organic layer was washed with water (twice), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by column chromatography to afford 3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-4- methyl-1-(2-(methylsulfonyl)ethyl)-1H-pyrazole-5-carbaldehyde (134, 130 mg). LCMS (ESI) Calcd. for C19H18ClFN4O4S: 452.1, found [M+H]+ = 453.2. [0938] Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-4-methyl-1- (2-(methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole, Example 108 [Step-3): To a solution of 3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-4-methyl-1-(2- (methylsulfonyl)ethyl)-1H-pyrazole-5-carbaldehyde (134, 100 mg, 0.22 mmol) in dichlorometane (3 mL), DAST (0.058 mL, 0.44 mmol) was added at 0 °C and stirred at ambient temperature for 12 h. After completion, the reaction mixture was quenched with saturated solution of NaHCO3 at 0 °C and extracted with dichloromethane (twice). Combined organic extracts was washed with water, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by reverse phase preparative HPLC to afford 3-(1-(2-chloro-4- fluorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-4-methyl-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol- 3-yl)-1,2,4-oxadiazole (Example 108, 50 mg). LCMS (ESI) Calcd. for C19H18ClF3N4O3S: 474.1, found [M+H]+ = 475.0.1H NMR (400 MHz, DMSO-d6): δH 7.64-7.33 (m, 3H), 7.28-7.23 (m, 1H), 4.77-4.74 (t, 2H), 3.78-3.75 (t, 2H), 3.05 (s, 3H), 2.38 (s, 3H), 1.74-1.71 (m, 2H), 1.49-1.46 (m, 2H). Example 110: Synthesis of 2-(2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)acetamido)-2-methylpropanoic acid (Example 110)
Figure imgf000253_0001
[0939] Synthesis of tert-butyl 2-(2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)acetamido)-2-methylpropanoate, 135 [Step 1]: To a stirred solution of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)acetic acid (Example 109, 150 mg, 0.4 mmol) in 1,2 dichloromethane (2 mL), tert-butyl 2-amino-2-methylpropanoate (90 mg, 0.5 mmol) and DIPEA (0.3 mL, 1.2 mmol) were added followed by addition of T3P (50% in ethyl acetate) (0.7 mL, 1.2 mmol). Reaction mixture was stirred for 16 h at ambient temperature. After completion, the reaction mixture was concentrated under reduced pressure, dissolved in dichloromethane and washed with water (twice). Combined organic extracts were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford tert-butyl 2-(2-(3-(3-(1-(2-chloro-4- fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)acetamido)-2- methylpropanoate (135, 150 mg). LCMS (ESI) Calcd. for C25H27ClF3N5O4: 553.1, found [M+H]+: 554.1. [0940] Synthesis of 2-(2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)acetamido)-2-methylpropanoic acid, Example 110 [Step 2]: To a stirred solution of tert-butyl 2-(2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol- 5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)acetamido)-2-methylpropanoate (135, 150 mg, 0.3 mmol) in 1,2 dichloromethane (4mL), trifluoroacetic acid (0.3 mL, 3 mmol) was added dropwise at 0 °C and stirred for 2 h at ambient temperature. After completion, reaction mixture was concentrated under reduced pressure to afford product which was purified by reverse phase preparative HPLC to afford 2-(2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol- 5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)acetamido)-2-methylpropanoic acid (Example 110, 110 mg). LCMS (ESI) Calcd. for C21H19ClF3N5O4: 497.1, found [M+H]+: 498.1.1H NMR (400 MHz, DMSO-d6): δH 12.36 (brs, 1H), 8.59 (s, 1H), 7.64-7.61 (m, 1H), 7.49 (dd, 1H),7.34-7.07 (m, 3H), 5.10 (s, 2H), 1.71 (s, 2H), 1.47 (s, 2H), 1.37 (s, 6H). Examples 111a & 111b: Synthesis of 1-((3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)- 1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)methyl)cyclopropane-1-carboxylic acid (Example 111a) and 1-((5-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol- 5-yl)-3-(difluoromethyl)-1H-pyrazol-1-yl)methyl)cyclopropane-1-carboxylic acid (Example 111b)
Figure imgf000254_0001
[0941] Synthesis of 1-((3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)methyl)cyclopropane-1-carboxylic acid, Example 111a and 1- ((5-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-3-(difluoromethyl)-1H- pyrazol-1-yl)methyl)cyclopropane-1-carboxylic acid, Example 111b [Step 1]: To a stirred solution of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1H-pyrazol-3-yl)-1,2,4- oxadiazole (136, 300 mg, 0.8 mmol) in THF (10 mL) was added NaH( 60%) (68 mg, 1.7 mmol) at 25 °C under nitrogen atmosphere. The reaction mixture was stirred for 15 min and ethyl 1- (bromomethyl) cyclopropanecarboxylate (210 mg, 1 mmol) was added. Resulting reaction mixture was stirred at ambient temperature for 16 h, quenched with saturated aqueous ammonium chloride solution and extracted with ethyl acetate and washed with water followed by brine wash. Combined organic extracts were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by reverse phase preparative HPLC to afford 1-((3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5- yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)methyl)cyclopropane-1-carboxylic acid (Example 111a, 20 mg) as peak 2 and 1-((5-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-3- (difluoromethyl)-1H-pyrazol-1-yl)methyl)cyclopropane-1-carboxylic acid (Example 111b, 20mg) as peak 1. Formation of desired product was confirmed by nOe. Example 111a: LCMS (ESI) Calcd. for C20H16ClF3N4O3: 452.1, found [M-H]- = 451.0, 453.0.1H NMR (400 MHz, DMSO-d6): δH 7.85-7.6 (m, 2H), 7.50-7.47 (dd, 1H), 7.27-7.22 (m, 1H), 7.20 (s, 1H), 4.47 (s, 2H), 1.71 (m, 2H), 1.47-1.44 (m, 2H), 1.11 (s, 2H), 1.02 (s, 2H). Example 111b: LCMS (ESI) Calcd. for C20H16ClF3N4O3 [M]: 452.81, found [M-H]-: 451, 453.1H NMR (400 MHz, DMSO-d6): δH 7.64-7.61 (m, 1H), 7.52-7.49 (dd,1H), 7.29 (s, 1H), 7.26 (dd, 1H), 7.21-6.94 (m, 1H), 4.82 (s, 2H), 1.72 (m, 2H), 1.51 (m, 2H), 1.04 (m, 2H), 0.80 (m, 2H). Example 112: Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1- phenylcyclopropyl)-1,2,4-oxadiazole (Example 112)
Figure imgf000255_0001
[0942] Synthesis of ethyl 5-(difluoromethyl)-1H-pyrazole-3-carboxylate, 13 [Step-1]: 2,2- difluoroethan-1-amine (138, 5.0 g, 61.7 mmol), tert-Butyl nitrite (8.8 mL, 74.0 mmol) and acetic acid (0.4 mL, 6.2 mmol) was taken in chloroform (5 ml) and heated to 55 °C for 20 min. The resultant solution was cooled at ambient temperature, added dropwise into a reaction flask containing ethyl propiolate (3.2 mL, 30.8 mmol) in chloroform (10 ml) at 0 °C and stirred the reaction mixture at ambient temperature for 12 h. After completion, the reaction mixture was concentrated, partitioned with ethyl acetate and water. Combined organic layer was collected, washed with water, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by column chromatography to afford ethyl 5-(difluoromethyl)- 1H-pyrazole-3-carboxylate (13, 3.2 g).1HNMR (400 MHz, DMSO-d6) δH 14.46 (s, 1H), 7.18-6.91 (m, 2H), 4.35-4.19 (m, 2H), 1.33-1.24 (m, 3H). [0943] Synthesis of ethyl 3-(difluoromethyl)-1-methyl-1H-pyrazole-5-carboxylate (139a) and ethyl 5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carboxylate (139) [step-2]: To a solution of ethyl 5-(difluoromethyl)-1H-pyrazole-3-carboxylate (13, 3.0 g, 15.8 mmol) in DMF (2 mL), K2CO3 (4.4 g, 31.6 mmol) was added at 0 °C and the reaction mixture was stirred for 40 min under nitrogen atmosphere. Iodomethane (1.7 mL, 28.4 mmol) was then added to the reaction mixture and stirred for 12 h at ambient temperature. After completion, ethyl acetate was added to the reaction mixture and washed with ice cold brine (thrice). The organic layer was collected, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified through by column chromatography to afford ethyl 3-(difluoromethyl)-1-methyl-1H- pyrazole-5-carboxylate (139a, 1.7 g) as peak 1 and ethyl 5-(difluoromethyl)-1-methyl-1H- pyrazole-3-carboxylate (139, 1.1 g) as peak 2. NOTE: The actual structure of desired isomer ethyl 5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carboxylate (139, peak 2) was confirmed through NOE study of two peaks. [0944] Analytical data of ethyl 3-(difluoromethyl)-1-methyl-1H-pyrazole-5-carboxylate (139a): LCMS (ESI) Calcd for C8H10F2N2O2: 204.1, found [M+H]+ = 205.0.1HNMR (400 MHz, DMSO-d6) δH 7.16-6.89 (m, 2H), 4.34-4.29 (m, 2H), 4.12 (s, 3H), 1.33-1.29 (t, 3H). [0945] Analytical data of ethyl 3-(difluoromethyl)-1-methyl-1H-pyrazole-5-carboxylate (139): LCMS (ESI) Calcd for C8H10F2N2O2: 204.1, found [M+H]+ = 205.0.1HNMR (400 MHz, DMSO-d6) δH 7.45-7.19 (t, 1H), 7.05 (s, 1H), 4.30-4.25 (m, 2H), 3.99 (s, 3H), 1.30-1.27 (t, 3H).ss [0946] Synthesis of 5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carboxylic acid (87) [Step 3]: To a stirred solution of ethyl 3-(difluoromethyl)-1-methyl-1H-pyrazole-5-carboxylate (139, 450 mg, 2.2 mmol) in tetrahydrofuran (2 mL), methanol (1 mL) and water (0.5 mL), LiOH.H2O (280 mg, 6.6 mmol) was added at 0 °C and the reaction mixture was stirred at ambient temperature for 12h. The reaction mixture was concentrated under reduced pressure, acidified with (1N) HCl up to pH 4-5 and extracted with ethyl acetate (thrice). The combined organic layer was washed with water, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford 5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carboxylic acid (87, 300 mg).1HNMR (400 MHz, DMSO-d6) δH 12.92 (s, 1H), 7.45-7.18 (t, 1H), 6.99 (s, 1H), 3.98 (s, 3H). [0947] Synthesis of (Z)-N'-hydroxy-1-phenylcyclopropane-1-carboximidamide (141) (Step-4): To a stirred solution of 1-phenylcyclopropane-1-carbonitrile (140, 500 mg, 3.5 mmol) in ethanol (2 mL), Na2CO3 (740 mg, 7.0 mmol) was added followed by NH2OH.HCl (485 mg, 7.0 mmol) and the reaction mixture was heated to reflux at 70 °C for 12h. After completion, the volatiles were evaporated under reduced pressure. The residue was diluted with water and extracted with ethyl acetate (thrice). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by column chromatography to afford (Z)-N'-hydroxy-1-phenylcyclopropane-1-carboximidamide (141, 450 mg). LCMS (ESI) Calcd for C10H12N2O: 176.1, found [M+H]+ = 176.6. [0948] Synthesis of (Z)-N'-((5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)-1- phenylcyclopropane-1-carboximidamide (142) (Step-5): To a stirred solution of 5- (difluoromethyl)-1-methyl-1H-pyrazole-3-carboxylic acid (100 mg, 0.6 mmol) and (Z)-N'-hydroxy- 1-phenylcyclopropane-1-carboximidamide (141, 150 mg, 0.9 mmol) in dichloromethane (4 mL), N,N-Diisopropylethylamine (0.2 ml, 1.1 mmol.), EDCI.HCl (140 mg, 0.7 mmol) and HOAt (15 mg, 0.1 mmol) were added at 0 °C and reaction mixture was stirred at ambient temperature for 16h. After completion, the reaction mixture was concentrated under reduced pressure, dissolved with ethyl acetate, washed with water (twice) and brine. The combined organic extract was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by column chromatography to afford (Z)-N'-((5-(difluoromethyl)-1-methyl-1H-pyrazole-3- carbonyl)oxy)-1-phenylcyclopropane-1-carboximidamide (142, 150 mg). LCMS (ESI) Calcd for C16H16F2N4O2: 334.1, found [M+H]+ = 335.3. [0949] Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-phenylcyclopropyl)- 1,2,4-oxadiazole (Example 112) [Step-6]: To a stirred solution of (Z)-N'-((5-(difluoromethyl)-1- methyl-1H-pyrazole-3-carbonyl)oxy)-1-phenylcyclopropane-1-carboximidamide (142, 150 mg, 0.5 mmol) in THF (2 mL), tetrabutylammonium hydroxide (0.1 mL, 0.1 mmol, 1M in methanol) was added and resulting reaction mixture was stirred at ambient temperature for 60 min. After completion, the reaction mixture was concentrated under reduced pressure, dissolved in ethyl acetate, washed with water (twice), dried over anhydrous Na2SO4, filtered and concentrated again under reduced pressure. The product was purified by reverse phase prep-HPLC and lyophilized to afford 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-phenylcyclopropyl)- 1,2,4-oxadiazole (Example 112, 53 mg). LCMS (ESI) Calcd for C16H14F2N4O: 316.1, found [M+H]+ = 317.1.1HNMR (400 MHz, DMSO-d6) δH 7.50-7.24 (m, 7H), 4.05 (s, 3H), 1.61-1.59 (m, 2H), 1.44-1.41 (m, 2H). [0950] Examples 113-131 were synthesized in a manner similar to Example 112. Example 113: Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2-fluoro-5- methylphenyl)cyclopropyl)-1,2,4-oxadiazole (Example 113) [0951] 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2-fluoro-5- methylphenyl)cyclopropyl)-1,2,4-oxadiazole was synthesized following Scheme 64 using (Z)-N'- ((5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)-1-(2-fluoro-5- methylphenyl)cyclopropane-1-carboximidamide. LCMS (ESI) Calcd for C17H15F3N4O: 348.1, found [M+H]+ = 349.1.1HNMR (400 MHz, DMSO-d6) δH 7.50-7.24 (m, 3H), 7.20-7.16 (m, 1H), 7.11-7.06 (m, 1H), 4.05 (s, 3H), 2.29 (s, 3H), 1.64-1.61 (m, 2H), 1.45-1.42 (m, 2H). Example 114: Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(pyridin-2- yl)cyclopropyl)-1,2,4-oxadiazole (Example 114) [0952] 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(pyridin-2-yl)cyclopropyl)-1,2,4- oxadiazole was synthesized following Scheme 64 using (Z)-N'-((5-(difluoromethyl)-1-methyl-1H- pyrazole-3-carbonyl)oxy)-1-(pyridin-2-yl)cyclopropane-1-carboximidamide. LCMS (ESI) Calcd for C15H13F2N5O: 317.1, found [M+H]+ = 318.1.1HNMR (400 MHz, DMSO-d6) δH 8.51 (d, 1H), 7.77-7.72 (m, 1H), 7.52-7.25 (m, 4H), 4.06 (s, 3H), 1.70-1.67 (m, 2H), 1.61-1.58 (m, 2H). Example 115: Synthesis of 3-(1-(2-bromophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1- methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 115) [0953] 3-(1-(2-bromophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4- oxadiazole was synthesized following Scheme 64 using (Z)-1-(2-bromophenyl)-N'-((5- (difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide. LCMS (ESI) Calcd for C16H13BrF2N4O: 395.2, found [M+H]+ = 396.1.1H NMR (400 MHz, DMSO-d6) δH 7.66 (d, 1H), 7.55 (dd, 1H), 7.50-7.24 (m, 4H), 4.05 (s, 3H), 1.74 (brs, 2H), 1.48-1.46 (m, 2H). Example 116: Synthesis of 3-(1-(2-chlorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1- methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 116) [0954] 3-(1-(2-chlorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4- oxadiazole was synthesized following Scheme 64 using (Z)-1-(2-chlorophenyl)-N'-((5- (difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide. LCMS (ESI) Calcd for C16H13ClF2N4O: 350.8, found [M+H]+ = 351.1.1H NMR (400 MHz, DMSO-d6) δH 7.58-7.56 (m, 1H), 7.50-7.48 (m, 1H), 7.41-7.24 (m, 4H), 4.04 (s, 3H), 1.73-1.70 (m, 2H), 1.48- 1.45 (m, 2H). Example 117: Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(pyridin-3- yl)cyclopropyl)-1,2,4-oxadiazole (Example 117) [0955] 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(pyridin-3-yl)cyclopropyl)-1,2,4- oxadiazole was synthesized following Scheme 64 using (Z)-N'-((5-(difluoromethyl)-1-methyl-1H- pyrazole-3-carbonyl)oxy)-1-(pyridin-3-yl)cyclopropane-1-carboximidamide. LCMS (ESI) Calcd for C15H13F2N5O: 317.1, found [M+H]+ = 318.1.1HNMR (400 MHz, DMSO-d6) δH 8.67 (d, 1H), 8.53-8.51 (dd, 1H), 7.88-7.85 (m, 1H), 7.51-7.24 (m, 3H), 4.05 (s, 3H), 1.64-1.61 (m, 2H), 1.58- 1.50 (m, 2H). Example 118: Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(pyridin-4- yl)cyclopropyl)-1,2,4-oxadiazole (Example 118) [0956] 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(pyridin-4-yl)cyclopropyl)-1,2,4- oxadiazole was synthesized following Scheme 64 using (Z)-N'-((5-(difluoromethyl)-1-methyl-1H- pyrazole-3-carbonyl)oxy)-1-(pyridin-4-yl)cyclopropane-1-carboximidamide. LCMS (ESI) Calcd for C15H13F2N5O: 317.1, found [M+H]+ = 318.1.1HNMR (400 MHz, DMSO-d6) δH 8.55-8.53 (m, 2H), 7.52-7.25 (m, 4H), 4.05 (s, 3H), 1.67-1.64 (m, 2H), 1.56-1.53 (m, 2H). Example 119: Synthesis of 3-(1-(3-chloro-5-fluorophenyl)cyclopropyl)-5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 119) [0957] 3-(1-(3-chloro-5-fluorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3- yl)-1,2,4-oxadiazole was synthesized following Scheme 64 using (Z)-1-(3-chloro-5- fluorophenyl)-N'-((5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1- carboximidamide. LCMS (ESI) Calcd for C16H12ClF3N4O: 368.1, found [M+H]+ = 369.0.1HNMR (400 MHz, DMSO-d6) δH 7.51-7.24 (m, 5H), 4.05 (s, 3H), 1.61-1.58 (m, 2H), 1.55-1.52 (m, 2H). Example 120: Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(2-(5-fluoro-2- methylphenyl)propan-2-yl)-1,2,4-oxadiazole (Example 120) [0958] 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(2-(5-fluoro-2-methylphenyl)propan-2- yl)-1,2,4-oxadiazole was synthesized following Scheme 64 using (Z)-N'-((5-(difluoromethyl)-1- methyl-1H-pyrazole-3-carbonyl)oxy)-1-(3-fluoro-5-methylphenyl)cyclopropane-1- carboximidamide. LCMS (ESI) Calcd for C17H15F3N4O: 348.1, found [M+H]+ = 349.1.1HNMR (400 MHz, DMSO-d6) δH 7.51-7.24 (m, 2H), 7.10-6.96 (m, 3H), 4.05 (s, 3H), 2.32 (s, 3H), 1.58- 1.55 (m, 2H), 1.46-1.44 (m, 2H). Example 121: Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(p- tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 121) [0959] 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(p-tolyl)cyclopropyl)-1,2,4- oxadiazole was synthesized following Scheme 64 using (Z)-N'-((5-(difluoromethyl)-1-methyl-1H- pyrazole-3-carbonyl)oxy)-1-(p-tolyl)cyclopropane-1-carboximidamide. LCMS (ESI) Calcd. for C17H16F2N4O: 330.1, found [M+H]+ = 331.0.1H NMR (400 MHz, DMSO-d6) δH 7.49-7.22 (m, 4H), 7.14 (d, 2H), 4.03 (s, 3H), 2.28 (s, 3H), 1.54-1.52 (m, 2H), 1.36 -1.34 (m, 2H). Example 122: Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(m- tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 122) [0960] 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(m-tolyl)cyclopropyl)-1,2,4- oxadiazole was synthesized following Scheme 64 using (Z)-N'-((5-(difluoromethyl)-1-methyl-1H- pyrazole-3-carbonyl)oxy)-1-(m-tolyl)cyclopropane-1-carboximidamide. LCMS (ESI) Calcd. for C17H16F2N4O: 330.1, found [M+H]+ = 331.1.1H NMR (400 MHz, DMSO-d6) δH 7.50-7.10 (m, 6H), 4.05 (s, 3H), 2.31 (s, 3H), 1.57-1.55 (m, 2H), 1.41-1.39 (m, 2H). Example 123: Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(3- methylpyridin-2-yl)cyclopropyl)-1,2,4-oxadiazole (Example 123) [0961] 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(3-methylpyridin-2-yl)cyclopropyl)- 1,2,4-oxadiazole was synthesized following Scheme 64 using (Z)-N'-((5-(difluoromethyl)-1- methyl-1H-pyrazole-3-carbonyl)oxy)-1-(3-methylpyridin-2-yl)cyclopropane-1-carboximidamide. LCMS (ESI) Calcd for C16H15F2N5O: 331.1, found [M+H]+ = 332.1.1HNMR (400 MHz, DMSO-d6) δH 8.37(d, 1H), 7.65-7.24 (m, 4H), 4.05 (s, 3H), 2.25 (s, 3H), 1.68-1.65 (m, 2H), 1.58-1.55 (m, 2H). Example 124: Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 124) [0962] 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3- yl)-1,2,4-oxadiazole was synthesized following Scheme 64 using (Z)-N'-((5-(difluoromethyl)-1- methyl-1H-pyrazole-3-carbonyl)oxy)-1-(2-(trifluoromethyl)phenyl)cyclopropane-1- carboximidamide. LCMS (ESI) Calcd for C17H13F5N4O: 384.1, found [M+H]+ = 385.1.1HNMR (400 MHz, DMSO-d6) δH 7.78-7.24 (m, 6H), 4.04 (s, 3H), 1.72 (brs, 2H), 1.55 (brs, 2H). Example 125: Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2- methylpyridin-3-yl)cyclopropyl)-1,2,4-oxadiazole (Example 125) [0963] 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2-methylpyridin-3-yl)cyclopropyl)- 1,2,4-oxadiazole was synthesized following Scheme 64 using (Z)-N'-((5-(difluoromethyl)-1- methyl-1H-pyrazole-3-carbonyl)oxy)-1-(2-methylpyridin-3-yl)cyclopropane-1-carboximidamide. LCMS (ESI) Calcd for C16H15F2N5O: 331.1, found [M+H]+ = 332.1.1HNMR (400 MHz, DMSO-d6) δH 8.41(d, 1H), 7.76(d, 1H), 7.50-7.23 (m, 4H), 4.05 (s, 3H), 2.45 (s, 3H), 1.71-1.68 (m, 2H), 1.48-1.45 (m, 2H). Example 126: Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2,5- difluorophenyl)cyclopropyl)-1,2,4-oxadiazole (Example 126) [0964] 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2,5-difluorophenyl)cyclopropyl)- 1,2,4-oxadiazole was synthesized following Scheme 64 using (Z)-N'-((5-(difluoromethyl)-1- methyl-1H-pyrazole-3-carbonyl)oxy)-1-(2,5-difluorophenyl)cyclopropane-1-carboximidamide. LCMS (ESI) Calcd for C16H12F4N4O: 352.1, found [M+H]+ = 353.1.1HNMR (400 MHz, DMSO-d6) δH 7.51-7.37 (m, 2H), 7.30-7.24 (m, 3H), 4.05 (s, 3H), 1.66-1.63 (m, 2H), 1.52-1.49 (m, 2H). Example 127: Synthesis of 3-(1-(2-chloro-5-fluorophenyl)cyclopropyl)-5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 127) [0965] 3-(1-(2-chloro-5-fluorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3- yl)-1,2,4-oxadiazole was synthesized following Scheme 64 using (Z)-1-(2-chloro-5- fluorophenyl)-N'-((5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1- carboximidamide. LCMS (ESI) Calcd for C16H12ClF3N4O: 368.0, found [M+H]+ = 369.0.1H NMR (400 MHz, DMSO-d6) δH 7.52-7.49 (m, 1H), 7.45-7.18 (m, 4H), 4.05 (s, 3H), 1.75 (s, 2H), 1.51 (s, 2H). Example 128: Synthesis of 3-(1-(2-chloro-3-fluorophenyl)cyclopropyl)-5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 128) [0966] 3-(1-(2-chloro-3-fluorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3- yl)-1,2,4-oxadiazole was synthesized following Scheme 64 using (Z)-1-(2-chloro-3- fluorophenyl)-N'-((5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1- carboximidamide. LCMS (ESI) Calcd for C16H12ClF3N4O: 368.1, found [M+H]+ = 369.0.1H NMR (400 MHz, DMSO-d6) δH 7.46-7.19 (m, 5H), 4.06 (s, 3H), 1.77 (s, 2H), 1.56 (s, 2H). Example 129: Synthesis of (5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2,5- dimethylphenyl) cyclopropyl)-1,2,4-oxadiazole (Example 129) [0967] (5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2,5-dimethylphenyl) cyclopropyl)- 1,2,4-oxadiazole was synthesized following Scheme 64 using (Z)-N'-((5-(difluoromethyl)-1- methyl-1H-pyrazole-3-carbonyl)oxy)-1-(2,5-dimethylphenyl)cyclopropane-1-carboximidamide. LCMS (ESI) Calcd. for C18H18F2N4O [M]: 344.36, found [M+H]+: 345.1.1HNMR (400 MHz, DMSO-d6) δH 7.50-7.23 (m, 2H), 7.18 (s, 1H), 7.09 (d, 1H), 7.03 (d, 1H), 4.04 (s, 3H), 2.27 (s, 3H), 2.21 (s, 3H), 1.63 (d, 2H), 1.36 (d, 2H). Example 130: Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2-methyl- 5-(trifluoromethyl)phenyl)cyclopropyl)-1,2,4-oxadiazole (Example 130) [0968] 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2-methyl-5-(trifluoromethyl)phenyl) cyclopropyl) -1,2,4-oxadiazole was synthesized following Scheme 64 using (Z)-N'-((5- (difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)-1-(2-methyl-5- (trifluoromethyl)phenyl)cyclopropane-1-carboximidamide. LCMS (ESI) Calcd. for C18H15F5N4O : 398.3, found [M+H]+: 399.1.1HNMR (400 MHz, DMSO-d6) δH : 7.69 (s, 1H), 7.61 (d, 1H), 7.50- 7.23 (m, 3H), 4.02 (d, 3H), 2.35 (s, 3H), 1.98-1.70 (m, 2H), 1.53-1.49 (m, 2H). Example 131: Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2- phenoxyphenyl)cyclopropyl)-1,2,4-oxadiazole (Example 131) [0969] 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2-phenoxyphenyl)cyclopropyl)- 1,2,4-oxadiazole was synthesized following Scheme 64 using (Z)-N'-((5-(difluoromethyl)-1- methyl-1H-pyrazole-3-carbonyl)oxy)-1-(2-phenoxyphenyl)cyclopropane-1-carboximidamide. 1HNMR (400 MHz, DMSO-d6) (at 100 °C) δH 7.45-7.32 (m, 4H), 7.20 (d, 2H), 7.15-7.10 (m, 2H) 7.03 (d, 2H), 6.92 (d, 1H), 4.06 (s, 3H), 1.61-1.58 (m, 2H), 1.45-1.42 (m, 2H). LCMS (ESI) Calcd for C22H18F2N4O2: 408.4, found [M+H]+ = 409.2. Example 132: Synthesis of 2-(1-(5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4- oxadiazol-3-yl)cyclopropyl)benzoic acid (Example 132)
Figure imgf000263_0001
[0970] Synthesis of 1-(2-bromophenyl)cyclopropane-1-carbonitrile, 144 [Step 1]: To a stirred suspension of sodium hydride (920 mg, 38.3 mmol) in DMSO (50 mL) at 0 °C, 2-(2- bromophenyl) acetonitrile (143, 3.0 g, 15.3 mmol) was added. The reaction mixture was stirred at ambient temperature for 1 h and 1,2-dibromoethane (1.6 mL, 18.4 mmol) was added. The resulting reaction mixture was stirred at ambient temperature for 16 h. After completion, the reaction mixture was diluted with ethyl acetate and washed with water and brine. Combined organic extract was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by flash column chromatography to afford 1-(2- bromophenyl)cyclopropane-1-carbonitrile (144, 2.0 g).1H NMR (400 MHz, DMSO-d6) δH 7.72 (d, 1H), 7.52 (d, 1H), 7.42 (t, 1H), 7.34 (t, 1H), 1.78-1.75 (m, 2H), 1.43-1.40 (m, 2H). [0971] Synthesis of 1-(2-vinylphenyl)cyclopropane-1-carbonitrile, 145 [Step 2]: In a sealed tube, a solution of 1-(2-bromophenyl)cyclopropane-1-carbonitrile (144, 1.1 g, 4.9 mmol) and tributyl(vinyl)stannane (2.2 mL, 7.4 mmol) in toluene (10 mL) was purged with Argon gas for 15 min and tetrakis triphenyl phosphine Pd (0) (570 mg, 0.5 mmol) was added. The reaction mixture was stirred at 100 °C for 16 h and concentrated under reduced pressure. The product was purified by flash chromatography to afford 1-(2-vinylphenyl)cyclopropane-1-carbonitrile (145, 680 mg). LCMS (ESI) Calcd. for C12H11N: 169.0, found [M+H]+ = 169.9.1H NMR (400 MHz, DMSO-d6) δH 7.68-7.66 (m, 1H), 7.40-7.37 (m, 2H), 7.33-7.31 (m, 1H), 7.27-7.20 (m, 1H), 5.89 (d, 1H), 5.51-5.48 (m, 1H), 1.76-1.73 (m, 2H), 1.38-1.30 (m, 2H). [0972] Synthesis of (Z)-N'-hydroxy-1-(2-vinylphenyl)cyclopropane-1-carboximidamide 146, [Step 3]: To a stirred solution of 1-(2-vinylphenyl)cyclopropane-1-carbonitrile (145, 680 mg, 4.0 mmol) in ethanol (12 mL), sodium carbonate (1.1 g, 10.0 mmol) and hydroxyl amine hydrochloride (700 mg, 10.0 mmol) were added. The reaction mixture was heated at 70 oC for 16 h. After completion, the reaction mixture was concentrated under reduced pressure, diluted with ethyl acetate and washed with water and by brine. The combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford (Z)-N'-hydroxy-1-(2-vinylphenyl)cyclopropane-1-carboximidamide (146, 580 mg). LCMS (ESI) Calcd. for C12H14N2O: 202.3, found [M+H]+ = 203.3. [0973] Synthesis of (Z)-N'-((5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)-1-(2- vinylphenyl)cyclopropane-1-carboximidamide, 147 [Step 4]: To a stirred solution of (Z)-N'- hydroxy-1-(2-vinylphenyl)cyclopropane-1-carboximidamide (146, 580 mg, 2.9 mmol), and 5- (difluoromethyl)-1-methyl-1H-pyrazole-3-carboxylic acid (200 mg, 1.1 mmol) in dichloromethane (10 mL), N,N-diisopropylethylamine (0.4 mL, 2.8 mmol), 1-hydroxy-7-azabenzotriazole (30 mg, 0.2 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (285 mg, 1.5 mmol) were added. The reaction mixture was stirred at ambient temperature for 16 h. After completion, the reaction mixture was diluted with ethyl acetate and washed with water and brine. Combined organic extract was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford (Z)-N'-((5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)-1- (2-vinylphenyl)cyclopropane-1-carboximidamide (147, 940 mg). LCMS (ESI) Calcd. for C18H18 F2N4O2: 360.1, found [M+H]+ = 361.4. [0974] Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2- vinylphenyl)cyclopropyl)-1,2,4-oxadiazole, 148 [Step 5]: To a stirred solution of (Z)-N'-((5- (difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)-1-(2-vinylphenyl)cyclopropane-1- carboximidamide (147, 940 mg, 2.6 mmol) in THF (10 mL), tetra butyl ammonium hydroxide (205 mg, 0.8 mmol) was added. The resulting reaction mixture was stirred at ambient temperature for 4 h and concentrated under reduced pressure. The residue was diluted with ethyl acetate and washed with water and brine. Combined organic extract was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford 5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2-vinylphenyl)cyclopropyl)-1,2,4-oxadiazole (148, 710 mg. LCMS (ESI) Calcd. for C18H16F2N4O: 342.2, found [M+H]+ = 343.2. [0975] Synthesis 2-(1-(5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3- yl)cyclopropyl)benzaldehyde, 149 [Step 6]: To a stirred solution of 5-(5-(difluoromethyl)-1- methyl-1H-pyrazol-3-yl)-3-(1-(2-vinylphenyl)cyclopropyl)-1,2,4-oxadiazole (148, 700 mg, 2.0 mmol) in 1,4-dioxane (15 mL) and water (8 mL) mixture at 0 °C, osmium tetroxide (50 mg, 0.20 mmol) and sodium periodate (855 mg, 4.0 mmol) were added. The reaction mixture was stirred at ambient temperature at for 16 h. After completion the reaction mixture was quenched with aqueous ammonium chloride, diluted with ethyl acetate and washed with water and brine. Combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by flash chromatography to afford 2-(1-(5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3- yl)cyclopropyl)benzaldehyde (149, 680 mg). LCMS (ESI) Calcd. for C17H14F2N4O2: 344.1, found [M+H]+ = 345.2. [0976] Synthesis 2-(1-(5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3- yl)cyclopropyl)benzoic acid, Example 132 [Step 7]: To a stirred solution of 2-(1-(5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3-yl)cyclopropyl)benzaldehyde (10, 700 mg, 2.0 mmol) in acetonitrile (20 mL) and water (10 mL), sodium chlorite (735 mg, 8.1 mmol), sodium dihydrogen phosphate (975 mg, 8.1 mmol) and hydrogen peroxide (1.1 mL, 40.7 mmol) were added. The reaction mixture was allowed to stir at ambient temperature for 16 h, diluted with ethyl acetate and washed with water and brine. Combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by reverse phase prep HPLC to afford 2-(1-(5-(5-(difluoromethyl)-1-methyl- 1H-pyrazol-3-yl)-1,2,4-oxadiazol-3-yl)cyclopropyl)benzoic acid (Example 132, 628 mg). LCMS (ESI) Calcd. for C17H14F2N4O3: 360.1, found [M+H]+ = 361.2.1H NMR (400 MHz, DMSO-d6) δH 7.74 (d, 1H), 7.52-7.26 (m, 5H), 4.04 (s, 3H), 1.61-1.60 (m, 2H), 1.37-1.36 (m, 2H). One carboxylic acid proton is exchangeable. Example 133: Synthesis of 2-(1-(5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4- oxadiazol-3-yl)cyclopropyl)benzamide (Example 133)
Figure imgf000266_0001
[0977] Synthesis of 2-(1-(5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3- yl)cyclopropyl)benzamide, Example 133 [Step 1]: To a stirred solution of 2-(1-(5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3-yl)cyclopropyl)benzoic acid (Example 132, 100 mg, 0.3 mmol) in DMF (2 mL), N,N-diisopropylethylamine (0.2 mL, 1.1 mmol) and HATU (265 mg, 0.7 mmol) were added. The reaction mixture was stirred at 0 °C for 30 min and ammonium chloride (45 mg, 0.8 mmol) was added. The resulting reaction mixture was stirred at ambient temperature for 16 h and quenched with crushed ice. The precipitate was filtered, washed with ice-cold water and dried under vacuum. The product was purified by reverse phase prep HPLC to afford 2-(1-(5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4- oxadiazol-3-yl)cyclopropyl)benzamide (Example 133, 44 mg). LCMS (ESI) Calcd. for C17H15F2N5O2: 359.1, found [M+H]+ = 360.2.1H NMR (400 MHz, DMSO-d6) δH 7.55-7.24 (m, 8H), 4.04 (s, 3H), 1.59-1.57 (m, 2H), 1.39-1.36 (m, 2H). Example 134: Synthesis of 2-(1-(5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4- oxadiazol-3-yl)cyclopropyl)-N-methylbenzamide (Example 134) Scheme 67 [0978] Synthesis of 2-(1-(5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3- yl)cyclopropyl)-N-methylbenzamide, Example 134 [Step 1]: To a stirred solution of 2-(1-(5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3-yl)cyclopropyl)benzoic acid (Example 132, 100 mg, 0.3 mmol) in DMF (2 mL), N,N-diisopropylethylamine (0.2 mL, 1.1 mmol) and HATU (265 mg, 0.7 mmol) were added. The reaction mixture was stirred at 0 °C for 30 min and a solution of methyl amine in tetrahydrofuran (0.4 mL, 0.8 mmol, 2M) was added. The resulting reaction mixture was stirred at ambient temperature for 16 h and quenched with crushed ice. The precipitate formed was filtered, washed with ice-cold water and dried under vacuum. The product was purified by reverse phase prep HPLC to afford 2-(1-(5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3-yl)cyclopropyl)-N-methylbenzamide (Example 134, 23 mg). LCMS (ESI) Calcd. for C18H17F2N5O2: 373.1, found [M+H]+ = 374.2.1H NMR (400 MHz, DMSO-d6) δH 7.99-7.98 (m, 1H), 7.55-7.51 (m, 1H), 7.47-7.43 (m, 1H), 7.41- 7.36 (m, 3H), 7.27-7.24 (m, 1H), 4.05 (s, 3H), 2.66 (d, 3H), 1.57-1.54 (m, 2H), 1.34-1.31 (m, 2H). Example 135: Synthesis of 2-(1-(5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4- oxadiazol-3-yl)cyclopropyl)-N,N-dimethylbenzamide (Example 135)
Figure imgf000267_0001
[0979] Synthesis of 2-(1-(5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3- yl)cyclopropyl)-N,N-dimethylbenzamide, 135 [Step 1]: To a stirred solution of 2-(1-(5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3-yl)cyclopropyl)benzoic acid (132, 100 mg, 0.3 mmol) in DMF (2 mL), N,N-diisopropylethylamine (0.2 mL, 1.1 mmol) and HATU (265 mg, 0.7 mmol) were added. The reaction mixture was stirred at 0 oC for 30 min and dimethylamine hydrochloride (30 mg, 0.4 mmol) was added. The resulting reaction mixture was stirred at ambient temperature for 16 h and quenched with crushed ice. The precipitate was filtered, washed with ice-cold water and dried under vacuum. The product was purified by reverse phase preparative HPLC to afford 2-(1-(5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)- 1,2,4-oxadiazol-3-yl)cyclopropyl)-N,N-dimethylbenzamide (135, 29 mg). LCMS (ESI) Calcd. for C19H19F2N5O2: 387.1, found [M+H]+ = 388.3.1H NMR (400 MHz, DMSO-d6) δH 7.58 (d, 1H), 7.50-7.20 (m, 5H), 4.04 (s, 3H), 2.89 (s, 3H), 2.65 (s, 3H), 1.52 (m, 4H). Example 136: Synthesis of 2-(1-(5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4- oxadiazol-3-yl)cyclopropyl)benzonitrile (Example 136)
Figure imgf000268_0001
[0980] Synthesis of 2-(1-(5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3- yl)cyclopropyl)benzonitrile, 136 [Step 1]: To a solution of 2-(1-(5-(5-(difluoromethyl)-1-methyl- 1H-pyrazol-3-yl)-1,2,4-oxadiazol-3-yl)cyclopropyl)benzamide (133, 90 mg, 0.3 mmol) and triethylamine (0.25 mL, 1.5 mmol) in dry dichloromethane (5 mL) at 0 °C, trifluoroacetic acid anhydride (265 mg, 1.3 mmol) was added dropwise. The reaction mixture was stirred at ambient temperature for 16 h, diluted with ethyl acetate and washed with ice-cold water. The combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by reverse phase prep HPLC to afford 2-(1-(5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3-yl)cyclopropyl)benzonitrile (136, 44 mg). LCMS (ESI) Calcd. for C17H13F2N5O: 341.1, found [M+H]+ = 342.2.1H NMR (400 MHz, DMSO-d6) δH 7.89 (d, 1H), 7.76-7.68 (m, 2H), 7.56 (t, 1H), 7.51-7.24 (m, 2H), 4.05 (s, 3H), 1.77- 1.74 (m, 2H), 1.61-1.58 (m, 2H). Example 137: Synthesis of (2-(1-(5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4- oxadiazol-3-yl)cyclopropyl)phenyl)methanol (Example 137)
Figure imgf000268_0002
[0981] Synthesis of (2-(1-(5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3- yl)cyclopropyl)phenyl)methanol, Example 138 [Step 1]: To a stirred solution of 2-(1-(5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3-yl)cyclopropyl)benzaldehyde (149, 200 mg, 0.6 mmol) in THF (3 mL), sodium borohydride (45 mg, 1.2 mmol) was added at 0°C. The resulting reaction mixture was stirred at ambient temperature for 4 h. The reaction mixture was quenched with aqueous ammonium chloride, extracted with ethyl acetate and washed with brine. Combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by flash chromatography to afford (2-(1-(5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3- yl)cyclopropyl)phenyl)methanol (Example 138, 165 mg). LCMS (ESI) Calcd. for C17H16F2N4O2: 346.1, found [M+H]+ = 347.1.1H NMR (400 MHz, DMSO-d6) δH 7.55-7.51 (m, 1H), 7.39-7.33 (m, 3H), 7.28-7.23 (m, 2H), 5.12 (t, 1H), 4.57 (d, 2H), 4.04 (s, 3H), 1.63-1.62 (m, 2H), 1.42-1.41 (m, 2H). [0982] Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2- (methoxymethyl)phenyl)cyclopropyl)-1,2,4-oxadiazole, Example 137 [Step 2]: To a stirred solution of (2-(1-(5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3- yl)cyclopropyl)phenyl)methanol (150, 140 mg, 0.4 mmol) in THF (3 mL) at 0 °C, sodium hydride (30 mg, 1.2 mmol) was added portion-wise and stirred for 1 h. Methyl iodide (0.05 mL, 0.6 mmol) was added and the resulting reaction mixture was stirred for at ambient temperature for 16 h. The reaction was quenched with aqueous ammonium chloride, extracted with ethyl acetate and washed with brine. Combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by reverse phase prep HPLC to afford 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2- (methoxymethyl)phenyl)cyclopropyl)-1,2,4-oxadiazole (Example 137, 28 mg). LCMS (ESI) Calcd. for C18H18F2N4O2: 360.1, found [M+H]+ = 361.2.1H NMR (400 MHz, DMSO-d6) δH 7.50-7.24 (m, 6H), 4.48 (s, 2H), 4.04 (s, 3H), 3.25 (s, 3H), 1.64 (brs, 2H), 1.43 (brs, 2H). Example 138: Synthesis of (2-(1-(5-(5-(difluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3- yl)cyclopropyl)phenyl)methanol (Example 138)
Figure imgf000269_0001
[0983] Synthesis of (2-(1-(5-(5-(difluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3- yl)cyclopropyl)phenyl)methanol, Example 138 [Step 1]: To a stirred solution of 2-(1-(5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3-yl)cyclopropyl)benzaldehyde (149, 30 mg, 0.1 mmol) in tetrahydrofuran (1 mL), sodium borohydride (6.6 mg, 0.2mmol) was added at 0 °C. The resulting reaction mixture was stirred at ambient temperature for 4 h. After completion, the reaction mixture was quenched with saturated solution of aqueous ammonium chloride. The aqueous phase was extracted with ethyl acetate (twice). The combined organic extracts were washed with brine, dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by reverse phase prep HPLC to afford (2-(1-(5-(5-(difluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3- yl)cyclopropyl)phenyl)methanol, (Example 138, 8mg). LCMS (ESI) Calcd. for C17H16F2N4O2: 346.1, found [M+H]+ = 347.1.1H NMR (400 MHz, DMSO-d6): δH 7.55-7.53 (m, 1H), 7.50-7.25 (m, 5H), 5.11 (t, 1H), 4.58-4.57 (m, 2H), 4.04 (s, 3H), 1.63 (brs, 2H), 1.42 (brs, 2H). Example 139: Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2- ethylphenyl)cyclopropyl)-1,2,4-oxadiazole (Example 139)
Figure imgf000270_0001
[0984] Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2- ethylphenyl)cyclopropyl)-1,2,4-oxadiazole, Example 139 [Step 6]: A stirred solution of 5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2-vinylphenyl)cyclopropyl)-1,2,4-oxadiazole (148, 150 mg, 0.4 mmol) in ethanol (4 mL) was purged with Argon gas for 5 min. Pd on C (60 mg, 10 %) was added to the solution and the mixture was hydrogenated using a H2 balloon for 2 h at ambient temperature. After completion, the mixture was passed through celite bed and concentrated under reduced pressure. The product was purified by RP prep HPLC purification to afford 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2-ethylphenyl)cyclopropyl)-1,2,4- oxadiazole (Example 139, 75 mg). LCMS (ESI) Calcd for C18H18F2N4O: 344.3, found [M+H]+ = 345.2.1H NMR (400 MHz, DMSO-d6) δH 7.50-7.17 (m, 6H), 4.04 (s, 3H), 2.66 (q, 2H), 1.66 (d, 2H), 1.39 (d, 2H), 1.12 (m, 3H). Example 140: Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2-(methyl- d3)phenyl)cyclopropyl)-1,2,4-oxadiazole (Example 140) Scheme 73 [0985] Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2-(methyl- d3)phenyl)cyclopropyl)-1,2,4-oxadiazole, Example 140, (Step-1): To a stirred solution of 3-(1-(2- bromophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 115, 80 mg, 0.2 mmol) in 1,4-dioxane (2 mL) and water (0.5mL) mixture, K3PO4 (115 mg, 0.6 mmol) and 4,4,5,5-tetramethyl-2-(methyl-d3)-1,3,2-dioxaborolane (45 mg, 0.3 mmol) were added and the reaction mixture was degassed with nitrogen gas for 10 minutes. Pd(dtbpf)Cl2 (15 mg, 0.02 mmol) was added to the reaction mixture and heated at 100 oC for 16h. After completion, the reaction mixture was filtered through celite bed, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The product was purified through reverse phase prep-HPLC to afford 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2-(methyl- d3)phenyl)cyclopropyl)-1,2,4-oxadiazole (Example 140, 7 mg). LCMS (ESI) Calcd for C17H13D3F2N4O: 333.2, found [M+H]+ = 334.1.1HNMR (400 MHz, DMSO-d6) δH 7.51-7.20 (m, 6H), 4.04 (s, 3H), 1.65 (brs, 2H), 1.39 (brs, 2H). Example 141: Synthesis of 3-(1-(2-cyclopropylphenyl)cyclopropyl)-5-(5-(difluoromethyl)-1- methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 141)
Figure imgf000272_0001
[0986] Synthesis of 3-(1-(2-cyclopropylphenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-methyl-1H- pyrazol-3-yl)-1,2,4-oxadiazole, Example 141 [Step 1]: To a stirred solution of 3-(1-(2- bromophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 115, 100 mg, 0.3 mmol) in toluene (2 mL) and water (0.1mL), cyclopropyl boronic acid (30 mg, 0.3 mmol) and K3PO4 (160 mg, 0.7 mmol) were added and degassed for 10 min. Pd(OAc)2 (6.0 mg, 0.02 mmol) was added to the reaction mixture and heated at 100 °C for 12 h with continuous stirring. After completion, the reaction mixture was concentrated under reduced pressure, dissolved in ethyl acetate and washed with water(twice). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product which was purified by reverse phase prep-HPLC to afford 3-(1-(2- cyclopropylphenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 141, 40 mg).1HNMR (400 MHz, DMSO-d6) δH 7.50-7.18 (m, 4H), 7.16 (t, 1H), 6.89 (d, 1H), 4.04 (s, 3H), 2.07-2.01 (m, 1H), 1.70 (s, 2H), 1.44 (s, 2H), 0.82 (d, 2H), 0.62 (d, 2H). LCMS (ESI) Calcd for C19H18F2N4O: 356.3, found [M+H]+ = 357.2. Example 142: Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2-fluoro-6- methylphenyl)cyclopropyl)-1,2,4-oxadiazole (Example 142)
Figure imgf000272_0002
Scheme 75 [0987] Synthesis of 2-(2-fluoro-6-methylphenyl)acetonitrile, 151 [Step 1]: To a stirred solution of 2-(bromomethyl)-1-fluoro-3-methylbenzene (150, 1.0 g, 4.9 mmol) in acetonitrile (10 mL), K2CO3 (1.4 g, 9.9 mmol) was added followed by trimethylsilylformonitrile (0.9 mL, 7.4 mmol) and the resulting reaction mixture was heated at 100 °C for 16h. After completion, the reaction mixture was dissolved in ethyl acetate, washed with water (thrice) and brine. The organic extract was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford 2-(2- fluoro-6-methyl-phenyl)acetonitrile (151, 650 mg). GCMS Calcd for C9H8FN: 149.1, found [M]+ = 149.2. [0988] Synthesis of 1-(2-fluoro-6-methylphenyl)cyclopropane-1-carbonitrile & 2-(2-fluoro-6- methylphenyl)acetonitrile 152a & 152b, [Step 2]: To a stirred solution of NaOH (2.1 g, 52.3 mmol) in water (7 mL), 1,2-dibromoethane (3.3 mL, 21.8 mmol), TBAB (280 mg, 0.9 mmol) and 2-(2-fluoro-6-methyl-phenyl)acetonitrile (151, 650 mg, 4.4 mmol) were added and the reaction mixture was heated at 100 °C for 12h. After completion, the reaction mixture was poured into cold water and extracted with ethyl acetate (thrice). Combined organic extract was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford 1-(2-fluoro-6-methylphenyl)cyclopropane-1-carbonitrile and 2-(2-fluoro-6- methylphenyl)acetonitrile (152a & 152b, 250 mg ). GCMS Calcd for C11H10FN: 175.2, found [M]+ = 175.1. GCMS Calcd for C9H8FN: 149.1, found [M]+ = 149.1. [0989] Synthesis of (Z)-1-(2-fluoro-6-methylphenyl)-N'-hydroxycyclopropane-1-carboximidamide & (Z)-2-(2-fluoro-6-methylphenyl)-N'-hydroxyacetimidamide, 153a & 153b [Step 3]: To a stirred solution of 1-(2-fluoro-6-methylphenyl)cyclopropane-1-carbonitrile and (Z)-2-(2-fluoro-6- methylphenyl)-N'-hydroxyacetimidamide (152a & 152b, 250 mg) in ethanol (2 mL), sodium carbonate (305 mg, 2.9 mmol) and hydroxylamine hydrochloride (200 mg, 2.9 mmol) were added and the reaction was heated at 70 °C for 12h. After completion, the volatiles were evaporated under reduced pressure, dissolved in water and extracted with ethyl acetate(thrice). Combined organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure and purified by combiflash column chromatography to afford (Z)-1-(2-fluoro-6-methylphenyl)-N'-hydroxycyclopropane-1-carboximidamide and (Z)-2-(2- fluoro-6-methylphenyl)-N'-hydroxyacetimidamide (153a & 153b, 270 mg). LCMS (ESI) Calcd for C11H13FN2O: 208.2, found [M+H]+ = 209.3. LCMS Calcd for C9H11FN2O: 182.0, found [M+H]+ = 183.2. [0990] Synthesis of (Z)-N'-((5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)-1-(2- fluoro-6-methylphenyl)cyclopropane-1-carboximidamide & (Z)-N'-((5-(difluoromethyl)-1-methyl- 1H-pyrazole-3-carbonyl)oxy)-2-(2-fluoro-6-methylphenyl)acetimidamide, 154a & 154b [Step 4]: To a stirred solution of 5-(difluoromethyl)-1-methyl-pyrazole-3-carboxylic acid (150 mg, 0.9 mmol) and (Z)-1-(2-fluoro-6-methylphenyl)-N'-hydroxycyclopropane-1-carboximidamide & (Z)-2- (2-fluoro-6-methylphenyl)-N'-hydroxyacetimidamide (153a & 153b, 265 mg) in dichloromethane (3 mL), N,N-Diisopropylethylamine (0.5 mL, 2.6 mmol ), EDC.HCl (210 mg, 1.1 mmol) and HOAt (25 mg, 0.2 mmol) were added at 0 °C and the reaction mixture was stirred at ambient temperature for 16h. After completion, the reaction mixture was concentrated, diluted with water and extracted with ethyl acetate (twice). Combined organic layer was washed with brine, dried over anhydrous Na2SO4, filtered, concentrated under reduced pressure and purified through combiflash column chromatography to afford (Z)-N'-((5-(difluoromethyl)-1-methyl-1H-pyrazole-3- carbonyl)oxy)-1-(2-fluoro-6-methylphenyl)cyclopropane-1-carboximidamide and (Z)-N'-((5- (difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)-2-(2-fluoro-6- methylphenyl)acetimidamide (154a & 154b, 200 mg). LCMS (ESI) Calcd for C17H17F3N4O2: 366.3, found [M+H]+ = 367. LCMS (ESI) Calcd for C15H15F3N4O2: 340.3, found [M+H]+ = 341.2. [0991] Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2-fluoro-6- methylphenyl)cyclopropyl)-1,2,4-oxadiazole & 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3- (2-fluoro-6-methylbenzyl)-1,2,4-oxadiazole, Example 142 & 155 [Step 5]: (Z)-N'-((5- (difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)-1-(2-fluoro-6- methylphenyl)cyclopropane-1-carboximidamide and (Z)-N'-((5-(difluoromethyl)-1-methyl-1H- pyrazole-3-carbonyl)oxy)-2-(2-fluoro-6-methylphenyl)acetimidamide (Example 142 & 155, 200 mg) in THF (2 mL), tetrabutylammonium hydroxide (0.2 ml, 0.02 mmol) was added and the reaction mixture was stirred at ambient temperature for 60 min. After completion, the reaction mixture was concentrated under reduced pressure, dissolved in ethyl acetate and washed with water(twice). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by reverse phase RP prep to afford 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2-fluoro-6- methylphenyl)cyclopropyl)-1,2,4-oxadiazole (Example 142, 15 mg) and 5-(5-(difluoromethyl)-1- methyl-1H-pyrazol-3-yl)-3-(2-fluoro-6-methylbenzyl)-1,2,4-oxadiazole (155, 30 mg).1H NMR (400 MHz, DMSO-d6)( Example 142): δH 7.51-7.22 (m, 3H), 7.09-7.02 (m,2H), 4.05 (s,3H), 2.33 (s,3H), 1.74 (s, 2H), 1,42 (s, 2H). LCMS (ESI) Calcd for C17H15F3N4O: 348.3, found [M+H]+ = 349.2.1H NMR (400 MHz, DMSO-d6) (155) δH 7.50-7.22 (m, 3H), 7.08-7.03 (m, 2H), 4.18 (s, 2H), 4.04 (s, 3H), 2.36 (s, 3H). LCMS (ESI) Calcd for C15H13F3N4O: 322.2, found [M+H]+ = 323.1. Example 143: Synthesis of 3-(1-(2-chloro-6-methylphenyl)cyclopropyl)-5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 143)
Figure imgf000275_0001
[0992] Synthesis of 2-(bromomethyl)-1-chloro-3-methylbenzene, 157 [Step 1]: To a suspension of (2-chloro-6-methylphenyl)methanol (156, 600 mg, 3.8 mmol) in dichloromethane, PBr3 (0.4 mL, 4.2 mmol) was added drop wise at 0 °C and the reaction mixture was stirred at same temperature for 45 min. After completion, the reaction mixture was quenched with NaHCO3 solution and extracted with dichloromethane (thirce). The combined organic extract was washed with brine and dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford 2-(bromomethyl)-1-chloro-3-methyl-benzene (157, 700 mg).1HNMR (400 MHz, DMSO-d6) δH 7.51-7.22 (m, 5H), 4.05 (s, 3H), 2.36 (s, 3H), 1.91-1.77 (m, 2H), 1.48-1.46 (m, 2H). [0993] Synthesis of 2-(2-chloro-6-methylphenyl)acetonitrile, 158 [Step 2]: To a stirred solution of 2-(bromomethyl)-1-chloro-3-methyl-benzene (157, 600 mg, 2.7 mmol) in acetonitrile (8 mL), K2CO3 (380 mg, 2.7 mmol) was added followed by trimethylsilylformonitrile (0.3 mL, 2.7 mmol) and the reaction mixture was heated at 100 °C for 16h. After completion, the reaction mixture was dissolved in ethyl acetate, washed with water (thrice) and brine. The organic extract was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford 2-(2- chloro-6-methyl-phenyl)acetonitrile (158, 550 mg). IR spectra showed cyanide peak and also NMR consistent with desired product.1HNMR (400 MHz, DMSO-d6) δH 7.39-7.37 (d, 1H), 7.31- 7.25 (m, 2H), 4.04 (s, 2H), 2.40 (s, 3H). [0994] Synthesis of 1-(2-chloro-6-methylphenyl)cyclopropane-1-carbonitrile, 159 [Step 3]: To a stirred solution of NaOH (1.7 g, 43.5 mmol) in water (10 mL), 2-(2-chloro-6-methyl- phenyl)acetonitrile (158, 600 mg, 3.6 mmol), 1,2-dibromoethane (0.3 mL, 3.6 mmol) and TBAB (235 mg, 0.7 mmol) were added and the reaction mixture was heated at 60 oC for 12h. After completion, the reaction mixture was poured into cold water and extracted with ethyl acetate (thrice). Combined organic extract was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford 1-(2-chloro-6-methyl- phenyl)cyclopropanecarbonitrile (159, 550 mg).1HNMR (400 MHz, DMSO-d6) δH 7.42-7-15 (m, 3H), 1.57 (s, 2H), 1.40 (s, 2H), 0.92 (s, 3H). [0995] Synthesis of (Z)-1-(2-chloro-6-methylphenyl)-N'-hydroxycyclopropane-1- carboximidamide, 160 [Step 4]: To a stirred solution of 1-(2-chloro-6-methyl- phenyl)cyclopropanecarbonitrile (159, 700 mg, 3.6 mmol) in ethanol (10 mL), sodium carbonate (775 mg, 7.3 mmol) and hydroxylamine hydrochloride (510 mg, 7.3 mmol) were added and the reaction was heated at 70 °C for 12h. After completion, the volatiles were evaporated under reduced pressure, dissolved in water and extracted with ethyl acetate (thrice). Combined organic extract was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by column chromatography to afford 1-(2- chloro-6-methyl-phenyl)-N'-hydroxy-cyclopropanecarboxamidamide (160, 250 mg). LCMS (ESI) Calcd for C11H13ClN2O: 224.1, found [M+H]+ = 225.2. [0996] Synthesis of (Z)-1-(2-chloro-6-methylphenyl)-N'-((5-(difluoromethyl)-1-methyl-1H- pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide, 161 [Step 5]: To a solution of 5- (difluoromethyl)-1-methyl-pyrazole-3-carboxylic acid (150 mg, 0.8 mmol) and 1-(2-chloro-6- methyl-phenyl)-N'-hydroxy-cyclopropanecarboxamidine (160, 210 mg, 0.9 mmol) in dichloromethane (5 mL), DIPEA (0.5 mL, 2.6 mmol), EDCI.HCl (245 mg, 1.3 mmol) and HOAt (10 mg, 0.1 mmol) were added at 0 °C and the reaction mixture was stirred at ambient temperature for 16h. After completion, the reaction mixture was diluted with dichloromethane and partitioned with water. Combined organic extract was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by combiflash column chromatography to afford (Z)-1-(2-chloro-6-methylphenyl)-N'-((5-(difluoromethyl)-1-methyl-1H- pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide (161, 130 mg). LCMS (ESI) Calcd for C17H17ClF2N4O2: 382.1, found [M+H]+ = 383.1. [0997] Synthesis of 3-(1-(2-chloro-6-methylphenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-methyl- 1H-pyrazol-3-yl)-1,2,4-oxadiazole, Example 143 [Step 6]: To a stirred solution of (Z)-1-(2-chloro- 6-methylphenyl)-N'-((5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1- carboximidamide (161, 110 mg, 0.3 mmol) in THF (5 mL), tetrabutylammonium hydroxide (0.02 mL, 0.02 mmol, 1M in methanol) was added and the resulting reaction mixture was stirred for 12h at ambient temperature. Reaction was monitored by LCMS. After completion, the reaction mixture was concentrated under reduced pressure, dissolved in ethyl acetate and washed with water(twice). The combined organic extract was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by reverse phase prep-HPLC to afford 3-(1-(2-chloro-6-methylphenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3- yl)-1,2,4-oxadiazole (Example 143, 13 mg). LCMS (ESI) Calcd for C17H15ClF2N4O: 364.1, found [M+H]+ = 365.2.1HNMR (400 MHz, DMSO-d6) δH 7.51-7.22 (m, 5H), 4.05 (s, 3H), 2.36 (s, 3H), 1.90-1.86 (m, 1H), 1.79-1.78 (m, 1H), 1.48-1.45 (m, 2H). Example 144: Synthesis of 3-(1-(5-bromo-2-methylphenyl)cyclopropyl)-5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 144)
Figure imgf000277_0001
[0998] Synthesis of 4-bromo-2-(bromomethyl)-1-methylbenzene, 163 [Step 1]: To a suspension of (5-bromo-2-methylphenyl) methanol (162, 1.5 g, 7.5 mmol) in dichloromethane (10 mL), PBr3 (0.8 mL, 8.2 mmol) was added drop wise at 0 °C and the reaction mixture was stirred at same temperature for 1h. After completion, the reaction mixture was quenched with aqueous NaHCO3 solution and partitioned with dichloromethane. The combined organic layer was washed with brine and dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford 4- bromo-2-(bromomethyl)-1-methylbenzene (163, 1.1 g).1H NMR (400 MHz, DMSO-d6) δH 7.63 (s, 1H), 7.42 (d, 1H), 7.18 (d, 1H), 4.68 (d, 2H), 2.31 (s, 3H). GCMS (ESI) Calcd. For C8H8Br2: 263.6, found [M]+ = 264.0. [0999] Synthesis of 2-(5-bromo-2-methylphenyl) acetonitrile, 164 [Step 2]: To a stirred solution of 4-bromo-2-(bromomethyl)-1-methylbenzene (163, 1.1 g, 4.2 mmol) in acetonitrile (10 mL), K2CO3 (575 mg, 4.2 mmol) was added followed by trimethylsilyl formonitrile (0.5 mL, 4.2 mmol) and the reaction mixture was heated at 100 °C for 16 h. After completion, the reaction mixture was dissolved in ethyl acetate, washed with water and brine. The organic extract was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford 2-(5-bromo-2- methylphenyl) acetonitrile (164, 845 mg).1H NMR (400 MHz, DMSO-d6) δH 7.49 (s, 1H), 7.37 (d, 1H), 7.35 (d, 1H), 3.62 (s, 2H), 2.28 (d, 3H). GCMS (ESI) Calcd. For C9H8BrN: 209.0, found [M]+ = 209.0. [1000] Synthesis of 1-(5-bromo-2-methylphenyl) cyclopropane-1-carbonitrile, 165 [Step 3]: To a stirred solution of NaOH (1.9 g, 48.3 mmol) in water (4 mL), 2-(5-bromo-2-methylphenyl) acetonitrile (164, 845 mg, 4.0 mmol), TBAB (260 mg, 0.8 mmol) and 1,2-dibromoethane (3.0 mL, 20.1 mmol) were added and the resultant reaction mixture was heated at 60 °C for 12 h. After completion, the reaction mixture was poured into cold water and extracted with ethyl acetate. Combined organic extract was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford 1-(5-bromo-2-methylphenyl) cyclopropane-1-carbonitrile (165, 930 mg).1H NMR (400 MHz, DMSO-d6) δH 7.59 (s, 1H), 7.49 (t, 1H), 7.24 (d, 1H), 2.30 (s, 3H), 1.73-1.63 (m, 2H), 1.46-1.41 (m, 2H). GCMS (ESI) Calcd. for C11H10BrN: 236.1, found [M]+ = 237.1. [1001] Synthesis of 1-(5-bromo-2-methylphenyl)-N'-hydroxycyclopropane-1-carboximidamide, 166 [Step 4]: To a stirred solution of 1-(5-bromo-2-methylphenyl) cyclopropane-1-carbonitrile (165, 930 mg, 3.9 mmol) in ethanol (10 mL), sodium carbonate (835 mg, 7.9 mmol) and hydroxylamine hydrochloride (545 mg, 7.9 mmol) were added and the reaction was heated at 70 °C for 16 h. After completion, the volatiles were evaporated under reduced pressure, dissolve in water and extracted with ethyl acetate. Combined organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by combi flash column chromatography to afford 1-(5-bromo-2-methylphenyl)-N'- hydroxycyclopropane-1-carboximidamide (166, 775 mg). LCMS (ESI) Calcd. for C11H13BrN2O: 269.1, found [M+H]+ = 269.0. [1002] Synthesis of 1-(5-bromo-2-methylphenyl)-N'-((5-(difluoromethyl)-1-methyl-1H-pyrazole-3- carbonyl)oxy)cyclopropane-1-carboximidamide, 167 [Step 5]: To a stirred solution of 5- (difluoromethyl)-1-methyl-1H-pyrazole-3-carboxylic acid (150 mg, 0.9 mmol) and 1-(5-bromo-2- methylphenyl)-N'-hydroxycyclopropane-1-carboximidamide (166, 252 mg, 0.9 mmol) in dichloromethane (4 mL), DIPEA (0.5 mL, 2.6 mmol), EDCI.HCl (245 mg, 1.3 mmol) and HOAt (10 mg, 0.1 mmol) were added at 0 °C and the reaction mixture was stirred at ambient temperature for 16h. After completion, the reaction mixture was diluted with dichloromethane and partitioned with water. Combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by combi flash column chromatography to afford 1-(5-bromo-2-methylphenyl)-N'-((5-(difluoromethyl)-1-methyl-1H- pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide (167, 360 mg). LCMS (ESI) Calcd. For C17H17BrF2N4O2: 427.2, found [M+H]+ = 427.1. [1003] Synthesis of 3-(1-(5-bromo-2-methylphenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-methyl- 1H-pyrazol-3-yl)-1,2,4-oxadiazole, Example 144 [Step 6]: To a stirred solution of 1-(5-bromo-2- methylphenyl)-N'-((5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1- carboximidamide (167, 235 mg, 0.55 mmol) in THF (5 mL), tetrabutylammonium hydroxide (29 mg, 0.1 mmol, 1M in methanol) was added and the resulting reaction mixture was stirred at ambient temperature for 2 h. After completion, the reaction mixture was concentrated under reduced pressure, dissolved in ethyl acetate and washed with water. The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by reverse phase prep-HPLC to afford 3-(1-(5-bromo-2- methylphenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 144, 30 mg).1HNMR (400 MHz, DMSO-d6) δH 7.54 (d, 1H), 7.44-7.39 (m, 3H), 7.28- 7.18 (m, 1H), 4.04 (s, 3H), 2.22 (s, 3H), 1.65 (d, 2H), 1.45-1.42 (q, 2H). LCMS (ESI) Calcd. For C17H15BrF2N4O: 409.2, found [M-H]- = 408.9. Example 145: Synthesis of (3-(1-(5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4- oxadiazol-3-yl)cyclopropyl)-4-methylphenyl)methanol (Example 145)
Figure imgf000279_0001
[1004] Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(2-methyl-5- vinylphenyl)cyclopropyl)-1,2,4-oxadiazole, 169 [Step 1]: To a stirred solution of potassium vinyl trifluoroborate (2, 80 mg, 0.6 mmol) in 1,4-dioxane (8 mL):Water (2mL) mixture, K2CO3 (255 mg, 1.8 mmol) and 3-(1-(5-bromo-2-methylphenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-methyl-1H- pyrazol-3-yl)-1,2,4-oxadiazole (168, 250 mg, 0.6 mmol) were added and degassed for 10 min. Pd(PPh3)4 (70 mg, 0.1 mmol) was then added to the reaction mixture and heated at 100 °C for 12 h. After completion, reaction mixture was filtered through celite bed, washed with ethyl acetate, dried over anhydrous Na2SO4, concentrated under reduced pressur and purified by combi flash column chromatography to afford 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3- (1-(2-methyl-5-vinylphenyl)cyclopropyl)-1,2,4-oxadiazole (169, 185 mg). LCMS (ESI) Calcd. For C19H18F2N4O: 356.3, found [M+H]+ = 357.4.1H NMR (400 MHz, DMSO-d6) δH 7.50-7.46 (m, 2H), 7.35 (d, 1H), 7.27 (s, 1H), 7.23-7.18 (m, 1H), 6.75-6.68 (m, 1H), 5.79 (t, 1H), 5.22 (d, 1H), 4.04 (s, 3H), 2.25 (s, 3H), 1.66 (s, 2H), 1.42 (s, 2H). [1005] Synthesis of 3-(1-(5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3- yl)cyclopropyl)-4-methylbenzaldehyde, 170 [Step 2]: To a solution of 5-(5-(difluoromethyl)-1- methyl-1H-pyrazol-3-yl)-3-(1-(2-methyl-5-vinylphenyl) cyclopropyl)-1,2,4-oxadiazole (169, 130 mg, 0.4 mmol) in acetone (8 mL) and water (2 mL) mixture, was added NMO (85 mg, 0.7 mmol) followed by the addition of OsO4 (0.4 mL, 0.04 mmol, 4% in water) and continue to stir at 0 °C for 2h. Then NaIO4 (385 mg, 1.8 mmol) was added to the reaction mixture at ice cold condition and the reaction mixture was stirred at ambient temperature for 3h. TLC showed full conversion of starting material with formation of new nonpolar spot. The reaction mixture was diluted with EtOAc and washed with water and brine. It was dried over Na2SO4, filtered and concentrated under reduced pressure to afford 3-(1-(5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4- oxadiazol-3-yl)cyclopropyl)-4-methylbenzaldehyde (170, 120 mg). LCMS (ESI) Calcd. For C18H16F2N4O2: 358.3, found [M+H]+ = 359.0. [1006] Synthesis of (3-(1-(5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3- yl)cyclopropyl)-4-methylphenyl)methanol, Example 145 [Step 3]: To a stirred solution of 3-(1-(5- (5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3-yl)cyclopropyl)-4- methylbenzaldehyde (170, 140 mg, 0.4 mmol) in methanol (6 mL), sodium borohydride (30 mg, 0.78 mmol) was added and the reaction mixture was stirred at ambient temperature for 16 h. After completion, the reaction mixture was diluted with ethyl acetate and washed with water and brine. It was dried over Na2SO4, filtered and concentrated under reduced pressure. The product was purified by reverse phase prep-HPLC to afford (3-(1-(5-(5-(difluoromethyl)-1-methyl-1H- pyrazol-3-yl)-1,2,4-oxadiazol-3-yl)cyclopropyl)-4-methylphenyl)methanol (Example 145, 85 mg). 1H NMR (400 MHz, DMSO-d6) δH 7.50 (s, 1H), 7.37-7.23 (m, 2H), 7.16 (t, 2H), 5.12 (t, 1H), 4.46 (d, 2H), 4.04 (s, 3H), 2.24 (s, 3H), 1.65 (d, 2H), 1.38-1.36 (q, 2H). LCMS (ESI) Calcd. For C18H18F2N4O2: 360.3, found [M+H]+: 361.2. Example 146: Synthesis of 3-(1-(2-(cyclopentyloxy)phenyl)cyclopropyl)-5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 146) Scheme 79 [1007] Synthesis of 2-(2-(cyclopentyloxy)phenyl)acetonitrile, 172 [Step 1]: To a stirred solution of 2-(2-hydroxyphenyl)acetonitrile (171, 500 mg, 4 mmol) and bromocyclopentane (840 mg, 5.5 mmol) in DMSO (5 mL), K2CO3 was added (1.0 g, 7.5 mmol). The reaction mixture was heated at 60 °C for 16 h. After completion, the reaction mixture was diluted with ethyl acetate, washed with water (thrice), brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford 2-(2-(cyclopentyloxy)phenyl)acetonitrile (3, 500 mg).1HNMR (400 MHz, DMSO-d6) δH 7.32-7.28 (m, 2H), 7.03 (d, 1H), 6.91 (t, 1H), 4.92-4.89 (m, 2H), 1.90-1.86 (m, 2H), 1.75 (s, 4H), 1.60 (brs, 2H). [1008] Synthesis of 1-(2-(cyclopentyloxy)phenyl)cyclopropane-1-carbonitrile, 173 [Step 2]: To a stirred solution of NaOH (1.3 g, 32 mmol) in water (3 mL), 2-(2- (cyclopentyloxy)phenyl)acetonitrile (172, 500 mg, 3.0 mmol), TBAB (180 mg, 0.5 mmol) and 1,2- dibromoethane (1.5 mL, 10 mmol) were added and the reaction mixture was heated at 60 °C for 12h. After completion, the reaction mixture was poured into cold water and extracted with ethyl acetate (thrice). Combined organic extract was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford 1-(2- (cyclopentyloxy)phenyl)cyclopropane-1-carbonitrile (173, 400 mg). GCMS Calcd. For C15H17NO: 227.3, [M/Z] = 227.1. [1009] Synthesis of (Z)-1-(2-(cyclopentyloxy)phenyl)-N'-hydroxycyclopropane-1- carboximidamide, 174 [Step 3]: To a stirred solution of 1-(2- (cyclopentyloxy)phenyl)cyclopropane-1-carbonitrile (173, 300 mg, 1.3 mmol) in ethanol (2 mL), hydroxylamine hydrochloride (180 mg, 2.5 mmol) and sodium carbonate (280 mg, 2.5 mmol) were added and the reaction was heated at 70 °C for 12h. After completion, the volatiles were evaporated under reduced pressure, dissolved in water and extracted with ethyl acetate( thrice). Combined organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified through column chromatography to afford (Z)-1-(2-(cyclopentyloxy)phenyl)-N'-hydroxycyclopropane-1- carboximidamide (174, 130 mg). LCMS (ESI) Calcd for C15H20N2O2: 260.3, found [M+H]+ = 261.3. [1010] Synthesis of (Z)-1-(2-(cyclopentyloxy)phenyl)-N'-((5-(difluoromethyl)-1-methyl-1H- pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide, 175 [Step 4]: To a solution of (Z)-1- (2-(cyclopentyloxy)phenyl)-N'-hydroxycyclopropane-1-carboximidamide (174, 130 mg, 0.5 mmol) and 5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carboxylic acid (80 mg, 0.4 mmol) in 1,2- dichloromethane (4 mL), DIPEA (0.3 mL, 1.4 mmol), EDCI.HCl (135 mg, 0.7 mmol) and HOAt (7 mg, 0.05 mmol) were added at 0 °C and the reaction mixture was stirred at ambient temperature for 16 h. After completion, the reaction mixture was diluted with dichloromethane and partitioned with water. Combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford (Z)-1-(2-(cyclopentyloxy)phenyl)-N'-((5- (difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide (175, 120 mg). LCMS (ESI) Calcd for C21H24F2N4O3: 418.4, found [M+H]+ = 419.4. [1011] Synthesis of 3-(1-(2-(cyclopentyloxy)phenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-methyl- 1H-pyrazol-3-yl)-1,2,4-oxadiazole, Example 146 [Step 5]: To a stirred solution of (Z)-1-(2- (cyclopentyloxy)phenyl)-N'-((5-(difluoromethyl)-1-methyl-1H-pyrazole-3- carbonyl)oxy)cyclopropane-1-carboximidamide (175, 100 mg, 0.2 mmol) in THF (2 mL), tetrabutylammonium hydroxide (12 mg, 0.05 mmol, 1 M in methanol) was added. The resulting reaction mixture was stirred at ambient temperature for 16 h. The reaction mixture was concentrated under reduced pressure, dissolved in ethyl acetate, washed with water, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by reverse phase prep HPLC purification to afford 3-(1-(2-(cyclopentyloxy)phenyl)cyclopropyl)- 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 146, 65 mg).1H NMR (400 MHz, DMSO-d6) (at 100 °C) δH 7.44-7.17 (m, 4H), 6.97-6.88 (m, 2H), 4.82 (brs, 1H), 4.04 (s, 3H), 1.77 (brs, 2H), 1.63-1.57 (m, 4H), 1.48 (s, 4H), 1.28 (s, 2H). LCMS (ESI) Calcd for C21H22F2N4O2: 400.4, found [M-H]+ = 401.2. Example 147: Synthesis of 3-(1-(5-chloro-2-methylphenyl)cyclopropyl)-5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 147)
Figure imgf000283_0001
[1012] Synthesis of 4-chloro-2-(chloromethyl)-1-methylbenzene, 177 [Step 1]: To a stirred solution of 5-chloro-2-methyl-phenyl)methanol (176, 1.5 g, 9.6 mmol) in dry dichloromethane (10 mL), thionyl chloride (2.1 mL, 28.7 mmol) and DMF (2.3 mL, 28.7 mmol) were added at 0 °C. Resulting reaction mixture was stirred at ambient temperature for 16 h, diluted with dichloromethane and washed with saturated solution of sodium bicarbonate followed by brine wash. Combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by flash column chromatography to afford 4-chloro-2-(chloromethyl)-1-methyl-benzene (177, 1.5 g).1H NMR (400 MHz, CDCl3): δH 7.30-7.29 (m, 1H), 7.21-7.18 (m, 1H), 7.12-7.10 (m, 1H), 4.53 (s, 2H), 2.37 (s, 3H). [1013] Synthesis of 2-(5-chloro-2-methylphenyl)acetonitrile, 178 [Step 2]: To a stirred solution of 4-chloro-2-(chloromethyl)-1-methyl-benzene (177, 3.0 g, 17.1 mmol) in acetonitrile (20 mL), potassium carbonate (2.3 g, 17.1 mmol) and trimethylsilylformonitrile (2.1 mL, 17.1 mmol) were added. Resulting reaction mixture was stirred at 90 °C for 16 h and concentrated under reduced pressure. The residue was diluted with ethyl acetate and washed with water followed by brine wash. Combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford 2-(5-chloro-2-methyl-phenyl)acetonitrile (178, 2.5 g). LCMS (ESI) Calcd. for C9H8ClN: 165.0, found [M-H]- = 164.2.1H NMR (400 MHz, CDCl3): δH 7.35 (s, 1H), 7.23-7.21 (m, 1H), 7.14 (d, 1H), 3.63 (s, 2H), 2.30 (s, 3H). [1014] Synthesis of 1-(5-chloro-2-methylphenyl)cyclopropane-1-carbonitrile, 179 [Step 3]: To a stirred solution of 2-(5-chloro-2-methyl-phenyl)acetonitrile (178, 1.5 g, 9.1 mmol) in DMF (40 mL), sodium hydride (1.0 g, 27.2 mmol) was added at 0 °C. The resulting suspension was allowed to stir at ambient temperature for 1 h, cooled to 0 °C and a solution of 1,2- dibromoethane (2.3 mL, 27.2 mmol) in DMF (10 mL) was added. The reaction mixture was allowed to stir at ambient temperature for 16 h, quenched with ice cold water and extracted with ethyl acetate. Combined organic extracts were washed with brine, dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford 1-(5-chloro-2-methyl- phenyl)cyclopropanecarbonitrile (179, 2.1 g). The product was carried to next step without further purification. [1015] Synthesis of (Z)-1-(5-chloro-2-methylphenyl)-N'-hydroxycyclopropane-1- carboximidamide, 180 [Step 4]: To a stirred solution of 1-(5-chloro-2-methyl- phenyl)cyclopropanecarbonitrile (179, 2.0 g, 10.4 mmol) in ethanol (20 mL), hydroxylamine hydrochloride (1.4 g, 20.9 mmol) and sodium carbonate (2.2 g, 20.9 mmol) were added. The reaction mixture was stirred at 80 °C for 16 h and volatiles were evaporated. The residue was diluted with ethyl acetate and washed with water followed by brine wash. Combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by flash chromatography to afford (Z)-1-(5-chloro-2- methylphenyl)-N'-hydroxycyclopropane-1-carboximidamide (180, 980 mg). LCMS (ESI) Calcd. for C11H13ClN2O: 224.1, found [M+H]+ = 225.2. [1016] Synthesis of (Z)-1-(5-chloro-2-methylphenyl)-N'-((5-(difluoromethyl)-1-methyl-1H- pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide, 181 [Step 5]: To a stirred solution of (Z)-1-(5-chloro-2-methylphenyl)-N'-hydroxycyclopropane-1-carboximidamide (180, 200 mg, 0.9 mmol) in dry dichloromethane (8 mL), DIPEA (0.4 mL, 2.2 mmol), EDC.HCl (205 mg, 1.1 mmol), HOAt (24 mg, 0.2 mmol) and 5-(difluoromethyl)-1-methyl-pyrazole-3-carboxylic acid (157 mg, 0.9 mmol) were added. Resulting reaction mixture was stirred at ambient temperature for 16 h, diluted with dichloromethane and washed with water followed by brine wash. Combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford (Z)-1-(5-chloro-2-methylphenyl)-N'-((5-(difluoromethyl)-1-methyl-1H- pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide (181, 350 mg). LCMS (ESI) Calcd. for C17H17ClF2N4O2: 382.1, found [M + H]+ = 383.3. The product was carried to next step without further purification. [1017] Synthesis of 3-(1-(5-chloro-2-methylphenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-methyl- 1H-pyrazol-3-yl)-1,2,4-oxadiazole, Example 147 [Step 6]: A solution of (Z)-1-(5-chloro-2- methylphenyl)-N'-((5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1- carboximidamide (181, 470 mg, 1.2 mmol) and tetra butyl ammonium hydroxide (0.16 mL, 0.25 mmol) in THF (10 mL) was stirred at ambient temperature for 16 h and volatiles were evaporated under reduced pressure. The product was purified by reverse phase preparative- HPLC to give 3-(1-(5-chloro-2-methylphenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-methyl-1H- pyrazol-3-yl)-1,2,4-oxadiazole (Example 147, 147 mg). LCMS (ESI) Calcd. for C17H15ClF2N4O: 364.1, found [M+H]+ = 365.1.1H NMR (400 MHz, DMSO-d6): δH 7.42-7.27 (m, 5H), 4.05 (s, 3H), 2.24 (s, 3H), 1.66 (brs, 2H), 1.44 (brs, 2H). Examples 148 & 149: Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(5- methoxy-2-methylphenyl)cyclopropyl)-1,2,4-oxadiazole (Example 148) and 3-(1-(5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3-yl)cyclopropyl)-4- methylphenol (Example 149)
Figure imgf000285_0001
[1018] Synthesis of 2-(chloromethyl)-4-methoxy-1-methylbenzene, 183 [Step 1]: To a stirred solution of (5-methoxy-2-methylphenyl)methanol (182, 1.1 g, 6.8 mmol) in dry dichloromethane (10 mL), thionyl chloride (1.4 mL, 19.7 mmol) and DMF (1.6 mL, 19.7 mmol) were added at 0 °C. Resulting reaction mixture was stirred at ambient temperature for 16 h, diluted with dichloromethane and washed with saturated solution of sodium bicarbonate followed by brine wash. Combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by flash column chromatography to afford 2-(chloromethyl)-4-methoxy-1-methylbenzene (183, 1.1 g).1H NMR (400 MHz, DMSO-d6): δH 7.13 (d, 1H), 6.98 (d, 1H), 6.84-6.81 (m, 1H), 4.73 (s, 2H), 3.72 (s, 3H), 2.29 (s, 3H). [1019] Synthesis of 2-(5-methoxy-2-methylphenyl)acetonitrile, 184 [Step 2]: To a stirred solution of 2-(chloromethyl)-4-methoxy-1-methylbenzene (183, 1.3 g, 7.6 mmol) in DMSO (5 mL), sodium cyanide (560 mg, 11.4 mmol) was added. Resulting reaction mixture was stirred at ambient temperature for 6 h, quenched with saturated solution of ferrous sulfate. The resulting aqueous solution was extracted with ethyl acetate and washed with water followed by brine wash. Combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford 2-(5-methoxy-2-methylphenyl)acetonitrile (184, 1 g).1H NMR (400 MHz, CDCl3): δH 7.10 (d, 1H), 6.91 (brs, 1H), 6.79-6.77 (m, 1H), 3.79 (s, 3H), 3.62 (s, 2H), 2.25 (s, 3H). [1020] Synthesis of 1-(5-methoxy-2-methylphenyl)cyclopropane-1-carbonitrile, 185 [Step 3]: To a stirred solution of 2-(5-methoxy-2-methylphenyl)acetonitrile (184, 500 mg, 3.1 mmol) in DMF (15 mL), sodium hydride (370 mg, 9.3 mmol) was added at 0 °C. The resulting suspension was allowed to stir at ambient temperature for 1 h, cooled to 0 °C and a solution of 1,2- dibromoethane (0.8 mL, 9.3 mmol) in DMF (5 mL) was added. The reaction mixture was allowed to stir at ambient temperature for 16 h, quenched with ice cold water and extracted with ethyl acetate. Combined organic extracts were washed with brine, dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford 1-(5-methoxy-2- methylphenyl)cyclopropane-1-carbonitrile (185, 800 mg). The product was carried to next step without further purification. [1021] Synthesis of (Z)-N'-hydroxy-1-(5-methoxy-2-methylphenyl)cyclopropane-1- carboximidamide, 186 [Step 4]: To a stirred solution of 1-(5-methoxy-2- methylphenyl)cyclopropane-1-carbonitrile (185, 800 mg) in ethanol (20 mL), hydroxylamine hydrochloride (650 mg, 9.4 mmol) and sodium carbonate (996 mg, 9.4 mmol) were added. The reaction mixture was stirred at 80 °C for 16 h and volatiles were evaporated. The residue was diluted with ethyl acetate and washed with water followed by brine wash. Combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by flash chromatography to afford (Z)-N'-hydroxy-1-(5- methoxy-2-methylphenyl)cyclopropane-1-carboximidamide (186, 300 mg). LCMS (ESI) Calcd. for C12H16N2O2: 220.1, found [M+H]+ = 221.2. [1022] Synthesis of (Z)-N'-((5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)-1-(5- methoxy-2-methylphenyl)cyclopropane-1-carboximidamide, 187 [Step 5]: To a stirred solution of (Z)-1-(5-chloro-2-methylphenyl)-N'-hydroxycyclopropane-1-carboximidamide (186, 300 mg, 1.4 mmol) in dry dichloromethane (10 mL), DIPEA (0.6 mL, 3.4 mmol), EDC.HCl (313 mg, 1.6 mmol), HOAt (37 mg, 0.2 mmol) and 5-(difluoromethyl)-1-methyl-pyrazole-3-carboxylic acid (239 mg, 1.4 mmol) were added. Resulting reaction mixture was stirred at ambient temperature for 16 h, diluted with dichloromethane and washed with water followed by brine wash. Combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford (Z)-N'-((5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)-1- (5-methoxy-2-methylphenyl)cyclopropane-1-carboximidamide (187, 450 mg). LCMS (ESI) Calcd. for C18H20F2N4O3: 378.1, found [M + H]+ = 379.2 The product was carried to next step without further purification. [1023] Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(5-methoxy-2- methylphenyl)cyclopropyl)-1,2,4-oxadiazole, Example 148 [Step 6]: A solution of (Z)-N'-((5- (difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)-1-(5-methoxy-2- methylphenyl)cyclopropane-1-carboximidamide (187, 640 mg, 1.6 mmol) and tetra butyl ammonium hydroxide (0.2 mL, 0.33 mmol) in THF (10 mL) was stirred at ambient temperature for 16 h and volatiles were evaporated under reduced pressure. The product was purified by reverse phase preparative HPLC to give 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(5- methoxy-2-methylphenyl)cyclopropyl)-1,2,4-oxadiazole (Example 148, 140 mg). LCMS (ESI) Calcd. for C18H18F2N4O2: 360.1, found [M+H]+ = 361.2.1H NMR (400 MHz, DMSO-d6): δH 7.50- 7.24 (m, 2H), 7.12 (d, 1H), 6.93 (d, 1H), 6.83-6.80 (m, 1H), 4.05 (s, 3H), 3.74 (s, 3H), 2.18 (s, 3H), 1.59-1.57 (m, 2H), 1.34-1.32 (s, 2H). [1024] Synthesis of 3-(1-(5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3- yl)cyclopropyl)-4-methylphenol, Example 149 [Step 7]: To a stirred solution of 5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(5-methoxy-2-methylphenyl)cyclopropyl)-1,2,4- oxadiazole (Example 148, 100 mg) in dichloromethane (5 mL) was cooled to -78 °C, boron tribromide (1M in dichloromethane) (1.6 mL, 1.7 mmol) was added dropwise and the reaction mixture was stirred at -78 °C. After 4 h, the reaction mixture was quenched saturated solution of sodium bicarbonate, extracted with dichloromethane, washed with water and brine. Combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by reverse phase preparative HPLC to give 3-(1-(5- (5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3-yl)cyclopropyl)-4-methylphenol (Example 149, 25 mg). LCMS (ESI) Calcd. for C17H16F2N4O2: 346.1, found [M+H]+ = 347.2.1H NMR (400 MHz, DMSO-d6): δH 9.17 (s, 1H), 7.50-7.24 (m, 2H), 6.98 (d, 1H), 6.77 (s, 1H), 6.63 (d, 1H), 4.04 (s, 3H), 2.13 (s, 3H), 1.61 (brs, 2H), 1.33 (brs, 2H). Example 150: Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(5-fluoro-2- methylphenyl)cyclopropyl)isoxazole (Example 150)
Figure imgf000288_0001
[1025] Synthesis of 1-(5-fluoro-2-methylphenyl)cyclopropane-1-carbonitrile, 189 [Step 1]: To a stirred solution of KOH (6.77 g, 121 mmol) in water(10 mL), 2-(5-fluoro-2-methyl- phenyl)acetonitrile (188, 1.5 g, 10.1 mmol) was added portion wise under inert atmosphere and stirred for 10 min. TBAB (648 mg, 2.0 mmol) and 1,2-dibromoethane (4.4 mL, 50.3 mmol) were added to the reaction mixture and stirred at 60 °C for 12 h. After completion (detected by TLC), the reaction mixture was poured into cold water and extracted with ethyl acetate. The combined organic extract was dried over Na2SO4 and concentrated under reduced pressure to afford 1-(5- fluoro-2-methylphenyl)cyclopropane-1-carbonitrile (1.20 g, 61% yield) .1H NMR (400 MHz, DMSO-d6) δ 7.30 (t, 1H), 7.22 - 7.19 (m, 1H), 7.15 - 7.10 (m, 1H), 2.43 (s, 3H), 1.69 - 1.67 (m, 2H), 1.41 - 1.38 (m, 2H). [1026] Synthesis of 1-(5-fluoro-2-methylphenyl)cyclopropane-1-carbaldehyde, 190 [Step 2]: A two neck round bottom flask was charged with 1-(5-fluoro-2-methylphenyl)cyclopropane-1- carbonitrile (189, 500 mg, 2.9 mmol) in Toluene (5mL) at -78 °C under inert atmosphere. DIBAL- H 1M solution in Toluene (3.7 mL, 3.7 mmol) was added dropwise to the reaction mixture and stirred for 2 h at -78 °C. After completion (detected by TLC), the reaction mixture was quenched with saturated NH4Cl and warmed upto ambient temperature. The reaction mixture was extracted with EtOAc. The combined organic extract was dried over Na2SO4 and concentrated under reduced pressure to afford 1-(5-fluoro-2-methylphenyl)cyclopropane-1-carbaldehyde (190, 300 mg, 58.9 % yield).1H NMR (400 MHz, DMSO-d6) δ 8.73 (s, 1H), 7.23-7.22 (m, 1H), 7.12 - 6.97 (m, 2H), 2.25 (s, 3H), 1.66 - 1.65 (m, 2H), 1.45-1.41 (m, 2H). [1027] Synthesis of (E)-1-(5-fluoro-2-methylphenyl)cyclopropane-1-carbaldehyde oxime, 191 [Step 3]: A round bottom flask was charged with 1-(5-fluoro-2-methylphenyl)cyclopropane-1- carbaldehyde (190, 300 mg, 1.7 mmol), NaOAc (276 mg, 3.4 mmol) and NH2OHHCl (234 mg, 3.4 mmol) in Methanol (5mL). The reaction mixture was stirred at ambient temperature for 12 h. After completion (detected by TLC), the reaction mixture was quenched with water and extracted with EtOAc. The combined organic extract was dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford (E)-1-(5-fluoro-2-methylphenyl)cyclopropane-1- carbaldehyde oxime (191, 320 mg, 98 % yield).1H NMR (400 MHz, DMSO-d6) δ 10.39 (s, 1H), 7.16-7.13 (m, 1H), 7.02-6.93 (m, 3H), 2.25 (s, 3H), 1.23-1.19 (m, 2H), 1.17-1.07 (m, 2H). [1028] Synthesis of (Z)-1-(5-fluoro-2-methylphenyl)-N-hydroxycyclopropane-1-carbimidoyl chloride, 192 [Step 4]: To a stirred solution of (E)-1-(5-fluoro-2-methylphenyl)cyclopropane-1- carbaldehyde oxime (191, 100 mg, 0.5 mmol) in DMF (3mL) was added NCS (76 mg, 0.6 mmol) at ambient temperature and stirred for 1 h. After completion (monitored by TLC), the reaction mixture was quenched with water and extracted with EtOAc. The combined EtOAc extract was washed with iced water, brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude was used for next step without any purification. [1029] Synthesis of 5-(difluoromethyl)-N-methoxy-N,1-dimethyl-1H-pyrazole-3-carboxamide, 194 [Step 5]: To a stirred solution of 5-(difluoromethyl)-1-methyl-pyrazole-3-carboxylic acid (193, 300 mg, 1.7 mmol) in dichloromethane (3mL), N-methoxymethanamine;hydrochloride (183 mg, 1.9 mmol), N-Methylmorpholine (0.21 mL, 1.9 mmol), and EDC.HCl (359 mg, 1.9 mmol) were added subsequently under inert atmosphere and stirred at ambient temperature for 12 h. After completion, the reaction mixture was quenched with water and extracted with dichloromethane. The combined organic extract was dried over Na2SO4 and concentrated under reduced pressure to afford 5-(difluoromethyl)-N-methoxy-N,1-dimethyl-1H-pyrazole-3-carboxamide (194, 290 mg, 77% yield).1H NMR (400 MHz, CDCl3) δ 6.95 (s, 1H), 6.72 (t, 1H), 4.04 (s, 3H), 3.74 (s, 3H), 3.41 (s, 3H). [1030] Synthesis of 5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carbaldehyde, 195 [Step 6]: A stirred solution of 5-(difluoromethyl)-N-methoxy-N,1-dimethyl-pyrazole-3-carboxamide (194, 350 mg, 1.6 mmol) in toluene (10mL), was added DIBAL-H 1M solution in toluene (568 mg, 3.4 mmol) dropwise at -78 °C under inert atmosphere and stirred for 2 h. After completion (monitored by TLC), the reaction mixture was quenched with saturated NH4Cl solution at -78 °C and warmed up to ambient temperature. The reaction mixture was extracted with EtOAc. The combined organic extract was dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford 5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carbaldehyde (195, 290 mg, 96 % yield).1H NMR (400 MHz, DMSO-d6) δ 9.88 (s, 1H), 7.33 (t, 1H), 7.06 (s, 1H), 4.04 (s, 3H). [1031] Synthesis of 5-(difluoromethyl)-3-ethynyl-1-methyl-1H-pyrazole, 196 [Step 7]: To a stirred solution of 5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carbaldehyde (195, 60 mg, 0.4 mmol) in methanol (5mL), 1-diazo-1-dimethoxyphosphoryl-propan-2-one (94 mg, 0.5 mmol) and K2CO3 (104 mg, 0.8 mmol) were added at 0 °C and the resulting yellow suspension was stirred at ambient temperature for 16 h. After completion, (analyzed by TLC), the reaction mixture was quenched with water and extracted with EtOAc. The combined organic extract was dried over Na2SO4 and concentrated under reduced pressure to afford desired product 5-(difluoromethyl)- 3-ethynyl-1-methyl-1H-pyrazole (196, 40 mg, 41% yield).1H NMR (400 MHz, DMSO-d6) δ 7.28 (t, 1H), 6.81 (s, 1H), 4.22 (s, 1H), 3.89 (s, 3H). [1032] Synthesis of 5-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(5-fluoro-2- methylphenyl)cyclopropyl)isoxazole, Example 150 [Step 8]: A round bottom flask was charged with (1Z)-1-(5-fluoro-2-methyl-phenyl)-N-hydroxy-cyclopropanecarboximidoyl chloride (192, 150 mg, 0.7 mmol) and 5-(difluoromethyl)-3-ethynyl-1-methyl-pyrazole (103 mg, 0.7 mmol) in THF (2mL) followed by Et3N (0.2 mL, 1.3 mmol) was added at ambient temperature and stirred for 16 h. After completion (monitored by TLC), the reaction mixture was quenched with water and extracted with EtOAc. The combined organic extract was dried over anhydrous Na2SO4 and concentrated under reduced pressure and purified by reverse phase HPLC to afford 5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-3-(1-(5-fluoro-2-methylphenyl)cyclopropyl)isoxazole (Example 150, 18 mg, 7.8 % yield).1H NMR (400 MHz, DMSO-d6): δ 7.34 (t, 1H), 7.22-7.19 (m, 2H), 7.08-7.03 (m, 2H), 6.48 (s, 1H), 3.95 (s, 3H), 2.20 (s, 3H), 1.52-1.49 (m, 2H), 1.36-1.23 (m, 2H). LC/MS: calculated for C18H16F3N3O [M]: 347.33, found, [M +H]+: 348.1. Example 151: Synthesis of 3-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-5-(1-(5-fluoro-2- methylphenyl)cyclopropyl)-1,2,4-oxadiazole (Example 151)
Figure imgf000290_0001
[1033] Synthesis of 5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carboxamide, 197 [Step 1: To a stirred solution of 5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carboxylic acid (87, 200 mg, 1.2 mmol) in THF (2mL) and DMF (1mL) were added HOBt (230 mg, 1.70 mmol),EDC.HCl (330 mg, 1.70 mmol) and DIPEA (0.62 mL, 4.6 mmol) followed by (NH4)2CO3 (440 mg, 4.6 mmol) and stirred the reaction mixture at ambient temperature for 17 h. After completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic extract was dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford 5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carboxamide (197, 100 mg). LCMS (ESI) Calcd. for C6H7F2N3O : 175.17; found :[M+H]+ : 175.9. [1034] Synthesis of 5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carbonitrile, 198 [Step 2]: To a stirred solution 5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carboxamide (197, 100 mg, 0.6 mmol) and triethylamine (0.20 mL, 1.6 mmol) in dichloromethane (2mL), was added Trifluoroacetic anhydride (0.1 mL, 0.8 mmol) at 0°C. The mixture was stirred at 0°C for 1 h and then the reaction mixture was stirred at ambient temperature for 2 h. After completion, the solvent was concentrated under reduce pressure and the residue was purified by silica gel column chromatography to afford 5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carbonitrile (198, 45 mg). GCMS (ESI) Calcd. for C6H5F2N3: 157.12; found: [M]+ : 157.1. [1035] Synthesis of (E)-5-(difluoromethyl)-N'-hydroxy-1-methyl-1H-pyrazole-3-carboximidamide, 199 [Step 3]: To a stirred suspension of 5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carbonitrile (198, 0.20 g, 1.3 mmol) and NH2OH.HCl (0.15 g, 1.9 mmol) in Water (1mL) was added NaHCO3 (0.16 g, 1.9 mmol) and the reaction mixture was refluxed for 6 h. After completion, concentrated the reaction mixture under reduced pressure. Dilute the residue with cold water (200 mL). Filter the resulting precipitate. Wash the resulting precipitate with cold water (50 mL) and dried under vacuum to obtain (E)-5-(difluoromethyl)-N'-hydroxy-1-methyl-1H-pyrazole-3- carboximidamide (199, 130 mg). LCMS (ESI) Calcd. for C6H8F2N4O :190.15; found: [M+H]+ : 191.0. [1036] Synthesis of (Z)-5-(difluoromethyl)-N'-((1-(5-fluoro-2-methylphenyl)cyclopropane-1- carbonyl)oxy)-1-methyl-1H-pyrazole-3-carboximidamide, 200 [Step 4]: To a stirred solution of 1- (5-fluoro-2-methylphenyl)cyclopropane-1-carboxylic acid (120 mg, 0.65 mmol) in DMA (2mL), DIPEA (0. mL, 1.3 mmol) was added followed by EDC.HCl (120 mg, 0.65 mmol) and HOBT (85 mg, 0.65 mmol) and the reaction mixture was allowed to stir for 10 min at 0°C. After that (E)-5- (difluoromethyl)-N'-hydroxy-1-methyl-1H-pyrazole-3-carboximidamide (199, 120 mg, 0.65 mmol) was added to the reaction mixture and the reaction mixture was allowed to stir at ambient temperature for 3 h. After completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic extract was dried with anhydrous Na2SO4 and purified by combi flash chromatography to afford (Z)-5-(difluoromethyl)-N'-((1-(5-fluoro-2- methylphenyl)cyclopropane-1-carbonyl)oxy)-1-methyl-1H-pyrazole-3-carboximidamide (200, 100 mg). LCMS (ESI) Calcd. for C17H17F3N4O2 : 366.3; found [M+H]+ = 367.2. [1037] Synthesis of 3-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-5-(1-(5-fluoro-2- methylphenyl)cyclopropyl)-1,2,4-oxadiazole, Example 151 [Step 5]: To a stirred solution of (Z)- 5-(difluoromethyl)-N'-((1-(5-fluoro-2-methylphenyl)cyclopropane-1-carbonyl)oxy)-1-methyl-1H- pyrazole-3-carboximidamide (200, 90 mg, 0.25 mmol) in acetonitrile (5mL) was added Tetrabutylammonium hydroxide (7 mg, 0.03 mmol) and the reaction mixture was allowed to stir at 120°C for 3 h. After completion, the reaction mixture was concentrated under reduced pressure and submitted for Prep-HPLC purification. After prep-purification followed by lyophilization to afford 3-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-5-(1-(5-fluoro-2- methylphenyl)cyclopropyl)-1,2,4-oxadiazole (Example 151, 30 mg) .LCMS (ESI) Calcd. for C17H15F3N4O : 348.32; found :[M]+ : 349.30.1H NMR (400 MHz, DMSO-d6): δH 7.46-7.27 (m, 3H), 7.16-7.13 (m, 1H), 7.04 (brs, 1H), 3.99 (s, 3H), 2.19 (s, 3H), 1.88-1.85 (t, 2H), 1.65-1.62 (t, 2H). Example 152: Synthesis of 2-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-5-(1-(5-fluoro-2- methylphenyl)cyclopropyl)-1,3,4-oxadiazole (Example 152) Scheme 84 [1038] Synthesis of 1-(5-fluoro-2-methylphenyl)cyclopropane-1-carbohydrazide, 202 [Step 1]: To a stirred solution of 1-(5-fluoro-2-methylphenyl)cyclopropane-1-carboxylic acid (201, 500 mg, 2.6 mmol) in DMA (2mL) was added DIPEA (0.9 mL, 5.2 mmol) followed by EDC.HCl (494 mg, 2.6 mmol) and HOBT (348 mg, 2.6 mmol) and stirred at 0 °C for 15 mins. N2H4.H2O (0.1 mL, 2.8 mmol) was added to the reaction mixture and the reaction mixture was allowed to stir at ambient temperature for 4 h. After completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic extract was collected, washed with brine, dried with anhydrous Na2SO4 and concentrated under reduced pressure to afford 1-(5-fluoro-2- methylphenyl)cyclopropane-1-carbohydrazide (202, 200 mg). LCMS (ESI): Calcd for C11H13FN2O: 208.23; found [M+H]+ = 209.1. [1039] Synthesis of 5-(difluoromethyl)-N'-(1-(5-fluoro-2-methylphenyl)cyclopropane-1-carbonyl)- 1-methyl-1H-pyrazole-3-carbohydrazide, 203 [Step 2]: To a stirred solution of 5-(difluoromethyl)- 1-methyl-1H-pyrazole-3-carboxylic acid (169 mg, 0.960 mmol) in DMA (2mL), was added DIPEA (0.3 mL, 1.9 mmol) followed by EDC.HCl (184 mg, 1.0 mmol) and HOBT (130 mg, 1.0 mmol) at 0 °C and stirred the reaction mixture for 15 mins.1-(5-fluoro-2-methylphenyl)cyclopropane-1- carbohydrazide (202, 200 mg, 1.0 mmol) was added and the reaction mixture was allowed to stir at ambient temperature for 4 h. After completion, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic extract was collected, washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The product was purified by column chromatography to afford 5-(difluoromethyl)-N'-(1-(5-fluoro-2- methylphenyl)cyclopropane-1-carbonyl)-1-methyl-1H-pyrazole-3-carbohydrazide (203, 70 mg) as brown liquid. LCMS (ESI): Calcd for C17H17F3N4O2: 366.34; found [M+H]+ = 367.3. [1040] Synthesis of 2-(5-(difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-5-(1-(5-fluoro-2- methylphenyl)cyclopropyl)-1,3,4-oxadiazole, Example 152 [Step 3]: To a stirred solution of 5- (difluoromethyl)-N'-(1-(5-fluoro-2-methylphenyl)cyclopropane-1-carbonyl)-1-methyl-1H-pyrazole- 3-carbohydrazide (203, 120 mg, 0.3 mmol) in MeCN (5mL) , POCl3 (0.1 mL, 1.3 mmol) was added and the reaction mixture was allowed to stir at 120 °C for 3 h. After completion, the reaction mixture was concentrated under reduced pressure and the product was purified by reverse phase Prep-HPLC and isolated compound was lyophilized to afford 2-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-5-(1-(5-fluoro-2-methylphenyl)cyclopropyl)-1,3,4- oxadiazole (Example 152, 20 mg). LCMS (ESI) Calcd. for C17H15F3N4O: [M] = 348.32; [M]+ =348.7.1H NMR (VT, 400 MHz, DMSO-d6): δH 7.42-7.22 (m, 3H), 7.09-7.06 (m, 2H), 4.00 (s, 3H), 2.28 (s, 3H), 1.80-1.77 (m, 2H), 1.52-1.49 (m, 2H). Example 153: Synthesis of 3-(1-(2-chloro-3-fluorophenyl)cyclopropyl)-5-(1-methyl-5- (trifluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 153) Scheme 85 [1041] Synthesis of 1-methyl-5-(trifluoromethyl)-1H-pyrazole-3-carboxylic acid, 205 [Step 1] : To a stirred solution of ethyl 1-methyl-5-(trifluoromethyl)-1H-pyrazole-3-carboxylate (204, 450 mg, 2.20 mmol) in THF(2 mL), methanol(1 mL) and water (0.5 mL), LiOH.H2O ( 278 mg, 6.61 mmol) was added at 0 °C and the reaction mixture was stirred for 12h at ambient temperature. The reaction mixture was concentrated under reduced pressure, acidified with (1N) HCl up to pH 4-5 and extracted with ethyl acetate (thrice). The combined organic layer was washed with water, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford 1- methyl-5-(trifluoromethyl)-1H-pyrazole-3-carboxylic acid (205, 300 mg).1HNMR (400 MHz, DMSO-d6) δH 13.02 (s, 1H), 7.28(s, 1H), 4.03 (s, 3H). [1042] Synthesis of (Z)-1-(2-chloro-3-fluorophenyl)-N'-((1-methyl-5-(trifluoromethyl)-1H- pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide, 206 [Step 2]: To a stirred solution of 1-methyl-5-(trifluoromethyl)-1H-pyrazole-3-carboxylic acid (205, 110 mg, 0.57 mmol) and (Z)-1- (2-chloro-3-fluorophenyl)-N'-hydroxycyclopropane-1-carboximidamide (Int.5 of Example 128, 143 mg, 0.62 mmol) in dichloromethane (2 mL), DIPEA (0.3 mL, 1.42 mmol), EDCI.HCl (163 mg, 0.85 mmol) and HOAt (15 mg, 0.11 mmol) were added and reaction mixture was stirred at ambient temperature for 16h. After completion, the reaction mixture was diluted with dichloromethane and partitioned with water. Combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford (Z)-1-(2-chloro-3- fluorophenyl)-N'-((1-methyl-5-(trifluoromethyl)-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1- carboximidamide (206, 150 mg). LCMS (ESI) Calcd for C16H13ClF4N4O2: 404.1, found [M+H]+ = 405.1 [1043] Synthesis of 3-(1-(2-chloro-3-fluorophenyl)cyclopropyl)-5-(1-methyl-5-(trifluoromethyl)- 1H-pyrazol-3-yl)-1,2,4-oxadiazole, Example 153 [Step 3]: To a stirred solution of (Z)-1-(2-chloro- 3-fluorophenyl)-N'-((1-methyl-5-(trifluoromethyl)-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1- carboximidamide (206, 150 mg, 0.4 mmol) in THF (1 mL), tetrabutylammonium hydroxide (0.04 mL, 0.04 mmol, 1M in methanol) was added and the reaction mixture was stirred at ambient temperature for 60 min. After completion, the reaction mixture was concentrated under reduced pressure, dissolved in ethyl acetate and washed with water (twice). The combined organic extract was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified through prep-HPLC (reverse phase) to afford 3-(1-(2-chloro-3- fluorophenyl)cyclopropyl)-5-(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 153, 14 mg). LCMS (ESI) Calcd for C16H11ClF4N4O: 386.1, found [M+H]+ = 387.0.1H NMR (400 MHz, DMSO-d6) δH 7.66 (s, 1H), 7.44 (d, 3H), 4.11 (s, 3H), 1.74 (brs, 2H), 1.52 (brs, 2H). Example 154: Synthesis of 3-(1-(2-chloro-5-fluorophenyl)cyclopropyl)-5-(1-methyl-5- (trifluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 154)
Figure imgf000295_0001
[1044] Synthesis of (Z)-1-(2-chloro-5-fluorophenyl)-N'-((1-methyl-5-(trifluoromethyl)-1H- pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide, 207 [Step 1]: To a stirred solution of 1-methyl-5-(trifluoromethyl)-1H-pyrazole-3-carboxylic acid (205, 110 mg, 0.6 mmol) and (Z)-1- (2-chloro-5-fluorophenyl)-N'-hydroxycyclopropane-1-carboximidamide (Int.4 of Example 127, 145 mg, 0.6 mmol) in dichloromethane (2 mL), DIPEA (0.3 mL, 1.42 mmol), EDCI.HCl (163 mg, 0.85 mmol) and HOAt (15 mg, 0.11 mmol) were added and the reaction mixture was stirred at ambient temperature for 16h. After completion, the reaction mixture was diluted with dichloromethane and partitioned with water. Combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford (Z)-1-(2-chloro-5- fluorophenyl)-N'-((1-methyl-5-(trifluoromethyl)-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1- carboximidamide (207, 170 mg). LCMS (ESI) Calcd for C16H13ClF4N4O2: 404.1, found [M+H]+ = 405.3. [1045] Synthesis of 3-(1-(2-chloro-5-fluorophenyl)cyclopropyl)-5-(1-methyl-5-(trifluoromethyl)- 1H-pyrazol-3-yl)-1,2,4-oxadiazole, Example 154 [Step 2]: To a stirred solution of (Z)-1-(2-chloro- 5-fluorophenyl)-N'-((1-methyl-5-(trifluoromethyl)-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1- carboximidamide (207, 150 mg, 0.4 mmol) in THF (1 mL), tetrabutylammonium hydroxide (0.04 mL, 0.04 mmol, 1M in methanol) was added and the reaction mixture was stirred at ambient temperature for 60 min. After completion, the reaction mixture was concentrated under reduced pressure, dissolved in ethyl acetate and washed with water (twice). The combined organic extract was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified through reverse phase prep-HPLC to afford 3-(1-(2-chloro-5- fluorophenyl)cyclopropyl)-5-(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 154, 67 mg). LCMS (ESI) Calcd for C16H11ClF4N4O: 386.1, found [M+H]+ = 387.0.1H NMR (400 MHz, DMSO-d6) δH 7.66 (s, 1H), 7.57-7.53 (m, 1H), 7.50-7.47 (m, 1H) 7.30-7.25(m, 1H), 4.11 (s, 3H), 1.73-1.70 (m, 2H), 1.54-1.52 (m, 2H). Example 155: Synthesis of 5-(3-(difluoromethyl)-1-(2-methoxyethyl)-1H-pyrazol-5-yl)-3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 155)
Figure imgf000296_0001
[1046] Synthesis of 3-(difluoromethyl)-1-(2-methoxyethyl)-1H-pyrazole-5-carboxylic acid, 208 [Step 1]: To an ice cold solution of ethyl 3-(difluoromethyl)-1-(2-methoxyethyl)-1H-pyrazole-5- carboxylate (14, 550 mg, 2.2 mmol) in THF (4 mL) and methanol (1 mL), an aqueous solution of lithium hydroxide (185 mg, 4.4 mmol) in water (2 mL) was added drop-wise. The reaction mixture was stirred at ambient temperature for 2 h. After completion, the volatiles were evaporated under reduced pressure. The aqueous phase was acidified with 1 N aqueous hydrochloric acid to ~pH-5 and extracted with a mixture of dichloromethane and isopropyl alcohol (9:1). Combined organic extract was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford 3-(difluoromethyl)-1-(2-methoxyethyl)-1H- pyrazole-5-carboxylic acid (208, 400 mg). LCMS (ESI) Calcd. for C8H10F2N2O3: 220.0, found [M+H]+ = 221.0. [1047] Synthesis of (Z)-N'-((3-(difluoromethyl)-1-(2-methoxyethyl)-1H-pyrazole-5-carbonyl)oxy)- 1-(o-tolyl)cyclopropane-1-carboximidamide, 209 [Step 2]: To a stirred solution of 3- (difluoromethyl)-1-(2-methoxyethyl)-1H-pyrazole-5-carboxylic acid (208, 400 mg, 1.8 mmol) and (Z)-N'-hydroxy-1-(o-tolyl)cyclopropane-1-carboximidamide (11, 345.6 mg, 1.8 mmol) in dichloromethane (20 mL), N,N-diisopropylethylamine (585.9 mg, 4.5 mmol), 1-hydroxy-7- azabenzotriazole (49.6 mg, 0.4 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (455 mg, 2.4 mmol) were added. The reaction mixture was stirred at ambient temperature for 16 h, diluted with ethyl acetate and washed with water and brine. Combined organic extract was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford (Z)-N'-((3-(difluoromethyl)-1-(2-methoxyethyl)-1H-pyrazole-5- carbonyl)oxy)-1-(o-tolyl)cyclopropane-1-carboximidamide (209, 440 mg). LCMS (ESI) Calcd. for C19H22F2N4O3: 392.2, found [M+H]+ = 393.4. [1048] Synthesis of 5-(3-(difluoromethyl)-1-(2-methoxyethyl)-1H-pyrazol-5-yl)-3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazole, Example 155 [Step 3]: To a stirred solution of (Z)-N'-((3- (difluoromethyl)-1-(2-methoxyethyl)-1H-pyrazole-5-carbonyl)oxy)-1-(o-tolyl)cyclopropane-1- carboximidamide (209, 416.4 mg, 1.0 mmol) in THF (10 mL), tetra butyl ammonium hydroxide (39.6 mg, 0.2 mmol) was added. The resulting reaction mixture was stirred at ambient temperature for 12 h and concentrated under reduced pressure. The residue was diluted with ethyl acetate and washed with water and brine. Combined organic extract was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by reverse phase prep HPLC to afford 5-(3-(difluoromethyl)-1-(2-methoxyethyl)-1H- pyrazol-5-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (Example 155, 287.2 mg). LCMS (ESI) Calcd. for C19H20F2N4O2: 374.1, found [M+H]+ = 375.3.1H NMR (400 MHz, DMSO-d6) δH 7.39- 7.37 (m, 2H), 7.27-6.97 (m, 4H), 4.77 (t, 2H), 3.73 (t, 2H), 3.16 (s, 3H), 2.29 (s, 3H), 1.70-1.67 (m, 2H), 1.45-1.42 (m, 2H). Example 156: Synthesis of 2-(3-(3-(1-(2-chloro-5-fluorophenyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)-1-(piperazin-1-yl)ethan-1-one (Example 156) [1049] 2-(3-(3-(1-(2-chloro-5-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-1-(piperazin-1-yl)ethan-1-one was synthesized following Scheme 87 using tert- butyl 4-(2-(3-(3-(1-(2-chloro-5-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)acetyl)piperazine-1-carboxylate. LCMS (ESI) Calcd. for C21H20ClF3N6O2: 480.1, found [M+H]+ = 481.1.1HNMR (400 MHz, DMSO-d6) δH 7.56-7.53 (m, 1H), 7.50-7.47 (m, 1H), 7.35-7.08 (m, 3H), 5.45 (s, 2H), 3.40-3.29 (m, 4H), 2.75-2.73 (m, 2H), 2.66-2.63 (m, 2H), 1.73- 1.70 (m, 2H), 1.53-1.51 (m, 2H) Example 157: Synthesis of 2-(3-(3-(1-(2-chloro-3-fluorophenyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)-1-(piperazin-1-yl)ethan-1-one (Example 157) [1050] 2-(3-(3-(1-(2-chloro-3-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)-1-(piperazin-1-yl)ethan-1-one was synthesized following Scheme 87 using tert- butyl 4-(2-(3-(3-(1-(2-chloro-3-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)acetyl)piperazine-1-carboxylate. LCMS (ESI) Calcd. for C21H20ClF3N6O2: 480.1, found [M+H]+ = 481.1.1HNMR (400 MHz, DMSO-d6) δH 7.44-7.08 (m, 5H), 5.45 (s, 2H), 3.49- 3.33 (m, 4H), 2.74 (brs, 2H), 2.65 (brs, 2H), 1.74 (brs, 2H), 1.51 (brs, 2H). Examples 158a & 158b: Synthesis of 3-(1-(2-chloro-3-fluorophenyl)cyclopropyl)-5-(5- (difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 158a) and 3-(1-(2-chloro-3-fluorophenyl)cyclopropyl)-5-(3-(difluoromethyl)-1-(2- (methylsulfonyl)ethyl)-1H-pyrazol-5-yl)-1,2,4-oxadiazole (Example 158b) Scheme 88 [1051] Synthesis of (Z)-1-(2-chloro-3-fluorophenyl)-N'-((5-(difluoromethyl)-1-(2- (methylsulfonyl)ethyl)-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide, 210 [Step- 1]: To a stirred solution of 5-(difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazole-3- carboxylic acid (along with other regioisomer) (68, 550 mg, 2.05 mmol), and (Z)-1-(2-chloro-3- fluorophenyl)-N'-hydroxycyclopropane-1-carboximidamide (516 mg, 2.26 mmol) in dichloromethane (10 mL), N,N-diisopropylethylamine (1.1 mL, 6.15 mmol), 1-hydroxy-7- azabenzotriazole (56 mg, 0.41 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (590 mg, 3.08 mmol) were added. The reaction mixture was stirred at ambient temperature for 16 h. After completion, the reaction mixture was diluted with ethyl acetate and washed with water and brine. Combined organic extract was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford (Z)-1-(2-chloro-3- fluorophenyl)-N'-((5-(difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazole-3- carbonyl)oxy)cyclopropane-1-carboximidamide (along with other regioisomer) (210, 550 mg). LCMS (ESI) Calcd. for C18H18ClF3N4O4S: 478.1, found [M+H]+ = 479.3. [1052] Synthesis of 3-(1-(2-chloro-3-fluorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1H-pyrazol- 3-yl)-1,2,4-oxadiazole, 211 [Step-2]: To a stirred solution of (Z)-1-(2-chloro-3-fluorophenyl)-N'- ((5-(difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1- carboximidamide (along with other regioisomer) (210, 500 mg, 1.04 mmol) in tetrahydrofuran (10 mL), tetra butyl ammonium hydroxide (1 mL, 1.04 mmol) was added. The resulting reaction mixture was stirred at ambient temperature for 12 h. After completion the reaction mixture was concentrated under reduced pressure. The residue was diluted with ethyl acetate and washed with water (thrice). Combined organic extract was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford 3-(1-(2-chloro-3- fluorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (211, 250 mg). LCMS (ESI) Calcd. for C15H10ClF3N4O: 354.1, found [M-H]- = 352.8. [1053] Synthesis 3-(1-(2-chloro-3-fluorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-(2- (methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole, Example 158a [Step-3]: To a stirred suspension of 3-(1-(2-chloro-3-fluorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1H-pyrazol-3-yl)- 1,2,4-oxadiazole (211, 250 mg, 0.7 mmol) and potassium carbonate (195 mg, 1.4 mmol) in tetrahydrofuran (5 mL) at 0 °C, 1-bromo-2-(methylsulfonyl)ethane (198 mg, 1.06 mmol) was added. The resulting reaction mixture was stirred at ambient temperature for 16 h. After completion, the reaction mixture was diluted with ethyl acetate and washed with ice-cold water and brine. Combined organic extract was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product were purified by reverse phase preparative HPLC to afford the first product as 3-(1-(2-chloro-3-fluorophenyl)cyclopropyl)-5-(5- (difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 158a, 95 mg) as Peak-1 and the second product as 3-(1-(2-chloro-3-fluorophenyl)cyclopropyl)-5-(3- (difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-5-yl)-1,2,4-oxadiazole (Example 158b, 32 mg) as Peak-2. [1054] 3-(1-(2-chloro-3-fluorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-(2- (methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole, Example 158a (Peak-1): LCMS (ESI) Calcd. for C18H16ClF3N4O3S: 460.1, found [M+H]+ = 461.1.1H NMR (400 MHz, DMSO-d6) δH 7.55-7.29 (m, 5H), 4.78-4.74 (t, 2H), 3.82-3.78 (t, 2H), 3.07 (s, 3H), 1.74 (s, 2H), 1.51 (s, 2H). Note: The structure of the compound was confirmed by NOE experiments. Example 159: Synthesis of 2-(3-(3-(1-(2-chloro-5-fluorophenyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-(piperazin-1-yl)ethan-1-one (Example 159)
Figure imgf000300_0001
[1055] Synthesis of methyl 5-(trifluoromethyl)-1H-pyrazole-3-carboxylate, 31 [Step 1]: To a solution of 5-(trifluoromethyl)-1H-pyrazole-3-carboxylic acid (30, 1.5 g, 8.3 mmol) in methanol (10 mL), sulfuric acid (1.8 mL, 25.0 mmol) was added drop wise at 0 °C. The reaction mixture was stirred at ambient temperature for 12 h. After completion, the reaction mixture was quenched with NaHCO3 solution and extracted with ethyl acetate (thrice). The combined organic layer was washed with brine and dried over anhydrous Na2SO4, and concentrated under reduced pressure to afford methyl 5-(trifluoromethyl)-1H-pyrazole-3-carboxylate (31, 1.3 g).1H NMR (400 MHz, DMSO-d6) δH 14.89 (s, 1H), 7.32 (s, 3H), 3.88 (s, 3H). [1056] Synthesis of methyl 1-(2-(tert-butoxy)-2-oxoethyl)-5-(trifluoromethyl)-1H-pyrazole-3- carboxylate and methyl 1-(2-(tert-butoxy)-2-oxoethyl)-3-(trifluoromethyl)-1H-pyrazole-5- carboxylate (212 and 212a) [Step 2]: To a stirred solution of methyl 5-(trifluoromethyl)-1H- pyrazole-3-carboxylate (31, 500 mg, 2.6 mmol) in THF (15 mL), K2CO3 (535 mg, 3.9 mmol) was added at 0 °C under nitrogen atmosphere and the reaction mixture was stirred for 30 minutes at same condition. Then tert-butyl 2-bromoacetate (0.5 mL, 3.1 mmol) was added and the reaction mixture was stirred at ambient temperature for 12h. After completion, the reaction mixture was diluted with ethyl acetate and washed with ice cold brine (thrice). The combined organic extract was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by column chromatography to afford methyl 1-(2-(tert-butoxy)-2-oxoethyl)- 3-(trifluoromethyl)-1H-pyrazole-5-carboxylate (212a, 200 mg) as Peak1 and methyl 1-(2-(tert- butoxy)-2-oxoethyl)-5-(trifluoromethyl)-1H-pyrazole-3-carboxylate (212, 450 mg) as Peak2.1H NMR (400 MHz, DMSO-d6) δH 7.46 (s, 1H), 5.25(s, 2H), 3.85 (s, 3H), 1.41(s, 9H). NOTE: The actual structure was confirmed through 2D & NOE experiments of two spots with batch Id 'CR620-SB-2023-09-80-PEAK-1' and 'CR620-SB-2023-09-80-PEAK-2'. [1057] Synthesis of 2-(3-(methoxycarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)acetic acid, 213 [Step 3]: To a stirred solution of methyl 1-(2-tert-butoxy-2-oxo-ethyl)-5-(trifluoromethyl)pyrazole- 3-carboxylate (212, 450 mg, 1.5 mmol) in dichloromethane (10 mL), trifluoroacetic acid (1.3 mL, 17.5 mmol) was added dropwise at 0 °C and stirred at ambient temperature for 2h. After completion, the volatiles were evaporated under reduced pressure to afford 2-(3- (methoxycarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)acetic acid (213, 450 mg).1H NMR (400 MHz, DMSO-d6) δH 13.64 (s, 1H), 7.46 (s, 1H), 5.24 (s, 2H), 3.85 (s, 3H). [1058] Synthesis of tert-butyl 4-(2-(3-(methoxycarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1- yl)acetyl)piperazine-1-carboxylate, 214 [Step 4]: To a stirred solution of DIPEA (1.4 mL, 7.9 mmol) in dichloromethane (10 mL), 2-(3-(methoxycarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1- yl)acetic acid (213, 400 mg, 1.6 mmol) was added followed by tert-butyl piperazine-1- carboxylate (445 mg, 2.4 mmol) at 0 °C. After 10 min, T3P (2.4 mL, 4.0 mmol, 50% in ethyl acetate) was added to the reaction mixture at 0°C and stirred at ambient temperature for 16 h. After completion, the reaction mixture was quenched with ice water and extracted with dichloromethane (twice). Combined organic extract was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by flash column chromatography to afford tert-butyl 4-(2-(3-(methoxycarbonyl)-5- (trifluoromethyl)-1H-pyrazol-1-yl)acetyl)piperazine-1-carboxylate (214, 450 mg). LCMS (ESI) Calcd for C17H23F3N4O5: 420.1, found [M+H]+ = 421.4. [1059] Synthesis of tert-butyl 4-(2-(3-(3-(1-(2-chloro-5-fluorophenyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)acetyl)piperazine-1-carboxylate, 215 [Step 5]: To a stirred solution of tert-butyl 4-(2-(3-(methoxycarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1- yl)acetyl)piperazine-1-carboxylate (214, 170 mg, 0.4 mmol) in toluene (4 mL), were added K2CO3 (110 mg, 0.9 mmol) and 1-(2-chloro-5-fluoro-phenyl)-N'-hydroxy- cyclopropanecarboxamidine (110 mg, 0.5 mmol). The resulting reaction mixture was heated at 90 °C for 16 h. After completion, the volatiles were concentrated under reduced pressure. The residue was diluted with ethyl acetate and washed with water followed by brine. The combined organic extracts were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by combi-flash chromatography to afford tert-butyl 4-(2-(3-(3-(1-(2-chloro-5-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(trifluoromethyl)-1H- pyrazol-1-yl)acetyl)piperazine-1-carboxylate (215, 120 mg). LCMS (ESI) Calcd for C26H27ClF4N6O4: 598.1, found [M+H]+ = 599.3. [1060] Synthesis of 2-(3-(3-(1-(2-chloro-5-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (trifluoromethyl)-1H-pyrazol-1-yl)-1-(piperazin-1-yl)ethan-1-one), Example 159 [Step 6]: To a solution of tert-butyl 4-(2-(3-(3-(1-(2-chloro-5-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (trifluoromethyl)-1H-pyrazol-1-yl)acetyl)piperazine-1-carboxylate (215, 100 mg, 0.2 mmol) in dichloromethane (4 mL), HCl in dioxane (0.6 mL, 2.50 mmol, 4M) was added at 0 °C and stirred for 2h at ambient temperature. After completion, the reaction mixture was concentrated under reduced pressure. The product was purified by reverse phase prep-HPLC to afford 2-(3-(3-(1-(2- chloro-5-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1- (piperazin-1-yl)ethan-1-one) (Example 159, 35 mg). LCMS (ESI) Calcd for C21H19ClF4N6O2: 498.8, found [M+H]+ = 499.1.1H NMR (400 MHz, DMSO-d6) δH 7.70 (s, 1H), 7.57-7.53 (m, 1H), 7.50-7.48 (m, 1H), 7.28-7.27(m,1H), 5.51(s, 2H), 3.42-3.34 (m, 2H), 3.31-3.29 (m, 3H), 2.72- 2.71 (m, 2H), 2.66-2.62 (m,2H), 1.74-1.71 (m, 2H), 1.55-1.52 (m, 2H). Example 160: Synthesis of 2-(3-(3-(1-(2-chloro-3-fluorophenyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)-1-(piperazin-1-yl)ethan-1-one (Example 160) [1061] 2-(3-(3-(1-(2-chloro-3-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(trifluoromethyl)- 1H-pyrazol-1-yl)-1-(piperazin-1-yl)ethan-1-one was synthesized following Scheme 89 using tert- butyl 4-(2-(3-(3-(1-(2-chloro-3-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(trifluoromethyl)- 1H-pyrazol-1-yl)acetyl)piperazine-1-carboxylate. LCMS (ESI) Calcd for C21H19ClF4N6O2: 498.8, found [M+H]+ = 499.0.1H NMR (400 MHz, DMSO-d6) (at 100 °C) δH 7.52 (s, 1H), 7.44-7.34 (m, 3H), 5.42 (s, 2H), 3.42 (t, 4H), 2.96-2.73 (m, 4H), 1.80-1.77 (m, 2H), 1.53-1.51 (m, 2H). Examples 161a & 161b: Synthesis of 2-(3-(3-(1-(2,4-dichlorophenyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)acetamide (Example 161a) and 2-(5-(3- (1-(2,4-dichlorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-3-(difluoromethyl)-1H-pyrazol-1- yl)acetamide, Example 161b
Figure imgf000303_0001
[1062] Synthesis of 1-(2,4-dichlorophenyl)cyclopropane-1-carbonitrile, 217 [Step 1]: To a stirred solution of NaOH (5.16 g, 129 mmol) in water(10 mL), 2-(2,4-dichlorophenyl)acetonitrile (216, 2.00 g, 10.8 mmol) and TBAB (690 mg, 2.15 mmol) were added at 0 °C. After 5 min 1,2- dibromoethane (8.1 mL, 53.8 mmol).was added dropwise and the resulting reaction mixture was heated at 60 °C for 12 hr. After completion, reaction mixture was poured into cold water and extracted with ethyl acetate (thrice). Combined organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to afford 1-(2,4-dichlorophenyl)cyclopropane- 1-carbonitrile (217, 2.1 g).1HNMR (400 MHz, DMSO-d6) δH 7.74 (brs, 1H), 7.56 (d, 1H), 7.48- 7.45 (m, 1H), 1.80-1.73 (m, 2H), 1.44-1.41 (m, 2H). [1063] Synthesis of (Z)-1-(2,4-dichlorophenyl)-N'-hydroxycyclopropane-1-carboximidamide, 218 [Step 2]: To a stirred solution of 1-(2,4-dichlorophenyl)cyclopropane-1-carbonitrile (217, 2.00 g, 9.43 mmol) in Ethanol (10 mL), Na2CO3 (2.00 g, 18.9 mmol) was added followed by NH2OH.HCl (1.31 g, 18.9 mmol) and the reaction mixture was heated at 70 °C for 12h. After completion, volatiles are evaporated under reduced pressure, diluted with water and extracted with ethyl acetate (thrice). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford (Z)-1-(2,4-dichlorophenyl)-N'- hydroxycyclopropane-1-carboximidamide (218, 1.8 g). LCMS (ESI) calculated for C10H10Cl2N2O [M]: 244.0, found [M+H]+: 245.2. [1064] Synthesis of (Z)-1-(2,4-dichlorophenyl)-N'-((5-(difluoromethyl)-1-(2- (methylsulfonyl)ethyl)-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide, 219, [Step 3]: To a stirred solution of 5-(difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazole-3- carboxylic acid (along with other regioisomer) (900 mg, 3.4 mmol) and (Z)-1-(2,4- dichlorophenyl)-N'-hydroxycyclopropane-1-carboximidamide (218, 905 mg, 3.7 mmol) in dichloromethane (10 mL), N,N-Diisopropylethylamine (1.8 ml, 10.1 mmol.), EDCI.HCl (965 mg, 5.0 mmol.) and HOAt (90 mg, 0.7 mmol.) were added at 0 °C and reaction mixture was stirred for 16h at ambient temperature. After completion the reaction mixture was concentrated under reduced pressure, dissolved with ethyl acetate, washed with water (twice) and brine. The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by column chromatography to afford (Z)-1-(2,4- dichlorophenyl)-N'-((5-(difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazole-3- carbonyl)oxy)cyclopropane-1-carboximidamide (along with other regioisomer) (219, 600mg). LCMS (ESI) Calcd for C18H18Cl2F2N4O4S [M]: 494.0, found [M+H]+: 495.1. [1065] Synthesis of 3-(1-(2,4-dichlorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1H-pyrazol-3-yl)- 1,2,4-oxadiazole, 220 [Step 4]: To a stirred solution of (Z)-1-(2,4-dichlorophenyl)-N'-((5- (difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1- carboximidamide (along with other regioisomer) (219, 550 mg, 0.4 mmol.) in THF (2mL), tetrabutylammonium hydroxide(1M in methanol, 1 mL, 1.1 mmol.) was added and resulting reaction mixture was stirred for 12 h at ambient temperature. After completion Reaction mixture was concentrated under reduced pressure, dissolved in ethyl acetate, washed with water (thrice), dried over anhydrous Na2SO4, filtered and concentrated again under reduced pressure. Product was purified through column chromatography to afford 3-(1-(2,4- dichlorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (220, 210 mg). LCMS (ESI) calculated for C15H10Cl2F2N4O [M]: 370.0, found [M+H]+: 371.2. [1066] Synthesis of 2-(3-(3-(1-(2,4-dichlorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)acetamide, Example 161a and 2-(5-(3-(1-(2,4- dichlorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-3-(difluoromethyl)-1H-pyrazol-1-yl)acetamide, Example 161b (Step 5): To a stirred suspension of 3-(1-(2,4-dichlorophenyl)cyclopropyl)-5-(5- (difluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (220, 200 mg, 0.4 mmol) and potassium carbonate (149 mg, 1.08 mmol) in THF (2 mL) at 0 °C, 2-bromoacetamide (89 mg, 065 mmol) was added. The resulting reaction mixture was stirred at ambient temperature for 16 h. After completion, the reaction mixture was diluted with ethyl acetate and washed with ice-cold water and brine. Combined organic extract was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The product was purified by reverse phase preparative HPLC to afford 2-(3-(3-(1-(2,4-dichlorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)acetamide (Example 161a, 30 mg) as Peak-1 and 2-(5-(3-(1- (2,4-dichlorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-3-(difluoromethyl)-1H-pyrazol-1- yl)acetamide (Example 161b, 17 mg) as Peak-2. [1067] 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)- 1H-pyrazol-1-yl)acetamide, Example 161a (Peak-1): LCMS (ESI) Calcd. for C17H13Cl2F2N5O2: 427.0, found [M+H]+ = 428.0.1H NMR (400 MHz, DMSO-d6) δH 7.72 (brs, 1H), 7.67 (d, 1H), 7.60 (d, 1H), 7.48-7.45 (m, 1H), 7.41-7.14 (m, 3H), 5.05 (s, 2H), 1.75-1.71 (m, 2H), 1.50-1.47 (m, 2H). Note: The structure of the final products was confirmed by NOE data analysis. Example 162: Synthesis of 2-(3-(3-(1-(2,4-dichlorophenyl)cyclopropyl)-1,2,4-oxadiazol-5- yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)-N-methylacetamide (Example 162) [1068] 2-(3-(3-(1-(2,4-dichlorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H- pyrazol-1-yl)-N-methylacetamide was synthesized following Scheme 90 using 2-bromo-N- methylacetamide. LCMS (ESI) Calcd for C18H15Cl2F2N5O2: 441.0, found [M+H]+ = 442.1.1H NMR (400 MHz, DMSO-d6 at 100 °C) δH 7.94 (brs, 1H), 7.60-7.59 (m, 2H), 7.44 (d, 1H), 7.38- 7.11 (m, 2H), 5.04 (s, 2H), 2.66 (s, 3H), 1.75 (s, 2H), 1.48 (s, 2H). Example 163: Synthesis of 3-(1-(2-bromo-6-methylphenyl)cyclopropyl)-5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 163)
Figure imgf000305_0001
[1069] Synthesis of 2-(2-bromo-6-methylphenyl)acetonitrile, 222 [Step 1]: To a stirred solution of 1-bromo-2-(bromomethyl)-3-methylbenzene (221, 800 mg, 3 mmol) in MeCN (10mL), K2CO3 (420 mg, 3 mmol) was added followed by trimethylsilylformonitrile (0.4 mL, 3 mmol) and the reaction mixture was heated at 100 °C for 16h. After completion, the reaction mixture was dissolved in ethyl acetate, washed with water(thrice) and brine. The organic extract was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford 2-(2- bromo-6-methylphenyl)acetonitrile (222, 600 mg). LCMS (ESI) Calcd for C9H8BrN: 210.07, found [M-2H]-: 208.0. [1070] Synthesis of 1-(2-bromo-6-methylphenyl)cyclopropane-1-carbonitrile, 223 [Step 2]: To a stirred solution of NaOH (1.1 g, 28 mmol) in Water (4mL), 2-(2-bromo-6- methylphenyl)acetonitrile (222, 500 mg, 2.3 mmol), TBAB (155 mg, 0.5 mmol) and 1,2- dibromoethane (2 mL, 12 mmol) were added and the reaction mixture was heated at 100 oC for 24 h. After completion, reaction mixture was poured into cold water and extracted with ethyl acetate( thrice). Combined organic layered was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford 1-(2-bromo-6- methylphenyl)cyclopropane-1-carbonitrile (223, 400 mg). GCMS Calcd. For C11H10BrN: = 236.11, [M/Z] = 236. [1071] Synthesis of (Z)-1-(2-bromo-6-methylphenyl)-N'-hydroxycyclopropane-1- carboximidamide, 224 [Step 3]: To a stirred solution of 1-(2-bromo-6- methylphenyl)cyclopropane-1-carbonitrile (223, 400 mg, 1.7 mmol) in ethanol (8 mL), hydroxylamine hydrochloride (240 mg, 3.5 mmol) and sodium carbonate (360 mg, 3.5 mmol) were added and the reaction was heated at 70 °C for 12 h. After completion volatiles were evaporated under reduced pressure, dissolved in water and extracted with ethyl acetate( thrice). Combined organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford the product which was purified through column chromatography(50% ethyl acetate in hexane as eluent) to afford (Z)-1-(2-bromo-6- methylphenyl)-N'-hydroxycyclopropane-1-carboximidamide (224, 120 mg). LCMS (ESI) Calcd for C11H13BrN2O: 269.1, found [M+2H]+: 272.0. [1072] Synthesis of (Z)-1-(2-bromo-6-methylphenyl)-N'-((5-(difluoromethyl)-1-methyl-1H- pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide, 225 [Step 4]: To a stirred solution of 5-(difluoromethyl)-1-methyl-pyrazole-3-carboxylic acid (80 mg, 0.4 mmol) and (Z)-1-(2-bromo- 6-methylphenyl)-N'-hydroxycyclopropane-1-carboximidamide (224, 135 mg, 0.5 mmol) in DCM (4mL), DIPEA (0.3 mL, 1.4 mmol), EDCI.HCl (130 mg, 0.7 mmol) and HOAt (7 mg, 0.05 mmol) were added at 0 °C and reaction mixture was stirred for 16 h at ambient temperature. After completion, the reaction mixture was diluted with dichloromethane and partitioned with water. Combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford (Z)-1-(2-bromo-6-methylphenyl)-N'-((5- (difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide (225, 120 mg) as sticky liquid. LCMS (ESI) Calcd for C17H17BrF2N4O2: 427.2, found [M+2H]+: 429.0. [1073] Synthesis of 3-(1-(2-bromo-6-methylphenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-methyl- 1H-pyrazol-3-yl)-1,2,4-oxadiazole, Example 163 [Step 5]: To a stirred solution of (Z)-1-(2-bromo- 6-methylphenyl)-N'-((5-(difluoromethyl)-1-methyl-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1- carboximidamide (7, 90 mg, 0.2 mmol) in THF (2mL), Tetrabutylammonium hydroxide (0.05 mmol1 M) was added. The resulting reaction mixture was stirred for 16 h at ambient temperature. The reaction mixture was concentrated under reduced pressure, dissolved in ethyl acetate, washed with water, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford product which was purified by reverse phase prep HPLC purification to afford 3-(1-(2-bromo-6-methylphenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-methyl-1H-pyrazol- 3-yl)-1,2,4-oxadiazole (Example 163, 28 mg).1HNMR (400 MHz, DMSO-d6) δH 7.50-7.16 (m, 5H), 4.05 (s, 3H), 2.37 (s, 3H), 1.92-1.90 (m, 1H), 1.81-1.80 (m, 1H), 1.50-1.45 (m, 2H). LCMS: Calcd for C17H15BrF2N4O: 409.2, found [M+2H]+: 411.0. Examples 164a & 164b: Synthesis of 3-(1-(2-chlorophenyl)cyclopropyl)-5-(5- (difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 164a) and 3-(1-(2-chlorophenyl)cyclopropyl)-5-(3-(difluoromethyl)-1-(2- (methylsulfonyl)ethyl)-1H-pyrazol-5-yl)-1,2,4-oxadiazole (Example 165b)
Figure imgf000307_0001
[1074] Synthesis of 1-(2-chlorophenyl)cyclopropane-1-carbonitrile, 227 [Step 1]: To a stirred solution of NaOH (7.9 g, 200.0 mmol) in water (15 mL), 2-(2-chlorophenyl)acetonitrile (1, 2.5 g, 16.5 mmol), TBAB (1.1 g, 3.3 mmol) and 1,2-dibromoethane (12 mL, 82.5 mmol) were added and the reaction mixture was heated at 60 °C for 12h. After completion, the reaction mixture was poured into cold water and extracted with ethyl acetate (thrice). Combined organic extract was collected, washed with brine, dried over anhydrous Na2SO4, filtered and, concentrated under reduced pressure to afford 1-(2-chlorophenyl)cyclopropane-1-carbonitrile (227, 2.5 g).1H NMR (400 MHz, DMSO-d6): δH 7.56-7.51 (m, 2H), 7.44-7.35 (m, 2H), 1.75-1.72 (m, 2H), 1.42-1.35 (m, 2H). [1075] Synthesis of (Z)-1-(2-chlorophenyl)-N'-hydroxycyclopropane-1-carboximidamide, 228 [Step 2]: To a stirred solution of 1-(2-chlorophenyl)cyclopropane-1-carbonitrile (227, 2.5 g, 14.1 mmol) in ethanol (30 mL) was added sodium carbonate (3.0 g, 28.1 mmol) followed by hydroxylamine hydrochloride (2.0 g, 28.1 mmol) and the reaction was heated at 70 oC for 12 h. After completion, the volatiles were removed under reduced pressure, dissolved in water and extracted with ethyl acetate. Combined organic extract was collected, washed with brine, dried over anhydrous Na2SO4 and, concentrated under reduced pressure and triturated with pentane to afford (Z)-1-(2-chlorophenyl)-N'-hydroxycyclopropane-1-carboximidamide (228, 2.6 g).1H NMR (400 MHz, DMSO-d6) δH 9.11 (s, 1H), 7.44-7.40 (m, 1H), 7.38-7.30 (m, 1H), 7.28-7.20 (m, 2H), 1.46-1.39 (m, 2H), 0.98-0.91 (m, 2H). [1076] Synthesis of (Z)-1-(2-chlorophenyl)-N'-((5-(difluoromethyl)-1H-pyrazole-3- carbonyl)oxy)cyclopropane-1-carboximidamide, 229 [Step 3]: To a stirred solution of (Z)-1-(2- chlorophenyl)-N'-hydroxycyclopropane-1-carboximidamide (228, 500 mg, 2.4 mmol) and 5- (difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazole-3-carboxylic acid (700 mg, 2.6 mmol) in dichloromethane (8 mL) were added DIPEA (1.2 mL, 7.1 mmol), EDC.HCl (905 mg, 4.7 mmol) and HOAt (50 mg, 0.5 mmol) at 0 °C and the reaction mixture was stirred at ambient temperature for 16 h. The reaction mixture was diluted with dichloromethane and washed with water. Organic extracts was collected, washed with brine, dried over anhydrous Na2SO4 and, concentrated under reduce pressure to afford (Z)-1-(2-chlorophenyl)-N'-((5-(difluoromethyl)-1H- pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide (229, 700 mg). LCMS (ESI) Calcd for C18H19ClF2N4O4S: 460.8; found [M+H]+ = 461.0. [1077] Synthesis of 3-(1-(2-chlorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1H-pyrazol-3-yl)- 1,2,4-oxadiazole, 230 [Step 4]: To a stirred solution of (Z)-1-(2-chlorophenyl)-N'-((5- (difluoromethyl)-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide (229, 700 mg, 1.5 mmol) in THF (10 mL), tetrabutylammonium hydroxide (0.2 mL, 0.3 mmol, 40% in water) was added and the resulting reaction mixture was stirred at ambient temperature for 2 h. The reaction mixture was diluted with ethyl acetate and washed with water (thrice). The combined organic extract was collected, washed with brine, dried over anhydrous Na2SO4, filtered and, concentrated under reduced pressure to afford 3-(1-(2-chlorophenyl)cyclopropyl)-5-(5- (difluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (230, 300 mg). LCMS (ESI) Calcd for C15H11ClF2N4O: 336.7; found [M+H]+ = 337.0. [1078] Synthesis of 3-(1-(2-chlorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-(2- (methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole & 3-(1-(2-chlorophenyl)cyclopropyl)-5- (3-(difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-5-yl)-1,2,4-oxadiazole, Examples 164a & 164b [Step 5]: To a stirred solution of 3-(1-(2-chlorophenyl)cyclopropyl)-5-(5- (difluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (230, 200 mg, 0.6 mmol) in THF (4 mL) was added K2CO3 (328 mg, 2.4 mmol) at 0 °C. After 15 min, 1-bromo-2-methylsulfonyl-ethane (222 mg, 1.2 mmol) was added to the reaction mixture and stirred at ambient temperature for 16 h. The reaction mixture was diluted with ethyl acetate and washed with water. The combined organic extracts was collected, washed with brine, dried over anhydrous Na2SO4 and, concentrated under reduced pressure. The product was purified by reverse phase prep- HPLC and isolated compound was lyophilized to afford 3-(1-(2-chlorophenyl)cyclopropyl)-5-(5- (difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 164a, 17 mg) and 3-(1-(2-chlorophenyl)cyclopropyl)-5-(3-(difluoromethyl)-1-(2-(methylsulfonyl)ethyl)- 1H-pyrazol-5-yl)-1,2,4-oxadiazole (Example 164b, 12 mg). Note: Structure was confirmed by NOE. [1079] Analytical data of 3-(1-(2-chlorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-(2- (methylsulfonyl)ethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole, Example 164a: LCMS (ESI) Calcd for C18H17ClF2N4O3S: 442.8; found [M+H]+ = 443.3.1H NMR (400 MHz, DMSO-d6) δH 7.58-7.55 (m, 1H), 7.50-7.48 (m, 1H), 7.41-7.28 (m, 4H), 4.75 (t, 2H), 3.80 (t, 2H), 3.06 (s, 3H), 1.73-1.70 (m, 2H), 1.48-1.45 (m, 2H). Examples 165a & 165b: Synthesis of 2-(3-(3-(1-(2-chloro-6-fluorophenyl)cyclopropyl)- 1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)acetamide (Example 165a) and 2- (5-(3-(1-(2-chloro-6-fluoro-phenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-3- (difluoromethyl)pyrazol-1-yl)acetamide (Example 165b)
Figure imgf000310_0001
[1080] Synthesis of 1-(2-chloro-6-fluorophenyl)cyclopropane-1-carbonitrile, 232 [Step 1]: To a stirred solution of NaOH (2.8 g, 70.8 mmol) in water (10 mL), 2-(2-chloro-6-fluoro- phenyl)acetonitrile (231, 1.0 g, 5.9 mmol), TBAB (0.4 g, 1.2 mmol) and 1,2-dibromoethane (4.6 mL, 29.5 mmol) were added and the reaction mixture was heated at 60 °C for 12h. After completion, reaction mixture was poured into cold water and extracted with ethyl acetate (thrice). Combined organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford as a 1-(2-chloro-6-fluoro- phenyl)cyclopropanecarbonitrile (232, 1.0 g).1HNMR (400 MHz, DMSO-d6) δH 7.53-7.47 (m, 1H), 7.44-7.42 (m, 1H), 7.35-7.30 (m, 1H), 1.89-1.86 (t, 2H), 1.47-1.45 (t, 2H). [1081] Synthesis of (Z)-1-(2-chloro-6-fluorophenyl)-N'-hydroxycyclopropane-1-carboximidamide, 233 [Step 2]: To a stirred solution of 1-(2-chloro-6-fluoro-phenyl)cyclopropanecarbonitrile (232, 1.0 g, 5.1 mmol) in ethanol (15 mL), sodium carbonate (1.1 g, 10.2 mmol) and hydroxylamine hydrochloride (0.7 g, 10.2 mmol) were added and the reaction was heated at 70 °C for 12h. After completion, the volatiles were evaporated under reduced pressure, dissolved in water and extracted with ethyl acetate (thrice). Combined organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford (Z)-1-(2-chloro- 6-fluoro-phenyl)-N'-hydroxy-cyclopropanecarboxamidine (233, 900 mg).1HNMR (400 MHz, DMSO-d6) δH 7.53-7.47 (m, 1H), 7.44-7.42 (m, 1H), 7.35-7.30 (m, 1H), 1.89-1.86 (t, 2H), 1.47- 1.45 (t, 2H). [1082] Synthesis of (Z)-1-(2-chloro-6-fluorophenyl)-N'-((5-(difluoromethyl)-1-(2- (methylsulfonyl)ethyl)-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide, 234 [Step 3]: To a solution of 5-(difluoromethyl)-1-(2-methylsulfonylethyl)pyrazole-3-carboxylic acid (500 mg, 1.9 mmol) (along with other regioisomer) and (Z)-1-(2-chloro-6-fluorophenyl)-N'- hydroxycyclopropane-1-carboximidamide (233, 500 mg, 1.4 mmol) in dichloromethane (10mL), DIPEA (1.0 mL, 5.6 mmol), EDCI.HCl (535 mg, 2.8 mmol) and HOAt (50 mg, 0.4 mmol) were added at 0 °C and the reaction mixture was stirred at ambient temperature for 16h. After completion, the reaction mixture was diluted with dichloromethane and partitioned with water. Combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by column chromatography to afford (Z)-1-(2- chloro-6-fluorophenyl)-N'-((5-(difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazole-3- carbonyl)oxy)cyclopropane-1-carboximidamide (234, 350 mg) along with other regioisomer. LCMS (ESI) Calcd for C18H18ClF3N4O4S: 478.0, found [M+H]+ = 479.3. [1083] Synthesis of 3-(1-(2-chloro-6-fluorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1H-pyrazol- 3-yl)-1,2,4-oxadiazole, 235 [Step 4]: To a stirred solution of (Z)-1-(2-chloro-6-fluorophenyl)-N'- ((5-(difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1- carboximidamide (234, 300 mg, 0.6 mmol) in THF (10 mL), Tetrabutylammonium hydroxide (2.0 mL, 1M in methanol) was added and the resulting reaction mixture was stirred at ambient temperature for 12 h. After completion, the reaction mixture was concentrated under reduced pressure, dissolved in ethyl acetate and washed with water (twice). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by column chromatography to afford 3-(1-(2-chloro-6- fluorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (235, 200 mg). LCMS (ESI) Calcd for C15H10ClF3N4O: 354.0, found [M+H]+ = 355.3. [1084] Synthesis of 2-(3-(3-(1-(2-chloro-6-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)acetamide, Example 165a and Example 165b [Step 5]: To a stirred solution of 3-(1-(2-chloro-6-fluorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1H-pyrazol-3- yl)-1,2,4-oxadiazole (235, 200 mg, 0.6 mmol) in THF (5 mL), K2CO3 (155 mg, 1.1 mmol) was added at 0 °C. After 15 min, 2-bromoacetamide (95 mg, 0.7 mmol) was added to the reaction mixture and stirred at ambient temperature for 16 h. After completion, the reaction mixture was dissolved in ethyl acetate and washed with water (twice). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by prep-HPLC purification to afford the first product as 2-(3-(3-(1-(2-chloro-6-fluoro- phenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)pyrazol-1-yl)acetamide (Example 165a, 20 mg) as Peak 1 and the second product as 2-(5-(3-(1-(2-chloro-6-fluoro- phenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-3-(difluoromethyl)pyrazol-1-yl)acetamide (Example 165b, 10 mg) as Peak 2. [1085] Analytical data of 2-(3-(3-(1-(2-chloro-6-fluoro-phenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)pyrazol-1-yl)acetamide, Example 165a : 1HNMR (400 MHz, DMSO-d6) δH 7.41(s, 1H), 7.49-7.14 (m, 6H), 5.05(s, 2H), 1.89(s, 2H), 1.75(s, 2H). LCMS (ESI) Calcd for C19H16ClF3N4O: 408.1, found [M+H]+ = 412.0. NOTE: The actual structure was confirmed through 2D &NOE experiments. Example 166: Synthesis of 2-(3-(3-(1-(2-chloro-6-fluorophenyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)acetamide (Example 166)
Figure imgf000312_0001
[1086] Synthesis of (Z)-1-(2-chloro-6-methylphenyl)-N'-((5-(difluoromethyl)-1-(2- (methylsulfonyl)ethyl)-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide, 236 [Step 1]: To a solution of 5-(difluoromethyl)-1-(2-methylsulfonylethyl)pyrazole-3-carboxylic acid (700 mg, 2.6 mmol) and 1-(2-chloro-6-methyl-phenyl)-N'-hydroxy-cyclopropanecarboxamidine (160, 645 mg, 2.8 mmol) in dichloromethane (20 mL), DIPEA (1.4 mL, 7.8 mmol), EDCI.HCl (750 mg, 3.9 mmol) and HOAt (70 mg, 0.5 mmol) were added at 0 °C and the reaction mixture was stirred at ambient temperature for 16h. After completion, the reaction mixture was diluted with dichloromethane and partitioned with water. Combined organic extract was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by column chromatography to afford (Z)-1-(2-chloro-6-methylphenyl)-N'-((5-(difluoromethyl)-1- (2-(methylsulfonyl)ethyl)-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide (236, 600 mg). LCMS (ESI) Calcd for C19H21ClF2N4O4S: 474.0, found [M+H]+ = 474.7. [1087] Synthesis of 3-(1-(2-chloro-6-methylphenyl)cyclopropyl)-5-(5-(difluoromethyl)-1H- pyrazol-3-yl)-1,2,4-oxadiazole, 237 [Step 2]: To a stirred solution of (Z)-1-(2-chloro-6- methylphenyl)-N'-((5-(difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazole-3- carbonyl)oxy)cyclopropane-1-carboximidamide (236, 600 mg, 1.3 mmol) in THF (10 mL), tetrabutylammonium hydroxide (4.0 mL, 4.0 mmol, 1M in methanol) was added and the resulting reaction mixture was stirred at ambient temperature for 12 h. After completion, the reaction mixture was concentrated under reduced pressure, dissolved in ethyl acetate and washed with water (twice). The combined organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford 3-(1-(2-chloro-6-methylphenyl)cyclopropyl)-5-(5- (difluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (237, 350 mg). LCMS (ESI) Calcd for C16H13ClF2N4O: 350.0, found [M+H]+ = 351.0. [1088] Synthesis of 2-(3-(3-(1-(2-chloro-6-methylphenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)acetamide, Example 166 [Step 3]: To a stirred solution of 3-(1- (2-chloro-6-methylphenyl)cyclopropyl)-5-(5-(difluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (237, 150 mg, 0.4 mmol) in THF (4 mL), K2CO3 (120 mg, 0.8 mmol) was added at 0 °C. After 15 min, 2-bromoacetamide (70 mg, 0.5 mmol) was added to the reaction mixture and stirred at ambient temperature for 16 h. After completion, the reaction mixture was diluted with ethyl acetate and washed with water (twice). The combined organic extract was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by reverse phase prep-HPLC to afford 2-(3-(3-(1-(2-chloro-6-methylphenyl)cyclopropyl)-1,2,4-oxadiazol-5- yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)acetamide (Example 166, 5 mg) as Peak-1 and 2-(5-(3-(1- (2-chloro-6-methyl-phenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-3-(difluoromethyl)pyrazol-1- yl)acetamide (3.0 mg) as Peak-2. [1089] Analytical data of 2-(3-(3-(1-(2-chloro-6-methylphenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)acetamide, Example 166 (Peak 1): 1H NMR (400 MHz, DMSO-d6) δH 7.71 (brs, 1H), 7.42 (brs, 1H), 7.33-7.24 (m, 5H), 5.06 (s, 2H), 2.36 (s, 3H), 1.88 (brs, 1H), 1.80 (brs, 1H), 1.47 (t, 2H). LCMS (ESI) Calcd for C18H16ClF2N5O2: 407.1, found [M+H]+ = 408.1. Note: NOTE: The actual structure was confirmed through HNMR study of two spots with batch Id 'CR620-SB-2023-10-40-P-F-Peak-1' and 'CR620-SB-2023-10-40-P-F-Peak- 2'. Peak-2 HNMR consistent with desired product along with other impurities. Examples 167a, 167b, & 168: Synthesis of 2-(3-(3-(1-(2-bromo-6-chloro-4- fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1- yl)acetamide (Example 167a), 2-(5-(3-(1-(2-bromo-6-chloro-4-fluorophenyl)cyclopropyl)- 1,2,4-oxadiazol-5-yl)-3-(difluoromethyl)-1H-pyrazol-1-yl)acetamide (Example 167b), and 2- (3-(3-(1-(2-chloro-4-fluoro-6-methylphenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)acetamide (Example 168)
Figure imgf000314_0001
[1090] Synthesis of 1-bromo-3-chloro-5-fluoro-2-methylbenzene, 239 [Step 1]: Sulfuric Acid (0.6 mL) and NBS (700 mg, 4 mmol) are added to a solution of 2-chloro-4-fluoro-1- methylbenzene (238, 500 mg, 3.5 mmol) in TFA (2.0 mL, 25 mmol). The reaction mixture was allowed to stir at ambient temperature for 18 h. Reaction mixture was quenched with saturated NaHCO3 solution and extracted with ethyl acetate. Organic extracts were evaporated under reduced pressure to afford product which was purified by combiflash chromatography to afford 1-bromo-3-chloro-5-fluoro-2-methylbenzene (239, 600 mg).1HNMR (400 MHz, DMSO- d6) δH 7.75 (d, 1H), 7.59 (d, 1H), 2.29 (s, 3H). [1091] Synthesis of 1-bromo-2-(bromomethyl)-3-chloro-5-fluorobenzene, 240 [Step 2]: AIBN (90 mg, 0.5 mmol) and NBS (580 mg, 3 mmol) were added to a solution of 1-bromo-3-chloro-5- fluoro-2-methylbenzene (239, 600 mg, 3 mmol) in MeCN (15mL). The reaction mixture was allowed to stir at 80 °C for 16 h. After stirring for 16 h at reflux the mixture was concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel to afford 1-bromo-2-(bromomethyl)-3-chloro-5-fluorobenzene (240, 750 mg). GCMS Calcd. for C7H4Br2ClF: [M] = 302.37, [M/Z] = 301.9. [1092] Synthesis of 2-(2-bromo-6-chloro-4-fluorophenyl)acetonitrile, 241[Step 3]: To a stirred solution of 1-bromo-2-(bromomethyl)-3-chloro-5-fluorobenzene (240, 750 mg, 2.5 mmol) in MeCN (10mL), K2CO3 (350 mg, 2.5 mmol) was added followed by trimethylsilylformonitrile (0.4 mL, 2.5 mmol) and the reaction mixture was heated at 100 °C for 16 h. After completion, the reaction mixture was dissolved in ethyl acetate, washed with water(thrice) and brine. The organic extract was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford product as 2-(2-bromo-6-chloro-4-fluorophenyl)acetonitrile (241, 600 mg). GCMS Calcd. for C8H4BrClFN: [M] = 248.48, [M/Z] = 249. [1093] Synthesis of 1-(2-bromo-6-chloro-4-fluorophenyl)cyclopropane-1-carbonitrile, 242 [Step 4]: To a stirred solution of NaOH (1.1 g, 30 mmol) in Water (5mL), 2-(2-bromo-6-chloro-4- fluorophenyl)acetonitrile (241, 600 mg, 2.5 mmol), TBAB (160 mg, 0.5 mmol) and 1,2- dibromoethane (2 mL, 12 mmol) were added and the reaction mixture was heated at 100 oC for 12h. After completion reaction mixture was poured into cold water and extracted with ethyl acetate( thrice). Combined organic layered was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford 1-(2-bromo-6-chloro-4- fluorophenyl)cyclopropane-1-carbonitrile (242, 650 mg). GCMS Calcd. For C10H6BrClFN: [M] = 274.52, [M/Z] = 274. [1094] Synthesis of (Z)-1-(2-bromo-6-chloro-4-fluorophenyl)-N'-hydroxycyclopropane-1- carboximidamide, 243 [Step 5]: To a stirred solution of 1-(2-bromo-6-chloro-4- fluorophenyl)cyclopropane-1-carbonitrile (242, 600 mg, 2 mmol) in Ethanol (10mL), sodium carbonate (460 mg, 4 mmol) and Hydroxylamine hydrochloride (305 mg, 4 mmol) were added and the reaction was heated at 70 oC for 12h. After completion volatiles were evaporated under reduced pressure, dissolved in water and extracted with ethyl acetate(thrice). Combined organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford product as (Z)-1-(2-bromo-6-chloro-4-fluorophenyl)-N'- hydroxycyclopropane-1-carboximidamide (243, 350 mg). LCMS (ESI) calculated for C10H9BrClFN2O [M]: 307.55, found [M+2]+: 309.14. [1095] Synthesis of (Z)-1-(2-bromo-6-chloro-4-fluorophenyl)-N'-((5-(difluoromethyl)-1-(2- (methylsulfonyl)ethyl)-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide, 244 [Step 6]: To a solution of 5-(difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazole-3-carboxylic acid (250 mg, 1 mmol)(along with other regioisomer) and (Z)-1-(2-bromo-6-chloro-4-fluorophenyl)-N'- hydroxycyclopropane-1-carboximidamide (243, 320 mg, 2 mmol) in 1,2-dichloromethane (5mL), DIPEA (0.5 mL, 3 mmol), EDCI.HCl (270 mg, 1.5 mmol) and HOAt (30 mg, 0.2 mmol) were added at 0 °C and the reaction mixture was stirred for 16h at ambient temperature. After completion the reaction mixture was diluted with dichloromethane and partitioned with water. Combined organic layer was dried over anhydrous Na2SO4, filtered, concentrated under reduced pressure to afford (Z)-1-(2-bromo-6-chloro-4-fluorophenyl)-N'-((5-(difluoromethyl)-1-(2- (methylsulfonyl)ethyl)-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide (244, 300 mg) along with other regioisomer. LCMS (ESI) calculated for C18H17BrClF3N4O4S [M]: 557.77, found [M+H]+: 558.8. [1096] Synthesis of 3-(1-(2-bromo-6-chloro-4-fluorophenyl)cyclopropyl)-5-(5-(difluoromethyl)- 1H-pyrazol-3-yl)-1,2,4-oxadiazole, 245 [Step 7]: To a stirred solution of (Z)-1-(2-bromo-6-chloro- 4-fluorophenyl)-N'-((5-(difluoromethyl)-1-(2-(methylsulfonyl)ethyl)-1H-pyrazole-3- carbonyl)oxy)cyclopropane-1-carboximidamide (244, 300 mg, 0.6 mmol) in THF (6mL), Tetrabutylammonium hydroxide( 1 M) (15 mg, 0.05 mmol) was added. The resulting reaction mixture was stirred for 16 h at ambient temperature. The mixture was passed through celite bed, washed with water then brine solution and extracted with ethyl acetate. The organics were then separated and dried under reduced pressure to afford product. Product was purified through prep-HPLC(RP) to afford 3-(1-(2-bromo-6-chloro-4-fluorophenyl)cyclopropyl)-5-(5- (difluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (245, 200 mg).1HNMR (at 100°C) (400 MHz, DMSO-d6) δH 7.89 (d, 1H), 7.59 (d, 1H), 7.20-6.93 (m, 2H), 1.78-1.75 (m, 2H), 1.52 (s, 2H). LC/MS: calculated for C15H9BrClF3N4O [M]: 433.61, found [M+2]+:435. Notes: 6 mg of int 10 was shipped. Rest amount were forwarded to next step. [1097] Synthesis of 2-(3-(3-(1-(2-bromo-6-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5- yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)acetamide, Example 167a and 2-(5-(3-(1-(2-bromo-6- chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-3-(difluoromethyl)-1H-pyrazol-1- yl)acetamide, Example 168b [Step 8]: To a stirred solution of 3-(1-(2-bromo-6-chloro-4- fluorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (245, 100 mg, 0.2 mmol) in THF (4mL), Cs2CO3 (150 mg, 0.4 mmol) was added at 0 °C. After 15 min, 2- bromoacetamide (50 mg, 0.3 mmol) was added to the reaction mixture and stirred at ambient temperature for 16 h. After completion, the mixture was diluted partitioned with ethyl acetate and water. The combined organic layer was collected, washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford mixture which was purified and separated through RP prep chromatography to afford as 2-(3-(3-(1-(2-bromo-6-chloro-4- fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)acetamide (Example 167a, 10 mg) as peak 1 and 2-(5-(3-(1-(2-bromo-6-chloro-4-fluorophenyl)cyclopropyl)- 1,2,4-oxadiazol-5-yl)-3-(difluoromethyl)-1H-pyrazol-1-yl)acetamide (Example 167b, 10 mg) as peak 2. [1098] Analytical data for peak 1: 1HNMR (at 100 °C) (400 MHz, DMSO-d6) δH 7.89 (d, 1H), 7.58 (d, 1H), 7.36-7.09 (m, 2H), 5.04 (s, 2H), 3.64 (s, 2H), 1.75 (s, 2H), 1.53 (s, 2H). LC/MS: calculated for C17H12BrClF3N5O2: 490.6, found [M+H]+ = 491.8. Notes: 10 mg of compound was shipped. Rest amount were forwarded to next step. Extra peak present in 1H NMR. [1099] Analytical data for peak 2: 1HNMR (400 MHz, DMSO-d6) δH 7.94 (d, 1H), 7.72 (d, 1H), 7.43 (s, 1H), 7.34-6.97 (m, 1H), 5.25 (s, 2H), 1.73 (s, 2H), 1.55 (s, 2H). LC/MS: calculated for C17H12BrClF3N5O2 [M]: 490.66, found [M+H]+:475. [1100] Synthesis of 2-(3-(3-(1-(2-chloro-4-fluoro-6-methylphenyl)cyclopropyl)-1,2,4-oxadiazol-5- yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)acetamide, Example 168 [Step 5]: To a stirred solution of 2-(3-(3-(1-(2-bromo-6-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)acetamide (50 mg, 0.1 mmol) in 1,4-Dioxane (2mL) and Water (0.2mL), K3PO4 (60 mg, 0.3 mmol) and Methyl boronic acid (1.50 eq, 9.1 mg, 0.153 mmol) were added at ambient temperature. It was then degassed with nitrogen for 10 minutes and PdCl2(dtbpf) (10 mg, 0.01 mmol) was added to it and the reaction mass was heated to 100 °C for 16h. After completion, the mixture was diluted partitioned with ethyl acetate and water. The combined organic layer was collected, washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford mixture which was purified and separated through reverse phase prep chromatography to afford 2-(3-(3-(1-(2-chloro-4-fluoro-6- methylphenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1- yl)acetamide(Example 168, 10 mg).1HNMR (400 MHz, DMSO-d6) (at 100 °C) δH 7.49 (d, 1H), 7.36-7.02 (m, 5H), 2.26 (s, 3H), 1.74 (d, 2H), 1.47 (d, 2H). LC/MS: calculated for C18H15ClF3N5O2 [M]: 425.79, found [M+H]+: 426. Examples 169: Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 169) Scheme 96 [1101] Synthesis of 1-(2-chloro-4-fluorophenyl)cyclopropane-1-carbonitrile, 247 [Step 1]: To a stirred solution of NaOH (850 mg, 21.2 mmol) in water (5 mL), 2-(2-chloro-4- fluorophenyl)acetonitrile (246, 300 mg, 1.8 mmol) and TBAB (115 mg, 0.4 mmol) were added at 0 °C. After 5 min, 1,2-dibromoethane (1.3 mL, 8.9 mmol) was added dropwise and the resulting reaction mixture was heated at 60 °C for 12 h. After completion, the reaction mixture was poured into cold water and extracted with ethyl acetate (thrice). Combined organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to afford 1-(2-chloro-4- fluorophenyl)cyclopropane-1-carbonitrile (247, 300 mg).1H NMR (400 MHz, DMSO-d6) δH 7.62- 7.55 (m, 2H), 7.29-7.24 (m, 1H), 1.76-1.73 (m, 2H), 1.43-1.40 (m.2H) [Note: HNMR contain extra peak.] [1102] Synthesis of (Z)-1-(2-chloro-4-fluorophenyl)-N'-hydroxycyclopropane-1-carboximidamide, 248 [Step 2]: To a stirred solution of 1-(2-chloro-4-fluorophenyl)cyclopropane-1-carbonitrile (247, 250 mg, 1.3 mmol) in ethanol (2mL), Na2CO3 (270 mg, 2.6 mmol) was added followed by NH2OH.HCl (180 mg, 2.6 mmol) and the reaction mixture was heated to reflux at 70 °C for 12h. After completion, the volatiles were evaporated under reduced pressure, diluted with water and extracted with ethyl acetate (thrice). The combined organic extract was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The product was purified by column chromatography to afford (Z)-1-(2-chloro-4-fluorophenyl)-N'-hydroxycyclopropane-1- carboximidamide (248, 250 mg). LCMS (ESI) Calcd for C10H10ClFN2O: 228.1, found [M+H]+ = 228.9. [1103] Synthesis of (Z)-1-(2-chloro-4-fluorophenyl)-N'-((5-(difluoromethyl)-1H-pyrazole-3- carbonyl)oxy)cyclopropane-1-carboximidamide, 250 [Step 3]: To a stirred solution of 5- (difluoromethyl)-1-methyl-1H-pyrazole-3-carboxylic acid (249, 85 mg, 0.5 mmol) and (Z)-1-(2- chloro-4-fluorophenyl)-N'-hydroxycyclopropane-1-carboximidamide (248, 140 mg, 0.6 mmol) in dichloromethane (1 mL), N,N-Diisopropylethylamine (2 mL, 1.2 mmol), EDCI.HCl (120 mg, 0.6 mmol) and HOAt (15 mg, 0.1 mmol) were added at 0 oC and the reaction mixture was stirred at ambient temperature for 16h. After completion, the reaction mixture was concentrated under reduced pressure, dissolved with ethyl acetate, washed with water, brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The product was purified by column chromatography to (Z)-1-(2-chloro-4-fluorophenyl)-N'-((5-(difluoromethyl)-1H-pyrazole-3- carbonyl)oxy)cyclopropane-1-carboximidamide (250, 140 mg). LCMS (ESI) Calcd for C16H14ClF3N4O2: 386.1, found [M+H]+ = 387.1. [1104] Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(5-(difluoromethyl)-1-methyl- 1H-pyrazol-3-yl)-1,2,4-oxadiazole, Example 169 (Step-4): To a stirred solution of (Z)-1-(2- chloro-4-fluorophenyl)-N'-((5-(difluoromethyl)-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1- carboximidamide (250, 140 mg, 0.4 mmol) in THF (2 mL), tetrabutylammonium hydroxide(0.1 mL, 0.1 mmol, 1M in methanol) was added and resulting reaction mixture was stirred at ambient temperature for 60 min. After completion, the reaction mixture was concentrated under reduced pressure, dissolved in ethyl acetate, washed with water, dried over anhydrous Na2SO4, filtered and concentrated again under reduced pressure. The product was purified by reverse phase prep-HPLC and lyophilized to afford 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(5- (difluoromethyl)-1-methyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 169, 27 mg). LCMS (ESI) Calcd for C16H12ClF3N4O: 368.1, found [M+H]+ = 369.0.1HNMR (400 MHz, DMSO-d6, 100 °C) δH 7.63-7.59 (m, 1H), 7.44-7.18 (m, 4H), 4.05 (s, 3H), 1.76-1.73 (m, 2H), 1.50-1.45 (m, 2H). Examples 170: Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(1-methyl-5- (trifluoromethyl)-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 170)
Figure imgf000319_0001
[1105] Synthesis of 1-methyl-5-(trifluoromethyl)-1H-pyrazole-3-carboxylic acid, 252 [Step 1]: To a stirred solution of methyl 1-methyl-5-(trifluoromethyl)-1H-pyrazole-3-carboxylate (251, 250 mg, 1.2 mmol) in THF (2 mL) and water (0.5 mL), LiOH.H2O (250 mg, 6.0 mmol) was added at 0 oC and the reaction mixture was stirred at ambient temperature for 12h. The reaction mixture was concentrated under reduced pressure, acidified with (1N) HCl up to pH- 4 to 5 and extracted with ethyl acetate (thrice). The combined organic extract was washed with water, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford 1-methyl-5- (trifluoromethyl)-1H-pyrazole-3-carboxylic acid (252, 200 mg).1HNMR (400 MHz, DMSO-d6) δH 13.19 (s, 1H), 7.29 (s, 1H), 4.02 (d, 3H). [1106] Synthesis of (Z)-1-(2-chloro-4-fluorophenyl)-N'-((1-methyl-5-(trifluoromethyl)-1H- pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide, 253 [Step 2]: To a stirred solution of 1-methyl-5-(trifluoromethyl)-1H-pyrazole-3-carboxylic acid (252, 80 mg, 0.4 mmol) and (Z)-1-(2- chloro-4-fluorophenyl)-N'-hydroxycyclopropane-1-carboximidamide (248, 125 mg, 0.5 mmol) in dichloromethane (1 mL), N,N-Diisopropylethylamine (0.2 mL, 0.8 mmol), EDCI.HCl (105 mg, 0.5 mmol) and HOAt (6.0 mg, 0.04 mmol) were added at 0 °C and the reaction mixture was stirred at ambient temperature for 16h. After completion, the reaction mixture was concentrated under reduced pressure, dissolved with ethyl acetate, washed with water, brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure The product was purified by column chromatography to (Z)-1-(2-chloro-4-fluorophenyl)-N'-((1-methyl-5-(trifluoromethyl)-1H-pyrazole- 3-carbonyl)oxy)cyclopropane-1-carboximidamide (253, 150 mg). LCMS (ESI) Calcd for C16H13ClF4N4O2: 404.1, found [M+H]+ = 405.2. [1107] Synthesis of 3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-5-(1-methyl-5-(trifluoromethyl)- 1H-pyrazol-3-yl)-1,2,4-oxadiazole, Example 170 (Step-3): To a stirred solution of (Z)-1-(2- chloro-4-fluorophenyl)-N'-((1-methyl-5-(trifluoromethyl)-1H-pyrazole-3- carbonyl)oxy)cyclopropane-1-carboximidamide (253, 120 mg, 0.3 mmol) in THF (2 mL), tetrabutylammonium hydroxide (0.06 mL, 0.06 mmol, 1M in methanol) was added and the resulting reaction mixture was stirred at ambient temperature for 60 min. After completion, the reaction mixture was concentrated under reduced pressure, dissolved in ethyl acetate, washed with water, dried over anhydrous Na2SO4, filtered and concentrated again under reduced pressure. The product was purified by reverse phase prep-HPLC and lyophilized to afford 3-(1- (2-chloro-4-fluorophenyl)cyclopropyl)-5-(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-1,2,4- oxadiazole (Example 170, 70 mg). LCMS (ESI) Calcd for C16H11ClF4N4O: 386.1, found [M+H]+ = 387.1.1HNMR (400 MHz, DMSO-d6) δH 7.65-7.61 (m, 2H), 7.51-7.48 (dd, 1H), 7.26-7.25 (m, 1H), 4.11 (s, 3H), 1.73-1.70 (m, 2H), 1.49-1.47 (m, 2H). Examples 183: Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)-N-methylacetamide (Example 183)
Figure imgf000320_0001
[1108] Synthesis of (Z)-2-(3-((((amino(1-(2-chloro-4- fluorophenyl)cyclopropyl)methylene)amino)oxy)carbonyl)-5-(difluoromethyl)-1H-pyrazol-1-yl)-N- methylacetamide, 254 [Step-1]: To a stirred solution of 5-(difluoromethyl)-1-(2-(methylamino)-2- oxoethyl)-1H-pyrazole-3-carboxylic acid (46, 140 mg, 0.6 mmol.) and (Z)-1-(2-chloro-5- fluorophenyl)-N'-hydroxycyclopropane-1-carboximidamide (248, 151 mg, 0.66 mmol) in dichloromethane (1mL), N,N-Diisopropylethylamine (0.3 ml, 1.5 mmol.), EDCI.HCl (173 mg, 0.9 mmol.) and HOAt (16 mg, 0.12 mmol.) were added at 0 °C and reaction mixture was stirred for 16h at ambient temperature. The reaction mixture was concentrated under reduced pressure, dissolved with ethyl acetate, washed with water, brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure The product was purified by column chromatography to afford (Z)-2-(3-((((amino(1-(2-chloro-4-fluorophenyl)cyclopropyl)methylene)amino)oxy)carbonyl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)-N-methylacetamide (254, 100 mg). LCMS (ESI) calculated for C18H17ClF3N5O3 [M]: 443.1, found [M+H]+: 443.9. [1109] Synthesis of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)-N-methylacetamide, Example 183 [Step-2]: To a stirred solution of (Z)-2-(3-((((amino(1-(2-chloro-4- fluorophenyl)cyclopropyl)methylene)amino)oxy)carbonyl)-5-(difluoromethyl)-1H-pyrazol-1-yl)-N- methylacetamide (254, 100 mg, 0.2 mmol.) in THF (2mL), tetrabutylammonium hydroxide(1M in methanol, 0.04 mL, 0.04 mmol.) was added and resulting reaction mixture was stirred for 60 min at ambient temperature. After completion Reaction mixture was concentrated under reduced pressure, dissolved in ethyl acetate, washed with water, dried over anhydrous Na2SO4, filtered and concentrated again under reduced pressure. Product was purified through prep-HPLC (Reverse phase) and lyophilized to afford Synthesis of 2-(3-(3-(1-(2-chloro-4- fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)-N- methylacetamide (Example 183, 33 mg). LCMS (ESI) calculated for C18H15ClF3N5O2 [M]: 425.1, found [M-H]-: 426.1.1HNMR (400 MHz, DMSO-d6) δH 8.21 (d, 1H), 7.64-7.61 (m, 1H), 7.51-7.48 (dd, 1H) 7.42-7.15(m, 3H), 5.06 (s, 2H), 2.66-2.62 (m, 3H), 1.73-1.70 (m, 2H), 1.49-1.46 (m, 2H). Examples 184: Synthesis of 3-(1-(5-fluoro-2-methylphenyl)cyclopropyl)-5-(1-phenyl-1H- pyrazol-3-yl)-1,2,4-oxadiazole (Example 184)
Figure imgf000321_0001
[1110] Synthesis of (Z)-1-(5-fluoro-2-methylphenyl)-N'-((1-phenyl-1H-pyrazole-3- carbonyl)oxy)cyclopropane-1-carboximidamide, 257 (Step 1): To a stirred solution of 1- phenylpyrazole-3-carboxylic acid (256, 150 mg, 0.8 mmol) and 1-(5-fluoro-2-methyl-phenyl)-N'- hydroxy-cyclopropanecarboxamidine (255, 150 mg, 0.7 mmol)) in dichloromethane (5 mL), DIPEA (0.4 mL, 2.2 mmol), EDC.HCl (275 mg, 1.4 mmol) and HOAt (15 mg, 0.1 mmol) were added at 0 °C and reaction mixture was stirred at ambient temperature. After completion, the reaction mixture was diluted with water and extracted with dichloromethane. The organic extract was dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford (Z)-1-(5- fluoro-2-methylphenyl)-N'-((1-phenyl-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1- carboximidamide (257, 130 mg). LCMS Calcd for C21H19FN4O2 : 378.4, found [M+H]+ = 379.2. [1111] Synthesis of 3-(1-(5-fluoro-2-methylphenyl)cyclopropyl)-5-(1-phenyl-1H-pyrazol-3-yl)- 1,2,4-oxadiazole, Example 184 (Step 2): To a stirred solution of (Z)-1-(5-fluoro-2-methylphenyl)- N'-((1-phenyl-1H-pyrazole-3-carbonyl)oxy)cyclopropane-1-carboximidamide (257, 300 mg, 0.8 mmol) in THF (5 mL), tetrabutylammonium hydroxide (0.05 mL, 0.1 mmol) was added and the reaction mixture was stirred at ambient temperature for 2h. After completion, the reaction mixture was diluted with ethyl acetate and washed with water (thrice). The combined organic extract was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The product was purified by reverse phase prep HPLC and lyophilized to afford 3-(1-(5-fluoro-2- methylphenyl)cyclopropyl)-5-(1-phenyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole (Example 184, 165 mg). LCMS (ESI) Calcd for C21H17FN4O: 360.3, found [M+H]+ = 361.2.1H NMR (400 MHz, DMSO-d6) δH 8.78 (d, 1H), 7.39 (d, 2H), 7.56 (t, 2H), 7.42 (t, 1H), 7.27-7.22 (m,3H), 7.11-7.06 (m,1H), 2.24 (s,3H), 1.68 (s, 2H), 1.46-1.43 (m, 2H). Examples 185a & 185b: Synthesis of (R)-2-(2-(3-(3-(1-(2-chloro-4- fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1- yl)acetamido)propanamide (Example 185a) and (S)-2-(2-(3-(3-(1-(2-chloro-4- fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1- yl)acetamido)propanamide (Example 185b)
Figure imgf000322_0001
[1112] Synthesis of 2-(2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)acetamido)propanamide, 259, [Step 1]: To a stirred solution of 2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H- pyrazol-1-yl)acetic acid (Example 109, 250 mg, 0.6 mmol ) in dichloromethane (2 mL), 2- aminopropanamide (258, 80 mg, 0.9 mmol) and DIPEA (0.3 mL, 1.8 mmol) were added followed by T3P (1.1 mL, 1.8 mmol, 50 % in ethyl acetate) and the reaction mixture was stirred at ambient temperature for 16h. After completion, the reaction mixture was diluted with dichloromethane and partitioned with water. Combined organic layer was dried over anhydrous Na2SO4, filtered, concentrated under reduced pressure and purified by reverse phase prep-HPLC to afford 2-(2- (3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H- pyrazol-1-yl)acetamido)propanamide (259, 80 mg). LCMS (ESI) Calcd for C20H18ClF3N6O3: 482.1, found [M+H]+ = 483.1. [1113] Synthesis of (S)-2-(2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)- 5-(difluoromethyl)-1H-pyrazol-1-yl)acetamido)propanamide, Example 185 [Step 1]: Racemic 2- (2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H- pyrazol-1-yl)acetamido)propanamide (259, 80 mg, 0.2 mmol) was separated by chiral separation to afford the first product as (R)-2-(2-(3-(3-(1-(2-chloro-4-fluorophenyl)cyclopropyl)- 1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)acetamido)propanamide (Example 185, 25 mg) as peak 1 and the second product as (S)-2-(2-(3-(3-(1-(2-chloro-4- fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1- yl)acetamido)propanamide (Example 186, 32 mg) as peak 2. Absolute stereochemistry known. [1114] Note: A reaction with (2R)-2-aminopropanamide was attempted to obtain (R)-2-(2-(3-(3- (1-(2-chloro-4-fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1- yl)acetamido)propenamide with known absolute configuration. After comparing the chiral HPLC of both isomers (PEAK1 & PEAK2) with this R-isomer, it was confirmed that PEAK1 is R-isomer and PEAK2 is S-isomer. Analytical data of (S)-2-(2-(3-(3-(1-(2-chloro-4- fluorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1- yl)acetamido)propanamide, Example 185b: LCMS (ESI) Calcd for C20H16ClF3N4O3: 452.09, found [M-H]- = 451.1.1HNMR (400 MHz, DMSO-d6) δH 8.53 (d, 1H), 7.65-7.61 (t, 1H), 7.51-7.50 (m,1H), 7.48 (s, 1H), 7.43-7.13 (m, 3H), 7.06 (s, 1H), 5.21-5.11 (m, 2H), 4.24-4.21 (m, 1H), 1.72 (s, 2H), 1.47 (brs, 2H), 1.24-1.22(m, 3H). [1115] Chiral prep HPLC procedure: HPLC SFC Prep Purification has been completed on Pic Solution 175 instrument equipped with Knauer UV Detector 40D by using I Cellulose J (30.0 mm x 250mm ), 5 min Column operating at 35 ºC temperature, maintaining flow rate of 90 ml/min ,using 85% CO2 in super critical state & 15% of (100% MeOH) as Mobile phase, Run this isocratic mixture up to 14.0 minutes and also maintained the isobaric condition of 100 bar at 220 nm wavelength. Examples 200a & 200b: Synthesis of 4-((5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)- 1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)benzoic acid (Example 200a) and 4-((3- (difluoromethyl)-5-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1- yl)methyl)benzoic acid (Example 200b)
Figure imgf000324_0001
[1116] Synthesis of methyl 4-((3-(difluoromethyl)-5-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5- yl)-1H-pyrazol-1-yl)methyl)benzoate, 101-3 and methyl 4-((5-(difluoromethyl)-3-(3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)benzoate, 101-4 [Step 1]: To a stirred solution of 5-(5-(difluoromethyl)-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazole (70, 200 mg, 0.632 mmol) in DMF (7 mL) was added K2CO3 (175 mg, 1.26 mmol) followed by addition of methyl 4-(bromomethyl)benzoate (101-2, 174 mg, 0.75 mmol) at ambient temperature and stirred for 16 h. The reaction mixture was diluted with ethyl acetate and washed by water (thrice) and brine, dried over anhydrous Na2SO4 and evaporated. The crude product was purified by column chromatography to give methyl 4-((3-(difluoromethyl)-5-(3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)benzoate as peak 1 (101-3, 220 mg) and methyl 4-((5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)methyl)benzoate as peak 2 (101-4, 90 mg). LCMS (ESI) Calcd. for C25H22F2N4O3: 464.17, found [M+H]+= 465.4. [1117] Compound 101-4: LCMS (ESI) Calcd. for C25H22F2N4O3: 464.17, found [M+H]+= 465.4. 1H NMR (400 MHz, d6-DMSO) δH: 7.94 (d, 2H), 7.55-7.29 (m, 5H), 7.24-7.19 (m, 3H), 5.27 (s, 2H), 3.84 (s, 3H), 2.26 (s, 3H), 1.75-1.65 (m, 2H), 1.45-1.39 (m, 2H). [1118] Compound 101-3: LCMS (ESI) Calcd. for C25H22F2N4O3: 464.17, found [M+H]+= 465.4. 1H NMR (400 MHz, d6-DMSO) δH: 7.91 (d, 2H), 7.48 (s, 1H), 7.36-7.01 (m, 7H), 5.89 (s, 2H), 3.84 (s, 3H), 2.21 (s, 3H), 1.59 (m, 2H), 1.40 (m, 2H). [1119] Synthesis of 4-((5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)methyl)benzoic acid, Example 200a [ Step 3]: To a stirred solution of methyl 4-((5- (difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1- yl)methyl)benzoate (101-4, 90 mg, 0.20 mmol) in THF (5 mL) and water (2 mL) was added LiOH.H2O (24 mg, 0.58 mmol) at 0 oC and stirred at ambient temperature for 16 h. The reaction mixture was cooled to 0C and acidified with saturated aqueous KHSO4 solution (pH: 4) and extracted with ethyl acetate (twice). The combined organic extract was washed with water, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by Prep HPLC and lyophilised to give 4-((5-(difluoromethyl)-3-(3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)benzoic acid (Example 200a, 55 mg). LCMS (ESI) Calcd. for C24H20F2N4O3: 450.15, found [M+H]+= 451.2.1H NMR (400 MHz, d6- DMSO) δH: 7.90 (d, 2H), 7.55-7.36 (m, 3H), 7.28-7.17 (m, 5H), 5.68 (s, 2H), 2.26 (s, 3H), 1.65- 1.63 (m, 2H), 1.39-1.38 (m, 2H). [1120] Synthesis of 4-((3-(difluoromethyl)-5-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)methyl)benzoic acid, Example 200b [ Step 2]: To a stirred solution of methyl 4-((3- (difluoromethyl)-5-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1- yl)methyl)benzoate (101-3, 200 mg, 0.43 mmol) in THF (6 mL) and water (2 mL) was added LiOH.H2O (90 mg, 2.15 mmol) at 0 oC and stirred at ambient temperature for 16 h. The reaction mixture was cooled to 0C and acidified with saturated aqueous KHSO4 solution (pH: 4) and extracted with ethyl acetate (twice). The combined organic extract was washed with water, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by Prep HPLC and lyophilised to give 4-((3-(difluoromethyl)-5-(3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)benzoic acid (Example 200b, 82 mg). LCMS (ESI) Calcd. for C24H20F2N4O3: 450.15, found [M-H]-= 449.3.1H NMR (400 MHz, d6- DMSO) δH: 7.88 (d, 2H), 7.48 (s, 1H), 7.37-7.35 (d, 1H), 7.28-7.01 (m, 6H), 5.88 (s, 2H), 2.22 (s, 3H), 1.60-1.58 (m, 2H), 1.41-1.40 (m, 2H). Examples 201a & 201b: Synthesis of 2-((5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)- 1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)thiazole-5-carboxylic acid (Example 201a) and 2-((3-(difluoromethyl)-5-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1- yl)methyl)thiazole-5-carboxylic acid (Example 201b)
Figure imgf000326_0001
[1121] Synthesis of methyl 2-methylthiazole-5-carboxylate, 2 [Step 1]: To a stirred solution of 2- methylthiazole-5-carboxylic acid (102-1, 2 g, 14.0 mmol) in methanol (25 mL) was added thionyl chloride (3.0 mL, 42 mmol) dropwise at 0 °C and stirred at 70 °C for 16 h. Volatiles were removed under reduced pressure and partitioned between EtOAc and water. The organic extract was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by combi flash chromatography to afford methyl 2- methylthiazole-5-carboxylate (102-2, 1.8 g). LCMS (ESI) Calcd. for C6H7NO2S: 157.02, found [M+H]+= 158.0. [1122] Synthesis of methyl 2-(bromomethyl)thiazole-5-carboxylate, 102-3 (Step 2): To a stirred solution of methyl 2-methylthiazole-5-carboxylate (102-2, 1 g, 6.4 mmol) in carbon tetrachloride (15 mL) was added NBS (1.4 g, 7.6 mmol) followed by AIBN (313 mg, 1.9 mmol) and stirred the reaction mixture at 80 °C for 16 h. Volatiles were removed under reduced pressure and partitioned between ethyl acetate and water. Organic layer was washed with saturated NaHCO3, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by combi flash chromatography to afford methyl 2-(bromomethyl)thiazole- 5-carboxylate (102-3, 700 mg). LCMS (ESI) Calcd. for C6H6BrNO2S: 234.93, found [M+H]+= 236.0. [1123] Synthesis of methyl 2-((5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5- yl)-1H-pyrazol-1-yl)methyl)thiazole-5-carboxylate, 102-5, and methyl 2-((3-(difluoromethyl)-5-(3- (1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)thiazole-5-carboxylate, 102- 6 [Step 3]: To a stirred solution of 5-(5-(difluoromethyl)-1H-pyrazol-3-yl)-3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazole (102-4, 300 mg, 0.9 mmol) in DMF (5 mL) was added K2CO3 (262 mg, 1.9 mmol) followed by methyl 2-(bromomethyl)thiazole-5-carboxylate (102-3, 448 mg, 1.9 mmol) and stirred at ambient temperature for 2 h. The reaction mixture was diluted with ice cold water and extracted with ethyl acetate. The organic extract was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by combi flash chromatography to afford methyl 2-((5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)- 1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)thiazole-5-carboxylate (102-5, 120 mg) and methyl 2-((3-(difluoromethyl)-5-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1- yl)methyl)thiazole-5-carboxylate (102-6, 250 mg). [1124] Compound 102-5: LCMS (ESI) Calcd. for C22H19F2N5O3S: 471.12, found [M+H]+= 472.32.1H NMR (400 MHz, DMSO-d6): δH 8.39 (s, 1H), 7.57-7.17 (m, 6H), 6.07 (s, 2H), 3.81 (s, 3H), 2.26 (s, 3H), 1.66 (m, 2H), 1.40 (m, 2H). [1125] Compound 102-6: LCMS (ESI) Calcd. for C22H19F2N5O3S: 471.12, found [M+H]+= 472.32.1H NMR (400 MHz, DMSO-d6): δH 8.33 (s, 1H), 7.52 (s, 1H), 7.34 (d, 1H), 7.29-7.04 (m, 4H), 6.23 (s, 2H), 3.84 (s, 3H), 2.21 (s, 3H), 1.58 (m, 2H), 1.39 (m, 2H). [1126] Synthesis of 2-((5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)methyl)thiazole-5-carboxylic acid, Example 201a [Step 4]: To a stirred solution of methyl 2-((5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1- yl)methyl)thiazole-5-carboxylate (102-5, 120 mg, 0.3 mmol) in THF (5 mL) and water (1 mL) was added LiOH.H2O (43 mg, 1 mmol) at 0 °C and stirred at ambient temperature for 2 h. Volatiles were removed under reduced pressure. It was diluted with water and washed with ethyl acetate. The aqueous extract was acidified with saturated aqueous NaHSO4 solution (pH: ~3) and extracted with ethyl acetate. The organic extract was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by prep HPLC, lyophilized to afford 2-((5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)methyl)thiazole-5-carboxylic acid (Example 201a, 55 mg). LCMS (ESI) Calcd. for C21H17F2N5O3S: 457.10, found [M+H]+= 458.2, 1H NMR (400 MHz, DMSO-d6): δH 7.89 (bs, 1H), 7.56-7.30 (m, 3H), 7.23-7.19 (m, 4H), 5.93 (s, 2H), 2.26 (s, 3H), 1.66 (m, 2H), 1.38 (m, 2H). [1127] Synthesis of 2-((3-(difluoromethyl)-5-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H- pyrazol-1-yl)methyl)thiazole-5-carboxylic acid, Example 201b [Step 5]: To a stirred solution of methyl 2-((3-(difluoromethyl)-5-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1- yl)methyl)thiazole-5-carboxylate (102-6, 280 mg, 0.5 mmol) in THF (6 mL) and water (1.5 mL) was added LiOH. H2O (90 mg, 2.1 mmol) at 0 °C and stirred the reaction mixture at ambient temperature for 2 h. Volatiles were removed under reduced pressure, diluted with minimum amount of water and washed with ethyl acetate. The aqueous extract was acidified with aqueous NaHSO4 solution until pH 2~3 and extracted with ethyl acetate. The organic extract was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by prep HPLC, lyophilized to afford 2-((3-(difluoromethyl)-5-(3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)thiazole-5-carboxylic acid (Example 201b, 135 mg). LCMS (ESI) Calcd. for C21H17F2N5O3S: 457.10, found [M+H]+= 458.2, 1H NMR (400 MHz, DMSO-d6):δH 7.78 (s, 1H), 7.49 (s, 1H), 7.35 (d, 1H), 7.28-7.01 (m, 5H), 6.10 (s, 2H), 2.23 (s, 3H), 1.62 (m, 2H), 1.39 (m, 2H). Examples 202a & 202b: Synthesis of 3-(3-(3-(1-(2,4-dichlorophenyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-5-(difluoromethyl)-1H-pyrazol-1-yl)propanoic acid (Example 202a) and 3- (5-(3-(1-(2,4-dichlorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-3-(difluoromethyl)-1H- pyrazol-1-yl)propanoic acid (Example 202b)
Figure imgf000328_0001
[1128] Synthesis of tert-butyl 3-[3-[3-[1-(2,4-dichlorophenyl)cyclopropyl]-1,2,4-oxadiazol-5-yl]-5- (difluoromethyl)pyrazol-1-yl]propanoate, 103-2 & 103-2a [Step 1]: To the stirred solution of 3-[1- (2,4-dichlorophenyl)cyclopropyl]-5-[5-(difluoromethyl)-1H-pyrazol-3-yl]-1,2,4-oxadiazole (103-1, 400 mg, 1.08 mmol) in DMF (4 mL), anhydrous K2CO3 (596 mg, 4.31 mmol) followed by tert- butyl 3-bromopropanoate (451 mg, 2.16 mmol) were added. Then the reaction mixture was heated at 100°C for 16 h. Reaction was diluted with cold water and extracted with ethyl acetate. Organic extract was washed with brine, dried over anhydrous Na2SO4, concentrated under reduced pressure to obtain crude. The product was purified by combi flash column chromatography to afford tert-butyl 3-[3-[3-[1-(2,4-dichlorophenyl)cyclopropyl]-1,2,4-oxadiazol-5- yl]-5-(difluoromethyl)pyrazol-1-yl]propanoate (103-2, 100 mg, 0.190 mmol) as the first fraction and tert-butyl 3-[5-[3-[1-(2,4-dichlorophenyl)cyclopropyl]-1,2,4-oxadiazol-5-yl]-3- (difluoromethyl)pyrazol-1-yl]propanoate (103-2a, 250 mg,0.476 mmol) as the second fraction. LCMS (ESI) calcd for C22H22Cl2F2N4O3: = 498.10, found [M+H]+ = 499.0. [1129] Synthesis of 3-(3-(3-(1-(2,4-dichlorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5- (difluoromethyl)-1H-pyrazol-1-yl)propanoic acid, Example 202a [Step 2]: To the stirred solution of tert-butyl 3-[3-[3-[1-(2,4-dichlorophenyl)cyclopropyl]-1,2,4-oxadiazol-5-yl]-5- (difluoromethyl)pyrazol-1-yl]propanoate (103-2, 72 mg, 0.144 mmol) in dichloromethane (3 mL), TFA (0.038 mL, 0.501 mmol) was added dropwise at 0°C. Reaction mixture was continued to stir at ambient temperature for 16 h. Solvent and TFA were evaporated under reduced pressure to get crude which was purified by reverse phase preparative HPLC to afford 3-[3-[3-[1-(2,4- dichlorophenyl)cyclopropyl]-1,2,4-oxadiazol-5-yl]-5-(difluoromethyl)pyrazol-1-yl]propanoic acid (Example 202a, 45 mg). LCMS (ESI) calcd for C18H14Cl2F2N4O3: = 442.04, found [M+H]+= 443.2. 1H NMR (400 MHz, DMSO-d6): δH 7.66(d, 1H), 7.60-7.35 (m, 3H), 7.23 (s, 1H), 4.49 (t, 2H), 2.79 (t, 2H), 1.73-1.72 (m, 2H), 1.48-1.45 (m, 2H). [1130] Synthesis of 3-(5-(3-(1-(2,4-dichlorophenyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-3- (difluoromethyl)-1H-pyrazol-1-yl)propanoic acid, Example 202b [Step 3]: To the stirred solution of tert-butyl 3-[5-[3-[1-(2,4-dichlorophenyl)cyclopropyl]-1,2,4-oxadiazol-5-yl]-3- (difluoromethyl)pyrazol-1-yl]propanoate (103-2a, 215 mg, 0.431 mmol) in dichloromethane (3 mL), TFA (0.038 mL, 0.501 mmol) was added dropwise at 0°C and the reaction was continued to stir at ambient temperature for 16 h. Solvent and TFA were evaporated under reduced pressure and the crude was purified by reverse phase preparative HPLC to afford 3-[5-[3-[1- (2,4-dichlorophenyl)cyclopropyl]-1,2,4-oxadiazol-5-yl]-3-(difluoromethyl)pyrazol-1-yl]propanoic acid (Example 202b, 123 mg). LCMS (ESI) calcd for C18H14Cl2F2N4O3: = 442.04, found [M+H]+= 443.2.1H NMR (400 MHz, DMSO-d6): δH 7.67 (d, 1H), 7.60-7.58 (s, 1H), 7.48-7.45 (m, 1H), 7.37 (s, 1H), 4.80 (t, 2H), 2.82 (t, 2H), 1.76 (t, 2H), 1.52-1.49 (m, 2H). Examples 203a & 203b: Synthesis of (1s,3s)-3-(5-(difluoromethyl)-3-(3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)-1-methoxycyclobutane-1- carboxylic acid (Example 203a) and (1s,3s)-3-(3-(difluoromethyl)-5-(3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)-1-methoxycyclobutane-1- carboxylic acids (Example 203b)
Figure imgf000330_0001
[1131] Synthesis of (1r,3r)-3-methoxy-3-(methoxycarbonyl)cyclobutyl 4-nitrobenzoate, 104-3 [Step 1]: To a stirred solution of methyl (1s,3s)-3-hydroxy-1-methoxycyclobutane-1-carboxylate (1, 500 mg, 3.1 mmol) in THF (7 mL) was added 4-nitrobenzoic acid (104-2, 1.1 g, 6.3 mmol) followed by triphenylphosphine (1.6 g, 6.2 mmol). Diisopropyl azodicarboxylate (1.2 mL, 6.2 mmol) was added at 0 °C and stirred at ambient temperature for 16 h. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic extract was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by combi flash chromatography to afford (1r,3r)-3-methoxy-3- (methoxycarbonyl)cyclobutyl 4-nitrobenzoate (104-3, 700 mg).1H NMR (400 MHz, DMSO-d6): δH 8.37-8.35 (d, 2H), 8.21-8.18 (d, 2H), 5.30-5.26 (m, 1H), 3.71 (s, 3H), 3.19 (s, 3H), 2.76-2.70 (m, 2H), 2.65-2.60 (m, 2H). [1132] Synthesis of methyl (1r,3r)-3-hydroxy-1-methoxycyclobutane-1-carboxylate, 104-4 (Step 2): To a stirred solution of (1r,3r)-3-methoxy-3-(methoxycarbonyl)cyclobutyl 4-nitrobenzoate (104-3, 600 mg, 1.9 mmol) in methanol (5 mL) was added K2CO3 (402 mg, 2.9 mmol) and stirred at ambient temperature for 30 min. The reaction mixture was filtered, and volatiles were removed under reduced pressure. The crude product was purified by combi flash chromatography to afford methyl (1r,3r)-3-hydroxy-1-methoxycyclobutane-1-carboxylate (104-4, 260 mg).1H NMR (400 MHz, DMSO-d6): δH 5.28 (d, 1H), 4.21-4.15 (m, 1H), 3.67 (s, 3H), 3.10 (s, 3H), 2.44-2.39 (m, 2H), 2.19-2.14 (m, 2H). [1133] Synthesis of methyl (1r,3r)-1-methoxy-3-(((trifluoromethyl)sulfonyl)oxy)cyclobutane-1- carboxylate, 104-5 [Step 3]: To a stirred solution of trifluoromethanesulfonic anhydride (0.3 mL, 1.8 mmol) in DCM (2 mL) was added pyridine (0.2 mL, 2 mmol) dropwise at 0 °C and stirred for 5 min. To this reaction mixture was added a solution of methyl (1r,3r)-3-hydroxy-1- methoxycyclobutane-1-carboxylate (104-4, 260 mg, 1.6 mmol) in DCM (1 mL) at 0 °C and stirred for 30 min. The reaction mixture was diluted with DCM and washed with water. The organic extract was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford methyl (1r,3r)-1-methoxy-3-(((trifluoromethyl)sulfonyl)oxy)cyclobutane-1- carboxylate (104-5, 460 mg).1H NMR (400 MHz, DMSO-d6): δH 4.93-4.87 (m, 1H), 3.72 (s, 3H), 3.17 (s, 3H), 2.98-2.93 (m, 2H), 2.43-2.38 (m, 2H). [1134] Synthesis of methyl (1s,3s)-3-(3-(difluoromethyl)-5-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)-1-methoxycyclobutane-1-carboxylate and methyl (1s,3s)-3-(5- (difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)-1- methoxycyclobutane-1-carboxylate, 104-7 and 104-8 [Step 4]: To a stirred solution of 5-(5- (difluoromethyl)-1H-pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (104-6, 180 mg, 0.6 mmol) in DCM (5 mL) was added N,N-diisopropylethylamine (0.4 mL, 2.3 mmol) and stirred for 5 min. A solution of methyl (1r,3r)-1-methoxy-3-(((trifluoromethyl)sulfonyl)oxy)cyclobutane-1- carboxylate (5, 460 mg, 1.6 mmol) in DCM (0.5 mL) was added dropwise to the reaction mixture and stirred at the ambient temperature for 16 h. Volatiles were removed under reduced pressure. The crude product was purified by combi flash chromatography to afford methyl (1s,3s)-3-(3-(difluoromethyl)-5-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)- 1-methoxycyclobutane-1-carboxylate (104-7, 200 mg) as peak 1 and methyl (1s,3s)-3-(5- (difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)-1- methoxycyclobutane-1-carboxylate (104-8, 70 mg) assign as peak 2. N1 and N2 linked compound was confirmed by nOe analysis. [1135] Compound 104-7: LCMS (ESI) Calcd. for C23H24F2N4O4: 458.18, found [M+H]+= 459.0; 1H NMR (400 MHz, DMSO-d6): δH 7.41-7.37 (m, 2H), 7.29-7.02 (m, 4H), 5.75 (s, 1H), 5.65-5.61 (m, 1H), 3.80 (s, 3H), 3.20 (s, 3H), 2.99-2.94 (m, 2H), 2.79-2.74 (m, 2H), 2.30 (s, 3H), 1.71 (m, 2H), 1.46 (m, 2H). [1136] Compound 104-8: LCMS (ESI) Calcd. for C23H24F2N4O4: 458.18, found [M+H]+= 459.2; 1H NMR (400 MHz, DMSO-d6):δH 7.56-7.20 (m, 6H), 4.97-4.93 (m, 1H), 3.78 (s, 3H), 3.20 (s, 3H), 3.02-2.97 (m, 2H), 2.84-2.79 (m, 2H), 2.27 (s, 3H), 1.68 (m, 2H), 1.40 (m, 2H). [1137] Synthesis of (1s,3s)-3-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5- yl)-1H-pyrazol-1-yl)-1-methoxycyclobutane-1-carboxylic acid, Example 203a [Step 5]: To a stirred solution of methyl (1s,3s)-3-(5-(difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)-1-methoxycyclobutane-1-carboxylate (104-8, 65 mg, 0.2 mmol) in THF (3 mL) and water (1.5 mL) was added LiOH.H2O (18 mg, 0.4 mmol) at 0 °C and stirred at ambient temperature for 2 h. The reaction mixture was diluted with water, acidified with saturated aqueous solution of KHSO4 (pH: ~3) and extracted with ethyl acetate. The organic extract was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by Prep HPLC and lyophilized to afford (1s,3s)-3-(5- (difluoromethyl)-3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)-1- methoxycyclobutane-1-carboxylic acid (Example 203a, 32 mg). LCMS (ESI) Calcd. For C22H22F2N4O4: 444.16; found [M+H]+: 445.3.1H NMR (400 MHz, DMSO-d6) δH: 13.18 (bs, 1H), 7.56-7.20 (m, 6H), 4.98-4.94 (m, 1H), 3.21 (s, 3H), 2.98-2.93 (m, 2H), 2.80-2.75 (m, 2H), 2.27 (s, 3H), 1.70-1.68 (m, 2H), 1.41-1.38 (m, 2H). [1138] Synthesis of (1s,3s)-3-(3-(difluoromethyl)-5-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5- yl)-1H-pyrazol-1-yl)-1-methoxycyclobutane-1-carboxylic acids, Example 203b [Step 6]: To a stirred solution of methyl (1s,3s)-3-(3-(difluoromethyl)-5-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-pyrazol-1-yl)-1-methoxycyclobutane-1-carboxylate (104-7, 200 mg, 0.4 mmol) in THF (4 mL) and water (1 mL) was added LiOH.H2O (73 mg, 1.7 mmol) at 0 °C and stirred at ambient temperature for 2 h. The reaction mixture was diluted with minimum amount of water, acidified with saturated aqueous solution of KHSO4 (pH: ~3) and extracted with ethyl acetate. The organic extract was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The organic extract was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by prep HPLC and lyophilized to afford (1s,3s)-3-(3-(difluoromethyl)-5-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5- yl)-1H-pyrazol-1-yl)-1-methoxycyclobutane-1-carboxylic acid (Example 203b, 135 mg). LCMS (ESI) Calcd. for C22H22F2N4O4: 444.2, found [M+H]+= 445.3, 1H NMR (400 MHz, DMSO-d6): δH 7.38-7.35 (m, 2H), 7.27-7.00 (m, 4H), 5.59 (m, 1H), 3.17 (s, 3H), 2.91-2.86 (m, 2H), 2.66-2.59 (m, 2H), 2.29 (s, 3H), 1.72-1.70 (m, 2H), 1.43-1.40 (m, 2H). Examples 204a & 204b: Synthesis of (1r,4r)-4-(3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-2H-indazol-2-yl)cyclohexane-1-carboxylic acid (Example 204a) and (1r,4r)- 4-(3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-indazol-1-yl)cyclohexane-1- carboxylic acid (Example 204b)
Figure imgf000333_0001
[1139] Synthesis of (Z)-N'-((1H-indazole-3-carbonyl)oxy)-1-(o-tolyl)cyclopropane-1- carboximidamide, 105-3 [Step 1]: To a stirred solution of 1H-indazole-3-carboxylic acid (105-1, 1.00 g, 6.15 mmol) in DMA (10 mL) were added DIPEA (3.20 mL, 18.4 mmol), EDC.HCl (1.91 g, 12.3 mmol) and HOBT (1.66 g, 12.3 mmol). The reaction mixture was stirred at RT for 15 min. To the resulting mixture was added N'-hydroxy-1-(o-tolyl)cyclopropanecarboxamidine (105- 2, 1.17 g, 6.15 mmol) and it was stirred at 25 °C for 16h. After completion, reaction mixture was diluted with water, extracted with ethyl acetate. The combined organic layer was washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure to get the crude product which was purified by combi flash column chromatography to afford (Z)-N'- ((1H-indazole-3-carbonyl)oxy)-1-(o-tolyl)cyclopropane-1-carboximidamide (105-3, 1.50 g,) as gummy substance. LCMS (ESI) calculated for C19H18N4O2: 334.14, found [M+H]+ : 335.4.1H NMR (400 MHz, DMSO-d6): δH 13.82 (s, 1H), 8.03 (d, 1H), 7.65 (d, 1H), 7.45-7.41 (m, 2H), 7.31- 7.27 (m, 1H), 7.213-7.18 (m, 3H), 5.92 (s, 2H), 2.46 (s, 3H), 1.51-1.48 (m, 2H), 1.05-1.03 (m, 2H). [1140] Synthesis of 5-(1H-indazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole, 105-4 [Step 2]: To a stirred solution of (Z)-N'-((1H-indazole-3-carbonyl)oxy)-1-(o-tolyl)cyclopropane-1- carboximidamide (105-3, 1.30 g, 3.89 mmol) in MeCN (15 mL), was added TBAH (121 mg, 0.47 mmol) at 25 °C. The reaction mixture was heated at 110 °C for 3h. Upon completion, the reaction mixture was cooled to room temperature, diluted with water and ethyl acetate. Organic layer was separated, washed with brine, dried over anhydrous sodium sulphate, concentrated under reduced pressure to get crude which was purified by combi flash column chromatography (using 20-25% EtOAc/Hexane) to afford 5-(1H-indazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazole (105-4, 600 mg) as off white solid. LCMS (ESI) calculated for C19H16N4O: 316.13, found [M+H]+ : 317.4.1H NMR (400 MHz, CDCl3): δH 8.24 (d, 1H), 7.59 (d, 1H), 7.52-7.48 (m, 1H), 7.44 (d, 1H), 7.38-7.35 (m, 1H), 7.27-7.22 (m, 3H), 2.39 (s, 3H), 1.87-1.84 (m, 2H), 1.49- 1.45 (m, 2H). [1141] Synthesis of methyl (1s,4s)-4-((methylsulfonyl)oxy)cyclohexane-1-carboxylate, 105-5 [Step 3A]: To a solution of methyl (1s,4s)-4-hydroxycyclohexane-1-carboxylate (105-5A, 1.00 g, 6.32 mmol) in DCM (10 mL) cooled to 0°C, was added triethylamine (1.8 mL, 12.6 mmol) followed by the addition of methanesulfonic anhydride (1.65 g, 9.48 mmol) portion wise at ice cool condition. The reaction mixture was stirred from 0 °C to 25 °C for 2h. After completion, the reaction mixture was diluted with DCM and water, organic layer was separated and washed with saturated NaHCO3 solution and brine, dried over sodium sulphate, concentrated under reduced pressure to get methyl (1s,4s)-4-((methylsulfonyl)oxy)cyclohexane-1-carboxylate (105-5, 1.10 g) as oil.1H NMR (400 MHz, CDCl3): δH 4.91-4.90 (m, 1H), 3.68 (s, 3H), 3.00 (s, 3H), 2.43-2.36 (m, 1H), 2.06-2.00 (m, 2H), 1.97-1.87 (m, 2H), 1.81-1.73 (m, 4H). [1142] Synthesis of methyl (1r,4r)-4-(3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-2H- indazol-2-yl)cyclohexane-1-carboxylate, 6 & methyl (1r,4r)-4-(3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-1H-indazol-1-yl)cyclohexane-1-carboxylate, 105-6a [Step 3]: To a solution of 5- (1H-indazol-3-yl)-3-[1-(o-tolyl)cyclopropyl]-1,2,4-oxadiazole (105-4, 400 mg, 1.26 mmol) in DMF (4 mL) was added K2CO3 (523 mg, 3.79 mmol) and the mixture was heated at 80 °C for 1h. To the resulting mixture was added a solution of methyl (1s,4s)-4-((methylsulfonyl)oxy) cyclohexane-1-carboxylate (1.20 g, 5.06 mmol) in DMF (0.50 mL) dropwise and the mixture stirred at 80 °C for 16 h. After completion, the reaction mixture was cooled to room temperature and extracted with EtOAc. The combined organic layer was washed with excess water, brine, dried over anhydrous sodium sulphate and concentrated to give crude product. The crude product was purified by combiflash column chromatography to afford two regio-isomers: methyl (1r,4r)-4-(3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-2H-indazol-2-yl)cyclohexane-1- carboxylate (105-6, 160 mg) with impurities as gummy solid. LCMS (ESI) calculated for C27H28N4O3: Exact Mass: 456.22, found [M+H]+ : 457.5 and methyl (1r,4r)-4-(3-(3-(1-(o-tolyl) cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-indazol-1-yl)cyclohexane-1-carboxylate (105-6a, 150 mg) as gummy solid. LCMS (ESI) calculated for C27H28N4O3: Exact Mass: 456.22, found [M+H]+: 457.5. [1143] Synthesis of (1r,4r)-4-(3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-2H-indazol-2- yl)cyclohexane-1-carboxylic acid, Example 204a [Step 5]: Methyl (1r,4r)-4-(3-(3-(1-(o- tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-2H-indazol-2-yl)cyclohexane-1-carboxylate (105-6, 160 mg, 0.350 mmol) was taken in THF (4mL) and Water (2mL) . Then was added LiOH.H2O (59 mg, 1.40 mmol) at 25 °C and the reaction mixture was stirred at 25 °C for 6h. After completion, the reaction mixture was concentrated under reduced pressure and the residue was acidified with aqueous 1 (N) HCl solution and extracted with 5% MeOH/DCM. The combined organic layer washed with brine, dried over anhydrous Na2SO4, concentrated under reduced pressure to get crude. The crude was purified by RP-PREP HPLC to afford (1r,4r)-4-(3-(3-(1-(o-tolyl) cyclopropyl)-1,2,4-oxadiazol-5-yl)-2H-indazol-2-yl) cyclohexane-1-carboxylic acid, (Example 204a, 43 mg) as white solid. LCMS (ESI) calcd. for C26H26N4O3 :442.20, found [M+H]+: 443.3, 1H NMR (400 MHz, DMSO-d6): δH 12.22 (brs, 1H), 8.02 (d, 1H), 7.85 (d, 1H), 7.45-7.36 (m, 3H), 7.24-7.20 (m, 3H), 5.41-5.37 (m, 1H), 2.37-2.34 (m, 4H), 2.16-2.02 (m, 6H), 1.77-1.74 (m, 2H), 1.54-1.47 (m, 4H). [1144] Synthesis of (1r,4r)-4-(3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-indazol-1- yl)cyclohexane-1-carboxylic acid, Example 204b [Step 5a]: To a solution of methyl (1r,4r)-4-(3- (3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-indazol-1-yl)cyclohexane-1-carboxylate (105- 6a, 150 mg, 0.33 mmol) in THF (4 mL) and water (2mL) was added LiOH.H2O (55 mg, 1.31 mmol) at 25 °C and the reaction mixture was stirred at 25 °C for 6 h. After completion, the reaction mixture was concentrated under reduced pressure and the residue was acidified with aqueous 1 (N) HCl solution and extracted with 5% MeOH/DCM. The combined organic layer washed with brine, dried over anhydrous Na2SO4, concentrated under reduced pressure to get crude. The crude was purified by RP-PREP HPLC to afford (1r,4r)-4-(3-(3-(1-(o-tolyl) cyclopropyl)-1,2,4-oxadiazol-5-yl)-1H-indazol-1-yl) cyclohexane-1-carboxylic acid (Example 204b, 101 mg) as white solid. LCMS (ESI) calcd. for C26H26N4O3 :442.20, found [M+H]+: 443.3, 1H NMR (400 MHz, DMSO-d6): δH 12.18 (brs, 1H), 8.12 (d, 1H), 7.99 (d, 1H), 7.57-7.54 (m, 1H), 7.44-7.40 (m, 2H), 7.25-7.21 (m, 3H), 4.87-4.85 (m, 1H), 2.49-2.38 (m, 1H), 2.30 (s, 3H), 2.09-1.99 (m, 6H), 1.78-1.75 (m, 2H), 1.71-1.64 (m, 2H), 1.43-1.41 (m, 2H). Examples 205a & 205b: Synthesis of (1r,4r)-4-(3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4- oxadiazol-5-yl)-5,6-dihydrocyclopenta[c] pyrazol-2(4H)-yl) cyclohexane-1-carboxylic acid (Example 205a) and (1r,4r)-4-(3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5,6- dihydrocyclopenta [c] pyrazol-1(4H)-yl) cyclohexane-1-carboxylic acid (Example 205b)
Figure imgf000336_0001
[1145] Synthesis of N'-((1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)oxy)-1-(o- tolyl)cyclopropane-1-carboximidamide, 106-3 [Step 1]: To a solution of 1,4,5,6- tetrahydrocyclopenta[c]pyrazole-3-carboxylic acid (106-1, 500 mg, 3.29 mmol), EDC.HCl (1.26 g, 6.58 mmol) and HOBt (889 mg, 6.58 mmol) in DMF (10 mL) was added DIPEA (2.3 mL, 13.2 mmol) at ambient temperature. After 15 min, N'-hydroxy-1-(o-tolyl) cyclopropane-1- carboximidamide (105-2, 625 mg, 3.29 mmol) was added, and the reaction mixture was stirred at ambient temperature for 16 h. The reaction mixture was diluted with ethyl acetate and washed with cold brine (three times). The organic phase was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford N'-((1,4,5,6- tetrahydrocyclopenta[c]pyrazole-3-carbonyl) oxy)-1-(o-tolyl) cyclopropane-1-carboximidamide (106-3, 1.00 g) which was used for the next step without further purification. LCMS (ESI) calcd. for C18H20N4O2: 324.16, found [M+H]+: 325.4. [1146] Synthesis of 5-(1,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)- 1,2,4-oxadiazole, 106-4 [Step 2]: To a solution of N'-((1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3- carbonyl)oxy)-1-(o-tolyl)cyclopropane-1-carboximidamide (106-3, 1.0 g, 3.08 mmol) in MeCN (15 mL) was added tetrabutylammonium hydroxide (0.24 mL, 40% in water, 0.37 mmol) and the reaction mixture was stirred at 100 °C for 3 h. The reaction mixture was concentrated under reduced pressure and purified on a silica gel column using 0-30% ethyl acetate in hexanes to afford 5-(1,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-3-(1-(o-tolyl) cyclopropyl)-1,2,4-oxadiazole (106-4, 600 mg). LCMS (ESI) calcd. for C18H18N4O: 306.15, found [M+H]+: 307.4. [1147] Synthesis of methyl (1r,4r)-4-(3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5,6- dihydrocyclopenta[c]pyrazol-2(4H)-yl)cyclohexane-1-carboxylate, 6 and methyl (1r,4r)-4-(3-(3- (1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5,6-dihydrocyclopenta[c]pyrazol-1(4H)- yl)cyclohexane-1-carboxylate, 106-7 [Step 3]: A solution of 5-(1,4,5,6- tetrahydrocyclopenta[c]pyrazol-3-yl)-3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazole (106-4, 600 mg, 1.96 mmol) in DMA (10 mL) was heated to 80 oC. After 10 min, a solution of methyl (1s,4s)-4- ((methylsulfonyl)oxy) cyclohexane-1-carboxylate (106-5, 1.85 g, 7.83 mmol) in DMA (6 mL) was added dropwise in two portions one hour apart. The reaction mixture was stirred at the same temperature for 16 h. After cooling to ambient temperature, the reaction mixture was diluted with ethyl acetate and washed with cold brine (two times). The reaction mixture was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. Purification on a silica gel column afforded two regioisomers. The faster eluting compound was methyl (1r,4r)-4-(3-(3- (1-(o-tolyl) cyclopropyl)-1,2,4-oxadiazol-5-yl)-5,6-dihydrocyclopenta[c]pyrazol-2(4H)-yl) cyclohexane-1-carboxylate (106-6, 310 mg). LCMS (ESI) calcd. for C26H30N4O3: 446.23, found [M+H]+: 447.2. The slower eluting compound was methyl (1r,4r)-4-(3-(3-(1-(o-tolyl) cyclopropyl)-1,2,4-oxadiazol-5-yl)-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl) cyclohexane-1- carboxylate (106-7, 120 mg,0.269 mmol). LCMS (ESI) calcd. for C26H30N4O3: 446.23, found [M+H]+: 447.2. [1148] Synthesis of (1r,4r)-4-(3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5,6- dihydrocyclopenta[c] pyrazol-2(4H)-yl) cyclohexane-1-carboxylic acid, Example 205b [Step 4]: To a solution of methyl (1r,4r)-4-(3-(3-(1-(o-tolyl) cyclopropyl)-1,2,4-oxadiazol-5-yl)-5,6- dihydrocyclopenta [c] pyrazol-2(4H)-yl) cyclohexane-1-carboxylate (106-6, 310 mg, 0.69 mmol) in THF (4 mL) and water (2 mL) was added LiOH·H2O (117 mg, 2.78 mmol) and the reaction mixture was stirred at ambient temperature for 16 h. The reaction mixture was concentrated under reduced pressure, the residue was acidified (pH 1) with 1N aqueous HCl solution and extracted with 10% MeOH in DCM. The COMBINED organic phase was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to get the crude. The crude product was purified by reverse phase preparative HPLC to afford (1r,4r)-4-(3-(3-(1-(o-tolyl) cyclopropyl)-1,2,4-oxadiazol-5-yl)-5,6-dihydrocyclopenta[c]pyrazol-2(4H)-yl) cyclohexane-1- carboxylic acid (Example 205b, 160 mg) as white solid. LCMS (ESI) calcd. for C25H28N4O3: 432.22, found [M+H]+: 433.6.1H NMR (400 MHz, DMSO-d6): δH 12.20 (brs, 1H), 7.38-7.36 (m, 1H), 7.25-7.19 (m, 3H), 4.93-4.87 (m, 1H), 2.77 (t, 2H), 2.66 (t, 2H), 2.42-2.35 (m, 2H), 2.30- 2.24 (m, 4H), 2.04-1.96 (m, 4H), 1.88-1.80 (m, 2H), 1.70-1.63 (m, 2H), 1.47-1.38 (m, 4H). [1149] Synthesis of (1r,4r)-4-(3-(3-(1-(o-tolyl)cyclopropyl)-1,2,4-oxadiazol-5-yl)-5,6- dihydrocyclopenta [c] pyrazol-1(4H)-yl) cyclohexane-1-carboxylic acid, Example 205a [Step 5]: To a solution of methyl (1r,4r)-4-(3-(3-(1-(o-tolyl) cyclopropyl) -1,2,4-oxadiazol-5-yl) -5,6- dihydrocyclopenta [c]pyrazol-1(4H)-yl) cyclohexane-1-carboxylate (106-7, 120 mg, 0.27 mmol) in THF (3 mL) and water (1.5 mL) was added LiOH·H2O (45 mg, 1.07 mmol) and the reaction mixture was stirred at ambient temperature for 16 h. The reaction mixture was concentrated under reduced pressure, the residue was acidified (pH 1) with 1N aqueous HCl solution and extracted with 10% MeOH in DCM. The combined organic phase was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to get the crude. The crude product was purified by reverse phase preparative HPLC afforded (1r,4r)-4-(3-(3-(1-(o-tolyl) cyclopropyl)-1,2,4-oxadiazol-5-yl)-5,6-dihydrocyclopenta[c]pyrazol-1(4H)-yl) cyclohexane-1- carboxylic acid (Example 205a, 35 mg) as white solid. LCMS (ESI) calcd. for C25H28N4O3: 432.22, found [M+H]+: 433.4.1H NMR (400 MHz, DMSO-d6): δH 12.05 (brs, 1H), 7.36 (d, 1H), 7.23-7.17 (m, 3H), 4.19-4.13 (m, 1H), 2.82 (t, 2H), 2.70 (t, 2H), 2.54-2.50 (m, 2H), 2.33-2.25 (m, 4H), 2.03-2.00 (m, 4H), 1.82-1.74 (m, 2H), 1.63-1.62 (m, 2H), 1.54-1.45 (m, 2H), 1.37-1.34 (m, 2H). BIOLOGICAL/ BIOCHEMICAL EVALUATION [1150] General protocol for in vitro analysis of compounds [1151] The inhibitory activity of the compounds of the present invention against POLRMT were determined by assays based on Bergbrede, T., et al., “An adaptable high-throughput technology enabling the identification of specific transcription modulators,” SLAC Discov., 22, 378–386 (2017). [1152] The ability of some compounds of the present invention to inhibit POLRMT were determined in a homogeneous TR-FRET Assay using high-throughput screening in a 384- well plate format. This method is used to monitor the activity of mitochondrial transcription through measurement of its product, a 407 bp long RNA transcript. Detection of the product is facilitated by hybridization of two DNA-oligonucleotide probes to specific and adjacent sequences within the RNA product sequence. Upon annealing of the probes, two fluorophores are coupled directly to an acceptor nucleotide probe (ATTO647, 5’), or introduced via a coupled streptavidin with a biotinylated donor nucleotide probe (Europium cryptate) that is brought into sufficient proximity to serve as a fluorescence-donor-acceptor pair. Thus, a FRET signal at 665 nm is generated upon excitation at 340 nm. [1153] Proteins used as transcription factors (POLRMT: NP_005026.3, TFAM: NP_003192.1, TFB2M: NP_071761.1) are diluted from their stocks to working concentrations of 1 µM, 20 µM and 4 µM respectively, in a dilution buffer containing 20 mM Tris-HCI (pH 8.0), 200 mM NaCl, 10% (v/v) glycerol, 1 mM Dithiothreitol (DTT), 0.5 mM EDTA. [1154] DNA template is a pUC18 plasmid with the mitochondrial light strand promotor sequence (1-477) cloned between HindIII and BamHI sites. The DNA template is restriction linearized proximal to the promotor 3’-end (pUC-LSP). [1155] The reaction mixture (10 uL) containing 7.5 nM POLRMT, 15 nM of TFB2M, 30 nM of TFAM , 0.5 nM of DNA template and 500 µM nucleotide triphosphate mix (NTPs) in a reaction buffer (containing 10 mM Tris-HCI (pH 7.5), 10 mM MgCl2, 40 mM NaCl, 10 mM DTT, 0.005% (w/v) Tween-20, 160 units/ml Rnase inhibitor and 0.1 mg/mL BSA) are dispensed to compounds in microplates, using a Thermo Multidrop® dispenser, and incubated at 37 °C in a VWR INCU- Line incubator for 60 minutes after mixing. No nucleotide triphosphate mix is added to negative control samples. Microplates with compounds to be tested in the assay are prepared from 10 mM compound stocks in 100% DMSO, equal amounts of DMSO without any compound are added to positive control and negative control samples. [1156] During the incubation, a mix of the detection reagents is prepared in a buffer such that the enzymatic reaction is terminated due to chelating of Mg-ions and increased ionic strength, containing 50 mM Tris-HCl (pH 7.5), 700 mM NaCl, 20 mM EDTA, and 0.01% (w/v) Tween-20. Europium-streptavidin is pre-incubated with a 200-fold molar excess of a random sequence oligonucleotide to block unspecific binding of oligo, for two hours at ambient temperature in the dark. Afterwards, the blocked Europium-streptavidin is kept on ice until use. [1157] At the end of the enzymatic reaction time, 5 µL detection oligo mix in the detection buffer is added, and assay plates are mixed and kept at ambient temperature for one hour, protected from light. The concentration of the Acceptor nucleotide oligo (e.g., ATTO647N-5 - ACAAAGAACCCTAACACCAG-3) and Donor nucleotide oligo (e.g., bio-5’-AACACATCTCT(- bio)GCCAAACCCCA-bio-3’) in each assay well is 1 nM, and 3 nM, respectively.0430 After incubation with oligo mix, 5 µL of pre-blocked Europium-streptavidin reagent is dispensed to each assay well, assay plates are again mixed and kept at ambient temperature for one hour, protected from light. [1158] The generated signal is measured with BMG Pherastar microtiter plate reader with a TRF light unit, using excitation at 340 nm, an integration time of 200 µs, and a delay time of 100 µs, before detection at 620 nm and 665 nm. The ratio of donor- and acceptor- fluorescence is used as a measure of the generated transcript product (i.e. enzymatic activity). Table 2. IC50 values for compounds.
Figure imgf000340_0001
Figure imgf000341_0001
Figure imgf000342_0001
Figure imgf000343_0001
Figure imgf000344_0001
Figure imgf000345_0001
Figure imgf000346_0001
Figure imgf000347_0001
Figure imgf000348_0001
Figure imgf000349_0001

Claims

CLAIMS What is claimed is: 1. A compound, or a pharmaceutically acceptable salt thereof, according to Formula (IId):
Figure imgf000350_0001
wherein X1-X5 are each independently a hydrogen, a halogen, a hydroxy, a cyano, a C1-C6 alkyl, a substituted C1-C6 alkyl, a C3-C6 cycloalkyl, a substituted C3-C6 cycloalkyl, a C1-C6 alkoxy, optionally substituted with an aryl, a C3-C10 cycloalkyl, -C(O)NH2, -C(O)NHY1, - C(O)NY1Y2, -COOH, -C(O)OY1, -Y1COOH, or -Y1OY2; Y1 and Y2 are each independently a C1-C6 alkyl optionally substituted with one or more halogen or hydroxy; R3 is a halogen, a hydrogen, a C1-C6 alkyl, a C1-C6 alkyl substituted with one or more halogen, or a C3-C10 cycloalkyl; and R4 is a hydrogen, a C1-C6 alkyl, or a C1-C6 alkyl substituted with one or more halogen; if R3 and R4 are optionally interconnected they form a C3-C6 cycloalkyl, a substituted C3-C6 cycloalkyl, 5-membered heterocyclic ring, a substituted 5-membered heterocyclic ring, 6-membered heterocyclic ring, a substituted 6-membered heterocyclic ring, a phenyl ring, or a substituted phenyl ring and R30-R34 are each independently a hydrogen, a carboxylic acid, an ester, a halogen, an amide, a substituted amide, a cyano, an ether, or a C1-C6 alkyl. 2. The compound of claim 1, wherein X1 is a C1-C6 alkyl or a halogen. 3. The compound of claim 2, wherein the C1-C6 alkyl is methyl. 4. The compound of claim 2, wherein the halogen is chlorine. 5. The compound of claim 1, wherein X2 and X4 are each independently a hydrogen or a halogen. 6. The compound of claim 1, wherein X3 is a hydrogen, a C1-C6 alkyl or a halogen. 7. The compound of claim 6, wherein the C1-C6 alkyl is methyl. 8. The compound of claim 6, wherein the halogen is chlorine or fluorine. 9. The compound of claim 1, wherein X5 is a C1-C6 alkyl or a hydrogen. 10. The compound of claim 1, wherein at least two of X2-X5 are hydrogen. 11. The compound of claim 1, wherein at least three of X2-X5 are hydrogen. 12. The compound of claim 1, wherein X2-X5 are hydrogen. 13. The compound of claim 1, wherein R3 is C1-C6 alkyl or C1-C6 alkyl substituted with one or more halogen. 14. The compound of claim 13, wherein the C1-C6 alkyl substituted with one or more halogen is -CHF2. 15. The compound of claim 13, wherein the C1-C6 alkyl is methyl. 16. The compound of claim 1, wherein R4 is hydrogen. 17. The compound of claim 1, wherein R30-R34 are hydrogen.
18. The compound of claim 1, wherein R30 is methyl, methoxy, carboxylic acid, -C(O)OCH3, cyano, amide, or substituted amide. 19. The compound of claim 1, wherein R31 is methyl, methoxy, carboxylic acid, -C(O)OCH3, cyano, amide, or substituted amide. 20. The compound of claim 1, wherein R32 is methyl, methoxy, carboxylic acid, -C(O)OCH3, cyano, amide, or substituted amide. 21. The compound of claim 1, wherein R33 is methyl, methoxy, carboxylic acid, -C(O)OCH3, cyano, amide, or substituted amide. 22. The compound of claim 1, wherein R34 is methyl, methoxy, carboxylic acid, -C(O)OCH3, cyano, amide, or substituted amide. 23. The compound of claim 1, wherein at least two of R30-R34 are hydrogen, -OCH3, - COOH, -C(O)NH2, -C(O)NHCH3, cyano, methyl, - C(O)OCH3, or fluorine. 24. The compound of claim 1, wherein X1-X5 are each independently hydrogen, halogen, Cl, F, or methyl, and R3-R4 are independently H, methyl, -CHF2, or -CF3. 25. The compound of claim 1, wherein at least one of R30-R34 is carboxylic acid. 26. The compound of claim 1, wherein at least one of R30-R34 is amide. 27. The compound of claim 1, wherein at least one of R30-R34 is ester. 28. The compound of claim 1, wherein at least one of R30-R34 is ether. 29. The compound of claim 1, wherein at least one of R30-R34 is cyano. 30. The compound of claim 1, wherein at least one of R30-R34 is methyl. 31. The compound of claim 1, wherein at least two of R30-R34 is carboxylic acid, amide, ester, ether, cyano, or methyl. 32. The compound of claim 1, wherein the compound comprises one of the following compounds:
Figure imgf000353_0001
Figure imgf000354_0001
Figure imgf000355_0001
Figure imgf000356_0001
Figure imgf000357_0001
33. A composition comprising one of the following compounds:
Figure imgf000357_0002
Figure imgf000358_0001
Figure imgf000359_0001
Figure imgf000360_0001
Figure imgf000361_0001
Figure imgf000362_0001
Figure imgf000363_0001
Figure imgf000364_0001
PCT/US2024/053724 2023-10-30 2024-10-30 Compositions and inhibitors of polrmt Pending WO2025096660A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363546388P 2023-10-30 2023-10-30
US63/546,388 2023-10-30

Publications (1)

Publication Number Publication Date
WO2025096660A1 true WO2025096660A1 (en) 2025-05-08

Family

ID=95581135

Family Applications (6)

Application Number Title Priority Date Filing Date
PCT/US2024/053722 Pending WO2025096658A1 (en) 2023-10-30 2024-10-30 Compositions and inhibitors of polrmt
PCT/US2024/053717 Pending WO2025096654A1 (en) 2023-10-30 2024-10-30 Compositions and inhibitors of polrmt
PCT/US2024/053720 Pending WO2025096657A1 (en) 2023-10-30 2024-10-30 Compositions and inhibitors of polrmt
PCT/US2024/053726 Pending WO2025096662A1 (en) 2023-10-30 2024-10-30 Compositions and inhibitors of polrmt
PCT/US2024/053724 Pending WO2025096660A1 (en) 2023-10-30 2024-10-30 Compositions and inhibitors of polrmt
PCT/US2024/053716 Pending WO2025096653A1 (en) 2023-10-30 2024-10-30 Compositions and inhibitors of polrmt

Family Applications Before (4)

Application Number Title Priority Date Filing Date
PCT/US2024/053722 Pending WO2025096658A1 (en) 2023-10-30 2024-10-30 Compositions and inhibitors of polrmt
PCT/US2024/053717 Pending WO2025096654A1 (en) 2023-10-30 2024-10-30 Compositions and inhibitors of polrmt
PCT/US2024/053720 Pending WO2025096657A1 (en) 2023-10-30 2024-10-30 Compositions and inhibitors of polrmt
PCT/US2024/053726 Pending WO2025096662A1 (en) 2023-10-30 2024-10-30 Compositions and inhibitors of polrmt

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2024/053716 Pending WO2025096653A1 (en) 2023-10-30 2024-10-30 Compositions and inhibitors of polrmt

Country Status (1)

Country Link
WO (6) WO2025096658A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080280876A1 (en) * 2006-12-15 2008-11-13 Hobson Adrian D Novel oxadiazole compounds
US8470811B2 (en) * 2010-05-08 2013-06-25 Bayer Intellectual Property Gmbh Substituted heterocyclylbenzylpyrazoles and use thereof
WO2023177700A2 (en) * 2022-03-16 2023-09-21 Anima Biotech Inc. C-myc mrna translation modulators and uses thereof in the treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101318689B1 (en) * 2008-09-25 2013-10-16 주식회사 녹십자 Sulfur containing pyrazole-heterocycle derivatives as cannabinoid cb1 receptor antagonists
WO2023034344A1 (en) * 2021-08-30 2023-03-09 Pretzel Therapeutics, Inc. Isoquinolinones and quinolinones as modulators of polrmt
US20250326732A1 (en) * 2021-08-30 2025-10-23 Pretzel Therapeutics, Inc. Chromen-2-one modulators of polrmt

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080280876A1 (en) * 2006-12-15 2008-11-13 Hobson Adrian D Novel oxadiazole compounds
US8470811B2 (en) * 2010-05-08 2013-06-25 Bayer Intellectual Property Gmbh Substituted heterocyclylbenzylpyrazoles and use thereof
WO2023177700A2 (en) * 2022-03-16 2023-09-21 Anima Biotech Inc. C-myc mrna translation modulators and uses thereof in the treatment of cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE PubChem 13 September 2019 (2019-09-13), ANONYMOUS: "3-[1-(5-Fluoro-2-methylphenyl)cyclopropyl]-5-(5-methoxy-1-methylpyrazol-3-yl)-1,2,4-oxadiazole | C17H17FN4O2 ", XP093311711, Database accession no. CID 139002672 *
DATABASE PubChem 15 June 2016 (2016-06-15), ANONYMOUS: "N-methyl-1-[5-(1-phenylpyrazol-3-yl)-1,2,4-oxadiazol-3-yl]propan-2-amine | C15H17N5O | ", XP093311718, Database accession no. CID 120387505 *
DATABASE PubChem 23 November 2020 (2020-11-23), ANONYMOUS: "5-[1-(2,6-Difluorophenyl)-4-methylpyrazol-3-yl]-3-[(2-methylphenyl)methyl]-1,2,4-oxadiazole | C20H16F2N4O | ", XP093311723, Database accession no. CID 154797673 *

Also Published As

Publication number Publication date
WO2025096658A1 (en) 2025-05-08
WO2025096654A1 (en) 2025-05-08
WO2025096657A1 (en) 2025-05-08
WO2025096653A1 (en) 2025-05-08
WO2025096662A1 (en) 2025-05-08

Similar Documents

Publication Publication Date Title
US8962623B2 (en) Aminopyrazine compounds
KR102822276B1 (en) Piperidinyl-3-(aryloxy)propanamide and propionate
CA3150701A1 (en) Alkynyl quinazoline compounds
AU2014342338A1 (en) Aminoheteroaryl benzamides as kinase inhibitors
WO2017044858A2 (en) Inhibitors of cyclin-dependent kinases
TW202229256A (en) Heteroaryl carboxamide compound
WO2023034346A1 (en) Chromen-2-one modulators of polrmt
CN111718332B (en) 2-substituted pyrazol amino-4-substituted amino-5-pyrimidine formamide compound, composition and application thereof
WO2025096660A1 (en) Compositions and inhibitors of polrmt
CN108368094B (en) Nonsteroidal glucocorticoid receptor modulators for topical drug delivery
WO2023034344A1 (en) Isoquinolinones and quinolinones as modulators of polrmt
WO2023034340A1 (en) Hydroxy and alkoxy coumarins as modulators of polrmt
US20250353816A1 (en) Quinolines as modulators of polrmt
US20250340516A1 (en) Isoquinolinones as Modulators of POLRMT
WO2023114539A1 (en) Amino chromen-2-one modulators of polrmt
EP4444727A1 (en) Amide-containing lonp1 inhibitor compounds, uses and methods
HK1258975B (en) Non-steroidal glucocorticoid receptor modulators for local drug delivery

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24886820

Country of ref document: EP

Kind code of ref document: A1